Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.21.21 - coagulation factor VIIa

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
6-phosphofructokinase deficiency
Frequency of five disease-causing genetic mutations in a large mixed-breed dog population (2011-2012).
Abortion, Habitual
Correlation between factor VII and PAI-1 genetic variants and recurrent miscarriage.
The -323P0/P10 factor VII gene polymorphism and the risk of recurrent miscarriage.
[The connection between Arg353Gln polymorphism of coagulation factor VII and recurrent miscarriages]
Abortion, Spontaneous
Influence of hemostatic factors on spontaneous abortion.
Septic miscarriage with toxic shock syndrome and disseminated intravascular coagulation (DIC): The role of surgery, recombinant activated factor VII and intravenous immunoglobulin (IVIG).
Sex hormones, hemostasis and early pregnancy loss.
[The connection between Arg353Gln polymorphism of coagulation factor VII and recurrent miscarriages]
Acidosis
A review of recombinant factor VII for refractory bleeding in nonhemophilic trauma patients.
Acidosis and correction of acidosis does not affect rFVIIa function in swine.
Acidosis and impaired blood coagulation: what and how to correct before using recombinant human factor VIIa.
Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis.
Concentration-dependent effect of hypocalcaemia on mortality of patients with critical bleeding requiring massive transfusion: a cohort study.
Damage control resuscitation: a sensible approach to the exsanguinating surgical patient.
Determinants of futility of administration of recombinant factor VIIa in trauma.
Effect of haemodilution, acidosis, and hypothermia on the activity of recombinant factor VIIa (NovoSeven).
Effect of recombinant factor VIIa as an adjunctive therapy in damage control for wartime vascular injuries: a case control study.
Near fatal hemorrhage in traumatic bilateral leg amputation with coagulopathy, acidosis, and hypothermia and salvage therapy with recombinant factor VIIa.
Recombinant activated coagulation factor VII and bleeding trauma patients.
Recombinant activated Factor VII as a hemostatic agent in very low birth weight preterms with gastrointestinal hemorrhage and disseminated intravascular coagulation.
Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry.
Recombinant activated factor VII in liver patients: a retrospective cohort study from Australia and New Zealand.
Recombinant factor VIIa in trauma patients with the 'triad of death'
Recombinant factor VIIa is effective at reversing coagulopathy in a lactic acidosis model.
Resuscitation and transfusion principles for traumatic hemorrhagic shock.
The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients.
The effects of acidosis and hypothermia on blood transfusion requirements following factor VII administration.
The utility of recombinant factor VIIa as a last resort in trauma.
Trends in trauma transfusion.
Use of Activated Recombinant Factor VII in Severe Bleeding - Evidence for Efficacy and Safety in Trauma, Postpartum Hemorrhage, Cardiac Surgery, and Gastrointestinal Bleeding.
Use of recombinant factor VIIa in the treatment of massive retroperitoneal bleeding due to severe necrotizing pancreatitis.
[Trauma-induced coagulopathy--mechanisms and state of the art treatment].
Acidosis, Lactic
Recombinant factor VIIa is effective at reversing coagulopathy in a lactic acidosis model.
Acquired Immunodeficiency Syndrome
Lupus anticoagulant associated with specific inhibition of factor VII in a patient with AIDS.
Activated Protein C Resistance
Associations between blood coagulation markers, NT-proBNP and risk of incident heart failure in older men: The British Regional Heart Study.
Atherogenic, hemostatic, and other potential risk markers in subjects with previous isolated myocardial infarction compared with long-standing uncomplicated stable angina.
Drospirenone as estrogen-free pill and hemostasis: coagulatory study results comparing a novel 4?mg formulation in a 24?+?4 cycle with desogestrel 75??g per day.
Effects of vaginally administered high estradiol doses on hormonal pharmacokinetics and hemostasis in postmenopausal women.
Physical activity and hemostatic and inflammatory variables in elderly men.
Acute Coronary Syndrome
A novel specific immunoassay for plasma two-chain factor VIIa: investigation of FVIIa levels in normal individuals and in patients with acute coronary syndromes.
Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance.
Early effects of low versus high dose atorvastatin treatment on coagulation and inflammation parameters in patients with acute coronary syndromes.
Factor VII levels, R353Q and -323P0/10 Factor VII variants, and the risk of acute coronary syndrome among Arab-African Tunisians.
Heightened thrombin formation but normal plasma levels of activated factor VII in patients with acute coronary syndromes.
Low plasma concentrations of coagulation factors II, VII and XI indicate increased risk among elderly with symptoms of heart failure.
Myocardial infarctions and other acute coronary syndromes in rare congenital bleeding disorders: a critical analysis of all reported cases.
Novel anticoagulant therapy: principle and practice.
Relationships between homocysteine, factor VIIa, and thrombin generation in acute coronary syndromes.
The decanucleotide polymorphism in the factor VII promoter predicts factor VII plasma levels but not the risk of acute coronary syndromes.
Acute Kidney Injury
Analysis of Outcomes Using Low-Dose and Early Administration of Recombinant Activated Factor VII in Cardiac Surgery.
Recombinant Activated Factor VII Use in Critically Ill Patients: Clinical Outcomes and Thromboembolic Events (April).
Recombinant factor VIIa treatment of bleeding associated with acute renal failure.
Viscoelastic haemostatic assays in the perioperative period of surgical procedures: Systematic review and meta-analysis.
[Acquired hemophilia complicated with hemorrhage induced acute renal failure]
Acute Lung Injury
A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome*
Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide.
Adrenal Insufficiency
Medication-related complications in the trauma patient.
Afibrinogenemia
Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review.
Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.
Bleeding characteristics and management of minor surgeries in rare bleeding disorders: report from a Turkish Pediatric Hematology Center.
Clinical audit of inherited bleeding disorders in a developing country.
Elimination of hepatitis C virus infection in patients with haemophilia in Belgium: A single-centre experience.
Factor deficiencies in pregnancy.
Inherited bleeding disorders: a 14-year retrospective study.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Prenatal diagnosis in rare bleeding disorders-An unresolved issue?
Rare bleeding disorders.
Surgical interventions in childhood rare factor deficiencies: a single-center experience from Turkey.
The animal models for hemorrhage and thrombosis in the neonate.
Thrombosis in rare bleeding disorders.
Unprovoked Pulmonary Embolism in Factor VII Deficiency.
Albuminuria
Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients.
Factor VII hyperactivity and endothelial cell damage are found in elderly hypertensives only when concomitant with microalbuminuria.
Amyloidosis
Acquired factor VII deficiency causing severe bleeding disorder secondary to AL amyloidosis of the liver.
[Case of factor VII deficiency with systemic amyloidosis having a unique clinical course such as splenic rupture]
[Combined deficiency of factor VII and X in a patient with multiple myeloma and amyloidosis]
Anaphylaxis
Allergy and inhibitors in hemophilia - a rare complication with potential novel solutions.
IgG4: a possible mediator of anaphylaxis in a haemophiliac patient.
Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor.
Peri-interventional control of haemostasis in a patient with combined coagulation factor V- and factor VIII-deficiency and anaphylaxis to fresh frozen plasma - a rare indication for recombinant factor VIIa.
Possible Anaphylaxis Due to Recombinant Factor VIIa Administration During Thoracic Aortic Surgery.
Recombinant factor VIIa in the treatment of bleeding in hemophilic children with inhibitors.
Anemia
A novel homozygous missense mutation in the factor VII gene of severe factor VII deficiency in a newborn baby.
Alternatives to allogeneic platelet transfusion.
Bleeding Gastric Heterotopic Polyp in the Duodenum of a Teenager with Severe Factor VII Deficiency.
Effect of recombinant factor VIIa as an adjunctive therapy in damage control for wartime vascular injuries: a case control study.
Macrohematuria as initial presentation in a girl with factor VIII and factor IX inhibitors associated with systemic lupus erythematosus.
Recombinant activated factor VII administration in a patient with congenital lack of factor VII undergoing laparoscopic hysterectomy: A case report.
Severe menorrhagia due to factor VII deficiency successfully treated by thermal balloon endometrial ablation.
Substitutes and alternatives to platelet transfusions in thrombocytopenic patients.
Two elderly patients with difficult-to-treat acquired hemophilia A.
[Thrombasthenia of Glanzmann. Vaginal hysterectomy treated with recombinant factor VIIa]
Anemia, Aplastic
Acquired factor VII deficiency associated with aplastic anaemia: correction with bone marrow transplantation.
Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII.
Deficiency of fibrinogen and factor VII following treatment of severe aplastic anaemia with anti-thymocyte globulin and high-dose methylprednisolone.
Efficacy and safety of recombinant factor VIIa in the treatment of bleeding episodes in patients with aplastic anemia.
Anemia, Iron-Deficiency
Bleeding Gastric Heterotopic Polyp in the Duodenum of a Teenager with Severe Factor VII Deficiency.
Anemia, Sickle Cell
Elevated urinary levels of thromboxane and prostacyclin metabolities in sickle cell disease reflects activated platelets in the circulation.
Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients.
Aneurysm
Bilateral total knee arthroplasty in a patient with hemophilia A, high inhibitor titre and aneurysma spurium of the popliteal artery. A case report.
Investigation of Outcomes Following Recombinant Activated FVII Use for Refractory Bleeding During Abdominal Aortic Aneurysm Repair.
Perioperative Use of Recombinant Factor VII to Prevent Intraoperative Aneurysm Rupture in High Risk Patients: A Preliminary Safety Evaluation.
The use of recombinant factor VIIa in controlling surgical bleeding in non-haemophiliac patients.
[Congenital factor VII deficiency and subarachnoidal haemorrhage due to intracranial aneurysm: a case report]
Aneurysm, Dissecting
A review of the off-label use of recombinant activated factor VII in a developing country tertiary care center.
Case 5-2006: recombinant factor VIIa in the management of postoperative bleeding after repair for inadvertently thrombolysed acute type A aortic dissection.
Combination use of platelets and recombinant activated factor VII for increased hemostasis during acute type a dissection operations.
Recombinant activated factor VII for postoperative hemorrhage following repair of acute type A aortic dissection.
Recombinant activated factor VII for refractory bleeding after acute aortic dissection surgery: a propensity score analysis.
Recombinant activated factor VII for treatment of refractory hemorrhage after surgery for acute aortic dissection.
Recombinant factor VIIa use in acute type A aortic dissection repair: A multicenter propensity-score-matched report from the Nordic Consortium for Acute Type A Aortic Dissection.
Successful Intraoperative Reversal of Heparin With Factor VII in a Patient With Protamine Reaction.
The prophylactic use of recombinant factor VIIa in a patient with DeBakey type III aortic dissection -A case report-.
[Treatment with activated factor VII after acute bleeding due to aortic dissection]
Aneurysm, False
Recombinant activated factor VII for false aneurysms in patients with normal haemostatic mechanisms.
Use of recombinant activated factor VII after axillofemoral bypass grafting.
[Reversal of acenocoumarol anticoagulation with activated factor VII in massive hemorrhage following rupture of a splenic artery pseudoaneurysm]
Aneurysm, Ruptured
Investigation of Outcomes Following Recombinant Activated FVII Use for Refractory Bleeding During Abdominal Aortic Aneurysm Repair.
Angina Pectoris
Coagulation factor VII and the risk of coronary heart disease in healthy men.
Factor VII and extrinsic pathway inhibitor in acute coronary disease.
[The alpha-defensins, peptides and proteins synthesized and liberated by neutrophils under atherosclerosis of different localization].
Angina, Stable
A protective contribution of the Q allele of the R353Q polymorphism of the Factor VII gene in individuals with chronic stable angina?
C-reactive protein plasma levels but not factor VII activity predict clinical outcome in patients undergoing elective coronary intervention.
Dietary factor VII activation does not increase plasma concentrations of prothrombin fragment 1+2 in patients with stable angina pectoris and coronary atherosclerosis.
Early changes in local hemostasis activation following percutaneous coronary intervention in stable angina patients: a comparison between drug-eluting and bare metal stents.
Heightened thrombin formation but normal plasma levels of activated factor VII in patients with acute coronary syndromes.
Role of coagulation factor VII in pathogenesis of ischemic heart disease.
[Factor VII detection and its association with lipid in ischaemic heart disease.]
Angina, Unstable
Activated and total coagulation factor VII, and fibrinogen in coronary artery disease.
Factor VII hyperactivity in acute myocardial thrombosis. A relation to the coagulation activation.
Gender difference in factor VII and in activated factor VII levels in unstable angina.
Heightened thrombin formation but normal plasma levels of activated factor VII in patients with acute coronary syndromes.
Inhibition of factor VIIa generation and prothrombin activation by treatment with enoxaparin in patients with unstable angina.
Role of coagulation factor VII in pathogenesis of ischemic heart disease.
[Factor VII detection and its association with lipid in ischaemic heart disease.]
Angiodysplasia
Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa.
Antiphospholipid Syndrome
Increase in the risk of ST elevation myocardial infarction is associated with homocysteine level.
Is the coexistence of thromboembolic events and Factor VII deficiency fortuitous?
[Diagnosis and treatment of coagulation disorders]
Antithrombin III Deficiency
[Gene diagnosis of antithrombin deficiency and factor VII deficiency]
[Hemostasis anomalies and prognosis during severe infectious purpura in children. Retrospective study in 69 cases]
Anus, Imperforate
Factor VII deficiency and developmental abnormalities in a patient with partial monosomy of 13q and trisomy of 16p: case report and review of the literature.
Aortic Aneurysm
Use of recombinant activated factor VII for bleeding following operations requiring cardiopulmonary bypass.
Aortic Aneurysm, Abdominal
Association analysis of genetic polymorphisms of factor V, factor VII and fibrinogen ? chain genes with human abdominal aortic aneurysm.
Congenital factor VII deficiency in a patient with an abdominal aortic aneurysm.
Investigation of Outcomes Following Recombinant Activated FVII Use for Refractory Bleeding During Abdominal Aortic Aneurysm Repair.
Repair of abdominal aortic aneurysm in severe Factor VII deficiency.
Role of recombinant factor VIIa in the treatment of intractable bleeding in vascular surgery.
The use of recombinant activated factor VII to control bleeding during repair of a suprarenal abdominal aortic aneurysm.
The use of recombinant-activated factor VII to successfully control postoperative critical bleeding after emergency repair of ruptured abdominal aortic aneurysm in a noncoagulopathic patient.
[Recombinant activated factor VII in the treatment of intractable non-surgical bleeding following major vascular procedures]
Aortic Aneurysm, Thoracic
Role of recombinant factor VIIa in the treatment of intractable bleeding in vascular surgery.
[Recombinant activated factor VII in the treatment of intractable non-surgical bleeding following major vascular procedures]
Aortic Coarctation
Recombinant factor VIIa for treatment of a child with severe factor VII deficiency and coarctation of the aorta.
Aortic Valve Stenosis
Aortic valve and coronary artery bypass surgery in a patient with factor VII deficiency.
Intra-Pericardial Use of Recombinant Factor VIIa in a Patient With Acute Hemorrhagic Pericardial Effusion Following Transcutaneous Aortic Valve Replacement-A Case Report.
Aphasia
[Complications during epilepsy surgery. Experience after 102 interventions between 1997 and 2001]
Appendicitis
Two-incision laparoscopic appendectomy for a severe hemophilia A child patient with coagulation factor VII deficiency: Case report and review of literature.
[Prophylactic use of a recombinant activated factor VII in delivery haemorrhage by caesarean in a woman with major factor VII deficiency: a case report].
Arterial Occlusive Diseases
Predictive value of coagulation tests in arterial thrombosis.
Arteriosclerosis
Homocysteine, factor VII and antithrombin III in subjects with different gene dosage for cystathionine beta-synthase.
Levels of haemostatic factors, arteriosclerosis and cardiovascular disease.
Arteriovenous Malformations
[Recombinant activated factor VII and intraoperative use of cell saver in neurosurgical treatment of arteriovenous malformation]
[Recombinant factor VII (NovoSeven) in intraoperative blood saving during neurosurgical treatment of the brain arteriovenous malformation]
Arthralgia
Demonstration of reactivity to airborne and food allergens in cutaneous vasculitis by variations in fibrinopeptide A and other blood coagulation, fibrinolysis and complement parameters.
Arthritis
Altered regulation of in-vivo coagulation in orthopedic patients prior to knee or hip replacement surgery.
Increase of activated factor VIIA and haemostatic molecular markers in juvenile chronic arthritis.
Role of the tissue factor pathway in synovial inflammation.
Arthritis, Juvenile
Increase of activated factor VIIA and haemostatic molecular markers in juvenile chronic arthritis.
Arthritis, Rheumatoid
A case of acquired hemophilia caused by factor VIII inhibitor with rheumatoid arthritis, successfully treated with immunosuppressive treatment and recombinant activated factor VII.
Aspergillosis
Recombinant factor VIIa in massive haemoptysis associated with chronic necrotising aspergillosis.
Successful use of recombinant FVIIa (Novoseven) in the management of pulmonary haemorrhage secondary to Aspergillus infection in a patient with leukaemia and acquired FVII deficiency.
Asthma
Development of Trypsin-Like Serine Protease Inhibitors as Therapeutic Agents: Opportunities, Challenges, and their Unique Structure-Based Rationales.
Ataxia
Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors.
Atherosclerosis
A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men.
Analysis of the substrate specificity of Factor VII activating protease (FSAP) and design of specific and sensitive peptide substrates.
Assessment of coronary heart disease risk by combined analysis of coagulation factors.
Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study Investigators.
Associations of fish intake and dietary n-3 polyunsaturated fatty acids with a hypocoagulable profile. The Atherosclerosis Risk in Communities (ARIC) Study.
Atherogenic effects in a non-human primate of Fusarium moniliforme cultures added to a carbohydrate diet.
Atherosclerosis and coronary bypass surgery in hereditary factor VII deficiency.
Coagulation factor VII and plasma triglycerides. Decreased catabolism as a possible mechanism of factor VII hyperactivity.
Constitutional, biochemical and lifestyle correlates of fibrinogen and factor VII activity in Polish urban and rural populations.
Correlation of factor VIIa values with factor VII gene polymorphism, fasting and postprandial triglyceride levels, and subclinical carotid atherosclerosis.
Determinants of population changes in fibrinogen and factor VII over 6 years: the Atherosclerosis Risk in Communities (ARIC) Study.
Dietary factor VII activation does not increase plasma concentrations of prothrombin fragment 1+2 in patients with stable angina pectoris and coronary atherosclerosis.
Effect of the factor VII R353Q missense mutation on plasma apolipoprotein B levels: impact of visceral obesity.
Extrahepatic synthesis of factor VII in human atherosclerotic vessels.
Factor VII hyperactivity in the elderly.
Fibrinogen, factor VII and PAI-1 genotypes and the risk of coronary and peripheral atherosclerosis: Edinburgh Artery Study.
Hemostasis and atherosclerosis.
Pleiotropic actions of factor Xa inhibition in cardiovascular prevention - mechanistic insights and implications for anti-thrombotic treatment.
Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors.
Risk factors, interventions and therapeutic agents in the prevention of atherosclerosis-related ischaemic diseases.
The possible role of hemorheology in atherothrombogenesis.
Thrombin generation markers and coronary heart disease risk factors in a Polish population sample.
Tissue factor binding of activated factor VII triggers smooth muscle cell proliferation via extracellular signal-regulated kinase activation.
Tissue factor isoforms in cancer and coagulation: may the best isoform win.
Tissue Factor-Factor VIIa complex induces cytokine expression in coronary artery smooth muscle cells.
[Coagulation factor VII--new physiopathological and therapeutic aspects]
[The alpha-defensins, peptides and proteins synthesized and liberated by neutrophils under atherosclerosis of different localization].
Atrial Fibrillation
Anticoagulation Therapy Considerations in Factor VII Deficiency.
Aortic valve and coronary artery bypass surgery in a patient with factor VII deficiency.
D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy.
Direct oral anticoagulants for atrial fibrillation in patients with congenital factor VII deficiency.
Factor VII -323 decanucleotide D/I polymorphism in atrial fibrillation: implications for the prothrombotic state and stroke risk.
Influence of warfarin therapy on activated factor VII clotting activity.
Management of a patient with atrial fibrillation and factor VII deficiency.
Medication-related complications in the trauma patient.
Mitral valve surgery in severe congenital factor VII deficiency.
Novel anticoagulant therapy: principle and practice.
Therapeutic plasma exchange as part of multimodal treatment of acquired hemophilia in a patient with concurrent acute intracerebral bleed and pulmonary embolism.
Bacteremia
Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock.
Bacterial Infections
Cytochemical determination of intracellular polymorphonuclear leukocyte elastase content in patients with severe bacterial infection and septicaemia correlated with coagulation parameters.
Beckwith-Wiedemann Syndrome
11p15 duplication and 13q34 deletion with Beckwith-Wiedemann syndrome and factor VII deficiency.
Bernard-Soulier Syndrome
A self-controlled comparative clinical trial to explore the effectiveness of three topical hemostatic agents for stopping severe epistaxis in pediatrics with inherited coagulopathies.
Clinical and laboratory features of 178 children with recurrent epistaxis.
Clinical benefit of recombinant factor VIIa in management of bleeds and surgery in two brothers suffering from the Bernard-Soulier syndrome.
Complementary effect of fibrinogen and rFVIIa on clotting ex vivo in Bernard-Soulier syndrome and combined use during three deliveries.
Hemostatic effect of activated recombinant factor VIIa in Bernard-Soulier syndrome: studies in an in vitro model.
Inherited Bleeding Disorders in the Obstetric Patient.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Redistribution and hemostatic action of recombinant activated factor VII associated with platelets.
Screening bleeding disorders in adolescents and young women with menorrhagia.
The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia.
To general haemostasis--the evidence-based route.
Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa.
Use of recombinant factor VIIa in the management and prophylaxis of bleeding episodes in two patients with Bernard-Soulier syndrome.
Use of recombinant factor VIIa in the management of severe bleeding episodes in patients with Bernard-Soulier syndrome.
[Recombinant factor VIIa in patients with platelet function disorders or thrombocytopenia]
beta-Thalassemia
Analysis of clinically relevant single-nucleotide polymorphisms by use of microelectronic array technology.
Bicuspid Aortic Valve Disease
Congenital Factor VII Deficiency in Association With Bicuspid Aortic Valve and Multicystic Dysplastic Kidney Disease in a Child.
Blindness, Cortical
Migraine, cortical blindness, multiple cerebral infarctions and hypocoagulopathy in celiac disease.
Blood Coagulation Disorders
[Homocystinuria. A type with vascular thrombosis and factor VII deficiency]
Blood Coagulation Disorders, Inherited
A rare inherited coagulation disorder: combined homozygous factor VII and factor X deficiency.
Advances in the treatment of inherited coagulation disorders.
An overview of inherited factor VII deficiency.
Clinical problems and surgical interventions in inherited factor VII deficiency.
Continuous infusion of recombinant activated factor VII for bleeding control after lobectomy in a patient with inherited factor VII deficiency.
Factor VII deficiency detected in pregnancy: a case report.
[Hemophilia and other inherited blood coagulation disorders in Poland]
[Use of recombinant, activated Factor VII in the treatment and prevention of bleeding complications in two female patients suffering from congenital XI factor deficiency during orthopedic and traumatology intervention. Case reports]
Blood Platelet Disorders
Effective treatment with recombinant factor VIIa of severe bleeding due to acquired factor VIII inhibitor and acquired thrombocytopathy.
Is the use of rFVIIa safe and effective in bleeding neonates? A retrospective series of 8 cases.
Modification of biological parameters after treatment with recombinant factor VIIa in a patient with thrombocytopathy due to storage pool disease.
Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease.
Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia.
[New possibilities in the management of hemorrhagic diathesis caused by factor deficiency and thrombocytopenia: recombinant active factor VII concentrate]
Blood-Borne Infections
Recombinant factor VIIa in joint and muscle bleeding episodes.
Bone Marrow Failure Disorders
Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review.
Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with thrombocytopenia due to chronic bone marrow failure: a network meta-analysis and systematic review.
Brain Contusion
Administration off label of recombinant factor-VIIa (rFVIIa) to patients with blunt or penetrating brain injury without coagulopathy.
FVIIa prevents the progressive hemorrhaging of a brain contusion by protecting microvessels via formation of the TF-FVIIa-FXa complex.
Hemostatic and neuroprotective effects of human recombinant activated factor VII therapy after traumatic brain injury in pigs.
Brain Death
Hypercoagulation following brain death cannot be reversed by the neutralization of systemic tissue factor.
Use of recombinant factor VIIa to facilitate organ donation in trauma patients with devastating neurologic injury.
Brain Diseases
Description of breed ancestry and genetic health traits in arctic sled dog breeds.
Recombinant activated factor VII for diffuse alveolar hemorrhage in microscopic polyangiitis.
The predictive value of admission and follow up factor V and VII levels in patients with acute hepatitis and coagulopathy.
[Predictive value of changes in the hemostasis system in patients with ischemic brain diseases]
Brain Edema
Liver transplantation in acute liver failure.
Brain Injuries
Extrapolation of battlefield resuscitative care to the civilian setting.
Reversal of coagulopathy in critically ill patients with traumatic brain injury: recombinant factor VIIa is more cost-effective than plasma.
The use of recombinant factor VIIa (NovoSeven) for treatment of active or impending bleeding in brain injury: broadening the indications.
[Use of activated recombinant factor VII in patients with brain injury or undergoing brain surgery]
Brain Injuries, Traumatic
Activity of factor VII in patients with isolated blunt traumatic brain injury: association with coagulopathy and progressive hemorrhagic injury.
Blood component therapy in trauma guided with the utilization of the perfusionist and thromboelastography.
Contribution of factor VII polymorphisms to coagulopathy in patients with isolated traumatic brain injury.
Effects of recombinant activated factor VII in traumatic nonsurgical intracranial hemorrhage.
Factor VII and the brain: time to get this research done!
Factor VIIa administration in traumatic brain injury: an AAST-MITC propensity score analysis.
Factor VIIa for correction of traumatic coagulopathy.
Haemostatic drugs for traumatic brain injury.
Hemostatic and neuroprotective effects of human recombinant activated factor VII therapy after traumatic brain injury in pigs.
Low-dose recombinant factor VIIa for reversing coagulopathy in patients with isolated traumatic brain injury.
Recombinant Activated Factor VII Use in Critically Ill Patients: Clinical Outcomes and Thromboembolic Events (April).
Recombinant factor VIIa for the correction of coagulopathy before emergent craniotomy in blunt trauma patients.
Recombinant factor VIIa to correct coagulopathy in patients with traumatic brain injury presenting to outlying facilities before transfer to the regional trauma center.
Recombinant factor VIIa: decreasing time to intervention in coagulopathic patients with severe traumatic brain injury.
Reversal of coagulopathy in critically ill patients with traumatic brain injury: recombinant factor VIIa is more cost-effective than plasma.
Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial.
The effect of rFVIIa on pro- and anti-inflamatory cytokines in serum and cerebrospinal fluid in a swine model of traumatic brain injury.
The role of recombinant-activated factor VII in bleeding trauma patients.
The role of thromboelastometry and recombinant factor VIIa in trauma.
The use of recombinant activated factor VIIa in coagulopathic traumatic brain injuries requiring emergent craniotomy: is it beneficial?
The use of recombinant factor VIIa (NovoSeven) for treatment of active or impending bleeding in brain injury: broadening the indications.
The use of recombinant factor VIIa in warfarin patients with traumatic brain injury: a retrospective case-control study.
Use of recombinant factor VIIa (rFVIIa) as pre-hospital treatment in a swine model of fluid percussion traumatic brain injury.
Uses of recombinant factor VIIa in trauma.
[Activity of factor VII in patients with isolated blunt traumatic brain injury: association with coagulopathy and progressive hemorrhagic injury].
[Role of small-dose recombinant human coagulation factor VIIa for coagulopathy in patients with isolated traumatic brain injury].
[The use of recombinant activated factor VII in traumatic intracranial haemorrhage]
Brain Ischemia
Cerebral ischemia and livedo reticularis in a patient with impairment of coagulation factor VII and free protein S.
Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial.
Brain Neoplasms
Intractable blood loss during brain tumour surgery in a child: effect of recombinant activated factor VII.
Recombinant activated factor VII in the treatment of near-fatal bleeding during pediatric brain tumor surgery. Report of two cases and review of the literature.
Recombinant factor VIIa for the prophylaxis of perioperative hemorrhage in a patient with congenital factor XI deficiency undergoing brain tumor neurosurgery.
Use of activated recombinant Factor VII (NovoSeven) during neurosurgery.
Use of recombinant factor VIIa (rFVIIa) to control intraoperative bleeding in pediatric brain tumor patients.
[Intraoperative use of activated recombinant factor VII in a patient with brain cancer]
Breast Neoplasms
Activation of ?1 integrins and caveolin-1 by TF/FVIIa promotes IGF-1R signaling and cell survival.
Association between the -402GA, -401GT, and -323ins10-bp polymorphisms of factor VII gene and breast cancer.
Breast cancer phenotypes regulated by tissue factor-factor VII pathway: Possible therapeutic targets.
Coagulation factor VII is regulated by androgen receptor in breast cancer.
Coagulation factor VIIa-mediated protease-activated receptor 2 activation leads to ?-catenin accumulation via the AKT/GSK3? pathway and contributes to breast cancer progression.
Effects of a 1-Year Physical Activity Intervention on Markers of Hemostasis among Breast Cancer Survivors: A Randomized Controlled Trial.
Formation of tissue factor-factor VIIa-factor Xa complex prevents apoptosis in human breast cancer cells.
Formation of tissue factor-factor VIIa-factor Xa complex promotes cellular signaling and migration of human breast cancer cells.
Hepatocyte nuclear factor-4-independent synthesis of coagulation factor VII in breast cancer cells and its inhibition by targeting selective histone acetyltransferases.
Interaction of human tumor cells with human platelets and the coagulation system.
Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells.
Selective and effective killing of angiogenic vascular endothelial cells and cancer cells by targeting tissue factor using a factor VII-targeted photodynamic therapy for breast cancer.
Simvastatin induces apoptosis in human breast cancer cells in a NFkappaB-dependent manner and abolishes the anti-apoptotic signaling of TF/FVIIa and TF/FVIIa/FXa.
Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice.
TFPI? and TFPI? are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity.
The tick-derived inhibitor Ixolaris prevents tissue factor signaling on tumor cells.
Tissue factor as a novel target for treatment of breast cancer.
Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration.
Tissue factor/factor VIIa induces cell survival and gene transcription by transactivation of the insulin-like growth factor 1 receptor.
Transcriptional program induced by factor VIIa-tissue factor, PAR1 and PAR2 in MDA-MB-231 cells.
Budd-Chiari Syndrome
Association of factor VII gene polymorphisms with Budd Chiari syndrome.
Hematological problems and liver disease.
Burkitt Lymphoma
Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII.
Successful Control of Massive Bleeding in a Child with Burkitt's Lymphoma via a Biosimilar Recombinant Activated Factor VII (AryoSeven™).
Successful management of bleeding with recombinant factor VIIa (NovoSeven) in a patient with Burkitt lymphoma and thrombosis of the left femoral and left common iliac veins.
Carcinogenesis
Blood coagulation factors as inflammatory mediators.
Coagulation factor VII gene polymorphisms are not associated with the occurrence or the survival of hepatocellular carcinoma: a report of 37 cases.
Ovarian cancer, the coagulation pathway, and inflammation.
Carcinoid Tumor
Role of factor VII in correcting dilutional coagulopathy and reducing re-operations for bleeding following non-traumatic major gastrointestinal and abdominal surgery.
Carcinoma
Activation of factor VII in patients with carcinoma of the prostate. A preliminary report.
Activation of human factor VII by factors IXa and Xa on human bladder carcinoma cells.
Anti-apoptotic genes are synergistically activated in OVSAYO cells cultured under conditions of serum starvation and hypoxia.
Binding of human factors VII and VIIa to a human bladder carcinoma cell line (J82). Implications for the initiation of the extrinsic pathway of blood coagulation.
Cholesterol Starvation and Hypoxia Activate the FVII Gene via the SREBP1-GILZ Pathway in Ovarian Cancer Cells to Produce Procoagulant Microvesicles.
Comparison of properties of cancer procoagulant and human amnion-chorion procoagulant.
Computer-assisted image analysis of neovascularization in thyroid neoplasms from dogs.
Cooperative interaction between factor VII and cell surface-expressed tissue factor.
Factor VIIa/tissue factor-catalyzed activation of factors IX and X on a cell surface and in suspension: a kinetic study.
Human plasma and recombinant factor VII. Characterization of O-glycosylations at serine residues 52 and 60 and effects of site-directed mutagenesis of serine 52 to alanine.
Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor.
Inhibition of recombinant human blood coagulation factor VIIa amidolytic and proteolytic activity by zinc ions.
Initiation of the extrinsic pathway of blood coagulation: evidence for the tissue factor dependent autoactivation of human coagulation factor VII.
Lipid starvation and hypoxia synergistically activate ICAM1 and multiple genes in an Sp1-dependent manner to promote the growth of ovarian cancer.
Plasma-dependent and -independent mechanisms of platelet aggregation induced by human tumour cell lines.
Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions.
Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells.
Several murine metastasizing tumors possess a cysteine proteinase with cancer procoagulant characteristics.
Studies of the activation of factor VII bound to tissue factor.
The gamma-carboxyglutamic acid domain of human factor VIIa is essential for its interaction with cell surface tissue factor.
Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis.
Unforeseen encounter of acquired hemophilia A in a preoperative case of periampullary carcinoma: A case report.
USE OF RECOMBINANT ACTIVATED FACTOR VIIa IN A-SIX-MONTH-OLD CHILD DUE TO MASSIVE HEMORRHAGE DURING ELECTIVE SURGERY FOR CHOROID PLEXUS CARCINOMA: CASE REPORT.
Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody.
Carcinoma, Bronchogenic
Acquired Factor VII Deficiency Associated with Bronchogenic Carcinoma: A Case Report.
Factor VII inhibitor.
[Acquired isolated factor VII deficiency and bronchogenic carcinoma. A case report]
Carcinoma, Hepatocellular
Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII.
An engineered tale-transcription factor rescues transcription of factor VII impaired by promoter mutations and enhances its endogenous expression in hepatocytes.
Biosynthesis and secretion of factor VII, protein C, protein S, and the Protein C inhibitor from a human hepatoma cell line.
CCAAT/Enhancer-binding Protein-beta Participates in Insulin-responsive Expression of the Factor VII Gene.
Coagulation factor VII and malignant progression of hepatocellular carcinoma.
Coagulation factor VII gene polymorphisms are not associated with the occurrence or the survival of hepatocellular carcinoma: a report of 37 cases.
Correction of both prothrombin time and primary haemostasis by recombinant factor VII during therapeutic alcohol injection of hepatocellular cancer in liver cirrhosis.
Factor VII promotes hepatocellular carcinoma progression through ERK-TSC signaling.
Factor VII Tokushima: the first case of factor VII Cys22Gly with the development of myocardial infarction in the proband receiving recombinant factor VIIa replacement therapy.
Factor VIIa binding and internalization in hepatocytes.
Internalization and degradation of recombinant human coagulation factor VIIa by the human hepatoma cell line HuH7.
Perioperative pharmacokinetics of factor VII concentrate during liver surgery in a patient with congenital factor VII deficiency: an individual mathematical model.
Transforming growth factor beta (TGF-beta) inhibits expression of fibrinogen and factor VII in a hepatoma cell line.
U1-snRNA-mediated rescue of mRNA processing in severe factor VII deficiency.
Carcinoma, Squamous Cell
Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody.
Cardiac Tamponade
Hemophilia A and concurrent factor VII deficiency. Studies of a patient with complicating cardiac tamponade.
Cardiomyopathy, Dilated
Description of breed ancestry and genetic health traits in arctic sled dog breeds.
Cardiomyopathy, Hypertrophic
Anticoagulation of a patient with hypertrophic cardiomyopathy and factor VII deficiency.
Cardiomyopathy, Restrictive
Severe deficiency of coagulation Factor VII results in spontaneous cardiac fibrosis in mice.
Cardiovascular Diseases
A chromogenic assay for coagulation factor VII: analytical performance characteristics and application in several diseases.
A new form of coagulation factor VII in plasma.
A novel form of factor VII in plasma from men at risk for cardiovascular disease.
Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients.
Alcohol consumption and hemostatic factors: analysis of the Framingham Offspring cohort.
An association between clotting factor VII and carotid intima-media thickness: the CARDIA study.
Association of blood pressure with fibrinolytic potential in the Framingham offspring population.
Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly: the Cardiovascular Health Study. Cardiovascular Health Study Investigators.
Associations of activated coagulation factor VII and factor VIIa-antithrombin levels with genome-wide polymorphisms and cardiovascular disease risk.
Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction--the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction.
Biochemical, molecular and clinical aspects of coagulation factor VII and its role in hemostasis and thrombosis.
Circulating markers of arterial thrombosis and late-stage age-related macular degeneration: a case-control study.
Coagulation factor VII, R353Q polymorphism, and serum choline-containing phospholipids in males at high risk for coronary heart disease.
Coagulation factor VII, serum-triglycerides and the R/Q353 polymorphism: differences between older men and women.
Complexity of the genetic contribution to factor VII deficiency in two Spanish families: clinical and biological implications.
Contribution of factor VII genotype to activated FVII levels. Differences in genotype frequencies between northern and southern European populations.
Dietary fatty acids, hemostasis, and cardiovascular disease risk.
Effect of alteration in triglyceride levels on factor VII-phospholipid complexes in plasma.
Effect of classic preconditioning on the gene expression pattern of rat hearts: a DNA microarray study.
Effects of Different Protein Sources on Plasminogen Inhibitor-1 and Factor VII Coagulant Activity Added to a Fat-Rich Meal in Type 2 Diabetes.
Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.
Environmental and genetic determinants of the hypercoagulable state and cardiovascular disease in renal transplant recipients.
Experimental thrombosis I: relation with fibrinogen and other haemostatic parameters.
Factor VII activity state in coronary artery disease.
Factor VII and ischaemic heart disease: epidemiological evidence.
Factor VII assays, plasma triglyceride levels, and cardiovascular disease risk.
Factor VII assays.
Factor VII coagulant activity (VIIc) and hypercoagulability in chronic renal disease and dialysis: relationship with dyslipidaemia, inflammation, and factor VII genotype.
Factor VII gene polymorphism, factor VII levels, and prevalent cardiovascular disease: the Framingham Heart Study.
Factor VII polymorphisms associated with plasma factor VII coagulant activity levels in healthy Tunisians.
Factor VII polymorphisms in populations with different risks of cardiovascular disease.
Factor VII R353Q polymorphism and lacunar stroke in Japanese hypertensive patients and normotensive controls.
Factor VII-phospholipid complex in male survivors of acute myocardial infarction.
Fibrinogen and factor VII in male neonates.
Fibrinogen and factor VII levels are related to adiposity but not to fetal growth or social class in children aged 10-11 years.
Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly. Results from The Cardiovascular Health Study.
Fluorogenic assay of activated factor VII. Plasma factor VIIa levels in relation to arterial cardiovascular diseases in Japanese.
Functional analysis of the genetic variability in the F7 gene promoter.
Genetic architecture of the F7 gene in a Spanish population: implication for mapping complex diseases and for functional assays.
Genetic determinants of plasma factor VII activity in the Japanese.
Genetic effects for plasma factor VII levels independent of and in common with triglycerides.
Genetic polymorphisms modify the response of factor VII to oral contraceptive use: an example of gene-environment interaction.
Haemostatic parameters and vascular risk.
Hemostatic factors as predictors of stroke and cardiovascular diseases: the FINRISK '92 Hemostasis Study.
Hemostatic factors as triggers of cardiovascular events.
Ixolaris, a novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick, Ixodes scapularis: identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex.
Lack of association between polymorphisms of the coagulation factor VII and myocardial infarction in middle-aged Spanish men.
Long-term anticoagulant treatment after acute myocardial infarction. The Warfarin Re-Infarction Study.
Overview of hemostatic factors involved in atherosclerotic cardiovascular disease.
Phospholipase C mediated inhibition of factor VII requires triglyceride-rich lipoproteins.
Physical excercise and thrombotic risk in the elderly.
Plasma fibrinogen and factor VII as risk factors for cardiovascular disease.
Plasma phospholipid fatty acid composition and factor VII coagulant activity.
Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors.
Probing the S2 site of factor VIIa to generate potent and selective inhibitors: the structure of BCX-3607 in complex with tissue factor-factor VIIa.
Prothrombin fragment F1 + 2: correlations with cardiovascular risk factors.
R353Q polymorphism in the factor VII gene and cardiovascular risk in Heterozygous Familial Hypercholesterolemia: a case-control study.
Reduced factor VII and factor VIII levels and prolonged thrombin-generation times during a healthy diet in middle-aged women with mild to moderate cardiovascular disease risk.
Relation of plasma coagulation factor VII and fibrinogen to carotid artery intima-media thickness.
Risk factors of ischemic cardiac disease in patients on continuous ambulatory peritoneal dialysis.
Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease.
Suppression of plasma-activated factor VII levels by warfarin therapy.
The effect of phospholipase C on plasma factor VII.
The F7 gene and clotting factor VII levels: dissection of a human quantitative trait locus.
The genetics of haemostasis: a twin study.
The relation of prothrombin times to coronary heart disease risk factors among men aged 31-45 years.
The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the cardiovascular health study.
Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC).
Tissue Factor/Factor FVII Complex Inhibitors in Cardiovascular Disease. Are Things Going Well?
[Activated factor VII as a new cardiovascular risk factor of atherothrombotic disease]
[Estrogen replacement in postmenopause, blood coagulation and fibrinolysis: comparison of a new kind of transdermal estradiol treatment with oral therapy with conjugated estrogens]
[Role of newly developed technology in blood coagulation disorders]
Carotid Artery Diseases
Correlation of factor VIIa values with factor VII gene polymorphism, fasting and postprandial triglyceride levels, and subclinical carotid atherosclerosis.
Relation between hemostatic variables and increase of common carotid intima-media thickness in patients with peripheral arterial disease.
Carotid Artery Thrombosis
Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis.
Effects of recombinant active site-blocked activated factor VII in rabbit models of carotid stenosis and myocardial infarction.
Carotid Stenosis
Effects of recombinant active site-blocked activated factor VII in rabbit models of carotid stenosis and myocardial infarction.
Ischemic stroke in a patient with moderate to severe inherited factor VII deficiency.
Cataract
A successful use of recombinant factor VIIa in a patient with inhibitors, for bilateral cataract operation and circumcision.
Short-course use of recombinant factor VIIa in a haemophilia patient with inhibitor undergoing cataract surgeries.
Successful use of recombinant factor VIIa in a haemophiliac with inhibitor undergoing cataract surgery.
Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency.
Celiac Disease
Migraine, cortical blindness, multiple cerebral infarctions and hypocoagulopathy in celiac disease.
Cerebral Hemorrhage
801 Effects of Recombinant Activated Factor VII on Perilesional Edema in Patients with Acute Intracerebral Hemorrhage.
A meta-analysis of the efficacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia.
A review of the off-label use of recombinant activated factor VII in a developing country tertiary care center.
Advances in the treatment of hemorrhagic stroke: a possible new treatment.
Association of protein Z and factor VII gene polymorphisms with risk of cerebral hemorrhage: a case-control and a family-based association study in a Chinese Han population.
Best evidence in anesthetic practice: Recombinant activated factor VII for acute intracerebral hemorrhage: a promising therapy for a devastating problem?
Can a subset of intracerebral hemorrhage patients benefit from hemostatic therapy with recombinant activated factor VII?
Cerebral hemorrhage treated with NovoSeven in acute promyelocytic leukemia.
Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings.
Clinical Strategies Against Early Hematoma Expansion Following Intracerebral Hemorrhage.
Coagulopathic patients with traumatic intracranial bleeding: defining the role of recombinant factor VIIa.
Complications in patients with intracerebral hemorrhage treated with recombinant factor VIIa.
Controversies of anticoagulation reversal in life-threatening bleeds.
Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage.
Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage.
Determinants of intracerebral hemorrhage growth: an exploratory analysis.
Dosing factor VIIa (recombinant) in nonhemophiliac patients with bleeding after cardiac surgery.
Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage: risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII.
Early hemostatic therapy using recombinant factor VIIa in a collagenase-induced intracerebral hemorrhage model in rats.
Early recombinant activated factor VII for intracerebral hemorrhage reduced hematoma growth and mortality, while improving functional outcomes.
Early recombinant factor VIIa therapy in acute intracerebral hemorrhage: promising approach.
Effect of Recombinant Activated Coagulation Factor VII on Hemorrhage Expansion Among Patients With Spot Sign-Positive Acute Intracerebral Hemorrhage: The SPOTLIGHT and STOP-IT Randomized Clinical Trials.
Effects of recombinant activated coagulation factor VII on apoptosis and expressions of Bcl-2 and Bax in rats with intracerebral hemorrhage.
Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage.
Emerging therapies for acute ischemic stroke.
Evidence for the use of recombinant factor VIIa in the prevention and treatment of bleeding in patients without hemophilia.
Generation of a human induced pluripotent stem cell line, YCMi002-A, from a Factor VII deficiency patient carrying F7 mutations.
Hemostatic therapy for the treatment of intracranial hemorrhage.
Hemostatic treatment in the early stage of intracerebral hemorrhage: the recombinant factor VIIa experience.
Impact of recombinant activated factor VII on health-related quality of life after intracerebral hemorrhage.
Intracerebral hemorrhage.
Intracerebral hemorrhage: outcomes and eligibility for factor VIIa treatment in a National Stroke Registry.
Intraoperative intravenous administration of rFVIIa and hematoma volume after early surgery for spontaneous intracerebral hemorrhage: a randomized prospective phase II study.
Is "compassionate use" compassionate?: rFVIIa for intracerebral hemorrhage.
Multiple intracranial hemorrhages at the time of a transiently prolonged activated partial thromboplastin time in an infant with congenital factor VII deficiency.
Myocardial injury in patients with intracerebral hemorrhage treated with recombinant factor VIIa.
Phenotypical variability in congenital FVII deficiency follows the ISTH-SSC severity classification guidelines: a review with illustrative examples from the clinic.
Polymorphisms in the coagulation factor VII gene and risk of primary intracerebral hemorrhage.
Potential applicability of recombinant factor VIIa for intracerebral hemorrhage.
Primary intracerebral hemorrhage.
Radiologic estimation of hematoma volume in intracerebral hemorrhage trial by CT scan.
Rapid warfarin reversal: a 3-factor prothrombin complex concentrate and recombinant factor VIIa cocktail for intracerebral hemorrhage.
Recombinant activated coagulation factor VII and prothrombin complex concentrates are equally effective in reducing hematoma volume in experimental warfarin-associated intracerebral hemorrhage.
Recombinant activated factor VII for acute intracerebral hemorrhage.
Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage.
Recombinant activated factor VII for acute intracerebral hemorrhage.
Recombinant activated factor VII for acute intracerebral hemorrhage: US phase IIA trial.
Recombinant activated factor VII for bleeding in patients without inherited bleeding disorders.
Recombinant activated factor VII given within 4 hours of intracerebral hemorrhage reduced hematoma growth.
Recombinant factor VIIa and the surgical patient.
Recombinant factor VIIa plus surgery for intracerebral hemorrhage.
Recombinant Human Coagulation Factor VIIa for Intracerebral Hemorrhage.
Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage.
Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage.
Safety of recombinant activated factor VII in patients with warfarin-associated hemorrhages of the central nervous system.
Successful treatment with rFVIIa of spontaneous intracerebral hemorrhage in a patient with mechanical prosthetic heart valves.
The effect of activated factor VII for intracerebral hemorrhage beyond 3 hours versus within 3 hours.
The effect of recombinant activated factor VII in the treatment of intracerebral hemorrhage on health plan budgets.
The practical management of intracerebral hemorrhage associated with oral anticoagulant therapy.
Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial.
Thromboembolic risks of recombinant factor VIIa Use in warfarin-associated intracranial hemorrhage: a case-control study.
Tissue factor in brain is not saturated with factor VIIa: implications for factor VIIa dosing in intracerebral hemorrhage.
Use of Recombinant Factor VIIa in Symptomatic Intracerebral Hemorrhage Following Intravenous Thrombolysis.
[Acute stroke therapy : Current developments.]
[Ethical and legal aspects of including patients unable to consent in acute therapy studies. Example of a medication study for the treatment of intracerebral hemorrhage--the Heidelberg procedure]
[Pharmacotherapy of stroke]
[Recombinant activated factor VII for spontaneous cerebral hemorrhage]
Cerebral Hemorrhage, Traumatic
Expansion of traumatic intracerebral hemorrhage: treatment implications with recombinant factor VIIa.
Recombinant factor VIIA in traumatic intracerebral hemorrhage: results of a dose-escalation clinical trial.
Cerebral Infarction
Association of beta-fibrinogen and factor VII polymorphism with plasma fibrinogen and factor VII levels, and no association of PAI-1 polymorphism with plasma PAI-1 levels in hemodialysis patients.
Polymorphisms of the coagulation factor VII gene and its plasma levels in relation to acute cerebral infarction differences in allelic frequencies between Chinese Han and European populations.
Prothrombotic gene polymorphisms and atherothrombotic cerebral infarction.
Risk of thromboembolic complications after intracerebral hemorrhage according to ethnicity.
[Polimorfismos asociados a disfunción endotelial y a un estado protrombótico en jóvenes mexicanos con infarto cerebral].
[Value of plasma tissue factor, tissue factor pathway inhibitor and factor VII assessments in patients with acute myocardial and cerebral infarction]
Cerebrovascular Disorders
Factor VII R353Q polymorphism and lacunar stroke in Japanese hypertensive patients and normotensive controls.
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
Polymorphisms of the factor VII gene and circulating FVII:C levels in relation to acute cerebrovascular disease and poststroke mortality.
Prothrombotic genetic risk factors in patients with coexisting migraine and ischemic cerebrovascular disease.
Risk factors for cerebrovascular disease and the role of coagulation and fibrinolysis.
[The thrombophilic status and ischemic cardiopathy]
Chagas Disease
Human acute Chagas disease: changes in factor VII, activated protein C and hepatic enzymes from patients of oral outbreaks in Pará State (Brazilian Amazon).
Cholangitis, Sclerosing
Segmental liver transplantation from non-heart beating donors-an early experience with implications for the future.
Cholecystitis
A new perspective on perioperative coagulation management in a patient with congenital factor VII deficiency: A case report.
Cholecystolithiasis
A new perspective on perioperative coagulation management in a patient with congenital factor VII deficiency: A case report.
Choledocholithiasis
Recombinant Factor VIIa Use for Endoscopic Retrograde Cholangiopancreatography With Sphincterotomy in a Patient With Choledocholithiasis and Unusual Coagulopathy.
Cholestasis, Intrahepatic
Hepatocyte transplantation for liver-based metabolic disorders.
Liver after hepatocyte transplantation for liver-based metabolic disorders in children.
Segmental liver transplantation from non-heart beating donors-an early experience with implications for the future.
Cholesteatoma
A case of Glanzmann's thrombasthenia successfully treated with recombinant factor viia during a surgical procedure: observations on the monitoring and the mechanism of action of this drug.
Choriocarcinoma
Recombinant factor VIIa in the management of pulmonary hemorrhage associated with metastatic choriocarcinoma.
Choroidal Neovascularization
Factor VII-verteporfin for Targeted Photodynamic Therapy in a Rat Model of Choroidal Neovascularization.
Chronic Urticaria
Interaction between C1-INA, coagulation, fibrinolysis and kinin system in hereditary angioneurotic edema (HANE) and urticaria.
The relationship between the severity of clinical symptoms of chronic urticaria and serum D-dimer levels.
Cleft Lip
Bilateral Cleft Lip and Palate Accompanied by 13q- Syndrome with Deficiencies of FVII and FX: A Case Report.
Cleft Palate
Bleeding Prophylaxis in a Child With Cleft Palate and Factor VII Deficiency: A Case Report.
Congenital combined defects of factor VII: a critical review.
coagulation factor ixa deficiency
A Candidate Activation Pathway for Coagulation Factor VII.
Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency.
Clinical and laboratory features of 178 children with recurrent epistaxis.
Iron studies in hemophilia.
Multiple congenital coagulopathies co-expressed with Von Willebrand's disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature.
Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
coagulation factor viia deficiency
"Case report". A case of haemorrhagic diathesis due to factor VII deficiency.
"Noninfective Endocarditis": A Case Report of Hereditary Coagulation Disorders in a 28-Year-Old Male.
11p15 duplication and 13q34 deletion with Beckwith-Wiedemann syndrome and factor VII deficiency.
3 ANESTHETIC MANAGEMENT OF LIVER TRANSPLANTATION FOR FACTOR VII DEFICIENCY IN A 6-MONTH-OLD CHILD-THROMBOELASTOGRAPHY-GUIDED INTRA-OPERATIVE REPLACEMENT OF RECOMBINANT FACTOR VIIa.
A case of heterozygous factor VII deficiency in pregnancy.
A case of intracranial hemorrhage in a neonate with congenital factor VII deficiency.
A case presenting concurrence of Marfan syndrome, Basedow's disease and Arg353Gln polymorphism-related factor VII deficiency.
A clinical evaluation of automated chromogenic tests as substitutes for conventional prothrombin time and activated partial thromboplastin time tests.
A coagulation factor VII deficiency protects against acute inflammatory responses in mice.
A Comparison Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Congenital Factor VII Deficiency.
A comprehensive review of rFVIIa use in a tertiary care pediatric center.
A forgotten or minimized head trauma, rather than a mild FVII deficiency, is the most likely cause of a subdural hematoma.
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
A Neonate with Acquired Factor VII Deficiency Successfully Managed with Immunomodulatory Therapy.
A new mutation in the HNF4 binding region of the factor VII promoter in a patient with severe factor VII deficiency.
A new perspective on perioperative coagulation management in a patient with congenital factor VII deficiency: A case report.
A new report of FVII-inhibitor in a patient suffering from severe congenital FVII deficiency.
A NlaIII polymorphism within the human factor VII gene.
A novel factor X mutation Cys81 by Arg and a reported factor VII polymorphism Arg353 replaced by Gln co-occured in a patient.
A novel gene insertion combined with a missense mutation causing factor VII deficiency in two unrelated Chinese families.
A novel homozygous missense mutation in the factor VII gene of severe factor VII deficiency in a newborn baby.
A novel homozygous missense mutation in the factor VII gene of severe factor VII deficiency in a pedigree: a description of two cases.
A novel missense mutation close to the charge-stabilizing system in a patient with congenital factor VII deficiency.
A novel missense mutation responsible for factor VII deficiency in research Beagle colonies.
A Novel Presentation of Metaphyseal Chondrodysplasia, Schmid Type with Factor VII Deficiency.
A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation.
A rare case of Glanzmann's thrombasthenia and factor VII deficiency due to a combination of pathogenic and non-pathogenic gene variants.
A Rare Case Report of Multiple Intracranial Aneurysms with Factor VII Deficiency.
A rare combination: congenital factor VII deficiency with Chiari malformation.
A rare inherited coagulation disorder: combined homozygous factor VII and factor X deficiency.
A Retrospective Analysis of Clinical and Laboratory Data of Patients with Factor VII Deficiency: A Single Centre Experience.
A review of long-term prophylaxis in the rare inherited coagulation factor deficiencies.
A self-controlled comparative clinical trial to explore the effectiveness of three topical hemostatic agents for stopping severe epistaxis in pediatrics with inherited coagulopathies.
A syndrome of factor VII deficiency and abnormal platelet release reaction.
A Thr359Met mutation in factor VII of a patient with a hereditary deficiency causes defective secretion of the molecule.
Abnormalities in liver function and coagulation profile following the Fontan procedure.
Acquired bleeding disorder in a patient with congenital factor VII deficiency.
Acquired Factor VII deficiency - a rare but important consideration.
Acquired factor VII deficiency associated with acute myeloid leukemia.
Acquired factor VII deficiency associated with aplastic anaemia: correction with bone marrow transplantation.
Acquired Factor VII Deficiency Associated with Bronchogenic Carcinoma: A Case Report.
Acquired factor VII deficiency associated with pleural liposarcoma.
Acquired factor VII deficiency associated with Wilms tumor.
Acquired factor VII deficiency causing severe bleeding disorder secondary to AL amyloidosis of the liver.
Acquired factor VII deficiency following FOLFOX in a patient with colorectal cancer who was also DPD deficient.
Acquired Factor VII Deficiency in Association with Pyelonephritis.
Acquired factor VII deficiency in hematopoietic stem cell transplant recipients.
Acquired isolated factor VII deficiency associated with severe bleeding and successful treatment with recombinant FVIIa (NovoSeven).
Acquired isolated factor VII deficiency during sepsis.
Acquired Isolated FVII Deficiency: An Underestimated and Potentially Important Laboratory Finding.
Activated factor IX-antithrombin III complexes in human blood: quantification by an enzyme-linked differential antibody immunoassay and determination of the in vivo half-life.
Activated FVII levels in factor VII Padua (Arg304Gln) coagulation disorder and in true factor VII deficiency: a study in homozygotes and heterozygotes.
Activation of Endoplasmic Reticulum Stress and Unfolded Protein Response in Congenital Factor VII Deficiency.
Acute Myelogenous Leukemia With Trisomy 8 and Concomitant Acquired Factor VII Deficiency.
Age estimates of ancestral mutations causing factor VII deficiency and Dubin-Johnson syndrome in Iranian and Moroccan Jews are consistent with ancient Jewish migrations.
Ala244Val is a common, probably ancient mutation causing factor VII deficiency in Moroccan and Iranian Jews.
An immunological investigation of hemophilia B with a tentative classification of the disease into five variants.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
An overview of inherited factor VII deficiency.
An unusual complication of ice skating and the emergence of a previously undiagnosed bleeding disorder.
Anaesthetic management of a parturient with factor VII deficiency and sepsis.
Analysis of biological phenotypes from 42 patients with inherited factor VII deficiency: can biological tests predict the bleeding risk?
Analysis of Phenotype and Genotypein an Inherited Coagulation Factor VII Deficiency Pedigree.
Analysis of the genotypes and phenotypes of 37 unrelated patients with inherited factor VII deficiency.
Anesthetic management of a patient with factor VII deficiency undergoing laparoscopic colectomy: a case report.
Another patient with a congenital hemorrhagic disorder intermediate between factor X and factor VII deficiency.
Anterior segment dysgenesis in a child with factor VII deficiency.
Anti- and procoagulant activities in factor VII-deficient subjects.
Anticoagulation of a patient with hypertrophic cardiomyopathy and factor VII deficiency.
Anticoagulation Therapy Considerations in Factor VII Deficiency.
Aortic valve and coronary artery bypass surgery in a patient with factor VII deficiency.
Application of radioisotope synovectomy in the ankle joint in a child with congenital factor VII deficiency.
Arg 304 Gln (FVII Padua) and Ala 294 Val mutations are equally present in patients with FVII deficiency and thrombosis.
Arthropathies in factor VII deficiency: a case report.
Arthropathy and surgery in congenital factor VII deficiency.
Assessing efficacy and therapeutic claims in emerging indications for recombinant factor VIIa: regulatory perspectives.
Associated prothrombotic conditions are probably responsible for the occurrence of thrombosis in almost all patients with congenital FVII deficiency. Critical review of the literature.
Asymptomatic factor VII deficiency in African Americans.
Asymptomatic factor VII deficiency: gene analysis and structure-function relationships.
Asymptomatic intracranial hemorrhage in a newborn with congenital factor VII deficiency and successful treatment with recombinant activated factor VII.
Atherosclerosis and coronary bypass surgery in hereditary factor VII deficiency.
Automated synthetic substrate assays for coagulopathies of dogs.
Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.
Avoiding Cardiovascular Collapse: Pediatric Cutaneous Mastocytosis and Anesthetic Challenges.
Bilateral Subdural Hematomas in an Adult With Hereditary Factor VII Deficiency: A Complication of Sit-ups and Inversion?
Bilateral subdural hematomas, an unusual vaso-occlusive event and prolonged prothrombin time in a 58-year-old victim of an armed robbery.
Biochemical, molecular and clinical aspects of coagulation factor VII and its role in hemostasis and thrombosis.
Bleeding Gastric Heterotopic Polyp in the Duodenum of a Teenager with Severe Factor VII Deficiency.
Bleeding manifestations in heterozygotes with congenital FVII deficiency: a comparison with unaffected family members during a long observation period.
Bleeding Prophylaxis in a Child With Cleft Palate and Factor VII Deficiency: A Case Report.
Bleeding symptoms at disease presentation and prediction of ensuing bleeding in inherited FVII deficiency.
Bleeding symptoms in heterozygous carriers of inherited coagulation disorders in southern Iran.
Bloody tears due to congenital factor VII deficiency.
Canine factor VII deficiency: lessons learned in applying methods-based laboratory proficiency testing.
Canine specific ELISA for coagulation factor VII.
Cardiac surgery with extracorporeal circulation in severe factor VII deficiency.
Cardiac Surgery Without Blood Products in a Jehovah's Witness Child With Factor VII Deficiency.
Carriers of factor VII deficiency are not always asymptomatic.
Case report of factor VII deficiency.
Case Report: A 70-Year-Old Man with Undiagnosed Factor VII Deficiency Presented with Acute Ischemic Stroke.
Case Report: Factor VII deficiency in an obstetrical patient.
Cerebral Venous Sinus Thrombosis in a Patient with Undiagnosed Factor VII Deficiency.
Change of coagulation after NovoSeven® use for bleeding during cardiac surgery.
Changes in haemostasis and thrombosis associated with thyroid disease: Presentation of 2 cases.
Characterisation of a large complex intragenic re-arrangement in the FVII gene (F7) avoiding misdiagnosis in inherited factor VII deficiency.
Characterization of a Cys329Gly mutation causing hereditary factor VII deficiency.
Characterization of mild coagulation factor VII deficiency: activity and clearance of the Arg315Trp and Arg315Lys variants in the Cys310-Cys329 loop (c170s).
Characterization of mutations causing factor VII deficiency in 61 unrelated Israeli patients.
Characterization of thrombin generation potential of leukemic and solid tumor cells by the calibrated automated thrombography.
Characterization of two novel splice site mutations in human factor VII gene causing severe plasma factor VII deficiency and bleeding diathesis.
Christmas disease associated with factor VII deficiency; case report with family survey.
Clinical and laboratory features of 178 children with recurrent epistaxis.
Clinical and Laboratory Findings in Jewish and Bedouin Patients in Southern Israel Who Were Diagnosed with Factor VII Deficiency.
CLINICAL ASPECTS OF CONGENITAL FACTOR VII DEFICIENCY.
Clinical audit of inherited bleeding disorders in a developing country.
Clinical efficacy and recovery levels of recombinant FVIIa (NovoSeven) in the treatment of intracranial haemorrhage in severe neonatal FVII deficiency.
Clinical experience with activated factor VII: focus on safety aspects.
Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings.
Clinical management of thrombosis in inherited factor VII deficiency: a description of two cases.
Clinical manifestations in 28 Italian and Iranian patients with severe factor VII deficiency.
Clinical manifestations, management, and molecular genetics in congenital factor VII deficiency: the International Registry on Congenital Factor VII Deficiency (IRF7)
Clinical phenotypes and factor VII genotype in congenital factor VII deficiency.
Clinical picture and management of congenital factor VII deficiency.
Clinical picture and treatment strategies in factor VII deficiency.
Clinical pictures and prevalence of factor VII deficiency in Northeastern of Iran.
Clinical problems and surgical interventions in inherited factor VII deficiency.
Clinical study of recovery and half-life of vapor-heated factor VII concentrate.
Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the european network of rare bleeding disorders.
Coagulation factor VII Gln100 --> Arg. Amino acid substitution at the epidermal growth factor 2-protease domain interface results in severely reduced tissue factor binding and procoagulant function.
Coagulation studies in patients with trisomy 8 syndrome.
Coexistence of Factor VII Deficiency and Hereditary Spastic Paraplegia in Two Siblings.
Coinheritance of Factor V (FV) Leiden enhances thrombin formation and is associated with a mild bleeding phenotype in patients homozygous for the FVII 9726+5G>A (FVII Lazio) mutation.
Color vision disturbances secondary to oral tranexamic acid.
Combined congenital dysfibrinogenemia and factor VII deficiency from mutations in the FGB and F7 genes.
Combined factor V and factor VII deficiency due to an independent segregation of the two defects.
Combined factor V and factor VII deficiency. Report of a case with a record on combined defects and considerations on the relevance of partial deficiency of coagulation factors.
Combined factor VII and factor VIII deficiency due to a casual association of heterozygosis for factor VII deficiency and hemophilia A.
Combined factor VII/protein C deficiency results in intrauterine coagulopathy in mice.
Combined mild PTC (plasma thromboplastin component) and factor VII deficiencies.
Comparative incidence of thrombosis in reported cases of deficiencies of factors of the contact phase of blood coagulation.
Complexity of the genetic contribution to factor VII deficiency in two Spanish families: clinical and biological implications.
Compound heterozygous mutations (p.Leu13Pro and p.Tyr294*) associated with factor VII deficiency cause impaired secretion through ineffective translocation and extensive intracellular degradation of factor VII.
Compound heterozygous mutations in severe factor VII deficiency including a novel nonsense mutation.
Compound Heterozygous Mutations in the F7 Gene in 2 Unrelated Families With Congenital Factor VII Deficiency.
Congenital Combined Bleeding Disorders, a Comprehensive Study of a Large Number of Iranian Patients.
Congenital combined defects of factor VII: a critical review.
Congenital deficiency of factor VII in subarachnoid hemorrhage.
Congenital deficiency of factor VII.
Congenital factor V deficiency: comparison of the severity of clinical presentations among patients with rare bleeding disorders.
Congenital factor VII abnormality discovered in an infant at a routine checkup.
Congenital factor VII deficiency and cerebrovascular stroke.
Congenital factor VII deficiency complicated with hemoperitoneum and intracranial hemorrhage: report of a case.
Congenital factor VII deficiency in a patient with an abdominal aortic aneurysm.
Congenital Factor VII Deficiency in Association With Bicuspid Aortic Valve and Multicystic Dysplastic Kidney Disease in a Child.
Congenital Factor VII Deficiency in Children at Tertiary Health Care Facility in Pakistan.
Congenital factor VII deficiency in Iraqi children (Single Centre Experience).
Congenital factor VII deficiency presenting as delayed bleeding following dental extraction. A review of the role of factor VII in coagulation.
Congenital factor VII deficiency presenting as iron deficiency anaemia--Case report.
Congenital factor VII deficiency presenting first time as isolated recurrent hematuria at late age.
Congenital factor VII deficiency with cerebral haemorrhage treated with prothrombin concentrate.
Congenital factor VII deficiency with normal Stuart activity: clinical, genetic and experimental observations.
Congenital factor VII deficiency.
Congenital factor VII deficiency. A case report.
Congenital factor VII deficiency. A report of four new cases.
Congenital factor VII deficiency. Clinical and laboratory characteristics of a newly discovered kindred.
Congenital factor VII deficiency. Two cases in children of cousins.
Congenital factor VII deficiency: a case report.
Congenital factor VII deficiency: haematological and genetic aspects.
Congenital factor VII deficiency: Multidisciplinary approach is the key to successful perioperative outcome.
Congenital factor VII deficiency: therapy with recombinant activated factor VII -- a critical appraisal.
Congenital factor VII deficiency; a review with a report of a case in an Indian infant.
Congenital factor XI and factor VII deficiencies assure an apparent opposite protection against arterial or venous thrombosis: An intriguing observation.
Congenital FVII Deficiency and Pulmonary Embolism : A Critical Appraisal of All Reported Cases.
Congenital FVII deficiency and thrombotic events after replacement therapy.
Congenital FX deficiency combined with other clotting defects or with other abnormalities: a critical evaluation of the literature.
Considerations on a Tentative Classification of FVII Deficiency Suited for Practical Clinical Purposes.
Constrictive pericarditis in a patient with inherited factor VII deficiency.
Continuous infusion of human prothrombin complex in a patient with congenital factor VII deficiency undergoing laparoscopic cholecystectomy: A case report from China.
Continuous infusion of recombinant activated factor VII during caesarean section delivery in a patient with congenital factor VII deficiency.
Continuous infusion of recombinant activated factor VII for bleeding control after lobectomy in a patient with inherited factor VII deficiency.
Continuous infusion of recombinant activated factor VII: a review of data in congenital hemophilia with inhibitors and congenital factor VII deficiency.
Continuous infusion of recombinant factor VIIa for surgery in patients with deficiency of factor VII.
Coronary artery stenosis treatment in aging patients with inherited Factor VII deficiency: Where do we stand?
Current status of hemophilia patients and recombinant coagulation factor concentrates in Japan.
Decreasing the Need for Transfusion: Infant Cardiac Surgery Using Hemodilution and Recombinant Factor VIIa.
Deep vein thrombosis and pulmonary embolism in congenital factor VII deficiency.
Description of breed ancestry and genetic health traits in arctic sled dog breeds.
Descriptive epidemiology of hemophilia and other coagulation disorders in mansoura, egypt: retrospective analysis.
Detecting coagulopathy in pediatric patients with post-tonsillectomy hemorrhage.
Detection of factor X activation in humans.
Detection of two missense mutations and characterization of a repeat polymorphism in the factor VII gene (F7).
Determinants of coagulation activation in humans.
Determinants of plasma factor VIIa levels in humans.
Development of a subdural vein thrombosis following aggressive factor VII replacement for postnatal intracranial haemorrhage in a homozygous factor VII-deficient infant.
Diagnosis and treatment discussion of congenital factor VII deficiency in pregnancy: A case report.
Diagnosis and treatment of a patient with gallstone ileus.
Diagnosis, clinical manifestations and management of rare bleeding disorders in Iran.
Differential functional readthrough over homozygous nonsense mutations contributes to the bleeding phenotype in coagulation factor VII deficiency.
Direct oral anticoagulants for atrial fibrillation in patients with congenital factor VII deficiency.
Direct oral anticoagulants in factor VII deficiency patient.
Discrepancies in FVII:C levels depending on the thromboplastin: about a case.
Discrepant ratios of arterial vs. venous thrombosis in hemophilias A and B as compared to FVII deficiency.
Disorders of menstruation and their effect on the quality of life in women with congenital factor VII deficiency.
Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
Dosing factor VIIa (recombinant) in nonhemophiliac patients with bleeding after cardiac surgery.
Double heterozygous mutations Gln100Leu and His348Gln of the F7 gene in a patient with factor VII deficiency.
Effectiveness of recombinant activated factor VII (rFVII a) for controlling intractable postpartum bleeding: report of two cases and literature review.
Electroimmunoassay of factor VII antigen.
Elevated prothrombin time on routine preoperative laboratory results in a healthy infant undergoing craniosynostosis repair: Diagnosis and perioperative management of congenital factor VII deficiency.
Elimination of hepatitis C virus infection in patients with haemophilia in Belgium: A single-centre experience.
Entering new areas in known fields: recombinant fusion protein linking recombinant factor VIIa with recombinant albumin (rVIIa-FP) - advancing the journey.
Eptacog alfa activated: a recombinant product to treat rare congenital bleeding disorders.
Ethnic Differences in Coagulation Factor Abnormalities After the Fontan Procedure.
Evaluation of a new chromogenic assay for factor VII and its application in patients on oral anticoagulant treatment.
Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study).
Evaluation of Bleeding Phenotype of Inherited Factor VII Deficiency in Children With a Bleeding Assessment Tool and Global Assays.
Evaluation of the Antihemostatic and Antithrombotic Effects of Lowering Coagulation Factor VII Levels in a Non-human Primate.
Evidence for the presence of tissue factor activity on subendothelium.
Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds.
Exclusion of the first EGF domain of factor VII by a splice site mutation causes lethal factor VII deficiency.
Expanded carrier screening and preimplantation genetic diagnosis in a couple who delivered a baby affected with congenital factor VII deficiency.
Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
F7 gene variants modulate protein levels in a large cohort of patients with factor VII deficiency. Results from a genotype-phenotype study.
Factor IX is activated in vivo by the tissue factor mechanism.
Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo.
Factor VII and haemostasis.
Factor VII antibody-neutralizing material in hereditary and acquired factor VII deficiency.
Factor VII central. A novel mutation in the catalytic domain that reduces tissue factor binding, impairs activation by factor Xa, and abolishes amidolytic and coagulant activity.
Factor VII congenital deficiency. Clinical picture and classification of the variants.
Factor VII deficiency - an enigma; clinicohematological profile in 12 cases.
Factor VII deficiency and a copper metabolism disorder in a patient with Klippel-Trenaunay syndrome.
Factor VII deficiency and developmental abnormalities in a patient with partial monosomy of 13q and trisomy of 16p: case report and review of the literature.
Factor VII deficiency and its treatment in delivery with recombinant factor VII.
Factor VII deficiency and pregnancy.
Factor VII deficiency and pregnancy: a case report and review of literature.
Factor VII deficiency and surgery. Is preoperative replacement therapy necessary?
Factor VII deficiency and the FVII mutation database.
Factor VII deficiency associated with nephrotic syndrome.
Factor VII deficiency associated with valproate treatment.
Factor VII deficiency caused by a structural variant N57D of the first epidermal growth factor domain.
Factor VII deficiency detected in pregnancy: a case report.
Factor VII deficiency diagnosed after minor genital trauma.
Factor VII Deficiency due to Compound Heterozygosity for Leu-48Pro Mutation and a Novel Pro260Leu Mutation.
Factor VII deficiency first observed at preoperative routine clotting test.
Factor VII deficiency impairs cutaneous wound healing in mice.
Factor VII deficiency in a mixed breed dog.
Factor VII deficiency in a patient with retinal arteriolar tortuosity syndrome.
Factor VII deficiency in an Alaskan malamute.
Factor VII deficiency in an East Indian family.
Factor VII deficiency in beagle dog plasma and its use in the assay of human factor VII.
Factor VII deficiency in major artery occlusion stroke.
Factor VII Deficiency in Patients Receiving Chronic Packed Cell Transfusions.
Factor VII deficiency in pregnancy and delivery: a case report.
Factor VII deficiency in pregnancy treated with recombinant factor VIIa.
Factor VII deficiency presenting as a possible child abuse.
Factor VII deficiency rescues the intrauterine lethality in mice associated with a tissue factor pathway inhibitor deficit.
Factor VII Deficiency Resulting in Acute Hemorrhage in Orthognathic Surgery: A Case Report.
Factor VII deficiency with intracranial hemorrhage: a case report.
Factor VII Deficiency, Masked by Warfarin Therapy, as a Cause of Bleeding After Cardiovascular Intervention.
Factor VII deficiency.
Factor VII Deficiency.
Factor VII deficiency.
Factor VII Deficiency.
Factor VII deficiency: a double heterozygote of an Arg402Stop with a deletion of the C-terminal five amino acids and a Thr359Met.
Factor VII deficiency: a novel missense variant and genotype-phenotype correlation in patients from Southern Italy.
Factor VII Deficiency: A Rare Case Report.
Factor VII Deficiency: A Single-Center Experience.
Factor VII deficiency: clinical manifestation of 717 subjects from Europe and Latin America with mutations in the factor 7 gene.
Factor VII Deficiency: Clinical Phenotype, Genotype and Therapy.
Factor VII deficiency: defining the clinical picture and optimizing therapeutic options.
Factor VII deficiency: do all need replacement for cardiac surgery?
Factor VII deficiency: immunological characterization of genetic variants and detection of carriers.
Factor VII deficiency: Unveiling the cellular and molecular mechanisms underlying three model alterations of the enzyme catalytic domain.
Factor VII Gene Defects: Review of Functional Studies and Their Clinical Implications
Factor VII gene intronic mutation in a lethal factor VII deficiency: effects on splice-site selection.
Factor VII half-life after transfusion of a steam-treated prothrombin complex concentrate in a patient with homozygous factor VII deficiency.
Factor VII Mie: homozygous asymptomatic type I deficiency caused by an amino acid substitution of His (CAC) for Arg(247) (CGC) in the catalytic domain.
Factor VII Morioka (FVII L-26P): a homozygous missense mutation in the signal sequence identified in a patient with factor VII deficiency.
Factor VII Padua 2: another factor VII abnormality with defective ox brain thromboplastin activation and a complex hereditary pattern.
Factor VII R110C: a novel missense mutation (Arg110Cys) in the second epidermal growth factor-like domain causing factor VII deficiency in members of a Japanese family.
Factor VII Toyama (Thr 359 Met): a homozygous missense mutation causing severe type I deficiency.
Factor VII verona coagulation disorder: double heterozygosis with an abnormal factor VII and heterozygous factor VII deficiency.
Factor VIIa for correction of traumatic coagulopathy.
Factor VIIa replacement therapy in factor VII deficiency.
Factor VIIa-antithrombin complexes in patients with arterial and venous thrombosis.
Familial factor VII deficiency with foetal and neonatal fatal cerebral haemorrhage associated with homozygosis to Gly180Arg mutation.
Familial haemophilia and factor VII deficiency.
Fatal intracranial hemorrhage in a newborn with factor VII deficiency.
First living-related liver transplant to cure factor VII deficiency.
First manifestation of a hereditary homozygous factor VII deficiency in a 3-year-old girl suspected as purpura fulminans.
First molecular characterization of a patient with combined factor V and factor VII deficiency.
Frequencies of mild factor V, VII and X deficiencies in a Japanese population.
Frequency of five disease-causing genetic mutations in a large mixed-breed dog population (2011-2012).
Functional and Molecular Characterization of C91S Mutation in the Second Epidermal Growth Factor-Like Domain of Factor VII.
Gene targeting of tissue factor, factor X, and factor VII in mice: their involvement in embryonic development.
Gene Therapy for Inherited Bleeding Disorders.
Generation of a human induced pluripotent stem cell line, YCMi002-A, from a Factor VII deficiency patient carrying F7 mutations.
Generation of genetically-altered mice producing very low levels of coagulation factorVII.
Genetic deficiency of factor VII and hemorrhagic diathesis. A case report and literature review.
Genetic diagnosis of haemophilia and other inherited bleeding disorders.
Genetic Panel Screening of Nearly 100 Mutations Reveals New Insights into the Breed Distribution of Risk Variants for Canine Hereditary Disorders.
Genotype and phenotype correlation in intracranial hemorrhage in neonatal factor VII deficiency among Thai children.
Genotype and phenotype relationships in 10 Pakistani unrelated patients with inherited factor VII deficiency.
Genotypic heterogeneity may explain phenotypic variations in inherited factor VII deficiency.
Glomerulitis and factor vii deficiency in Familial Mediterranean fever.
Granulomatous Pneumocystis carinii pneumonia in a non-AIDS patient: an atypical presentation.
HAART and Mycobacterium avium complex in an HIV infected patient with severe factor VII deficiency.
Haemoperitoneum associated with ovulation in women with bleeding disorders: the case for conservative management and the role of the contraceptive pill.
Hematology of experimental acute Sarcocystis bovicanis infection in calves. II. Serum biochemistry and hemostasis studies.
Hemipelvectomy after severe pelvic injury in Factor VII deficiency toddler.
Hemophagocytic lymphohistiocytosis and congenital factor VII deficiency: a case report.
Hemophilia A and concurrent factor VII deficiency. Studies of a patient with complicating cardiac tamponade.
Hemophilia B with associated factor VII deficiency: a distinct variant of hemophilia B with low factor VII activity and normal factor VII antigen.
Hemorrhagic diathesis due to factor VII deficiency.
Hemorrhagic stroke in a child with protein S and factor VII deficiencies.
Hepatocyte transplantation for inherited factor VII deficiency.
Hepatocyte transplantation for liver-based metabolic disorders.
Hereditary bleeding disorders in Riyadh, Saudi Arabia.
Hereditary factor VII deficiency and increased contact activation time.
Hereditary factor VII deficiency in a Chinese family.
Hereditary Factor VII deficiency in newborns.
Hereditary factor VII deficiency in pregnancy: peripartum treatment with factor VII concentrate.
Hereditary factor VII deficiency in the Alaskan Klee Kai dog.
HEREDITARY FACTOR VII DEFICIENCY IN THE ASIAN ELEPHANT (ELEPHAS MAXIMUS) CAUSED BY A F7 MISSENSE MUTATION.
Hereditary factor VII deficiency in two siblings: two different clinical presentation.
Hereditary factor VII deficiency: heterogeneity defined by combined functional and immunochemical analysis.
Hereditary factor VII deficiency: report of a case of intracranial hemorrhage.
Heterozygous congenital Factor VII deficiency with the 9729del4 mutation, associated with severe spontaneous intracranial bleeding in an adolescent male.
Heterozygous factor VII deficiency and severe hemophilia A in the same kindred.
Hip surgery in a patient with severe factor VII deficiency.
Hobby-induced factor VII deficiency.
Home treatment for patients with congenital bleeding disorders in a developing country.
Homozygous 2bp deletion in the human factor VII gene: a non-lethal mutation that is associated with a complete absence of circulating factor VII.
Homozygous congenital factor VII deficiency with a novel mutation, associated with severe spontaneous intracranial bleeding in a neonate.
Homozygous FVII deficiencies with different reactivity towards tissue thromboplastins of different origin.
How to evaluate phenotype-genotype relationship in rare coagulation haemorrhagic disorders: examples from FVII deficiency.
Human factor VII deficiency caused by S339C mutation located adjacent to the specificity pocket of the catalytic domain.
Identification of genetic defects underlying FVII deficiency in 10 patients belonging to eight unrelated families of the North provinces from Tunisia.
Identification of two novel mutations in three children with congenital factor VII deficiency.
Impact of Telemedicine Tools on Record Keeping and Compliance in Haemophilia Care.
Impaired secretion of carboxyl-terminal truncated factor VII due to an F7 nonsense mutation associated with FVII deficiency.
In vivo studies of the role of factor VII in hemostasis.
Inadvertent propagation of factor VII deficiency in a canine mucopolysaccharidosis type I research breeding colony.
Incidence of hereditary bleeding disorders in Bradford, UK: variation with ethnic group.
Increase in the risk of ST elevation myocardial infarction is associated with homocysteine level.
Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect.
Influence of factor V HR2 on thrombin generation and clinical manifestation in rare bleeding disorders.
Inherited bleeding disorders in Indian women with menorrhagia.
Inherited bleeding disorders in the Eastern Province of Saudi Arabia.
Inherited factor VII deficiency and surgery: clinical data are the best criteria to predict the risk of bleeding.
Inherited factor VII deficiency: genetics and molecular pathology.
Inherited factor VII deficiency: identification of two novel mutations (A191V and T239P) in the catalytic domain.
Inherited factor VII deficiency: molecular genetics and pathophysiology.
Inhibitor development after liver transplantation in congenital factor VII deficiency.
Inhibitor development in patients with congenital factor VII deficiency, a study on 50 Iranian patients.
Inhibitor in Congenital Factor VII Deficiency; a Rare but Serious Therapeutic Challenge-A Systematic Literature Review.
Inhibitor to factor VII in severe factor VII deficiency: detection and course of the inhibitory response.
Inhibitors against rFVIIa in patients with severe congenital FVII deficiency: A case series.
Inhibitors to factor VII in congenital factor VII deficiency.
Intracellular evaluation of ER targeting elucidates a mild form of inherited coagulation deficiency.
Intracellular readthrough of nonsense mutations by aminoglycosides in coagulation factor VII.
Intracranial bleeding following soccer-related head trauma in a young student with occult factor VII deficiency.
Intracranial hemorrhage in congenital factor VII deficiency.
Intraoperative use of recombinant activated factor VII (rFVIIa).
Invasive EEG-electrodes in presurgical evaluation of epilepsies: Systematic analysis of implantation-, video-EEG-monitoring- and explantation-related complications, and review of literature.
Invasive procedures and minor surgery in factor VII deficiency.
In vitro expression of mutant factor VII proteins and characterization of their clinical significance.
Is prophylaxis required for delivery in women with factor VII deficiency?
Is the coexistence of thromboembolic events and Factor VII deficiency fortuitous?
Ischemic stroke in a patient with moderate to severe inherited factor VII deficiency.
Ischemic strokes in congenital bleeding disorders: comparison with myocardial infarction and other acute coronary syndromes.
Isolated acquired factor VII deficiency: review of the literature.
Isolated factor VII deficiency diagnosed after a life-threatening brain haemorrhage.
Isolation of hepatocytes from livers from non-heart-beating donors for cell transplantation.
Isotypic analysis of antibodies against activated Factor VII in patients with Factor VII deficiency using the x-MAP technology.
Japanese collaborative study to assess inter-laboratory variation in factor VII activity assays.
Japanese family with congenital factor VII deficiency.
Kidney Transplant in a Patient With Factor VII Deficiency: Case Report.
Laboratory evaluation of hemorrhagic coagulopathies in small animal practice.
Lack of bleeding in patients with severe factor VII deficiency.
Lethal factor VII deficiency due to novel mutations in the F7 promoter: Functional analysis reveals disruption of HNF4 binding site.
Life-threatening bleeding in a case of autoantibody-induced factor VII deficiency.
Life-threatening bleeding in a patient with a lupus inhibitor and probable acquired factor VII deficiency.
Life-threatening bleeding in factor VII deficiency: the role of prenatal diagnosis and primary prophylaxis.
Life-threatening menorrhagia secondary to Factor VII deficiency and leiomyomata.
Liver after hepatocyte transplantation for liver-based metabolic disorders in children.
Liver cell transplantation.
Liver transplant for congenital factor VII deficiency.
Liver transplantation for factor VII deficiency.
Liver transplantation for treatment of severe S-adenosylhomocysteine hydrolase deficiency.
Long-term follow-up of prophylaxis with recombinant activated factor VII in patients with congenital factor VII deficiency.
Long-term FVII substitution in a preterm infant with severe gastrointestinal bleeding and FVII deficiency due to a homozygous donor splice mutation IVS4+1G-->A.
Long-term prophylaxis in severe factor VII deficiency.
Long-term successful percutaneous coronary intervention in factor VII deficiency.
Low endoscopy bleeding risk in patients with congenital bleeding disorders.
Lower extremity compartment syndrome in the setting of iliofemoral deep vein thrombosis, phlegmasia cerulea dolens and factor VII deficiency.
Lower extremity salvage complicated by recurrent microvascular thrombosis in a patient with congenital factor VII deficiency.
Major differences in bleeding symptoms between factor VII deficiency and hemophilia B.
Management of a patient with atrial fibrillation and factor VII deficiency.
Management of a patient with Factor VII deficiency.
Management of concomitant factor VII deficiency and Factor V Leiden mutation.
Management of intracranial haemorrhage in a newborn with inherited factor VII deficiency with the use of rFVIIa aliquots.
Management of intracranial surgery for refractory epilepsy in severe factor VII deficiency: choosing the optimal dosing regimen.
Management of Kidney Transplantation in a Factor VII-Deficient Patient: Case Report.
Management of Labour and Delivery in a Patient With Acquired Factor VII Deficiency With Inhibitor: A Case Report.
Management of Pregnancy in a Chilean Patient with Congenital Deficiency of Factor VII and Glanzmann's Thrombasthenia Variant.
Management of pregnancy in women with factor VII deficiency: A case series.
Management of Surgical Third Lower Molar Extraction and Postoperative Progress in Patients With Factor VII Deficiency: A Clinical Protocol and Focus on This Rare Pathologic Entity.
Managing incidentally diagnosed isolated factor VII deficiency perioperatively: a brief expert consensus report.
Measurement of the procoagulant activity of factor VII in patients with liver cirrhosis and normal prothrombin activity: evaluation of the bleeding risk.
Mechanism underlying factor VII deficiency in Jewish populations with the Ala244Val mutation.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Menorrhagia caused by severe hereditary factor VII deficiency. Case 1.
Migraine, cortical blindness, multiple cerebral infarctions and hypocoagulopathy in celiac disease.
Mild factor VII deficiency due to heterozygosis is not associated with a bleeding tendency.
Mitral valve surgery in severe congenital factor VII deficiency.
Models of blood coagulation.
Modulation of factor VII levels by intron 7 polymorphisms: population and in vitro studies.
Molecular analysis in a patient with severe factor VII deficiency and an inhibitor: report of a novel mutation (S103G).
Molecular analysis of factor VII deficiency in Italy: a frequent mutation (FVII Lazio) in a repeated intronic region.
Molecular analysis of Polish patients with factor VII deficiency.
Molecular analysis of the genotype-phenotype relationship in factor VII deficiency.
Molecular and clinical aspects of factor VII deficiency.
Molecular basis of hereditary factor VII deficiency in India: five novel mutations including a double missense mutation (Ala191Glu; Trp364Cys) in 11 unrelated patients.
Molecular biology and clinical manifestation of hereditary factor VII deficiency.
Molecular characterisation and three-dimensional structural analysis of mutations in 21 unrelated families with inherited factor VII deficiency.
Molecular characterization of four novel mutations causing factor VII deficiency.
Molecular Characterization of Iranian Patients with Inherited Coagulation Factor VII Deficiency.
Molecular defects in CRM+ factor VII deficiencies: modelling of missense mutations in the catalytic domain of FVII.
Molecular determination of the breakpoints of a 161 556 bp deletion at chromosome 13q34 that presented as severe factor VII deficiency in a neonate.
Molecular mechanism of dysfunctional factor VII associated with the homozygous missense mutation 331Gly to Ser.
Molecular mechanisms of FVII deficiency: expression of mutations clustered in the IVS7 donor splice site of factor VII gene.
Molecular variant of factor VII.
Monitoring of hemostatic status in four patients being treated with recombinant factor VIIa.
Multiple cerebral aneurysms in factor VII deficiency.
Multiple congenital coagulopathies co-expressed with Von Willebrand's disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature.
Multiple extractions in a patient with factor VII deficiency.
Multiple intracranial hemorrhages at the time of a transiently prolonged activated partial thromboplastin time in an infant with congenital factor VII deficiency.
Mutation in the factor VII hepatocyte nuclear factor 4?-binding site contributes to factor VII deficiency.
Mutation pattern in clinically asymptomatic coagulation factor VII deficiency.
National survey of patients with hemophilia and other congenital bleeding disorders in Thailand.
Natural and engineered carboxy-terminal variants: decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiency.
Neonatal intracranial hemorrhage secondary to congenital factor VII deficiency: two case reports.
Newly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven(®)).
Next-generation sequencing and recombinant expression characterized aberrant splicing mechanisms and provided correction strategies in factor VII deficiency.
Novel factor VII gene mutations in six families with hereditary coagulation factor VII deficiency.
Novel IVS7+1G>T mutation of life-threatening congenital factor VII deficiency in neonates: A retrospective study in China.
Novel mutation in coagulation factor VII (Carmel mutation): Identification and characterization.
NovoSeven (recombinant factor VIIa) in centeral nervous systems bleeds.
NovoSeven as a universal haemostatic agent.
Obstetric analgesia and anaesthesia in women with inherited bleeding disorders.
Occult hemophilia as a cause of postoperative and postpartum hemorrhage. With special reference to factor VII deficiency.
Occult hepatitis B virus infection in Greek patients with congenital bleeding disorders.
Occurrence of hereditary leaky red cell syndrome and partial coagulation factor VII deficiency in a Spanish family.
Of four mutations in the factor VII gene in Tunisian patients, one novel mutation (Ser339Phe) in three unrelated families abrogates factor X activation.
Off-Label Recombinant Factor VIIa Use and Thrombosis in Children: A Multi-center Cohort Study.
Off-label use of rFVIIa in children with excessive bleeding: A consecutive study of 153 off-label uses in 139 children.
On a case of-Christmas disease associated with factor VII deficiency.
One-step chromogenic equivalent of activated partial thromboplastin time evaluated for clinical application.
Open heart surgery with factor VII deficiency.
Open-heart surgery in an infant with heterozygous factor VII deficiency.
Orbital Compartment Syndrome Following Post-Traumatic Subgaleal Hematoma.
Orthopaedic surgery in severe bleeding disorders: a low-volume, high-cost procedure.
Outcome of intracranial hemorrhage in infants with congenital factor VII deficiency.
Outcome of laparoscopic ovariohysterectomy or ovariectomy in dogs with von Willebrand disease or factor VII deficiency: 20 cases (2012-2014).
Overview of the human pharmacokinetics of recombinant activated factor VII.
Palliative open heart surgery in an infant with factor VII deficiency.
Paracetamol poisoning unmasking factor VII deficiency.
Pathogenetic role of Factor VII deficiency and thrombosis in cross-reactive material positive patients.
Pediatric cardiac intervention in a case of congenital factor VII deficiency: a challenge to overcome.
Pediatric cardiac surgery under cardiopulmonary bypass in factor VII deficiency.
Percutaneous Nephrolithotomy in Rare Bleeding Disorders: A Case Report and Review of the Literature.
Peri-operative replacement therapy with factor VII concentrate in a patient with severe factor VII deficiency.
Perioperative pharmacokinetics of factor VII concentrate during liver surgery in a patient with congenital factor VII deficiency: an individual mathematical model.
Persistent uterine and vaginal hemorrhage in a beagle with factor VII deficiency.
Persistent validity of a classification of congenital factor X defects based on clotting, chromogenic and immunological assays even in the molecular biology era.
Pharmacodynamics of recombinant activated factor VII and plasma-derived factor VII in a cohort of severe FVII deficient patients.
Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency.
Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect.
Pharmacokinetic properties of two different recombinant activated factor VII formulations.
Pharmacokinetics and pharmacodynamics of a recombinant fusion protein linking activated coagulation factor VII with human albumin (rVIIa-FP) in patients with congenital FVII deficiency.
Pharmacokinetics, pharmacodynamics and safety of recombinant canine FVIIa in a study dosing one haemophilia A and one haemostatically normal dog.
Pharmacology and clinical use of recombinant activated factor seven in neurosciences.
Phenotypic and genotypic characterization of Factor VII deficiency patients from Western India.
Phenotypic and genotypic characterization of four factor VII deficiency patients from central China.
Phenotypical variability in congenital FVII deficiency follows the ISTH-SSC severity classification guidelines: a review with illustrative examples from the clinic.
Plasma thromboplastin antecedent (Factor XI) deficiency in a black family.
Plummer-Vinson Syndrome With Concomitant Factor VII Deficiency.
Point-of-Care Thromboelastography for Intrathecal Drain Management in Patients With Coagulopathy and Thoracic Aorta Surgery: A Case Report.
Possible homozygous factor VIIR disorder associated with fibrinolytic hyperactivity.
Posterior reversible encephalopathy syndrome (PRES) in pregnancy: a diagnostic challenge to obstetricians.
Postoperative bleeding with factor VII deficiency: case report.
Potential predictors of bleeding risk in inherited factorVII deficiency. Clinical, biological and molecular criteria.
Pregnancy and oral contraceptives in congenital bleeding disorders of the vitamin K-dependent coagulation factors.
Pregnancy in women with congenital factor VII deficiency.
Prenatal diagnosis in rare bleeding disorders-An unresolved issue?
Prenatal diagnosis of severe factor VII deficiency using mutation detection and linkage analysis.
Prenatal exclusion of severe factor VII deficiency by DNA sequencing.
Prenatal exclusion of severe factor VII deficiency.
Preparation of factor VII concentrate using CNBr-activated Sepharose 4B immunoaffinity chromatography.
Prevalence of factor VII deficiency and molecular characterization of the F7 gene in Brazilian patients.
Prevalence of HIV infection in a cohort of patients with congenital coagulation defects of the prothrombin complex factors.
Preventing Surgical and Postpartum Hemorrhage in an Active Duty Patient With an Undiagnosed Coagulopathy at a Military Treatment Facility.
Prevention of bleeding and hemorrhagic complications in surgical patients with inherited factor VII deficiency.
Prevention of Bleeding Complications in Neonates With Liver Failure Undergoing Surgery Using Recombinant Factor VIIa.
Primary factor VII deficiency.
Primary prophylaxis for children with severe congenital factor VII deficiency - Clinical and laboratory assessment.
Prolongation of prothrombin time in the presence of rivaroxaban: is this the only cause?
Prophylactic effect of recombinant factor VIIa in factor VII deficient patients.
Prophylactic effect of recombinant factor VIIa with congenital factor VII deficiency.
Prophylactic therapy in a pregnant woman with severe factor VII deficiency.
Prophylactic treatment of a small child with severe factor VII deficiency using repeat dosing from a single vial of recombinant activated factor VII.
Prophylactic treatment of hereditary severe factor VII deficiency in pregnancy.
Prophylaxis and therapy with factor VII concentrate (human) immuno, vapor heated in patients with congenital factor VII deficiency: a summary of case reports.
Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER).
Prophylaxis of peripartum haemorrhage using recombinant factor VIIa (rfVIIa) in pregnant women with congenital factor VII deficiency: A case report and literature review.
Prophylaxis with recombinant-activated factor VII (rFVIIa) for minimally invasive surgery in a patient with congenital factor VII deficiency: a case report with a single-low dose of rFVIIa.
Prophylaxis with rFVIIa before third molar extraction in a patient with factor VII deficiency.
Prostate surgery in severe congenital factor VII deficiency: A case report.
Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.
Prothrombin complex concentrate for factor VII replacement in a patient undergoing left ventricular assist device implantation with factor VII deficiency.
Psychosocial Impact and Disease Management in Patients with Congenital Factor VII Deficiency.
Pulmonary embolism in a patient with mild factor VII deficiency after administration of recombinant activated factor VII during a urological procedure.
Pulmonary embolism in congenital bleeding disorders: intriguing discrepancies among different clotting factors deficiencies.
Radiographic abnormalities in coagulation factor VII deficiency.
Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias.
Rare bleeding disorders-old diseases in the era of novel options for therapy.
Rare bleeding disorders: spectrum of disease and clinical manifestations in the Pakistani population.
Rare factor VII variant inherited through genetic variant in proband's mother and another genetic variant in proband's father.
Rare inherited coagulation disorders in India.
Rare inherited coagulation disorders in young children in Oman.
Rational Use of Recombinant Factor VIIa in Clinical Practice.
Recombinant Activated Factor VII (Eptacog Alfa Activated, NovoSeven®) in Patients with Rare Congenital Bleeding Disorders. A Systematic Review on its Use in Surgical Procedures.
Recombinant activated factor VII (rFVIIa, NovoSeven).
Recombinant activated factor VII as a universal haemostatic agent.
Recombinant activated factor VII for a patient with factor VII deficiency undergoing urgent intracerebral haematoma evacuation with underlying cavernous angioma.
Recombinant activated factor VII in clinical practice: a 2014 update.
Recombinant activated factor VII in patients at high risk of bleeding.
Recombinant activated factor VII: 30 years of research and innovation.
Recombinant activated factor VII: mechanisms of action and current indications.
Recombinant coagulation factor VIIa: from the concept to clinical application in hemophilia treatment in 2000.
Recombinant Factor VIIa (Eptacog Alfa): A Review of its Use in Congenital Hemophilia with Inhibitors, Acquired Hemophilia, and Other Congenital Bleeding Disorders.
Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders.
Recombinant factor VIIa for long-term replacement therapy in patients with congenital factor VII deficiency.
Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia.
Recombinant factor VIIa for the treatment of congenital factor VII deficiency.
Recombinant factor VIIa for treatment of a child with severe factor VII deficiency and coarctation of the aorta.
Recombinant factor VIIa prophylaxis in a patient with severe congenital factor VII deficiency.
Recombinant factor VIIa treatment for asymptomatic factor VII deficient patients going through major surgery.
Recombinant Factor VIIa Use for Endoscopic Retrograde Cholangiopancreatography With Sphincterotomy in a Patient With Choledocholithiasis and Unusual Coagulopathy.
Recombinant factor VIIa: a universal hemostatic agent?
Recombinant FVIIa concentrate-associated thrombotic events in congenital bleeding disorders other than hemophilias.
Recombinant, activated factor VII for surgery in factor VII deficiency: a prospective evaluation - the surgical STER.
Rectus muscle sheath haematoma in a patient with congenital FX deficiency and in another with congenital FVII deficiency.
Recurrent Bleedings in Newborn: A Factor VII Deficiency Case Report.
Recurrent intracranial hemorrhage in an infant with congenital factor VII deficiency.
Recurrent mutations and genotype-phenotype correlations in hereditary factor VII deficiency in Korea.
Recurrent pre-retinal haemorrhages associated with coagulation factor VII deficiency.
Redistribution and hemostatic action of recombinant activated factor VII associated with platelets.
Registry of Hemophilia and other bleeding disorders in Syria.
Regulatory polymorphisms underlying complex disease traits.
Repair of abdominal aortic aneurysm in severe Factor VII deficiency.
Repeated recombinant activated factor VII administration in a patient with congenital factor VII deficiency undergoing modified radical hysterectomy: a case report.
Replacement therapy for bleeding episodes in factor VII deficiency. A prospective evaluation.
Replacement therapy in inherited factor VII deficiency: occurrence of adverse events and relation with surgery.
Residual factor VII activity and different hemorrhagic phenotypes in CRM(+) factor VII deficiencies (Gly331Ser and Gly283Ser).
Resistance to activated protein C: evaluation of three functional assays.
Response to treatment and adverse events associated with use of recombinant activated factor VII in children: a retrospective cohort study.
Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
rFVIIa administered by continuous infusion during surgery in patients with severe congenital FVII deficiency.
Robustness of factor assays following cordocentesis in the prenatal diagnosis of haemophilia and other bleeding disorders.
Role of clinical and laboratory parameters for treatment choice in patients with inherited FVII deficiency undergoing surgical procedures: evidence from the STER registry.
Role of the 2 adenine (g.11293_11294insAA) insertion polymorphism in the 3' untranslated region of the factor VII (FVII) gene: molecular characterization of a patient with severe FVII deficiency.
Second trimester antenatal diagnosis in rare coagulation factor deficiencies.
Segmental liver transplantation from non-heart beating donors-an early experience with implications for the future.
Selection of replacement therapy for patients with severe factor VII deficiency.
Sensitivities of thromboplastins to factor VII deficiency.
Sensitivity of different prothrombin time assays to factor VII deficiency in canine plasma.
Sensitivity of different thromboplastin reagents to factor VII deficiency in the blood of beagle dogs.
Serendipitous Discovery of Factor VII Deficiency and the Ensuing Dilemma.
Severe arterial thrombosis in a congenitally factor VII deficient patient.
Severe coagulation factor VII deficiency caused by a novel homozygous mutation (p. Trp284Gly) in loop 140s.
Severe congenital Factor VII deficiency associated with the 13q deletion syndrome.
Severe Congenital Factor VII Deficiency with Normal Perioperative Coagulation Profile Based on ROTEM Analysis in a Hepatectomy.
Severe deficiency of coagulation Factor VII results in spontaneous cardiac fibrosis in mice.
Severe factor VII deficiency caused by a novel mutation His348 to Gln in the catalytic domain.
Severe factor VII deficiency caused by a novel point mutation (Arg353Pro) combined with a rare Cys22Arg mutation.
Severe factor VII deficiency caused by mutations abolishing the cleavage site for activation and altering binding to tissue factor.
Severe factor VII deficiency due to a mutation disrupting a hepatocyte nuclear factor 4 binding site in the factor VII promoter.
Severe factor VII deficiency due to a mutation disrupting an Sp1 binding site in the factor VII promoter.
Severe factor VII deficiency with recurrent intracranial haemorrhages owing to double heterozygosity for a splice site mutation of an IVS4 and a novel nonsense mutation in exon 8 (Gln211-->Term).
Severe FVII deficiency caused by a new point mutation combined with a previously undetected gene deletion.
Severe menorrhagia due to factor VII deficiency successfully treated by thermal balloon endometrial ablation.
Significance and causes of abnormal preoperative coagulation test results in children.
Spectrum of factor X gene mutations in Iranian patients with congenital factor X deficiency.
Spontaneous chronic subdural hematoma in young adult: the role of missing coagulation facto.
Spontaneous hemorrhage after external ventricular drain placement in the setting of low factor VII secondary to liver cirrhosis.
Spontaneous umbilical cord haematoma and congenital factor VII deficiency.
Steps towards an effective treatment strategy in congenital factor VII deficiency.
Studies on a family with the factor VII defect.
Studies on immunological assay of vitamin K dependent factors. I. Measurement of factor VII antigen by radioimmunoassay.
Study of different factor VII deficiency variants in nine families from Spain.
Subdural Hematoma From an Acquired Factor VII Deficiency: Is It the Lupus or the Anticoagulant?
Subgaleal hematoma with delayed proptosis and corneal ulceration.
Substitution therapy of congenital factor VII deficiency at an extended operation with extracorporeal circulation.
Successful control of central nervous system bleeding in two newborns with severe factor VII deficiency using rFVIIa administered via Port-a-Cath.
Successful coronary artery bypass graft surgery in severe congenital factor VII deficiency: Perioperative treatment with factor VII concentrate.
Successful coronary artery bypass graft surgery in severe congenital factor VII deficiency: Perioperative treatment with pd-factor VII concentrate.
Successful coronary artery bypass grafting in a patient with severe FVII deficiency and minimal use of recombinant FVIIa.
Successful excision of hemorrhagic cavernous angioma in a patient with severe factor VII deficiency: perioperative treatment with factor VII concentrate.
Successful management of maternal factor VII deficiency in a cesarean section.
Successful prophylactic use of recombinant activated factor VII (rFVIIa) in a patient with congenital FVII deficiency and inhibitors to FVII.
Successful prophylaxis against intracranial hemorrhage using weekly administration of activated recombinant factor VII in a newborn with severe factor VII deficiency.
Successful prophylaxis of intracranial hemorrhage in infants with severe congenital factor VII deficiency.
Successful short-term oral surgery prophylaxis with rFVIIa in severe congenital factor VII deficiency.
Successful Splenectomy Management in a Patient With Moderate Factor VII Deficiency and Concomitant Severe Hereditary Spherocytosis.
Successful treatment of hereditary factor VII deficiency presented for the first time with epistaxis in pregnancy: a case report.
Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature.
Successful treatment of mixed-type autoimmune hemolytic anemia with rituximab in a child following liver transplantation.
Successful use of recombinant activated factor VII administered via automated bolus pump following emergency laparoscopic appendectomy in a patient with mild congenital FVII deficiency: Case report.
Successful use of recombinant FVIIa (Novoseven) in the management of pulmonary haemorrhage secondary to Aspergillus infection in a patient with leukaemia and acquired FVII deficiency.
Successful use of recombinant VIIa (Novoseven) and endometrial ablation in a patient with intractable menorrhagia secondary to FVII deficiency.
Successful use of rFVIIa for major breast surgery prophylaxis in congenital factor VII deficiency.
Successful use of rFVIIa for major breast surgery prophylaxis in congenital factor VII deficiency: a case report.
Surgery for scoliosis in congenital factor VII deficiency.
SURGERY IN PATIENTS WITH CONGENITAL FACTOR VII DEFICIENCY (CONGENITAL HYPOPROCONVERTINEMIA). EXPERIENCE WITH ONE CASE AND REVIEW OF THE LITERATURE.
Surgery in patients with congenital factor VII deficiency - a single center study.
Surgery in patients with congenital factor VII deficiency: A single center experience.
Surgical Aortic Valve Replacement in an Adult Patient With Congenital Factor VII Deficiency: A Case Report of Perioperative Coagulation Management.
Surgical interventions in childhood rare factor deficiencies: a single-center experience from Turkey.
Sustained correction of FVII deficiency in dogs using AAV-mediated expression of zymogen FVII.
Synergistic effect of factor VII gene polymorphisms causing mild factor VII deficiency in a case of severe factor X deficiency.
Synovectomy for haemophilic arthropathy: 6-21 years of follow-up in 16 patients.
Synovectomy of the elbow in a patient with factor VII deficiency (hypoconvertinemia).
Takayasu Arteritis Presenting as Renovascular Hypertension and Renal Failure in a Patient with Factor VII Deficiency.
The clinical and laboratory significance of cases of congenital FX deficiency due to defects in the Gla-domain.
The clinical significance of the lack of arterial or venous thrombosis in patients with congenital prothrombin or FX deficiency.
The clotting action of Russell viper venom. 1954.
The congenital factor VII abnormalities (dysproconvertinemias). The genetic plot thickens.
The danger of using a sledgehammer to crack a nut: ROTEM-guided administration of recombinant activated factor VII in a patient with refractory bleeding post-ventricular assist device implantation.
The importance of tissue factor source in the management of Factor VII deficiency.
The K-test (trypsin clotting time) in coumarin treated patients and in congenital deficiencies and abnormalities of the prothrombin complex.
The molecular basis of low activity levels of coagulation factor VII: a Brazilian cohort.
The paradoxical association between inherited factor VII deficiency and venous thrombosis.
The role of tissue factor in the production of thrombin.
The significance of published polymorphisms in 14 cases of mild factor VII deficiency.
The spectrum of factor VII deficiencies and abnormalities.
The Story of Serum Prothrombin Conversion Accelerator, Proconvertin, Stable Factor, Cothromboplastin, Prothrombin Accelerator or Autoprothrombin I, and Their Subsequent Merging into Factor VII.
The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding.
The use of recombinant activated factor VII in congenital and acquired factor VII deficiencies.
The use of recombinant activated factor VII in the circumcision operation in the case of a congenital factor VII deficiency.
The use of recombinant activated factor VII in three patients with central nervous system hemorrhages associated with factor VII deficiency.
Thromboelastographic monitoring of the efficacy of recombinant factor VIIa administration in a parturient with factor VII deficiency.
Thromboembolism in congenital factor VII deficiency.
Thromboembolism in patients with hereditary deficiency of coagulation factors.
Thrombosis in a bleeding disorder: case of thromboembolism in factor VII deficiency.
Thrombosis in inherited factor VII deficiency.
Thrombosis in rare bleeding disorders.
Thrombosis: a study of coagulation parameters and mechanisms during allograft rejection.
Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC).
Tissue factor pathway inhibitor activity in factor VII deficiency.
Total hip arthroplasty in severe congenital factor VII deficiency: successful use of recombinant activated factor VII for hemostasis.
Tranexamic acid without prophylactic factor replacement for prevention of bleeding in hereditary bleeding disorder patients undergoing endoscopy: a pilot study.
Transmission of factor VII deficiency through liver transplantation.
Treatment of bleeding after kidney biopsy with recombinant activated factor VII.
Treatment of congenital factor VII deficiency with a new concentrate.
Treatment of factor VII deficiency with recombinant factor VIIa.
Treatment of factor XI inhibitor using recombinant activated factor VIIa.
Triple coronary artery bypass graft surgery in a patient with factor VII deficiency: a case report.
Twenty two novel mutations of the factor VII gene in factor VII deficiency.
Two new double mutant alleles of the F7 gene and a literature review on alleles with two mutations in FVII deficiency.
Two novel cases of cerebral haemorrhages at the neonatal period associated with inherited factor VII deficiency, one of them revealing a new nonsense mutation (Ser52Stop).
Two novel factor VII gene mutations in a Chinese family with factor VII deficiency.
Two novel mutations in severe factor VII deficiency.
Two typical hereditary charts of congenital factor VII deficiency.
Two-incision laparoscopic appendectomy for a severe hemophilia A child patient with coagulation factor VII deficiency: Case report and review of literature.
U1-snRNA-mediated rescue of mRNA processing in severe factor VII deficiency.
Uncomplicated stereotactic and open neurosurgical procedures in patients with factor VII deficiency.
Unlabeled uses of factor VIIa (recombinant) in pediatric patients.
Unprovoked Pulmonary Embolism in Factor VII Deficiency.
Use of global assays to understand clinical phenotype in congenital factor VII deficiency.
Use of recombinant factor VII for tooth extractions in a patient with severe congenital factor VII deficiency: a case report.
Use of recombinant factor VIIa in hereditary bleeding disorders.
Use of recombinant factor VIIa in surgery in factor-VII-deficient patients.
Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies.
Use of thromboelastography and thrombin generation assay to predict clinical phenotype in patients with severe FVII deficiency.
Using a minigene approach to characterize a novel splice site mutation in human F7 gene causing inherited factor VII deficiency in a Chinese pedigree.
Variation of factor VII 140s and 170s loops in fishes: evolutionary aspects and comparison with mutations found in FVII deficiency.
Vena porta thrombosis in patient with inherited factor VII deficiency.
Visually Disabling Non-Traumatic Orbital Hemorrhage in an Anticoagulated Patient with Factor VII Deficiency.
Vitamin K-Dependent Coagulation Factors That May be Responsible for Both Bleeding and Thrombosis (FII, FVII, and FIX).
Warfarin management in the setting of FVII deficiency and mechanical circulatory support.
Warfarin-induced factor VII deficiency and the bleeding time.
Whole-exome sequencing provides insights into monogenic disease prevalence in Northwest Russia.
Women and inherited bleeding disorders: menstrual issues.
Women with congenital factor VII deficiency: clinical phenotype and treatment options from two international studies.
[A case of congenital factor VII deficiency (author's transl)]
[A case of congenital hemorrhagic diathesis due to factor VII deficiency (hypoproconvertinemia)]
[A family of congenital factor VII deficiency (author's transl)]
[A new case of homozygous congenital factor VII deficiency. Associated factor X deficiency in some members of the family]
[A Quebec family with factor VII deficiency]
[Acquired and repeated factor VII deficiency during infections outbreaks: case-report]
[Acquired factor VII deficiency]
[Acquired isolated factor VII deficiency and bronchogenic carcinoma. A case report]
[An acquired isolated transitory factor VII deficiency]
[An inherited coagulation factor VII deficiency pedigree caused by homozygous mutation of His348Gln].
[Anaesthetic management of a parturient with a severe factor VII deficiency: was activated factor VII really necessary?].
[Analysis of a Chinese pedigree affected with hereditary factor VII deficiency caused by compound heterozygous variants of F7 gene].
[Analysis of an inherited FVII deficiency pedigree caused by homozygosity of Thr359Met]
[Analysis of Phenotype and L12R Mutation in Signal Peptide and 3' Non-translation Region c11814-insAA Mutation of F7 Gene in a Family with Hereditary Coagulation Factor VII Deficiency].
[Analysis of the gene mutation in an inherited FVII deficiency patient].
[Anesthesia and coagulation factor VII deficiency]
[Anesthesia and factor VII deficiency]
[Anesthesia in a patient with hereditary factor VII deficiency]
[Anesthesia in congenital factor VII deficiency]
[Application of heat-treated factor VII concentrates in a patient with congenital factor VII deficiency during labor]
[Assay of factor VII antigen by enzyme-linked immunosorbent assay (ELISA)]
[Bleeding after cardiac surgery: the role of recombinant factor VIIa]
[Blood transfusion as substitution therapy in factor V- and factor VII deficiency.]
[Case of congenital factor VII deficiency]
[Case of factor VII deficiency with systemic amyloidosis having a unique clinical course such as splenic rupture]
[Classical factor VII deficiency: biological and genetic evaluation of 3 families]
[Clinical and blood coagulation studies in patients with congenital factor VII deficiency]
[Clinical assessment of potential fields of application of recombinant factor VIIa in internal and pediatric diseases. Recommendations of an expert group.]
[Clinical studies of familial hereditary factor VII deficiency (author's transl)]
[Coagulation factor VII deficiency in 3 patients with trisomy 8]
[Coagulation factor VII deficiency in a chronic carrier of the B virus]
[Coagulation factor VII--new physiopathological and therapeutic aspects]
[Concurrent obstetric disease and ischemic ictus in 2 cases with moderated factor VII deficiency]
[Congenital factor VII deficiency (author's transl)]
[Congenital factor VII deficiency and subarachnoidal haemorrhage due to intracranial aneurysm: a case report]
[Congenital factor VII deficiency as a cause of obstetrical and gynecological hemorrhages]
[Congenital factor VII deficiency associated with idiopathic osteopsathyrosis of Lobstein type.]
[Congenital factor VII deficiency revealed by post-circumcision bleeding].
[Congenital factor VII deficiency. Report of 4 cases]
[Congenital factor VII deficiency: about two family cases].
[Congenital factor VII deficiency; family investigation and physiological studies on factor VII.]
[Congenital factor VII deficiency]
[Congenital hypoproconvertinemia; case of congenital factor VII deficiency and brief review of literature.]
[Contribution to the clinical picture of congenital factor VII deficiency]
[Differential diagnosis of factor VII deficiency in the newborn.]
[Double heterozygous mutations of non-canonical splice (IVS1a + 5g > a) and His348Gln caused inherited coagulation factor VII deficiency]
[Efficacy of Recombinant Activated Factor VII for Intractable Bleeding after Cardiovascular Surgery].
[Epistaxis due to coagulation disorder in factor VII deficiency.]
[Factor VII deficiency and homocystinuria. Chance association or syndrome?]
[Factor VII deficiency and surgery: infusion of fresh-frozen plasma in a case report]
[Factor VII deficiency and surgery: is preoperative replacement necessary?]
[Factor VII deficiency and surgery]
[Factor VII deficiency revealed by intracranial hemorrhage.]
[Factor VII deficiency--case report]
[Factor VII deficiency. Preparation for surgical intervention]
[Factor VII deficiency]
[Gastrectomy for a patient with congenital factor VII deficiency--a case report]
[Gastrectomy in congenital factor VII deficiency with substitution of factor VII concentrate]
[Gene diagnosis of antithrombin deficiency and factor VII deficiency]
[Genetic analysis of hereditary factor VII deficiency from a Chinese pedigree]
[Genetic diagnosis of hereditary coagulation disorders]
[Genotype and phenotype analysis of congenital coagulator factor VII deficiency in four Chinese pedigrees].
[Haplotype Analysis of Coagulation Factor VII Gene in a Patient with Congenital Coagulation Factor VII Deficiency with Heterozygous p.Arg337Cys Mutation and o.Aro413Gin Polymorphism..]
[Hemorrhage from the palatal tonsils in the course of angina in a child with factor VII deficiency]
[Hemorrhagic diathesis due to factor VII deficiency (hypoproconvertinemia).]
[Hemostasis anomalies and prognosis during severe infectious purpura in children. Retrospective study in 69 cases]
[Hereditary coagulation factor VII deficiency in a case]
[Hereditary heterozygote factor VII deficiency]
[Hereditary heterozygous factor VII deficiency in patients undergoing surgery : Clinical relevance].
[Homocystinuria and factor VII deficiency]
[Homocystinuria. A type with vascular thrombosis and factor VII deficiency]
[Inherited bleeding disorders common in Jews].
[Inherited coagulation factor VII deficiency caused by double heterozygotic mutations Arg304Gln and Arg304Trp]
[Inherited factor VII deficiency and pregnancy. Apropos of 1 case]
[Intracranial hemorrhage in an infant with congenital factor VII deficiency]
[Isolated acquired factor VII deficiency in patient with severe head trauma: use of factor VII (factor VII-LFB]
[Liver cirrhosis with factor VII deficiency: a case report and literature review].
[Molecular genetic analysis for a pedigree with severe hereditary coagulation factor VII deficiency]
[Mutation analysis and prenatal diagnosis for a family affected with congenital factor VII deficiency].
[Novel double heterozygous mutations on Met306Val and Thr181Asn related to a hereditary coagulation factor VII deficiency]
[On a case of Christmas disease associated with factor VII deficiency.]
[Panorama of congenital disorders of hemostasis diseases at University Hospital of Brazzaville, Congo]
[Postpartum haemorrhage and factor VII deficiency].
[Practical approaches for surgical procedures in congenital factor VII deficiency]
[Pregnancy and delivery in a case with congenital factor VII deficiency]
[Pregnancy and labor in severe hereditary factor VII deficiency]
[Primary biliary cirrhosis combined with factor VII deficiency: a case report]
[Prophylactic use of a recombinant activated factor VII in delivery haemorrhage by caesarean in a woman with major factor VII deficiency: a case report].
[Recombinant activated factor VII in paediatric practice. Universal hemostatic agent?]
[Recurrent intracranial hemorrhage in a nursing infant with congenital factor VII deficiency. Survival and follow-up after neurosurgical intervention]
[Serious congenital deficiency of FVII and acquired idiopathic thrombocytopenic purpura--the rare combination of two bleeding disorders]
[Significant decrease in factor VII activity by tissue thromboplastin derived from rabbit brain in a patient with congenital factor VII deficiency (FVII Padua)].
[Studies on inherited coagulation factor VII deficiency and tissue factor abnormality in a pedigree]
[Study of prothrombin conversion in a case of congenital proconvertin deficiency (factor VII deficiency of serum prothrombin conversion accelerator deficiency.]
[Subcutaneous hematomas, reduced Quick value. Factor VII deficiency]
[Successful gastric resection in a male patient with factor VII deficiency and telangiectasia]
[The change and significance of coagulation activity in bleomycin-induced lung fibrosis in rats]
[The influence of factor VII deficiency on cardiac operations with extracorporeal circulation]
[Two novel mutations in one pedigree with here-ditary Factor VII deficiency].
[Variants of factor VII deficiency]
coagulation factor xa deficiency
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
A NlaIII polymorphism within the human factor VII gene.
A rare inherited coagulation disorder: combined homozygous factor VII and factor X deficiency.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Autologous bone marrow transplantation and factor XII, factor VII, and protein C deficiencies. Report of a new association and its possible relationship to endothelial cell injury.
Clinical analysis of six cases of multiple myeloma first presenting with coagulopathy.
Clinical audit of inherited bleeding disorders in a developing country.
Congenital bleeding disorders of the vitamin K-dependent clotting factors.
Diagnostic Error of a Patient with Combined Inherited Factor VII and Factor X Deficiency due to Accidental Ingestion of a Diphacinone Rodenticide.
Factor VII and factor X deficiency in a child with a chromosome 13q duplication and deletion.
Frequencies of mild factor V, VII and X deficiencies in a Japanese population.
Haemoperitoneum associated with ovulation in women with bleeding disorders: the case for conservative management and the role of the contraceptive pill.
Inherited bleeding disorders in Indian women with menorrhagia.
Inherited bleeding disorders in the Eastern Province of Saudi Arabia.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Rare inherited coagulation disorders in India.
Recombinant human factor VIIa in the management of amyloid-associated factor X deficiency.
Successful perioperative management of factor X deficiency associated with primary amyloidosis.
Synergistic effect of factor VII gene polymorphisms causing mild factor VII deficiency in a case of severe factor X deficiency.
The K-test (trypsin clotting time) in coumarin treated patients and in congenital deficiencies and abnormalities of the prothrombin complex.
[A new case of homozygous congenital factor VII deficiency. Associated factor X deficiency in some members of the family]
[Factors VII, VIII, IX, and X: molecular genetics and gene diagnosis]
[Gene analysis of a combined inherited factor VII and factor X deficiency pedigree].
[The change and significance of coagulation activity in bleomycin-induced lung fibrosis in rats]
coagulation factor xia deficiency
A novel congenital haemostatic defect: combined factor VII and factor XI deficiency.
Activated factor IX-antithrombin III complexes in human blood: quantification by an enzyme-linked differential antibody immunoassay and determination of the in vivo half-life.
Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency.
An illustrative case and a review on the dosing of recombinant factor VIIa in congenital factor XI deficiency.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review.
Changes in haemostasis and thrombosis associated with thyroid disease: Presentation of 2 cases.
Characterization of combined factor VII and factor XI deficiencies.
Clinical and laboratory features of 178 children with recurrent epistaxis.
Descriptive epidemiology of hemophilia and other coagulation disorders in mansoura, egypt: retrospective analysis.
Factor IX is activated in vivo by the tissue factor mechanism.
Factor XII deficiency acquired by orthotopic liver transplantation: case report and review of the literature.
Low endoscopy bleeding risk in patients with congenital bleeding disorders.
Lower doses of rFVIIa therapy are safe and effective for surgical interventions in patients with severe FXI deficiency and inhibitors.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Monitoring low dose recombinant factor VIIa therapy in patients with severe factor XI deficiency undergoing surgery.
Multiple congenital coagulopathies co-expressed with Von Willebrand's disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature.
Obstetric analgesia and anaesthesia in women with inherited bleeding disorders.
Perioperative use of modified thrombelastography in factor XI deficiency: a helpful method to assess drug effects.
Recombinant factor VIIa for the prophylaxis of perioperative hemorrhage in a patient with congenital factor XI deficiency undergoing brain tumor neurosurgery.
Recombinant factor VIIa to prevent surgical bleeding in factor XI deficiency.
Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with congenital factor XI deficiency.
Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency.
The rare inherited coagulation disorders.
The role of recombinant factor VIIa for obstetric block in women with severe factor XI deficiency.
The use of recombinant factor VIIa (NovoSeven) in a patient with a factor XI deficiency and a circulating anticoagulant.
Unprovoked Pulmonary Embolism in Factor VII Deficiency.
Use of recombinant factor VIIa for hip replacement surgery in a patient with severe factor XI deficiency and drug-induced platelet defect.
[Inherited bleeding disorders common in Jews].
[Use of recombinant, activated Factor VII in the treatment and prevention of bleeding complications in two female patients suffering from congenital XI factor deficiency during orthopedic and traumatology intervention. Case reports]
coagulation factor xiia deficiency
Inherited bleeding disorders in Indian women with menorrhagia.
Resistance to activated protein C: evaluation of three functional assays.
Colic
Whole blood re-calcification time in equine colic.
Colitis
Rectal amputation sparing by haemostatic therapy with recombinant factor VIIa in a patient with cytomegalovirus-related colitis.
Colonic Neoplasms
A recombinant adenovirus vector encoding the light chain of human coagulation factor VII and IgG1 Fc fragment to targeting tissue factor for colorectal cancer immunotherapy in the mouse model.
Factor VIIa regulates the expression of caspase-3, MMP-9, and CD44 in SW620 colon cancer cells involving PAR2/MAPKs/NF-?B signaling pathways.
The FVIIa-tissue factor complex induces the expression of MMP7 in LOVO cells in vitro.
Tissue factor-factor VIIa regulates interleukin-8, tissue factor and caspase-7 expression in SW620 cells through protease-activated receptor-2 activation.
Tissue factor-targeted lidamycin inhibits growth and metastasis of colon carcinoma.
Tissue factor/activated factor VIIa induces matrix metalloproteinase-7 expression through activation of c-Fos via ERK1/2 and p38 MAPK signaling pathways in human colon cancer cell.
[Ectopic expression and clinical significance of tissue factor/coagulation factor VII complex in colorectal cancer.]
[Investigation of the mechanisms of coagulation factor VIIa-induced colon cancer SW620 cell proliferation and migration]
[Mechanism of cross talk between tissue factor/active coagulation factor VII and epidermal growth factor receptor signalings in colon cancer cells in culture].
[Regulation of promatrilysin expression by tissue factor/actived coagulation factor VII complex in LoVo colon cancer cell line.]
Colorectal Neoplasms
A recombinant adenovirus vector encoding the light chain of human coagulation factor VII and IgG1 Fc fragment to targeting tissue factor for colorectal cancer immunotherapy in the mouse model.
Acquired factor VII deficiency following FOLFOX in a patient with colorectal cancer who was also DPD deficient.
Coagulation factor levels in non-metastatic colorectal cancer patients.
Crosstalk between TF/FVIIa and EGFR signaling in colorectal cancer cells.
Extrahepatic synthesis of coagulation factor VII by colorectal cancer cells promotes tumor invasion and metastasis.
Inhibition of tissue factor-factor VIIa proteolytic activity blunts hepatic metastasis in colorectal cancer.
[Ectopic expression and clinical significance of tissue factor/coagulation factor VII complex in colorectal cancer.]
Coma
Factor VII levels as a guide to prognosis in fulminant hepatic failure.
Use of recombinant factor VIIa in US military casualties for a five-year period.
Common Variable Immunodeficiency
Severe menorrhagia due to factor VII deficiency successfully treated by thermal balloon endometrial ablation.
Communicable Diseases
Distal deep venous thrombosis in a hemophilia A patient with inhibitor and severe infectious disease, 18 days after recombinant activated factor VII transfusion.
Compartment Syndromes
Early treatment with recombinant factor VIIa results in greater efficacy with less product.
Lower extremity compartment syndrome in the setting of iliofemoral deep vein thrombosis, phlegmasia cerulea dolens and factor VII deficiency.
Successful use of recombinant factor VIIa (NovoSeven) in children with compartment syndrome: two case reports.
Successful use of recombinant factor VIIa in a child with Schoenlein-Henoch purpura presenting with compartment syndrome and severe factor XIII deficiency.
Thigh Compartment Syndrome in a Factor VII Deficient High School Football Player: 2322 June 2, 3: 55 PM - 4: 15 PM.
Use of Recombinant Factor VIIa for Bleeding Control in Treatment of Acute Extremity Compartment Syndrome Secondary to Primary Myelofibrosis: A Case Report.
Confusion
Prolongation of prothrombin time in the presence of rivaroxaban: is this the only cause?
Congenital Abnormalities
Arthropathy and surgery in congenital factor VII deficiency.
Defining the role of recombinant activated factor VII in pediatric cardiac surgery: where should we go from here?
Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients.
Identification of a congenital defect of factor VII in a colony of beagle dogs: the clinical use of the plasma.
The congenital factor VII abnormalities (dysproconvertinemias). The genetic plot thickens.
Use of recombinant activated factor VII for reduction of perioperative blood loss during elective surgical correction of spine deformity in a Jehovah's Witness. Case repor.
[DYSERGIC ANGIOPATHY (OF THE TYPE OF ANAPHYLACTOID VASCULAR PURPURA) ASSOCIATED WITH A CONGENITAL DEFECT OF FACTOR VII.]
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Unlabeled uses of factor VIIa (recombinant) in pediatric patients.
Contracture
Feasibility of using recombinant factor VIIa in continuous infusion.
Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures.
Corneal Opacity
Anterior segment dysgenesis in a child with factor VII deficiency.
Coronary Artery Disease
A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men.
A genome-wide association study identifies new loci for factor VII and implicates factor VII in ischemic stroke etiology.
A protective contribution of the Q allele of the R353Q polymorphism of the Factor VII gene in individuals with chronic stable angina?
Activated and total coagulation factor VII, and fibrinogen in coronary artery disease.
Activated factor VII levels in patients with angiographically confirmed coronary artery disease.
Activation of coagulation factor VII during alimentary lipemia.
Activity of factor VIIa and von Willebrand factor in non-insulin-dependent diabetic subjects with coronary artery disease.
Angiotensin-converting enzyme insertion/deletion genotype is associated with the activities of plasma coagulation factor VII and X independent of triglyceride metabolism.
Aortic valve and coronary artery bypass surgery in a patient with factor VII deficiency.
Association between R353Q polymorphism for coagulative factor VII and severity of coronary artery disease in Iranian population.
Association of factor VII genotype with plasma factor VII activity and antigen levels in healthy Indian adults and interaction with triglycerides.
Atherosclerosis and coronary bypass surgery in hereditary factor VII deficiency.
Classical risk factors and emerging elements in the risk profile for coronary artery disease.
Contribution of coagulation factor VII R353Q, -323P0/10 and HVR4 polymorphisms to coronary artery disease in Tunisians.
Coronary artery disease and factor VII hyperactivity in elderly Japanese.
Coronary artery plaque disruption as cause of acute myocardial infarction during cesarean section with spinal anesthesia.
Dietary factor VII activation does not increase plasma concentrations of prothrombin fragment 1+2 in patients with stable angina pectoris and coronary atherosclerosis.
Differences in postprandial lipaemic response between Northern and Southern Europeans.
Effect of lipid-lowering treatment on factor VII profile in hyperlipidemic patients.
Effects of coagulation Factor VII polymorphisms on the coronary artery disease in Japanese: Factor VII polymorphism and coronary disease.
Effects of simvastatin or hormone replacement therapy, or both, on fibrinogen, factor VII, and plasminogen activator inhibitor levels in postmenopausal women with proven coronary artery disease.
Elevation of factor VII activity and mass in coronary artery disease of varying severity.
Evidence that factor VII levels correlate strongly with fibrinopeptide A release: evaluation by an ex vivo method.
Factor VII activity state in coronary artery disease.
Factor VII levels in patients undergoing coronary angiography: factor VII and coronary artery disease.
Fibrinogen, factor VII clotting activity and coronary artery disease severity.
Fluorogenic assay of activated factor VII. Plasma factor VIIa levels in relation to arterial cardiovascular diseases in Japanese.
Genetic contribution to circulating levels of hemostatic factors in healthy families with effects of known genetic polymorphisms on heritability.
Genetic contribution to factor VII levels in families of patients undergoing coronary arteriography.
Genetic determinants of plasma factor VII activity in the Japanese.
Genotype associations of factor VII gene with plasma factor VII coagulant activity and antigen levels in healthy Chinese.
Genotype-phenotype relationship of F7 R353Q polymorphism and plasma factor VII coagulant activity in Asian Indian families predisposed to coronary artery disease.
Hemostatic risk factors of coronary artery disease in the Chinese.
Influence of polymorphisms in the factor VII gene promoter on activated factor VII levels and on the risk of myocardial infarction in advanced coronary atherosclerosis.
Initiation of blood coagulation: the tissue factor/factor VIIa complex.
Joint effect of G1691A factor V point mutation and factor VII Arg/Gln(353) gene polymorphism on the risk of premature coronary artery disease.
Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and coagulation factor VII Arg353-->Gln polymorphism in Korean patients with coronary artery disease.
Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction in patients undergoing coronary angiography.
Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease.
Polymorphisms of factor V, factor VII, and fibrinogen genes. Relevance to severity of coronary artery disease.
Promoter methylation in coagulation F7 gene influences plasma FVII concentrations and relates to coronary artery disease.
R353Q polymorphism in the factor VII gene and cardiovascular risk in Heterozygous Familial Hypercholesterolemia: a case-control study.
Racial variation of factor VII activity and antigen levels and their correlates in healthy Chinese and Indians at low and high risk for coronary artery disease.
Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty.
Relationships of insulin and intact and split proinsulin to haemostatic function in young men with and without coronary artery disease.
Risk factors for cerebrovascular disease and the role of coagulation and fibrinolysis.
Specific assays of hemostasis proteins: factor VII.
Successful treatment of severe bleeding with recombinant factor VIIa after kidney transplantation.
The -323Ins10 polymorphism for factor VII is not associated with coronary atherosclerosis in symptomatic men. The REGRESS study group.
The effects of three factor VII polymorphisms on factor VII coagulant levels in healthy Singaporean Chinese, Malay and Indian newborns.
[Activated factor VII as a new cardiovascular risk factor of atherothrombotic disease]
[Myocardial infarction during pregnancy]
[Role of the hemostatic system in pathogenesis of atherosclerosis as the main etiology of coronary ischemia] [corrected]
Coronary Disease
A functional haplotype in the 5' flanking region of the factor VII gene is associated with an increased risk of coronary heart disease.
A protective contribution of the Q allele of the R353Q polymorphism of the Factor VII gene in individuals with chronic stable angina?
A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome.
Activated protein C ratio, plasma tissue factor activity and activated factor VII in Chinese patients with coronary heart disease.
Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency.
Angiotensin-converting enzyme insertion/deletion genotype is associated with the activities of plasma coagulation factor VII and X independent of triglyceride metabolism.
Antithrombotic therapy in the primary prevention of acute myocardial infarction.
Are risk factors for atherothrombotic disease associated with back pain sickness absence? The Whitehall II Study.
Association between polymorphisms in the coagulation factor VII gene and coronary heart disease risk in different ethnicities: a meta-analysis.
Association Between R353Q (rs6046) Polymorphism in Factor VII with Coronary Heart Disease.
Association between the factor VII haplotype containing the -402A allele and myocardial infarction in a population of elderly men at high risk for coronary heart disease.
Association of ACE and FACTOR VII gene variability with the risk of coronary heart disease in north Indian population.
Associations of activated coagulation factor VII and factor VIIa-antithrombin levels with genome-wide polymorphisms and cardiovascular disease risk.
Associations of plasma fibrinogen and factor VII clotting activity with coronary heart disease and stroke: prospective cohort study from the screening phase of the Thrombosis Prevention Trial.
Atorvastatin reduces plasma levels of factor VII activity and factor VII antigen in patients with hyperlipidemia.
Carotid artery measures are strongly associated with left ventricular mass in older adults (a report from the Cardiovascular Health Study).
Coagulation factor VII and inflammatory markers in patients with coronary heart disease.
Coagulation factor VII and the risk of coronary heart disease in healthy men.
Coagulation factor VII in middle-aged women with and without coronary heart disease.
Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Role of plasma lipoproteins and factor VII genotype.
Coagulation factor VII, R353Q polymorphism, and serum choline-containing phospholipids in males at high risk for coronary heart disease.
Complexity of the genetic contribution to factor VII deficiency in two Spanish families: clinical and biological implications.
Constitutional, biochemical and lifestyle correlates of fibrinogen and factor VII activity in Polish urban and rural populations.
Correlates of blood pressure in community-dwelling older adults. The Cardiovascular Health Study. Cardiovascular Health Study (CHS) Collaborative Research Group.
Dietary fatty acids and blood coagulation.
Effect of meat replacement by tofu on CHD risk factors including copper induced LDL oxidation.
Effect of the Mediterranean Diet on Fasting Concentrations of Activated Factor VII in Healthy Persons.
Effects of coagulation Factor VII polymorphisms on the coronary artery disease in Japanese: Factor VII polymorphism and coronary disease.
Environmental influences on hemostasis and thrombosis. Diet and smoking.
Epidemiological and genetic associations of activated factor XII concentration with factor VII activity, fibrinopeptide A concentration, and risk of coronary heart disease in men.
Factor VII and extrinsic pathway inhibitor in acute coronary disease.
Factor VII, antithrombin III, leukocyte and platelet counts in a sample of black and white Zimbabwean blood donors.
Factor VII, blood lipids and fat intake: gene-nutrient interaction and risk of coronary heart disease with the factor VII R353Q polymorphism.
Fat consumption and factor VII coagulant activity in middle-aged men. An association between a dietary and thrombogenic coronary risk factor.
FVII gene R353Q polymorphism and coronary heart disease: a meta-analysis including 3258 subjects.
Genetic and environmental determinants of factor VII coagulant activity in ethnic groups at differing risk of coronary heart disease.
Genetic polymorphisms of factor VII are not associated with arterial thrombosis.
Haplotype and genotype effects of the F7 gene on circulating factor VII, coagulation activation markers and incident coronary heart disease in UK men.
Hemostasis and cardiovascular risk. The British and European experience.
Hemostatic factors in the Coronary Artery Risk Development in Young Adults (CARDIA) Study.
Influence of factor VII gene polymorphisms and environmental factors on plasma coagulation factor VII concentrations in middle-aged women with and without manifest coronary heart disease.
Influences of lipid and non-lipid nutritional parameters on factor VII coagulant activity in normal subjects: the Nove study.
Interrelationships of factor VII activity and plasma leptin with insulin resistance in coronary heart disease.
Lipolysis of triglyceride-rich lipoproteins activates coagulant factor XII: a study in familial lipoprotein-lipase deficiency.
Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk?
Plasma factor VII, triglyceride concentration and fibrin degradation products in primary hyperlipidemia: a clinical and laboratory study.
Plasma fibrinogen explains much of the difference in risk of coronary heart disease between France and Northern Ireland. The PRIME study.
Population correlates of coagulation factor VII. Importance of age, sex, and menopausal status as determinants of activated factor VII.
Positive association between self-reported fatty food consumption and factor VII coagulant activity, a risk factor for coronary heart disease, in 4246 middle-aged men.
Postprandial lipaemia and haemostatic factors.
Prevalence in a Tunisian Arabic population of factor VII DNA variants and relation to factor VII plasma levels.
Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study.
Relation of hemostatic risk factors to other risk factors for coronary heart disease and to sex hormones in men.
Relationship of tissue factor pathway inhibitor activity to plasma lipoproteins and myocardial infarction at a young age.
Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls.
The Northwick Park Heart Study: Evidence from the Laboratory.
Thrombin generation markers and coronary heart disease risk factors in a Polish population sample.
Two common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration.
Weight-loss induced changes in plasma factor VII coagulant activity and relation to the factor VII Arg/Gln353 polymorphism in moderately obese adults.
[Coagulant activity of factor VII (FVIIc) in the elderly with ischemic heart disease]
[Correlation between polymorphisms in the coagulation factor VII gene hypervariable region 4 site and the risk of coronary heart disease in population with different ethnic backgrounds: a Meta-analysis].
[Effect of the Mediterranean diet on fasting concentrations of activated factor VII in healthy persons]
[Factor VII and protein-C markers are no prognostic indicators in acute coronary heart disease]
[Study of the inhibitory effect of NF-kappaB decoy on tissue factor gene expression and FVII activation in cultured human umbilical vein endothelial cells]
[Study on plasma coagulation factor VII (FVII) levels and polymorphisms of FVII gene in patients with coronary heart disease]
[The influence of hormone replacement therapy containing transdermal 17-beta estradiol and oral medroxyprogesterone acetate on coagulation and fibrinolysis]
[The thrombophilic status and ischemic cardiopathy]
Coronary Stenosis
Coronary artery stenosis treatment in aging patients with inherited Factor VII deficiency: Where do we stand?
Coronary Thrombosis
Influence of stearic acid on hemostatic risk factors in humans.
Plasma fibrinogen and factor VII as risk factors for cardiovascular disease.
Postprandial lipaemia and haemostatic factors.
The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study.
Craniocerebral Trauma
A forgotten or minimized head trauma, rather than a mild FVII deficiency, is the most likely cause of a subdural hematoma.
Administration off label of recombinant factor-VIIa (rFVIIa) to patients with blunt or penetrating brain injury without coagulopathy.
Effects of recombinant activated factor VII in traumatic nonsurgical intracranial hemorrhage.
Intracranial bleeding following soccer-related head trauma in a young student with occult factor VII deficiency.
Medication-related complications in the trauma patient.
Recombinant activated coagulation factor VII and bleeding trauma patients.
Treatment of severe coagulopathy after gunshot injury to the head using recombinant activated factor VII.
[Isolated acquired factor VII deficiency in patient with severe head trauma: use of factor VII (factor VII-LFB]
[The use of recombinant activated factor VII in traumatic intracranial haemorrhage]
Craniosynostoses
Elevated prothrombin time on routine preoperative laboratory results in a healthy infant undergoing craniosynostosis repair: Diagnosis and perioperative management of congenital factor VII deficiency.
Crigler-Najjar Syndrome
Hepatocyte transplantation for liver-based metabolic disorders.
Isolation of hepatocytes from livers from non-heart-beating donors for cell transplantation.
Liver after hepatocyte transplantation for liver-based metabolic disorders in children.
Crohn Disease
Recombinant factor VIIa for severe gastrointestinal hemorrhage associated with Crohn disease.
Successful treatment of severe gastrointestinal bleeding secondary to Crohn disease with recombinant factor VIIa.
The use of recombinant factor VIIa in controlling surgical bleeding in non-haemophiliac patients.
Cystic Fibrosis
Expanded carrier screening and preimplantation genetic diagnosis in a couple who delivered a baby affected with congenital factor VII deficiency.
Recombinant activated factor VII for massive hemoptysis in patients with cystic fibrosis.
Cystinuria
Frequency of five disease-causing genetic mutations in a large mixed-breed dog population (2011-2012).
Cystitis
Off-label use of recombinant factor VIIa in patients following bone marrow transplantation.
Pilot study to test the efficacy and safety of activated recombinant factor VII (NovoSeven) in the treatment of refractory hemorrhagic cystitis following high-dose chemotherapy.
Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation.
Recombinant activated factor VII to control life-threatening haemorrhagic radiation cystitis.
Recombinant factor VIIa to treat late radiation-induced hemorrhagic cystitis: a case report.
Successful treatment of cyclophosphamide induced intractable hemorrhagic cystitis with recombinant FVIIa (NovoSeven) after allogenic bone marrow transplantation.
Cysts
Prophylactic preparation and surgical extirpation of a very large abdominal blood cyst in a severe haemophilia A patient with inhibitors managed by rFVIIa.
Death, Sudden, Cardiac
[The advisability of modifying the current outline of blood coagulation]
Dementia, Vascular
Hemostasis abnormalities in patients with vascular dementia and Alzheimer's disease.
Dengue
Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study.
Cost-utility analysis of an adjunctive recombinant activated factor VIIa for on-demand treatment of bleeding episodes in dengue haemorrhagic fever.
Diagnostic laboratory for bleeding disorders ensures efficient management of haemorrhagic disorders.
Effectiveness of Recombinant Activated Factor VII (rFVII a) for Controlling Intractable Postpartum Bleeding in a case of Dengue Hemorrhagic Fever.
Recombinant activated factor VII usage in life threatening hemorrhage: a pediatric experience.
Successful use of N-acetyl cysteine and activated recombinant factor VII in fulminant hepatic failure and massive bleeding secondary to dengue hemorrhagic fever.
The use of recombinant activated factor VII for controlling life-threatening bleeding in Dengue Shock Syndrome.
Dermatitis, Phototoxic
Selective and effective killing of angiogenic vascular endothelial cells and cancer cells by targeting tissue factor using a factor VII-targeted photodynamic therapy for breast cancer.
Diabetes Complications
Qualitative and quantitative studies of autoantibodies to phospholipids in diabetes mellitus.
Diabetes Insipidus, Nephrogenic
A case of a novel mutant vasopressin receptor-dependent nephrogenic diabetes insipidus with bilateral non-obstructive hydronephrosis in a middle aged man: differentiation from aquaporin-dependent nephrogenic diabetes insipidus by response of factor VII and von Willebrand factor to 1-diamino-8-arginine vasopressin administration.
Diabetes Mellitus
Analysis of the correlation between plasma coagulation factor VII, PAI-1, and uric acid with insulin resistance and macrovascular complications in elderly patients with type 2 diabetes.
Blood glucose may condition factor VII levels in diabetic and normal subjects.
Effects of lipids and lipid-lowering therapy on hemostatic factors in patients with myocardial infarction.
Factor VII activity is an independent predictor of cardiovascular mortality in elderly women of a Sicilian population: results of an 11-year follow-up.
Factor VII, tissue factor pathway inhibitor, and monocyte tissue factor in diabetes mellitus: influence of type of diabetes, obesity index, and age.
Factor VIIa and tissue factor procoagulant activity in diabetes mellitus after acute ischemic stroke: impact of hyperglycemia.
Fibrinogen and factor VII levels improve with glycemic control in patients with type 1 diabetes mellitus who have microvascular complications.
Fluorogenic assay of activated factor VII. Plasma factor VIIa levels in relation to arterial cardiovascular diseases in Japanese.
Genetic influence of the R/Q353 genotype on factor VII activity is overwhelmed by environmental factors in Chinese patients with Type II (non-insulin-dependent) diabetes mellitus.
Interrelationship between coagulation factor VII and obesity in diabetes mellitus (type 2).
Metformin reduces circulating factor VII concentrations in patients with type 2 diabetes mellitus.
Study of factor VII, tissue factor pathway inhibitor and monocyte tissue factor in noninsulin-dependent diabetes mellitus.
Tissue Factor, Tissue Factor Pathway Inhibitor and Factor VII Activity in Cardiovascular Complicated Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 1
Fibrinogen and factor VII levels improve with glycemic control in patients with type 1 diabetes mellitus who have microvascular complications.
PAI-1 and factor VII activity are higher in IDDM patients with microalbuminuria.
Risk factors for cardiovascular disease in IDDM. A study of identical twins.
Whole-Blood Tissue Factor Procoagulant Activity Is Elevated in Type 1 Diabetes and Effects of Hyperglycemia and Hyperinsulinemia.
Diabetes Mellitus, Type 2
A chromogenic assay for coagulation factor VII: analytical performance characteristics and application in several diseases.
Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria.
Activity of factor VIIa and von Willebrand factor in non-insulin-dependent diabetic subjects with coronary artery disease.
Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients.
Analysis of the correlation between plasma coagulation factor VII, PAI-1, and uric acid with insulin resistance and macrovascular complications in elderly patients with type 2 diabetes.
Blood coagulation and fibrinolysis in obese NIDDM patients.
Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM.
Effects of Different Protein Sources on Plasminogen Inhibitor-1 and Factor VII Coagulant Activity Added to a Fat-Rich Meal in Type 2 Diabetes.
Effects of fish oil supplements in NIDDM subjects. Controlled study.
Effects of heparin treatment on hemostatic abnormalities in obese non-insulin-dependent diabetic patients.
Factor VII gene polymorphisms, factor VII:C levels and features of insulin resistance in non-insulin-dependent diabetes mellitus.
Metformin reduces circulating factor VII concentrations in patients with type 2 diabetes mellitus.
Postmenopause hormone treatment in women with NIDDM or impaired glucose tolerance: the MEDIA randomized clinical trial.
Study of factor VII, tissue factor pathway inhibitor and monocyte tissue factor in noninsulin-dependent diabetes mellitus.
Thrombogenic factors are related to urinary albumin excretion rate in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients.
Tissue Factor, Tissue Factor Pathway Inhibitor and Factor VII Activity in Cardiovascular Complicated Type 2 Diabetes Mellitus.
Tissue factor/factor VIIa signalling promotes cytokine-induced beta cell death and impairs glucose-stimulated insulin secretion from human pancreatic islets.
Whole-Blood Tissue Factor Procoagulant Activity Is Elevated in Type 1 Diabetes and Effects of Hyperglycemia and Hyperinsulinemia.
Diabetic Retinopathy
Successful use of recombinant activated factor VII in the treatment of vitreous haemorrhage: a report of seven cases.
Disseminated Intravascular Coagulation
A coagulation factor VII deficiency protects against acute inflammatory responses in mice.
A comparison of methods for the measurement of activated factor VII.
A method for the determination of activated factor VII using bovine and rabbit brain thromboplastins: demonstration of increased levels in disseminated intravascular coagulation.
A novel hemostatic agent: the potential role of recombinant activated factor VII (rFVIIa) in anesthetic practice.
Administration of recombinant activated factor VII (NovoSeven) in three cases of uncontrolled bleeding caused by disseminated intravascular coagulopathy.
Consumption of plasma factor VII in a rabbit model of non-overt disseminated intravascular coagulation.
Control of disseminated intravascular coagulation in Klippel-Trenaunay-Weber syndrome using enoxaparin and recombinant activated factor VIIa: a case report.
Desmopressin-induced Moschcowitz-like syndrome after treatment of uterine atonic bleeding in a 28-year-old pregnant woman: case report and overview of the literature.
Disseminated intravascular coagulation associated with low factor VII. Evidence for a new type of hemostatic disorder.
Effectiveness of recombinant activated factor VII in haemorragic cancer-related disseminated intravascular coagulation: a case report.
Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
Experimental gram-negative septicemia: thromboplastin generation in mononuclear phagocytes from different anatomical sites.
Factor VIIa in puerperal hemorrhage with disseminated intravascular coagulation.
Factor VIIa treatment of DIC as a clinical manifestation of amniotic fluid embolism in a patient with fetal demise.
Levels of activated factor VII in patients with disseminated intravascular coagulation.
Low plasma FVII:C and activated FVII as predictive markers for overt disseminated intravascular coagulation.
Management of factor VIII inhibitors: evolution and current status.
Measurement of tissue factor messenger RNA levels in leukocytes from patients in hypercoagulable state caused by several underlying diseases.
Pediatric off-label use of recombinant factor VIIa.
Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review.
Prevention of Bleeding Complications in Neonates With Liver Failure Undergoing Surgery Using Recombinant Factor VIIa.
Recombinant activated Factor VII as a hemostatic agent in very low birth weight preterms with gastrointestinal hemorrhage and disseminated intravascular coagulation.
Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation.
Recombinant activated factor VII in hemophagocytic lymphohistiocytosis with disseminated intravascular coagulation.
Recombinant activated factor VII in patients with cancer and hemorrhagic disseminated intravascular coagulation.
Recombinant factor VIIa to successfully manage disseminated intravascular coagulation from amniotic fluid embolism.
Recombinant factor VIIa: safety and efficacy.
Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy.
Safety profile of recombinant factor VIIa.
Septic miscarriage with toxic shock syndrome and disseminated intravascular coagulation (DIC): The role of surgery, recombinant activated factor VII and intravenous immunoglobulin (IVIG).
Splenic artery aneurysm presenting as a submucosal gastric lesion: A case report.
Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII.
Successful treatment with recombinant blood factor VIIa in severe postpartum hemorrhage-induced disseminated intravascular coagulation.
Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review.
Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model.
The use of recombinant factor VIIa (NovoSeven) for treatment of active or impending bleeding in brain injury: broadening the indications.
Timely 'off-label' use of recombinant activated factor VII (NovoSeven(®)) can help in avoiding hysterectomy in intractable obstetric bleeding complicated with disseminated intravascular coagulation: A case report and review of the literature.
Treatment of intra-abdominal bleeding with recombinant activated factor VII in a patient with disseminated intravascular coagulation secondary to septic shock.
Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage.
[Clinical assessment of potential fields of application of recombinant factor VIIa in internal and pediatric diseases. Recommendations of an expert group.]
[Hemostasis anomalies and prognosis during severe infectious purpura in children. Retrospective study in 69 cases]
[Plasma factor VII levels in disseminated intravascular coagulation]
[Successful application of recombinant activated factor VII in a patient with HELLP syndrome and disseminated intravascular coagulation]
Diverticular Diseases
Successful treatment of massive acute lower gastrointestinal bleeding in diverticular disease of colon, with activated recombinant factor VII (NovoSeven).
Down Syndrome
Homocysteine, factor VII and antithrombin III in subjects with different gene dosage for cystathionine beta-synthase.
Drug Resistant Epilepsy
Management of intracranial surgery for refractory epilepsy in severe factor VII deficiency: choosing the optimal dosing regimen.
Ductus Arteriosus, Patent
Recombinant Activated Factor VIIa (rFVIIa) Treatment in Very-Low-Birth-Weight (VLBW) Premature Infants with Acute Pulmonary Hemorrhage: A Single-Center, Retrospective Study.
Duodenal Ulcer
The use of recombinant factor VIIa in controlling surgical bleeding in non-haemophiliac patients.
Dyslipidemias
Characteristics of the insulin resistance syndrome in a Japanese population. The Jichi Medical School Cohort Study.
Coagulation factor VII and plasma triglycerides. Decreased catabolism as a possible mechanism of factor VII hyperactivity.
Effect of the factor VII R353Q missense mutation on plasma apolipoprotein B levels: impact of visceral obesity.
Interrelationships of factor VII activity and plasma leptin with insulin resistance in coronary heart disease.
Relationship between plasma protein S levels and apolipoprotein C-II in Japanese middle-aged obese women and young nonobese women.
[Fibrinogen and factor VII in women with dyslipidemia. The preliminary results of the Bellvitge-Costa de Ponent Study. The Bellvitge Study Group]
Dyspnea
Combined factor VII and protein C deficiency found in a patient with peripheral pulmonary artery stenosis accompanied by progressive pulmonary hypertension and hemoptysis.
The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia.
Unprovoked Pulmonary Embolism in Factor VII Deficiency.
Ecchymosis
Asymptomatic intracranial hemorrhage in a newborn with congenital factor VII deficiency and successful treatment with recombinant activated factor VII.
Echinococcosis
Hydatid cyst surgery complicated by hemorrhage resistant to activated recombinant factor VII, in a hemophiliac A patient with an inhibitor.
Ehlers-Danlos Syndrome
The successful use of recombinant factor VIIa in a patient with vascular-type Ehlers-Danlos syndrome.
Whole-exome sequencing provides insights into monogenic disease prevalence in Northwest Russia.
Embolic Stroke
Individualized antithrombotic therapy.
Embolism
Amniotic fluid embolism.
Complications of recombinant activated human coagulation factor VII.
Factor VIIa treatment of DIC as a clinical manifestation of amniotic fluid embolism in a patient with fetal demise.
Hematologic correlates of left atrial spontaneous echo contrast and thromboembolism in nonvalvular atrial fibrillation.
Recombinant factor VIIa after amniotic fluid embolism and disseminated intravascular coagulopathy.
Recombinant factor VIIa to successfully manage disseminated intravascular coagulation from amniotic fluid embolism.
Successful placement of a right ventricular assist device for treatment of a presumed amniotic fluid embolism.
Thromboembolic complications associated with factor VIIa administration.
Use of Recombinant Factor VIIa in Patients with Amniotic Fluid Embolism.
Use of Recombinant Factor VIIa in Patients with Amniotic Fluid Embolism: A Systematic Review of Case Reports.
Embolism, Amniotic Fluid
Amniotic fluid embolism.
Factor VIIa treatment of DIC as a clinical manifestation of amniotic fluid embolism in a patient with fetal demise.
Recombinant factor VIIa after amniotic fluid embolism and disseminated intravascular coagulopathy.
Recombinant factor VIIa to successfully manage disseminated intravascular coagulation from amniotic fluid embolism.
Successful placement of a right ventricular assist device for treatment of a presumed amniotic fluid embolism.
Use of Recombinant Factor VIIa in Patients with Amniotic Fluid Embolism.
Use of Recombinant Factor VIIa in Patients with Amniotic Fluid Embolism: A Systematic Review of Case Reports.
End Stage Liver Disease
Recombinant factor VIIa improves coagulopathy caused by liver failure.
Endometrial Hyperplasia
Recombinant activated factor VII administration in a patient with congenital lack of factor VII undergoing laparoscopic hysterectomy: A case report.
Endotoxemia
Enhanced lipid peroxidation in hepatic cirrhosis.
Recombinant nematode anticoagulant protein c2, an inhibitor of tissue factor/factor VIIa, attenuates coagulation and the interleukin-10 response in human endotoxemia.
Enterocolitis, Necrotizing
Spontaneous liver hemorrhage during laparotomy for necrotizing enterocolitis: a potential role for recombinant factor VIIa.
Use of recombinant factor VIIa in infants with severe coagulopathy.
Eosinophilia
A severe deficiency of coagulation factor VIIa results in attenuation of the asthmatic response in mice.
Epidural Abscess
Heterozygous congenital Factor VII deficiency with the 9729del4 mutation, associated with severe spontaneous intracranial bleeding in an adolescent male.
Epilepsy
Factor VII deficiency and developmental abnormalities in a patient with partial monosomy of 13q and trisomy of 16p: case report and review of the literature.
Migraine and prothrombotic genetic risk factors.
Epistaxis
A novel hemostatic agent: the potential role of recombinant activated factor VII (rFVIIa) in anesthetic practice.
A patient homozygous for a Gly354Cys mutation in factor VII that results in severely impaired secretion of the molecule, but not complete deficiency.
A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa.
Bilateral subdural hematomas, an unusual vaso-occlusive event and prolonged prothrombin time in a 58-year-old victim of an armed robbery.
Color vision disturbances secondary to oral tranexamic acid.
Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage.
Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
Inherited factor VII deficiency and surgery: clinical data are the best criteria to predict the risk of bleeding.
Marked bleeding diathesis in patients with platelet dysfunction due to a novel mutation in RASGRP2, encoding CalDAG-GEFI (p.Gly305Asp).
Newly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven(®)).
NovoSeven in warfarin-treated patients.
Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors.
Successful epistaxis control in a patient with Glanzmann thrombasthenia by increased bolus injection dose of recombinant factor VIIa.
Successful management of bleeding with recombinant factor VIIa (NovoSeven) in a patient with Burkitt lymphoma and thrombosis of the left femoral and left common iliac veins.
Successful treatment of hereditary factor VII deficiency presented for the first time with epistaxis in pregnancy: a case report.
Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa.
Uncomplicated stereotactic and open neurosurgical procedures in patients with factor VII deficiency.
Use of recombinant activated factor VII to control bleeding in a young child with qualitative platelet disorder: a case report.
[Epistaxis due to coagulation disorder in factor VII deficiency.]
Esophageal and Gastric Varices
A case of bleeding gastric varices treated with recombinant factor VII.
Laboratory evidence for hypercoagulability in cirrhotic patients with history of variceal bleeding.
Recombinant-activated factor VII as hemostatic therapy in eight cases of severe hemorrhage from esophageal varices.
[Recombinant factor VII in the treatment of acute hemorrhage due to esophageal varices.]
Esophageal Neoplasms
Plummer-Vinson Syndrome With Concomitant Factor VII Deficiency.
Essential Hypertension
Factor VII hyperactivity and endothelial cell damage are found in elderly hypertensives only when concomitant with microalbuminuria.
Low order correlations of lipoprotein(a) with other blood lipids and with coagulation and fibrinolysis parameters in hypertensive and diabetic patients.
Exanthema
Use of recombinant activated factor VII in primary postpartum hemorrhage: the Northern European registry 2000-2004.
Factor V Deficiency
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
Abnormalities in liver function and coagulation profile following the Fontan procedure.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review.
Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.
Clinical audit of inherited bleeding disorders in a developing country.
Descriptive epidemiology of hemophilia and other coagulation disorders in mansoura, egypt: retrospective analysis.
Elimination of hepatitis C virus infection in patients with haemophilia in Belgium: A single-centre experience.
Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study).
Frequencies of mild factor V, VII and X deficiencies in a Japanese population.
Frequency of specific coagulation inhibitors and antiphospholipid antibodies in Tunisian haemophiliacs.
Increase in the risk of ST elevation myocardial infarction is associated with homocysteine level.
Rare inherited coagulation disorders in India.
Refractory Epistaxis due to Severe Factor V Deficiency with Inhibitor.
The use of activated recombinant coagulation factor VII during haemarthroses and synovectomy in a patient with congenital severe factor V deficiency.
Treatment of Massive Cecal Bleeding in a 28-Year-Old Patient with Homozygous Factor V Deficiency with Activated Factor VII.
Factor VII Deficiency
"Case report". A case of haemorrhagic diathesis due to factor VII deficiency.
"Noninfective Endocarditis": A Case Report of Hereditary Coagulation Disorders in a 28-Year-Old Male.
11p15 duplication and 13q34 deletion with Beckwith-Wiedemann syndrome and factor VII deficiency.
3 ANESTHETIC MANAGEMENT OF LIVER TRANSPLANTATION FOR FACTOR VII DEFICIENCY IN A 6-MONTH-OLD CHILD-THROMBOELASTOGRAPHY-GUIDED INTRA-OPERATIVE REPLACEMENT OF RECOMBINANT FACTOR VIIa.
A case of heterozygous factor VII deficiency in pregnancy.
A case of intracranial hemorrhage in a neonate with congenital factor VII deficiency.
A case presenting concurrence of Marfan syndrome, Basedow's disease and Arg353Gln polymorphism-related factor VII deficiency.
A clinical evaluation of automated chromogenic tests as substitutes for conventional prothrombin time and activated partial thromboplastin time tests.
A coagulation factor VII deficiency protects against acute inflammatory responses in mice.
A Comparison Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Congenital Factor VII Deficiency.
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
A Neonate with Acquired Factor VII Deficiency Successfully Managed with Immunomodulatory Therapy.
A new mutation in the HNF4 binding region of the factor VII promoter in a patient with severe factor VII deficiency.
A new perspective on perioperative coagulation management in a patient with congenital factor VII deficiency: A case report.
A NlaIII polymorphism within the human factor VII gene.
A novel gene insertion combined with a missense mutation causing factor VII deficiency in two unrelated Chinese families.
A novel homozygous missense mutation in the factor VII gene of severe factor VII deficiency in a newborn baby.
A novel homozygous missense mutation in the factor VII gene of severe factor VII deficiency in a pedigree: a description of two cases.
A novel missense mutation close to the charge-stabilizing system in a patient with congenital factor VII deficiency.
A novel missense mutation responsible for factor VII deficiency in research Beagle colonies.
A Novel Presentation of Metaphyseal Chondrodysplasia, Schmid Type with Factor VII Deficiency.
A rare case of Glanzmann's thrombasthenia and factor VII deficiency due to a combination of pathogenic and non-pathogenic gene variants.
A Rare Case Report of Multiple Intracranial Aneurysms with Factor VII Deficiency.
A rare combination: congenital factor VII deficiency with Chiari malformation.
A Retrospective Analysis of Clinical and Laboratory Data of Patients with Factor VII Deficiency: A Single Centre Experience.
A self-controlled comparative clinical trial to explore the effectiveness of three topical hemostatic agents for stopping severe epistaxis in pediatrics with inherited coagulopathies.
A syndrome of factor VII deficiency and abnormal platelet release reaction.
A Thr359Met mutation in factor VII of a patient with a hereditary deficiency causes defective secretion of the molecule.
Abnormalities in liver function and coagulation profile following the Fontan procedure.
Acquired bleeding disorder in a patient with congenital factor VII deficiency.
Acquired Factor VII deficiency - a rare but important consideration.
Acquired factor VII deficiency associated with acute myeloid leukemia.
Acquired factor VII deficiency associated with aplastic anaemia: correction with bone marrow transplantation.
Acquired Factor VII Deficiency Associated with Bronchogenic Carcinoma: A Case Report.
Acquired factor VII deficiency associated with pleural liposarcoma.
Acquired factor VII deficiency associated with Wilms tumor.
Acquired factor VII deficiency causing severe bleeding disorder secondary to AL amyloidosis of the liver.
Acquired factor VII deficiency following FOLFOX in a patient with colorectal cancer who was also DPD deficient.
Acquired Factor VII Deficiency in Association with Pyelonephritis.
Acquired factor VII deficiency in hematopoietic stem cell transplant recipients.
Acquired isolated factor VII deficiency associated with severe bleeding and successful treatment with recombinant FVIIa (NovoSeven).
Acquired isolated factor VII deficiency during sepsis.
Activated factor IX-antithrombin III complexes in human blood: quantification by an enzyme-linked differential antibody immunoassay and determination of the in vivo half-life.
Activated FVII levels in factor VII Padua (Arg304Gln) coagulation disorder and in true factor VII deficiency: a study in homozygotes and heterozygotes.
Activation of Endoplasmic Reticulum Stress and Unfolded Protein Response in Congenital Factor VII Deficiency.
Acute Myelogenous Leukemia With Trisomy 8 and Concomitant Acquired Factor VII Deficiency.
Age estimates of ancestral mutations causing factor VII deficiency and Dubin-Johnson syndrome in Iranian and Moroccan Jews are consistent with ancient Jewish migrations.
Ala244Val is a common, probably ancient mutation causing factor VII deficiency in Moroccan and Iranian Jews.
An immunological investigation of hemophilia B with a tentative classification of the disease into five variants.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
An overview of inherited factor VII deficiency.
An unusual complication of ice skating and the emergence of a previously undiagnosed bleeding disorder.
Anaesthetic management of a parturient with factor VII deficiency and sepsis.
Analysis of biological phenotypes from 42 patients with inherited factor VII deficiency: can biological tests predict the bleeding risk?
Analysis of Phenotype and Genotypein an Inherited Coagulation Factor VII Deficiency Pedigree.
Analysis of the genotypes and phenotypes of 37 unrelated patients with inherited factor VII deficiency.
Anesthetic management of a patient with factor VII deficiency undergoing laparoscopic colectomy: a case report.
Another patient with a congenital hemorrhagic disorder intermediate between factor X and factor VII deficiency.
Anterior segment dysgenesis in a child with factor VII deficiency.
Anti- and procoagulant activities in factor VII-deficient subjects.
Anticoagulation of a patient with hypertrophic cardiomyopathy and factor VII deficiency.
Anticoagulation Therapy Considerations in Factor VII Deficiency.
Aortic valve and coronary artery bypass surgery in a patient with factor VII deficiency.
Application of radioisotope synovectomy in the ankle joint in a child with congenital factor VII deficiency.
Arthropathies in factor VII deficiency: a case report.
Arthropathy and surgery in congenital factor VII deficiency.
Asymptomatic factor VII deficiency in African Americans.
Asymptomatic factor VII deficiency: gene analysis and structure-function relationships.
Asymptomatic intracranial hemorrhage in a newborn with congenital factor VII deficiency and successful treatment with recombinant activated factor VII.
Atherosclerosis and coronary bypass surgery in hereditary factor VII deficiency.
Automated synthetic substrate assays for coagulopathies of dogs.
Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.
Avoiding Cardiovascular Collapse: Pediatric Cutaneous Mastocytosis and Anesthetic Challenges.
Bilateral Subdural Hematomas in an Adult With Hereditary Factor VII Deficiency: A Complication of Sit-ups and Inversion?
Bilateral subdural hematomas, an unusual vaso-occlusive event and prolonged prothrombin time in a 58-year-old victim of an armed robbery.
Bleeding Gastric Heterotopic Polyp in the Duodenum of a Teenager with Severe Factor VII Deficiency.
Bleeding Prophylaxis in a Child With Cleft Palate and Factor VII Deficiency: A Case Report.
Bleeding symptoms in heterozygous carriers of inherited coagulation disorders in southern Iran.
Bloody tears due to congenital factor VII deficiency.
Canine factor VII deficiency: lessons learned in applying methods-based laboratory proficiency testing.
Cardiac surgery with extracorporeal circulation in severe factor VII deficiency.
Cardiac Surgery Without Blood Products in a Jehovah's Witness Child With Factor VII Deficiency.
Carriers of factor VII deficiency are not always asymptomatic.
Case report of factor VII deficiency.
Case Report: A 70-Year-Old Man with Undiagnosed Factor VII Deficiency Presented with Acute Ischemic Stroke.
Case Report: Factor VII deficiency in an obstetrical patient.
Cerebral Venous Sinus Thrombosis in a Patient with Undiagnosed Factor VII Deficiency.
Change of coagulation after NovoSeven® use for bleeding during cardiac surgery.
Changes in haemostasis and thrombosis associated with thyroid disease: Presentation of 2 cases.
Characterisation of a large complex intragenic re-arrangement in the FVII gene (F7) avoiding misdiagnosis in inherited factor VII deficiency.
Characterization of a Cys329Gly mutation causing hereditary factor VII deficiency.
Characterization of mild coagulation factor VII deficiency: activity and clearance of the Arg315Trp and Arg315Lys variants in the Cys310-Cys329 loop (c170s).
Characterization of mutations causing factor VII deficiency in 61 unrelated Israeli patients.
Characterization of two novel splice site mutations in human factor VII gene causing severe plasma factor VII deficiency and bleeding diathesis.
Christmas disease associated with factor VII deficiency; case report with family survey.
Clinical and laboratory features of 178 children with recurrent epistaxis.
Clinical and Laboratory Findings in Jewish and Bedouin Patients in Southern Israel Who Were Diagnosed with Factor VII Deficiency.
CLINICAL ASPECTS OF CONGENITAL FACTOR VII DEFICIENCY.
Clinical audit of inherited bleeding disorders in a developing country.
Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings.
Clinical management of thrombosis in inherited factor VII deficiency: a description of two cases.
Clinical manifestations in 28 Italian and Iranian patients with severe factor VII deficiency.
Clinical manifestations, management, and molecular genetics in congenital factor VII deficiency: the International Registry on Congenital Factor VII Deficiency (IRF7)
Clinical phenotypes and factor VII genotype in congenital factor VII deficiency.
Clinical picture and management of congenital factor VII deficiency.
Clinical picture and treatment strategies in factor VII deficiency.
Clinical pictures and prevalence of factor VII deficiency in Northeastern of Iran.
Clinical problems and surgical interventions in inherited factor VII deficiency.
Coagulation studies in patients with trisomy 8 syndrome.
Coexistence of Factor VII Deficiency and Hereditary Spastic Paraplegia in Two Siblings.
Color vision disturbances secondary to oral tranexamic acid.
Combined congenital dysfibrinogenemia and factor VII deficiency from mutations in the FGB and F7 genes.
Combined factor V and factor VII deficiency due to an independent segregation of the two defects.
Combined factor V and factor VII deficiency. Report of a case with a record on combined defects and considerations on the relevance of partial deficiency of coagulation factors.
Combined factor VII and factor VIII deficiency due to a casual association of heterozygosis for factor VII deficiency and hemophilia A.
Combined mild PTC (plasma thromboplastin component) and factor VII deficiencies.
Complexity of the genetic contribution to factor VII deficiency in two Spanish families: clinical and biological implications.
Compound heterozygous mutations (p.Leu13Pro and p.Tyr294*) associated with factor VII deficiency cause impaired secretion through ineffective translocation and extensive intracellular degradation of factor VII.
Compound heterozygous mutations in severe factor VII deficiency including a novel nonsense mutation.
Compound Heterozygous Mutations in the F7 Gene in 2 Unrelated Families With Congenital Factor VII Deficiency.
Congenital combined defects of factor VII: a critical review.
Congenital deficiency of factor VII in subarachnoid hemorrhage.
Congenital deficiency of factor VII.
Congenital factor VII abnormality discovered in an infant at a routine checkup.
Congenital factor VII deficiency and cerebrovascular stroke.
Congenital factor VII deficiency complicated with hemoperitoneum and intracranial hemorrhage: report of a case.
Congenital factor VII deficiency in a patient with an abdominal aortic aneurysm.
Congenital Factor VII Deficiency in Association With Bicuspid Aortic Valve and Multicystic Dysplastic Kidney Disease in a Child.
Congenital Factor VII Deficiency in Children at Tertiary Health Care Facility in Pakistan.
Congenital factor VII deficiency in Iraqi children (Single Centre Experience).
Congenital factor VII deficiency presenting as delayed bleeding following dental extraction. A review of the role of factor VII in coagulation.
Congenital factor VII deficiency presenting as iron deficiency anaemia--Case report.
Congenital factor VII deficiency presenting first time as isolated recurrent hematuria at late age.
Congenital factor VII deficiency with cerebral haemorrhage treated with prothrombin concentrate.
Congenital factor VII deficiency with normal Stuart activity: clinical, genetic and experimental observations.
Congenital factor VII deficiency.
Congenital factor VII deficiency. A case report.
Congenital factor VII deficiency. A report of four new cases.
Congenital factor VII deficiency. Clinical and laboratory characteristics of a newly discovered kindred.
Congenital factor VII deficiency. Two cases in children of cousins.
Congenital factor VII deficiency: a case report.
Congenital factor VII deficiency: haematological and genetic aspects.
Congenital factor VII deficiency: Multidisciplinary approach is the key to successful perioperative outcome.
Congenital factor VII deficiency: therapy with recombinant activated factor VII -- a critical appraisal.
Congenital factor VII deficiency; a review with a report of a case in an Indian infant.
Congenital factor XI and factor VII deficiencies assure an apparent opposite protection against arterial or venous thrombosis: An intriguing observation.
Constrictive pericarditis in a patient with inherited factor VII deficiency.
Continuous infusion of human prothrombin complex in a patient with congenital factor VII deficiency undergoing laparoscopic cholecystectomy: A case report from China.
Continuous infusion of recombinant activated factor VII during caesarean section delivery in a patient with congenital factor VII deficiency.
Continuous infusion of recombinant activated factor VII for bleeding control after lobectomy in a patient with inherited factor VII deficiency.
Continuous infusion of recombinant activated factor VII: a review of data in congenital hemophilia with inhibitors and congenital factor VII deficiency.
Coronary artery stenosis treatment in aging patients with inherited Factor VII deficiency: Where do we stand?
Current status of hemophilia patients and recombinant coagulation factor concentrates in Japan.
Decreasing the Need for Transfusion: Infant Cardiac Surgery Using Hemodilution and Recombinant Factor VIIa.
Deep vein thrombosis and pulmonary embolism in congenital factor VII deficiency.
Description of breed ancestry and genetic health traits in arctic sled dog breeds.
Descriptive epidemiology of hemophilia and other coagulation disorders in mansoura, egypt: retrospective analysis.
Detecting coagulopathy in pediatric patients with post-tonsillectomy hemorrhage.
Detection of factor X activation in humans.
Detection of two missense mutations and characterization of a repeat polymorphism in the factor VII gene (F7).
Determinants of coagulation activation in humans.
Determinants of plasma factor VIIa levels in humans.
Development of a subdural vein thrombosis following aggressive factor VII replacement for postnatal intracranial haemorrhage in a homozygous factor VII-deficient infant.
Diagnosis and treatment discussion of congenital factor VII deficiency in pregnancy: A case report.
Diagnosis and treatment of a patient with gallstone ileus.
Diagnosis, clinical manifestations and management of rare bleeding disorders in Iran.
Differential functional readthrough over homozygous nonsense mutations contributes to the bleeding phenotype in coagulation factor VII deficiency.
Direct oral anticoagulants for atrial fibrillation in patients with congenital factor VII deficiency.
Direct oral anticoagulants in factor VII deficiency patient.
Discrepancies in FVII:C levels depending on the thromboplastin: about a case.
Disorders of menstruation and their effect on the quality of life in women with congenital factor VII deficiency.
Dosing factor VIIa (recombinant) in nonhemophiliac patients with bleeding after cardiac surgery.
Double heterozygous mutations Gln100Leu and His348Gln of the F7 gene in a patient with factor VII deficiency.
Effectiveness of recombinant activated factor VII (rFVII a) for controlling intractable postpartum bleeding: report of two cases and literature review.
Electroimmunoassay of factor VII antigen.
Elevated prothrombin time on routine preoperative laboratory results in a healthy infant undergoing craniosynostosis repair: Diagnosis and perioperative management of congenital factor VII deficiency.
Elimination of hepatitis C virus infection in patients with haemophilia in Belgium: A single-centre experience.
Entering new areas in known fields: recombinant fusion protein linking recombinant factor VIIa with recombinant albumin (rVIIa-FP) - advancing the journey.
Eptacog alfa activated: a recombinant product to treat rare congenital bleeding disorders.
Ethnic Differences in Coagulation Factor Abnormalities After the Fontan Procedure.
Evaluation of a new chromogenic assay for factor VII and its application in patients on oral anticoagulant treatment.
Evaluation of Bleeding Phenotype of Inherited Factor VII Deficiency in Children With a Bleeding Assessment Tool and Global Assays.
Evidence for the presence of tissue factor activity on subendothelium.
Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds.
Exclusion of the first EGF domain of factor VII by a splice site mutation causes lethal factor VII deficiency.
Expanded carrier screening and preimplantation genetic diagnosis in a couple who delivered a baby affected with congenital factor VII deficiency.
Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
F7 gene variants modulate protein levels in a large cohort of patients with factor VII deficiency. Results from a genotype-phenotype study.
Factor IX is activated in vivo by the tissue factor mechanism.
Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo.
Factor VII and haemostasis.
Factor VII antibody-neutralizing material in hereditary and acquired factor VII deficiency.
Factor VII central. A novel mutation in the catalytic domain that reduces tissue factor binding, impairs activation by factor Xa, and abolishes amidolytic and coagulant activity.
Factor VII congenital deficiency. Clinical picture and classification of the variants.
Factor VII deficiency - an enigma; clinicohematological profile in 12 cases.
Factor VII deficiency and a copper metabolism disorder in a patient with Klippel-Trenaunay syndrome.
Factor VII deficiency and developmental abnormalities in a patient with partial monosomy of 13q and trisomy of 16p: case report and review of the literature.
Factor VII deficiency and its treatment in delivery with recombinant factor VII.
Factor VII deficiency and pregnancy.
Factor VII deficiency and pregnancy: a case report and review of literature.
Factor VII deficiency and surgery. Is preoperative replacement therapy necessary?
Factor VII deficiency and the FVII mutation database.
Factor VII deficiency associated with nephrotic syndrome.
Factor VII deficiency associated with valproate treatment.
Factor VII deficiency caused by a structural variant N57D of the first epidermal growth factor domain.
Factor VII deficiency detected in pregnancy: a case report.
Factor VII deficiency diagnosed after minor genital trauma.
Factor VII Deficiency due to Compound Heterozygosity for Leu-48Pro Mutation and a Novel Pro260Leu Mutation.
Factor VII deficiency first observed at preoperative routine clotting test.
Factor VII deficiency impairs cutaneous wound healing in mice.
Factor VII deficiency in a mixed breed dog.
Factor VII deficiency in a patient with retinal arteriolar tortuosity syndrome.
Factor VII deficiency in an Alaskan malamute.
Factor VII deficiency in an East Indian family.
Factor VII deficiency in beagle dog plasma and its use in the assay of human factor VII.
Factor VII deficiency in major artery occlusion stroke.
Factor VII Deficiency in Patients Receiving Chronic Packed Cell Transfusions.
Factor VII deficiency in pregnancy and delivery: a case report.
Factor VII deficiency in pregnancy treated with recombinant factor VIIa.
Factor VII deficiency presenting as a possible child abuse.
Factor VII deficiency rescues the intrauterine lethality in mice associated with a tissue factor pathway inhibitor deficit.
Factor VII Deficiency Resulting in Acute Hemorrhage in Orthognathic Surgery: A Case Report.
Factor VII deficiency with intracranial hemorrhage: a case report.
Factor VII Deficiency, Masked by Warfarin Therapy, as a Cause of Bleeding After Cardiovascular Intervention.
Factor VII deficiency.
Factor VII Deficiency.
Factor VII deficiency.
Factor VII Deficiency.
Factor VII deficiency: a double heterozygote of an Arg402Stop with a deletion of the C-terminal five amino acids and a Thr359Met.
Factor VII deficiency: a novel missense variant and genotype-phenotype correlation in patients from Southern Italy.
Factor VII Deficiency: A Rare Case Report.
Factor VII Deficiency: A Single-Center Experience.
Factor VII deficiency: clinical manifestation of 717 subjects from Europe and Latin America with mutations in the factor 7 gene.
Factor VII Deficiency: Clinical Phenotype, Genotype and Therapy.
Factor VII deficiency: defining the clinical picture and optimizing therapeutic options.
Factor VII deficiency: do all need replacement for cardiac surgery?
Factor VII deficiency: immunological characterization of genetic variants and detection of carriers.
Factor VII deficiency: Unveiling the cellular and molecular mechanisms underlying three model alterations of the enzyme catalytic domain.
Factor VII gene intronic mutation in a lethal factor VII deficiency: effects on splice-site selection.
Factor VII half-life after transfusion of a steam-treated prothrombin complex concentrate in a patient with homozygous factor VII deficiency.
Factor VII Mie: homozygous asymptomatic type I deficiency caused by an amino acid substitution of His (CAC) for Arg(247) (CGC) in the catalytic domain.
Factor VII Morioka (FVII L-26P): a homozygous missense mutation in the signal sequence identified in a patient with factor VII deficiency.
Factor VII Padua 2: another factor VII abnormality with defective ox brain thromboplastin activation and a complex hereditary pattern.
Factor VII R110C: a novel missense mutation (Arg110Cys) in the second epidermal growth factor-like domain causing factor VII deficiency in members of a Japanese family.
Factor VII Toyama (Thr 359 Met): a homozygous missense mutation causing severe type I deficiency.
Factor VII verona coagulation disorder: double heterozygosis with an abnormal factor VII and heterozygous factor VII deficiency.
Factor VIIa for correction of traumatic coagulopathy.
Factor VIIa replacement therapy in factor VII deficiency.
Factor VIIa-antithrombin complexes in patients with arterial and venous thrombosis.
Familial factor VII deficiency with foetal and neonatal fatal cerebral haemorrhage associated with homozygosis to Gly180Arg mutation.
Familial haemophilia and factor VII deficiency.
Fatal intracranial hemorrhage in a newborn with factor VII deficiency.
First living-related liver transplant to cure factor VII deficiency.
First manifestation of a hereditary homozygous factor VII deficiency in a 3-year-old girl suspected as purpura fulminans.
First molecular characterization of a patient with combined factor V and factor VII deficiency.
Frequencies of mild factor V, VII and X deficiencies in a Japanese population.
Frequency of five disease-causing genetic mutations in a large mixed-breed dog population (2011-2012).
Functional and Molecular Characterization of C91S Mutation in the Second Epidermal Growth Factor-Like Domain of Factor VII.
Gene Therapy for Inherited Bleeding Disorders.
Generation of a human induced pluripotent stem cell line, YCMi002-A, from a Factor VII deficiency patient carrying F7 mutations.
Genetic Panel Screening of Nearly 100 Mutations Reveals New Insights into the Breed Distribution of Risk Variants for Canine Hereditary Disorders.
Genotype and phenotype correlation in intracranial hemorrhage in neonatal factor VII deficiency among Thai children.
Genotype and phenotype relationships in 10 Pakistani unrelated patients with inherited factor VII deficiency.
Genotypic heterogeneity may explain phenotypic variations in inherited factor VII deficiency.
Glomerulitis and factor vii deficiency in Familial Mediterranean fever.
Granulomatous Pneumocystis carinii pneumonia in a non-AIDS patient: an atypical presentation.
HAART and Mycobacterium avium complex in an HIV infected patient with severe factor VII deficiency.
Haemoperitoneum associated with ovulation in women with bleeding disorders: the case for conservative management and the role of the contraceptive pill.
Hematology of experimental acute Sarcocystis bovicanis infection in calves. II. Serum biochemistry and hemostasis studies.
Hemipelvectomy after severe pelvic injury in Factor VII deficiency toddler.
Hemophagocytic lymphohistiocytosis and congenital factor VII deficiency: a case report.
Hemophilia A and concurrent factor VII deficiency. Studies of a patient with complicating cardiac tamponade.
Hemophilia B with associated factor VII deficiency: a distinct variant of hemophilia B with low factor VII activity and normal factor VII antigen.
Hemorrhagic diathesis due to factor VII deficiency.
Hemorrhagic stroke in a child with protein S and factor VII deficiencies.
Hepatocyte transplantation for inherited factor VII deficiency.
Hepatocyte transplantation for liver-based metabolic disorders.
Hereditary bleeding disorders in Riyadh, Saudi Arabia.
Hereditary factor VII deficiency and increased contact activation time.
Hereditary factor VII deficiency in a Chinese family.
Hereditary Factor VII deficiency in newborns.
Hereditary factor VII deficiency in pregnancy: peripartum treatment with factor VII concentrate.
Hereditary factor VII deficiency in the Alaskan Klee Kai dog.
HEREDITARY FACTOR VII DEFICIENCY IN THE ASIAN ELEPHANT (ELEPHAS MAXIMUS) CAUSED BY A F7 MISSENSE MUTATION.
Hereditary factor VII deficiency in two siblings: two different clinical presentation.
Hereditary factor VII deficiency: heterogeneity defined by combined functional and immunochemical analysis.
Hereditary factor VII deficiency: report of a case of intracranial hemorrhage.
Heterozygous congenital Factor VII deficiency with the 9729del4 mutation, associated with severe spontaneous intracranial bleeding in an adolescent male.
Heterozygous factor VII deficiency and severe hemophilia A in the same kindred.
Hip surgery in a patient with severe factor VII deficiency.
Hobby-induced factor VII deficiency.
Home treatment for patients with congenital bleeding disorders in a developing country.
Homozygous 2bp deletion in the human factor VII gene: a non-lethal mutation that is associated with a complete absence of circulating factor VII.
Homozygous congenital factor VII deficiency with a novel mutation, associated with severe spontaneous intracranial bleeding in a neonate.
Human factor VII deficiency caused by S339C mutation located adjacent to the specificity pocket of the catalytic domain.
Identification of two novel mutations in three children with congenital factor VII deficiency.
Impact of Telemedicine Tools on Record Keeping and Compliance in Haemophilia Care.
In vivo studies of the role of factor VII in hemostasis.
Inadvertent propagation of factor VII deficiency in a canine mucopolysaccharidosis type I research breeding colony.
Incidence of hereditary bleeding disorders in Bradford, UK: variation with ethnic group.
Increase in the risk of ST elevation myocardial infarction is associated with homocysteine level.
Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect.
Inherited bleeding disorders in Indian women with menorrhagia.
Inherited bleeding disorders in the Eastern Province of Saudi Arabia.
Inherited factor VII deficiency and surgery: clinical data are the best criteria to predict the risk of bleeding.
Inherited factor VII deficiency: genetics and molecular pathology.
Inherited factor VII deficiency: identification of two novel mutations (A191V and T239P) in the catalytic domain.
Inherited factor VII deficiency: molecular genetics and pathophysiology.
Inhibitor development after liver transplantation in congenital factor VII deficiency.
Inhibitor development in patients with congenital factor VII deficiency, a study on 50 Iranian patients.
Inhibitor in Congenital Factor VII Deficiency; a Rare but Serious Therapeutic Challenge-A Systematic Literature Review.
Inhibitor to factor VII in severe factor VII deficiency: detection and course of the inhibitory response.
Inhibitors to factor VII in congenital factor VII deficiency.
Intracranial bleeding following soccer-related head trauma in a young student with occult factor VII deficiency.
Intracranial hemorrhage in congenital factor VII deficiency.
Invasive EEG-electrodes in presurgical evaluation of epilepsies: Systematic analysis of implantation-, video-EEG-monitoring- and explantation-related complications, and review of literature.
Invasive procedures and minor surgery in factor VII deficiency.
Is the coexistence of thromboembolic events and Factor VII deficiency fortuitous?
Ischemic stroke in a patient with moderate to severe inherited factor VII deficiency.
Ischemic strokes in congenital bleeding disorders: comparison with myocardial infarction and other acute coronary syndromes.
Isolated acquired factor VII deficiency: review of the literature.
Isolated factor VII deficiency diagnosed after a life-threatening brain haemorrhage.
Isolation of hepatocytes from livers from non-heart-beating donors for cell transplantation.
Isotypic analysis of antibodies against activated Factor VII in patients with Factor VII deficiency using the x-MAP technology.
Japanese family with congenital factor VII deficiency.
Kidney Transplant in a Patient With Factor VII Deficiency: Case Report.
Laboratory evaluation of hemorrhagic coagulopathies in small animal practice.
Lack of bleeding in patients with severe factor VII deficiency.
Lethal factor VII deficiency due to novel mutations in the F7 promoter: Functional analysis reveals disruption of HNF4 binding site.
Life-threatening bleeding in a case of autoantibody-induced factor VII deficiency.
Life-threatening bleeding in a patient with a lupus inhibitor and probable acquired factor VII deficiency.
Life-threatening bleeding in factor VII deficiency: the role of prenatal diagnosis and primary prophylaxis.
Life-threatening menorrhagia secondary to Factor VII deficiency and leiomyomata.
Liver after hepatocyte transplantation for liver-based metabolic disorders in children.
Liver cell transplantation.
Liver transplant for congenital factor VII deficiency.
Liver transplantation for factor VII deficiency.
Liver transplantation for treatment of severe S-adenosylhomocysteine hydrolase deficiency.
Long-term follow-up of prophylaxis with recombinant activated factor VII in patients with congenital factor VII deficiency.
Long-term prophylaxis in severe factor VII deficiency.
Long-term successful percutaneous coronary intervention in factor VII deficiency.
Low endoscopy bleeding risk in patients with congenital bleeding disorders.
Lower extremity compartment syndrome in the setting of iliofemoral deep vein thrombosis, phlegmasia cerulea dolens and factor VII deficiency.
Lower extremity salvage complicated by recurrent microvascular thrombosis in a patient with congenital factor VII deficiency.
Major differences in bleeding symptoms between factor VII deficiency and hemophilia B.
Management of a patient with atrial fibrillation and factor VII deficiency.
Management of a patient with Factor VII deficiency.
Management of concomitant factor VII deficiency and Factor V Leiden mutation.
Management of intracranial haemorrhage in a newborn with inherited factor VII deficiency with the use of rFVIIa aliquots.
Management of intracranial surgery for refractory epilepsy in severe factor VII deficiency: choosing the optimal dosing regimen.
Management of Kidney Transplantation in a Factor VII-Deficient Patient: Case Report.
Management of Labour and Delivery in a Patient With Acquired Factor VII Deficiency With Inhibitor: A Case Report.
Management of Pregnancy in a Chilean Patient with Congenital Deficiency of Factor VII and Glanzmann's Thrombasthenia Variant.
Management of pregnancy in women with factor VII deficiency: A case series.
Management of Surgical Third Lower Molar Extraction and Postoperative Progress in Patients With Factor VII Deficiency: A Clinical Protocol and Focus on This Rare Pathologic Entity.
Managing incidentally diagnosed isolated factor VII deficiency perioperatively: a brief expert consensus report.
Mechanism underlying factor VII deficiency in Jewish populations with the Ala244Val mutation.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Menorrhagia caused by severe hereditary factor VII deficiency. Case 1.
Migraine, cortical blindness, multiple cerebral infarctions and hypocoagulopathy in celiac disease.
Mild factor VII deficiency due to heterozygosis is not associated with a bleeding tendency.
Mitral valve surgery in severe congenital factor VII deficiency.
Molecular analysis in a patient with severe factor VII deficiency and an inhibitor: report of a novel mutation (S103G).
Molecular analysis of factor VII deficiency in Italy: a frequent mutation (FVII Lazio) in a repeated intronic region.
Molecular analysis of Polish patients with factor VII deficiency.
Molecular analysis of the genotype-phenotype relationship in factor VII deficiency.
Molecular and clinical aspects of factor VII deficiency.
Molecular basis of hereditary factor VII deficiency in India: five novel mutations including a double missense mutation (Ala191Glu; Trp364Cys) in 11 unrelated patients.
Molecular biology and clinical manifestation of hereditary factor VII deficiency.
Molecular characterisation and three-dimensional structural analysis of mutations in 21 unrelated families with inherited factor VII deficiency.
Molecular characterization of four novel mutations causing factor VII deficiency.
Molecular Characterization of Iranian Patients with Inherited Coagulation Factor VII Deficiency.
Molecular defects in CRM+ factor VII deficiencies: modelling of missense mutations in the catalytic domain of FVII.
Molecular determination of the breakpoints of a 161 556 bp deletion at chromosome 13q34 that presented as severe factor VII deficiency in a neonate.
Molecular mechanisms of FVII deficiency: expression of mutations clustered in the IVS7 donor splice site of factor VII gene.
Molecular variant of factor VII.
Monitoring of hemostatic status in four patients being treated with recombinant factor VIIa.
Multiple cerebral aneurysms in factor VII deficiency.
Multiple congenital coagulopathies co-expressed with Von Willebrand's disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature.
Multiple extractions in a patient with factor VII deficiency.
Multiple intracranial hemorrhages at the time of a transiently prolonged activated partial thromboplastin time in an infant with congenital factor VII deficiency.
Mutation in the factor VII hepatocyte nuclear factor 4?-binding site contributes to factor VII deficiency.
Mutation pattern in clinically asymptomatic coagulation factor VII deficiency.
National survey of patients with hemophilia and other congenital bleeding disorders in Thailand.
Natural and engineered carboxy-terminal variants: decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiency.
Neonatal intracranial hemorrhage secondary to congenital factor VII deficiency: two case reports.
Newly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven(®)).
Next-generation sequencing and recombinant expression characterized aberrant splicing mechanisms and provided correction strategies in factor VII deficiency.
Novel factor VII gene mutations in six families with hereditary coagulation factor VII deficiency.
Novel IVS7+1G>T mutation of life-threatening congenital factor VII deficiency in neonates: A retrospective study in China.
Obstetric analgesia and anaesthesia in women with inherited bleeding disorders.
Occult hemophilia as a cause of postoperative and postpartum hemorrhage. With special reference to factor VII deficiency.
Occult hepatitis B virus infection in Greek patients with congenital bleeding disorders.
Occurrence of hereditary leaky red cell syndrome and partial coagulation factor VII deficiency in a Spanish family.
Off-Label Recombinant Factor VIIa Use and Thrombosis in Children: A Multi-center Cohort Study.
Off-label use of rFVIIa in children with excessive bleeding: A consecutive study of 153 off-label uses in 139 children.
On a case of-Christmas disease associated with factor VII deficiency.
One-step chromogenic equivalent of activated partial thromboplastin time evaluated for clinical application.
Open heart surgery with factor VII deficiency.
Open-heart surgery in an infant with heterozygous factor VII deficiency.
Orbital Compartment Syndrome Following Post-Traumatic Subgaleal Hematoma.
Orthopaedic surgery in severe bleeding disorders: a low-volume, high-cost procedure.
Outcome of intracranial hemorrhage in infants with congenital factor VII deficiency.
Outcome of laparoscopic ovariohysterectomy or ovariectomy in dogs with von Willebrand disease or factor VII deficiency: 20 cases (2012-2014).
Palliative open heart surgery in an infant with factor VII deficiency.
Paracetamol poisoning unmasking factor VII deficiency.
Pathogenetic role of Factor VII deficiency and thrombosis in cross-reactive material positive patients.
Pediatric cardiac intervention in a case of congenital factor VII deficiency: a challenge to overcome.
Pediatric cardiac surgery under cardiopulmonary bypass in factor VII deficiency.
Percutaneous Nephrolithotomy in Rare Bleeding Disorders: A Case Report and Review of the Literature.
Peri-operative replacement therapy with factor VII concentrate in a patient with severe factor VII deficiency.
Perioperative pharmacokinetics of factor VII concentrate during liver surgery in a patient with congenital factor VII deficiency: an individual mathematical model.
Persistent uterine and vaginal hemorrhage in a beagle with factor VII deficiency.
Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency.
Pharmacology and clinical use of recombinant activated factor seven in neurosciences.
Phenotypic and genotypic characterization of Factor VII deficiency patients from Western India.
Phenotypic and genotypic characterization of four factor VII deficiency patients from central China.
Plasma thromboplastin antecedent (Factor XI) deficiency in a black family.
Plummer-Vinson Syndrome With Concomitant Factor VII Deficiency.
Point-of-Care Thromboelastography for Intrathecal Drain Management in Patients With Coagulopathy and Thoracic Aorta Surgery: A Case Report.
Possible homozygous factor VIIR disorder associated with fibrinolytic hyperactivity.
Posterior reversible encephalopathy syndrome (PRES) in pregnancy: a diagnostic challenge to obstetricians.
Postoperative bleeding with factor VII deficiency: case report.
Pregnancy in women with congenital factor VII deficiency.
Prenatal diagnosis of severe factor VII deficiency using mutation detection and linkage analysis.
Prenatal exclusion of severe factor VII deficiency by DNA sequencing.
Prenatal exclusion of severe factor VII deficiency.
Preparation of factor VII concentrate using CNBr-activated Sepharose 4B immunoaffinity chromatography.
Prevalence of factor VII deficiency and molecular characterization of the F7 gene in Brazilian patients.
Prevalence of HIV infection in a cohort of patients with congenital coagulation defects of the prothrombin complex factors.
Prevention of bleeding and hemorrhagic complications in surgical patients with inherited factor VII deficiency.
Prevention of Bleeding Complications in Neonates With Liver Failure Undergoing Surgery Using Recombinant Factor VIIa.
Primary factor VII deficiency.
Primary prophylaxis for children with severe congenital factor VII deficiency - Clinical and laboratory assessment.
Prolongation of prothrombin time in the presence of rivaroxaban: is this the only cause?
Prophylactic effect of recombinant factor VIIa with congenital factor VII deficiency.
Prophylactic therapy in a pregnant woman with severe factor VII deficiency.
Prophylactic treatment of a small child with severe factor VII deficiency using repeat dosing from a single vial of recombinant activated factor VII.
Prophylactic treatment of hereditary severe factor VII deficiency in pregnancy.
Prophylaxis and therapy with factor VII concentrate (human) immuno, vapor heated in patients with congenital factor VII deficiency: a summary of case reports.
Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER).
Prophylaxis of peripartum haemorrhage using recombinant factor VIIa (rfVIIa) in pregnant women with congenital factor VII deficiency: A case report and literature review.
Prophylaxis with recombinant-activated factor VII (rFVIIa) for minimally invasive surgery in a patient with congenital factor VII deficiency: a case report with a single-low dose of rFVIIa.
Prophylaxis with rFVIIa before third molar extraction in a patient with factor VII deficiency.
Prostate surgery in severe congenital factor VII deficiency: A case report.
Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.
Prothrombin complex concentrate for factor VII replacement in a patient undergoing left ventricular assist device implantation with factor VII deficiency.
Psychosocial Impact and Disease Management in Patients with Congenital Factor VII Deficiency.
Pulmonary embolism in a patient with mild factor VII deficiency after administration of recombinant activated factor VII during a urological procedure.
Radiographic abnormalities in coagulation factor VII deficiency.
Rare bleeding disorders: spectrum of disease and clinical manifestations in the Pakistani population.
Rare factor VII variant inherited through genetic variant in proband's mother and another genetic variant in proband's father.
Rare inherited coagulation disorders in India.
Rational Use of Recombinant Factor VIIa in Clinical Practice.
Recombinant activated factor VII (rFVIIa, NovoSeven).
Recombinant activated factor VII for a patient with factor VII deficiency undergoing urgent intracerebral haematoma evacuation with underlying cavernous angioma.
Recombinant activated factor VII in clinical practice: a 2014 update.
Recombinant activated factor VII: mechanisms of action and current indications.
Recombinant coagulation factor VIIa: from the concept to clinical application in hemophilia treatment in 2000.
Recombinant Factor VIIa (Eptacog Alfa): A Review of its Use in Congenital Hemophilia with Inhibitors, Acquired Hemophilia, and Other Congenital Bleeding Disorders.
Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders.
Recombinant factor VIIa for long-term replacement therapy in patients with congenital factor VII deficiency.
Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia.
Recombinant factor VIIa for the treatment of congenital factor VII deficiency.
Recombinant factor VIIa for treatment of a child with severe factor VII deficiency and coarctation of the aorta.
Recombinant factor VIIa prophylaxis in a patient with severe congenital factor VII deficiency.
Recombinant factor VIIa treatment for asymptomatic factor VII deficient patients going through major surgery.
Recombinant factor VIIa: a universal hemostatic agent?
Recombinant, activated factor VII for surgery in factor VII deficiency: a prospective evaluation - the surgical STER.
Recurrent Bleedings in Newborn: A Factor VII Deficiency Case Report.
Recurrent intracranial hemorrhage in an infant with congenital factor VII deficiency.
Recurrent mutations and genotype-phenotype correlations in hereditary factor VII deficiency in Korea.
Recurrent pre-retinal haemorrhages associated with coagulation factor VII deficiency.
Regulatory polymorphisms underlying complex disease traits.
Repair of abdominal aortic aneurysm in severe Factor VII deficiency.
Repeated recombinant activated factor VII administration in a patient with congenital factor VII deficiency undergoing modified radical hysterectomy: a case report.
Replacement therapy for bleeding episodes in factor VII deficiency. A prospective evaluation.
Replacement therapy in inherited factor VII deficiency: occurrence of adverse events and relation with surgery.
Residual factor VII activity and different hemorrhagic phenotypes in CRM(+) factor VII deficiencies (Gly331Ser and Gly283Ser).
Resistance to activated protein C: evaluation of three functional assays.
Response to treatment and adverse events associated with use of recombinant activated factor VII in children: a retrospective cohort study.
Segmental liver transplantation from non-heart beating donors-an early experience with implications for the future.
Selection of replacement therapy for patients with severe factor VII deficiency.
Sensitivities of thromboplastins to factor VII deficiency.
Sensitivity of different prothrombin time assays to factor VII deficiency in canine plasma.
Sensitivity of different thromboplastin reagents to factor VII deficiency in the blood of beagle dogs.
Serendipitous Discovery of Factor VII Deficiency and the Ensuing Dilemma.
Severe arterial thrombosis in a congenitally factor VII deficient patient.
Severe coagulation factor VII deficiency caused by a novel homozygous mutation (p. Trp284Gly) in loop 140s.
Severe congenital Factor VII deficiency associated with the 13q deletion syndrome.
Severe Congenital Factor VII Deficiency with Normal Perioperative Coagulation Profile Based on ROTEM Analysis in a Hepatectomy.
Severe factor VII deficiency caused by a novel mutation His348 to Gln in the catalytic domain.
Severe factor VII deficiency caused by a novel point mutation (Arg353Pro) combined with a rare Cys22Arg mutation.
Severe factor VII deficiency caused by mutations abolishing the cleavage site for activation and altering binding to tissue factor.
Severe factor VII deficiency due to a mutation disrupting a hepatocyte nuclear factor 4 binding site in the factor VII promoter.
Severe factor VII deficiency due to a mutation disrupting an Sp1 binding site in the factor VII promoter.
Severe factor VII deficiency with recurrent intracranial haemorrhages owing to double heterozygosity for a splice site mutation of an IVS4 and a novel nonsense mutation in exon 8 (Gln211-->Term).
Severe menorrhagia due to factor VII deficiency successfully treated by thermal balloon endometrial ablation.
Significance and causes of abnormal preoperative coagulation test results in children.
Spectrum of factor X gene mutations in Iranian patients with congenital factor X deficiency.
Spontaneous chronic subdural hematoma in young adult: the role of missing coagulation facto.
Spontaneous hemorrhage after external ventricular drain placement in the setting of low factor VII secondary to liver cirrhosis.
Spontaneous umbilical cord haematoma and congenital factor VII deficiency.
Steps towards an effective treatment strategy in congenital factor VII deficiency.
Studies on a family with the factor VII defect.
Studies on immunological assay of vitamin K dependent factors. I. Measurement of factor VII antigen by radioimmunoassay.
Study of different factor VII deficiency variants in nine families from Spain.
Subdural Hematoma From an Acquired Factor VII Deficiency: Is It the Lupus or the Anticoagulant?
Subgaleal hematoma with delayed proptosis and corneal ulceration.
Substitution therapy of congenital factor VII deficiency at an extended operation with extracorporeal circulation.
Successful control of central nervous system bleeding in two newborns with severe factor VII deficiency using rFVIIa administered via Port-a-Cath.
Successful coronary artery bypass graft surgery in severe congenital factor VII deficiency: Perioperative treatment with factor VII concentrate.
Successful coronary artery bypass graft surgery in severe congenital factor VII deficiency: Perioperative treatment with pd-factor VII concentrate.
Successful excision of hemorrhagic cavernous angioma in a patient with severe factor VII deficiency: perioperative treatment with factor VII concentrate.
Successful management of maternal factor VII deficiency in a cesarean section.
Successful prophylaxis against intracranial hemorrhage using weekly administration of activated recombinant factor VII in a newborn with severe factor VII deficiency.
Successful prophylaxis of intracranial hemorrhage in infants with severe congenital factor VII deficiency.
Successful short-term oral surgery prophylaxis with rFVIIa in severe congenital factor VII deficiency.
Successful Splenectomy Management in a Patient With Moderate Factor VII Deficiency and Concomitant Severe Hereditary Spherocytosis.
Successful treatment of hereditary factor VII deficiency presented for the first time with epistaxis in pregnancy: a case report.
Successful treatment of mixed-type autoimmune hemolytic anemia with rituximab in a child following liver transplantation.
Successful use of rFVIIa for major breast surgery prophylaxis in congenital factor VII deficiency.
Successful use of rFVIIa for major breast surgery prophylaxis in congenital factor VII deficiency: a case report.
Surgery for scoliosis in congenital factor VII deficiency.
SURGERY IN PATIENTS WITH CONGENITAL FACTOR VII DEFICIENCY (CONGENITAL HYPOPROCONVERTINEMIA). EXPERIENCE WITH ONE CASE AND REVIEW OF THE LITERATURE.
Surgery in patients with congenital factor VII deficiency - a single center study.
Surgery in patients with congenital factor VII deficiency: A single center experience.
Surgical Aortic Valve Replacement in an Adult Patient With Congenital Factor VII Deficiency: A Case Report of Perioperative Coagulation Management.
Surgical interventions in childhood rare factor deficiencies: a single-center experience from Turkey.
Synergistic effect of factor VII gene polymorphisms causing mild factor VII deficiency in a case of severe factor X deficiency.
Synovectomy for haemophilic arthropathy: 6-21 years of follow-up in 16 patients.
Synovectomy of the elbow in a patient with factor VII deficiency (hypoconvertinemia).
Takayasu Arteritis Presenting as Renovascular Hypertension and Renal Failure in a Patient with Factor VII Deficiency.
The clinical and laboratory significance of cases of congenital FX deficiency due to defects in the Gla-domain.
The clotting action of Russell viper venom. 1954.
The congenital factor VII abnormalities (dysproconvertinemias). The genetic plot thickens.
The importance of tissue factor source in the management of Factor VII deficiency.
The K-test (trypsin clotting time) in coumarin treated patients and in congenital deficiencies and abnormalities of the prothrombin complex.
The paradoxical association between inherited factor VII deficiency and venous thrombosis.
The role of tissue factor in the production of thrombin.
The significance of published polymorphisms in 14 cases of mild factor VII deficiency.
The spectrum of factor VII deficiencies and abnormalities.
The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding.
The use of recombinant activated factor VII in congenital and acquired factor VII deficiencies.
The use of recombinant activated factor VII in the circumcision operation in the case of a congenital factor VII deficiency.
The use of recombinant activated factor VII in three patients with central nervous system hemorrhages associated with factor VII deficiency.
Thromboelastographic monitoring of the efficacy of recombinant factor VIIa administration in a parturient with factor VII deficiency.
Thromboembolism in congenital factor VII deficiency.
Thromboembolism in patients with hereditary deficiency of coagulation factors.
Thrombosis in a bleeding disorder: case of thromboembolism in factor VII deficiency.
Thrombosis in inherited factor VII deficiency.
Thrombosis: a study of coagulation parameters and mechanisms during allograft rejection.
Tissue factor pathway inhibitor activity in factor VII deficiency.
Total hip arthroplasty in severe congenital factor VII deficiency: successful use of recombinant activated factor VII for hemostasis.
Transmission of factor VII deficiency through liver transplantation.
Treatment of congenital factor VII deficiency with a new concentrate.
Treatment of factor VII deficiency with recombinant factor VIIa.
Treatment of factor XI inhibitor using recombinant activated factor VIIa.
Triple coronary artery bypass graft surgery in a patient with factor VII deficiency: a case report.
Twenty two novel mutations of the factor VII gene in factor VII deficiency.
Two novel cases of cerebral haemorrhages at the neonatal period associated with inherited factor VII deficiency, one of them revealing a new nonsense mutation (Ser52Stop).
Two novel factor VII gene mutations in a Chinese family with factor VII deficiency.
Two novel mutations in severe factor VII deficiency.
Two typical hereditary charts of congenital factor VII deficiency.
Two-incision laparoscopic appendectomy for a severe hemophilia A child patient with coagulation factor VII deficiency: Case report and review of literature.
U1-snRNA-mediated rescue of mRNA processing in severe factor VII deficiency.
Uncomplicated stereotactic and open neurosurgical procedures in patients with factor VII deficiency.
Unlabeled uses of factor VIIa (recombinant) in pediatric patients.
Unprovoked Pulmonary Embolism in Factor VII Deficiency.
Use of global assays to understand clinical phenotype in congenital factor VII deficiency.
Use of recombinant factor VII for tooth extractions in a patient with severe congenital factor VII deficiency: a case report.
Use of recombinant factor VIIa in hereditary bleeding disorders.
Use of recombinant factor VIIa in surgery in factor-VII-deficient patients.
Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies.
Using a minigene approach to characterize a novel splice site mutation in human F7 gene causing inherited factor VII deficiency in a Chinese pedigree.
Vena porta thrombosis in patient with inherited factor VII deficiency.
Visually Disabling Non-Traumatic Orbital Hemorrhage in an Anticoagulated Patient with Factor VII Deficiency.
Warfarin-induced factor VII deficiency and the bleeding time.
Whole-exome sequencing provides insights into monogenic disease prevalence in Northwest Russia.
Women with congenital factor VII deficiency: clinical phenotype and treatment options from two international studies.
[A case of congenital factor VII deficiency (author's transl)]
[A case of congenital hemorrhagic diathesis due to factor VII deficiency (hypoproconvertinemia)]
[A family of congenital factor VII deficiency (author's transl)]
[A new case of homozygous congenital factor VII deficiency. Associated factor X deficiency in some members of the family]
[A Quebec family with factor VII deficiency]
[Acquired and repeated factor VII deficiency during infections outbreaks: case-report]
[Acquired factor VII deficiency]
[Acquired isolated factor VII deficiency and bronchogenic carcinoma. A case report]
[An acquired isolated transitory factor VII deficiency]
[An inherited coagulation factor VII deficiency pedigree caused by homozygous mutation of His348Gln].
[Anaesthetic management of a parturient with a severe factor VII deficiency: was activated factor VII really necessary?].
[Analysis of a Chinese pedigree affected with hereditary factor VII deficiency caused by compound heterozygous variants of F7 gene].
[Analysis of an inherited FVII deficiency pedigree caused by homozygosity of Thr359Met]
[Anesthesia and coagulation factor VII deficiency]
[Anesthesia and factor VII deficiency]
[Anesthesia in a patient with hereditary factor VII deficiency]
[Anesthesia in congenital factor VII deficiency]
[Application of heat-treated factor VII concentrates in a patient with congenital factor VII deficiency during labor]
[Assay of factor VII antigen by enzyme-linked immunosorbent assay (ELISA)]
[Bleeding after cardiac surgery: the role of recombinant factor VIIa]
[Blood transfusion as substitution therapy in factor V- and factor VII deficiency.]
[Case of congenital factor VII deficiency]
[Case of factor VII deficiency with systemic amyloidosis having a unique clinical course such as splenic rupture]
[Classical factor VII deficiency: biological and genetic evaluation of 3 families]
[Clinical and blood coagulation studies in patients with congenital factor VII deficiency]
[Clinical assessment of potential fields of application of recombinant factor VIIa in internal and pediatric diseases. Recommendations of an expert group.]
[Clinical studies of familial hereditary factor VII deficiency (author's transl)]
[Coagulation factor VII deficiency in 3 patients with trisomy 8]
[Coagulation factor VII deficiency in a chronic carrier of the B virus]
[Concurrent obstetric disease and ischemic ictus in 2 cases with moderated factor VII deficiency]
[Congenital factor VII deficiency (author's transl)]
[Congenital factor VII deficiency and subarachnoidal haemorrhage due to intracranial aneurysm: a case report]
[Congenital factor VII deficiency as a cause of obstetrical and gynecological hemorrhages]
[Congenital factor VII deficiency associated with idiopathic osteopsathyrosis of Lobstein type.]
[Congenital factor VII deficiency revealed by post-circumcision bleeding].
[Congenital factor VII deficiency. Report of 4 cases]
[Congenital factor VII deficiency: about two family cases].
[Congenital factor VII deficiency; family investigation and physiological studies on factor VII.]
[Congenital factor VII deficiency]
[Congenital hypoproconvertinemia; case of congenital factor VII deficiency and brief review of literature.]
[Contribution to the clinical picture of congenital factor VII deficiency]
[Differential diagnosis of factor VII deficiency in the newborn.]
[Double heterozygous mutations of non-canonical splice (IVS1a + 5g > a) and His348Gln caused inherited coagulation factor VII deficiency]
[Efficacy of Recombinant Activated Factor VII for Intractable Bleeding after Cardiovascular Surgery].
[Epistaxis due to coagulation disorder in factor VII deficiency.]
[Factor VII deficiency and homocystinuria. Chance association or syndrome?]
[Factor VII deficiency and surgery: infusion of fresh-frozen plasma in a case report]
[Factor VII deficiency and surgery: is preoperative replacement necessary?]
[Factor VII deficiency and surgery]
[Factor VII deficiency revealed by intracranial hemorrhage.]
[Factor VII deficiency--case report]
[Factor VII deficiency. Preparation for surgical intervention]
[Factor VII deficiency]
[Gastrectomy for a patient with congenital factor VII deficiency--a case report]
[Gastrectomy in congenital factor VII deficiency with substitution of factor VII concentrate]
[Gene diagnosis of antithrombin deficiency and factor VII deficiency]
[Genetic analysis of hereditary factor VII deficiency from a Chinese pedigree]
[Genetic diagnosis of hereditary coagulation disorders]
[Genotype and phenotype analysis of congenital coagulator factor VII deficiency in four Chinese pedigrees].
[Haplotype Analysis of Coagulation Factor VII Gene in a Patient with Congenital Coagulation Factor VII Deficiency with Heterozygous p.Arg337Cys Mutation and o.Aro413Gin Polymorphism..]
[Hemorrhage from the palatal tonsils in the course of angina in a child with factor VII deficiency]
[Hemorrhagic diathesis due to factor VII deficiency (hypoproconvertinemia).]
[Hemostasis anomalies and prognosis during severe infectious purpura in children. Retrospective study in 69 cases]
[Hereditary coagulation factor VII deficiency in a case]
[Hereditary heterozygote factor VII deficiency]
[Hereditary heterozygous factor VII deficiency in patients undergoing surgery : Clinical relevance].
[Homocystinuria and factor VII deficiency]
[Homocystinuria. A type with vascular thrombosis and factor VII deficiency]
[Inherited bleeding disorders common in Jews].
[Inherited coagulation factor VII deficiency caused by double heterozygotic mutations Arg304Gln and Arg304Trp]
[Inherited factor VII deficiency and pregnancy. Apropos of 1 case]
[Intracranial hemorrhage in an infant with congenital factor VII deficiency]
[Isolated acquired factor VII deficiency in patient with severe head trauma: use of factor VII (factor VII-LFB]
[Liver cirrhosis with factor VII deficiency: a case report and literature review].
[Molecular genetic analysis for a pedigree with severe hereditary coagulation factor VII deficiency]
[Mutation analysis and prenatal diagnosis for a family affected with congenital factor VII deficiency].
[Novel double heterozygous mutations on Met306Val and Thr181Asn related to a hereditary coagulation factor VII deficiency]
[On a case of Christmas disease associated with factor VII deficiency.]
[Panorama of congenital disorders of hemostasis diseases at University Hospital of Brazzaville, Congo]
[Postpartum haemorrhage and factor VII deficiency].
[Practical approaches for surgical procedures in congenital factor VII deficiency]
[Pregnancy and delivery in a case with congenital factor VII deficiency]
[Pregnancy and labor in severe hereditary factor VII deficiency]
[Primary biliary cirrhosis combined with factor VII deficiency: a case report]
[Prophylactic use of a recombinant activated factor VII in delivery haemorrhage by caesarean in a woman with major factor VII deficiency: a case report].
[Recombinant activated factor VII in paediatric practice. Universal hemostatic agent?]
[Recurrent intracranial hemorrhage in a nursing infant with congenital factor VII deficiency. Survival and follow-up after neurosurgical intervention]
[Significant decrease in factor VII activity by tissue thromboplastin derived from rabbit brain in a patient with congenital factor VII deficiency (FVII Padua)].
[Studies on inherited coagulation factor VII deficiency and tissue factor abnormality in a pedigree]
[Subcutaneous hematomas, reduced Quick value. Factor VII deficiency]
[Successful gastric resection in a male patient with factor VII deficiency and telangiectasia]
[The change and significance of coagulation activity in bleomycin-induced lung fibrosis in rats]
[The influence of factor VII deficiency on cardiac operations with extracorporeal circulation]
[Variants of factor VII deficiency]
Factor X Deficiency
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
A NlaIII polymorphism within the human factor VII gene.
A rare inherited coagulation disorder: combined homozygous factor VII and factor X deficiency.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Autologous bone marrow transplantation and factor XII, factor VII, and protein C deficiencies. Report of a new association and its possible relationship to endothelial cell injury.
Clinical analysis of six cases of multiple myeloma first presenting with coagulopathy.
Clinical audit of inherited bleeding disorders in a developing country.
Congenital bleeding disorders of the vitamin K-dependent clotting factors.
Diagnostic Error of a Patient with Combined Inherited Factor VII and Factor X Deficiency due to Accidental Ingestion of a Diphacinone Rodenticide.
Factor VII and factor X deficiency in a child with a chromosome 13q duplication and deletion.
Frequencies of mild factor V, VII and X deficiencies in a Japanese population.
Haemoperitoneum associated with ovulation in women with bleeding disorders: the case for conservative management and the role of the contraceptive pill.
Inherited bleeding disorders in Indian women with menorrhagia.
Inherited bleeding disorders in the Eastern Province of Saudi Arabia.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Rare inherited coagulation disorders in India.
Recombinant human factor VIIa in the management of amyloid-associated factor X deficiency.
Successful perioperative management of factor X deficiency associated with primary amyloidosis.
Synergistic effect of factor VII gene polymorphisms causing mild factor VII deficiency in a case of severe factor X deficiency.
The K-test (trypsin clotting time) in coumarin treated patients and in congenital deficiencies and abnormalities of the prothrombin complex.
[A new case of homozygous congenital factor VII deficiency. Associated factor X deficiency in some members of the family]
[Factors VII, VIII, IX, and X: molecular genetics and gene diagnosis]
[Gene analysis of a combined inherited factor VII and factor X deficiency pedigree].
[The change and significance of coagulation activity in bleomycin-induced lung fibrosis in rats]
Factor XI Deficiency
A novel congenital haemostatic defect: combined factor VII and factor XI deficiency.
Activated factor IX-antithrombin III complexes in human blood: quantification by an enzyme-linked differential antibody immunoassay and determination of the in vivo half-life.
Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency.
An illustrative case and a review on the dosing of recombinant factor VIIa in congenital factor XI deficiency.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review.
Changes in haemostasis and thrombosis associated with thyroid disease: Presentation of 2 cases.
Characterization of combined factor VII and factor XI deficiencies.
Clinical and laboratory features of 178 children with recurrent epistaxis.
Descriptive epidemiology of hemophilia and other coagulation disorders in mansoura, egypt: retrospective analysis.
Factor IX is activated in vivo by the tissue factor mechanism.
Factor XII deficiency acquired by orthotopic liver transplantation: case report and review of the literature.
Low endoscopy bleeding risk in patients with congenital bleeding disorders.
Lower doses of rFVIIa therapy are safe and effective for surgical interventions in patients with severe FXI deficiency and inhibitors.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Monitoring low dose recombinant factor VIIa therapy in patients with severe factor XI deficiency undergoing surgery.
Multiple congenital coagulopathies co-expressed with Von Willebrand's disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature.
Obstetric analgesia and anaesthesia in women with inherited bleeding disorders.
Perioperative use of modified thrombelastography in factor XI deficiency: a helpful method to assess drug effects.
Recombinant factor VIIa for the prophylaxis of perioperative hemorrhage in a patient with congenital factor XI deficiency undergoing brain tumor neurosurgery.
Recombinant factor VIIa to prevent surgical bleeding in factor XI deficiency.
Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with congenital factor XI deficiency.
Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency.
The rare inherited coagulation disorders.
The role of recombinant factor VIIa for obstetric block in women with severe factor XI deficiency.
The use of recombinant factor VIIa (NovoSeven) in a patient with a factor XI deficiency and a circulating anticoagulant.
Unprovoked Pulmonary Embolism in Factor VII Deficiency.
Use of recombinant factor VIIa for hip replacement surgery in a patient with severe factor XI deficiency and drug-induced platelet defect.
[Inherited bleeding disorders common in Jews].
[Use of recombinant, activated Factor VII in the treatment and prevention of bleeding complications in two female patients suffering from congenital XI factor deficiency during orthopedic and traumatology intervention. Case reports]
Factor XII Deficiency
Inherited bleeding disorders in Indian women with menorrhagia.
Resistance to activated protein C: evaluation of three functional assays.
Factor XIII Deficiency
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.
Clinical audit of inherited bleeding disorders in a developing country.
Inherited bleeding disorders in Indian women with menorrhagia.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Rare inherited coagulation disorders in India.
Successful use of recombinant factor VIIa in a child with Schoenlein-Henoch purpura presenting with compartment syndrome and severe factor XIII deficiency.
Familial Mediterranean Fever
Glomerulitis and factor vii deficiency in Familial Mediterranean fever.
Fatty Liver
Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men--role of the metabolic syndrome.
Preliminary experience with use of recombinant activated factor VII to control postpartum hemorrhage in acute fatty liver of pregnancy and other pregnancy-related liver disorders.
Recombinant activated factor VII in the management of acute fatty liver of pregnancy: A case report.
Use of FloSeal hemostatic matrix in a patient with severe postpartum hemorrhage.
Fetal Death
Factor VIIa treatment of DIC as a clinical manifestation of amniotic fluid embolism in a patient with fetal demise.
Fibroma
Genetic deficiency of factor VII and hemorrhagic diathesis. A case report and literature review.
Fibrosarcoma
The effect of Warfarin and factor VII on tissue procoagulant activity and pulmonary seeding.
Gallstones
Continuous infusion of human prothrombin complex in a patient with congenital factor VII deficiency undergoing laparoscopic cholecystectomy: A case report from China.
Gastrointestinal Hemorrhage
Novel IVS7+1G>T mutation of life-threatening congenital factor VII deficiency in neonates: A retrospective study in China.
Recombinant activated Factor VII as a hemostatic agent in very low birth weight preterms with gastrointestinal hemorrhage and disseminated intravascular coagulation.
Recombinant activated factor VIIa to treat refractory lower gastrointestinal hemorrhage in a patient with recently implanted mechanical valve: a case report.
Recombinant factor VIIa for severe gastrointestinal hemorrhage associated with Crohn disease.
Recombinant factor VIIa for treatment of gastrointestinal hemorrhage following rattlesnake envenomation.
Successful treatment of massive gastrointestinal hemorrhage in acute biphenotypic leukemia with recombinant factor VIIa (NovoSeven).
Transfusion Interventions in Critical Bleeding Requiring Massive Transfusion: A Systematic Review.
Genetic Diseases, Inborn
Diagnosis and treatment discussion of congenital factor VII deficiency in pregnancy: A case report.
[Congenital factor VII deficiency revealed by post-circumcision bleeding].
[Factor VII deficiency revealed by intracranial hemorrhage.]
Gingivitis
Total Extraction as a Treatment for Anaemia in a Patient of Glanzmann's Thrombasthenia with Chronic Gingival Bleed: Case Report.
Glioblastoma
Successful treatment of recurrent preoperative bleeding of glioblastoma with recombinant activated factor VII: pathophysiological hypothesis.
Transcriptional program induced by factor VIIa-tissue factor, PAR1 and PAR2 in MDA-MB-231 cells.
Glioma
EGFP-EGF1-conjugated nanoparticles for targeting both neovascular and glioma cells in therapy of brain glioma.
Inhibition of tissue factor/protease-activated receptor-2 signaling limits proliferation, migration and invasion of malignant glioma cells.
Recombinant epidermal growth factor-like domain-1 from coagulation factor VII functionalized iron oxide nanoparticles for targeted glioma magnetic resonance imaging.
Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis.
VEGF Expression in Human Glioma Cells Treated with Tissue Factor and FVIIa.
Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody.
Glucose Intolerance
Effects of dietary fat modification on fibrinogen, factor VII, and plasminogen activator inhibitor-1 activity in subjects with impaired glucose tolerance.
Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study.
Glycogen Storage Disease
Hepatocyte transplantation for liver-based metabolic disorders.
Liver cell transplantation.
Graves Disease
A case presenting concurrence of Marfan syndrome, Basedow's disease and Arg353Gln polymorphism-related factor VII deficiency.
Heart Arrest
Case report: Intraoperative thrombosis cardiac arrest in extended right hepatectomy involving use of local haemostatic agent in intraoperative cell salvage (ICS) and administration of recombinant activated factor VII (rFVIIa).
Factor VIIa treatment of DIC as a clinical manifestation of amniotic fluid embolism in a patient with fetal demise.
Thrombogenic side-effects of recombinant factor VIIa after use in coronary artery bypass surgery.
Heart Defects, Congenital
An evaluation of eptacog alfa in nonhaemophiliac conditions.
Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy.
Factor VII for excessive bleeding following congenital heart disease surgery.
Recombinant factor VII for severe bleeding during extracorporeal membrane oxygenation following open heart surgery.
Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease.
Recombinant factor VIIa to control excessive bleeding following surgery for congenital heart disease in pediatric patients.
rFVIIa in the treatment of persistent hemorrhage in pediatric patients on ECMO following surgery for congenital heart disease.
Severe deficiency of coagulation Factor VII results in spontaneous cardiac fibrosis in mice.
Successful use of recombinant activated FVII and aminocaproic acid in four neonates with life-threatening hemorrhage.
Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with congenital factor XI deficiency.
Thrombotic risk of recombinant factor seven in pediatric cardiac surgery: a single institution experience.
Use of Recombinant Activated Factor VII for Controlling Refractory Postoperative Bleeding in Children Undergoing Cardiac Surgery With Cardiopulmonary Bypass.
[New possibilities in the postoperative measures to prevent bleeding in cardiac surgery. Will the recombinant activated factor VII improve surgical results?]
Heart Diseases
Activity of factor VIIa and von Willebrand factor in non-insulin-dependent diabetic subjects with coronary artery disease.
Assay of factor VII activity by two techniques: evidence for increased conversion of VII to alpha VIIa in hyperlipidaemia, with possible implications for ischaemic heart disease.
Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease.
Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study of Women's Health Across the Nation (SWAN).
Factor VII and extrinsic pathway inhibitor in acute coronary disease.
Factor VII and ischaemic heart disease: epidemiological evidence.
Factor VII hyperactivity and ischaemic heart disease.
Factor VII hyperactivity in acute myocardial thrombosis. A relation to the coagulation activation.
Factor-VII activity and ischaemic heart disease: fatal and non-fatal events.
Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study.
Genes, coagulation and cardiovascular risk.
Haemostatic variables in Pacific Islanders apparently free from stroke and ischaemic heart disease--the Kitava Study.
Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study.
Improvement of factor VII clotting activity following long-term NCPAP treatment in obstructive sleep apnoea syndrome.
Plasma factor VIIa: measurement and potential clinical significance.
Postprandial activation of coagulant factor VII by long-chain dietary fatty acids.
Reduction of factor VII coagulant activity (VIIC), a risk factor for ischaemic heart disease, by fixed dose warfarin: a double blind crossover study.
Regulatory polymorphisms underlying complex disease traits.
Role of coagulation factor VII in pathogenesis of ischemic heart disease.
Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease.
Strenuous exercise, plasma fibrinogen, and factor VII activity.
The -323Ins10 polymorphism for factor VII is not associated with coronary atherosclerosis in symptomatic men. The REGRESS study group.
The protein concentration of blood coagulation factor VII can be measured equally well in plasma and serum.
Tissue factor interactions with factor VII: measurement and clinical significance of factor VIIa in plasma.
Vitamin K-dependent clotting factors are elevated in young adults who have close relatives with ischemic heart disease.
[Activated factor VII as a new cardiovascular risk factor of atherothrombotic disease]
[Evaluation of coagulation and fibrinolysis systems in women at peri- and postmenopausal age qualified for hormone replacement therapy]
[Factor VII detection and its association with lipid in ischaemic heart disease.]
Heart Failure
Factor VII and extrinsic pathway inhibitor in acute coronary disease.
Hemostatic Markers in Congestive Heart Failure Dogs with Mitral Valve Disease.
Levels of vitamin K-dependent procoagulant and anticoagulant proteins in over-anticoagulated patients.
Low plasma concentrations of coagulation factors II, VII and XI indicate increased risk among elderly with symptoms of heart failure.
Heart Rupture
[Medical-surgical management of traumatic cardiac rupture: Relevance of recombinant activated factor VII]
Heart Septal Defects, Atrial
Congenital FX deficiency combined with other clotting defects or with other abnormalities: a critical evaluation of the literature.
Pediatric cardiac surgery under cardiopulmonary bypass in factor VII deficiency.
Recombinant factor VIIa to control excessive bleeding following surgery for congenital heart disease in pediatric patients.
Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant.
Heart Septal Defects, Ventricular
Congenital FX deficiency combined with other clotting defects or with other abnormalities: a critical evaluation of the literature.
Recombinant factor VIIa to control excessive bleeding following surgery for congenital heart disease in pediatric patients.
The Use of Activated Factor VII for Ventricular Septal Defect Closure in a Pediatric Patient With Hemophilia A and a High Titer of Inhibitor.
Heart Valve Diseases
Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery.
HELLP Syndrome
A novel use of recombinant factor VIIa in HELLP syndrome associated with spontaneous hepatic rupture and abdominal compartment syndrome.
Liver rupture in a patient with HELLP syndrome successfully treated with extensive surgery combined with recombinant factor VIIa.
Successful use of recombinant factor VIIa for massive bleeding after caesarean section due to HELLP syndrome.
[Successful application of recombinant activated factor VII in a patient with HELLP syndrome and disseminated intravascular coagulation]
Hemangioma, Cavernous
Recombinant activated factor VII for a patient with factor VII deficiency undergoing urgent intracerebral haematoma evacuation with underlying cavernous angioma.
Successful excision of hemorrhagic cavernous angioma in a patient with severe factor VII deficiency: perioperative treatment with factor VII concentrate.
Hemangiopericytoma
Application of recombinant activated factor VII during surgery for a giant skull base hemangiopericytoma to achieve safe hemostasis. Case report.
Hemangiosarcoma
Use of recombinant activated factor VII for bleeding following resection of mediastinal angiosarcoma.
Hemarthrosis
A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors.
Acquired Factor VIII Inhibitors: Three Cases.
Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII.
Arthropathies in factor VII deficiency: a case report.
Arthropathy and surgery in congenital factor VII deficiency.
Congenital factor VII deficiency. A report of four new cases.
Long-term prophylaxis in severe factor VII deficiency.
Newly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven(®)).
Phenotypical variability in congenital FVII deficiency follows the ISTH-SSC severity classification guidelines: a review with illustrative examples from the clinic.
Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors.
Recombinant factor VIIa for the treatment of congenital factor VII deficiency.
Severe factor VII deficiency due to a mutation disrupting an Sp1 binding site in the factor VII promoter.
Single-dose recombinant activated factor VII for the treatment of joint bleeds in hemophilia patients with inhibitors.
Uncomplicated stereotactic and open neurosurgical procedures in patients with factor VII deficiency.
Hematemesis
Long-term FVII substitution in a preterm infant with severe gastrointestinal bleeding and FVII deficiency due to a homozygous donor splice mutation IVS4+1G-->A.
Hematologic Diseases
Acquired factor VII deficiency associated with acute myeloid leukemia.
Hematologic Neoplasms
Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII.
Efficacy of recombinant factor VIIa for severe bleeding complicated by platelet transfusion refractoriness in patients with hematologic malignancies.
Elevated extracellular trap formation and contact system activation in acute leukemia.
Recombinant factor VIIa for the management of severe hemorrhages in patients with hematologic malignancies.
The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review.
Hematoma, Subdural
A forgotten or minimized head trauma, rather than a mild FVII deficiency, is the most likely cause of a subdural hematoma.
Bilateral Subdural Hematomas in an Adult With Hereditary Factor VII Deficiency: A Complication of Sit-ups and Inversion?
Coagulopathic patients with traumatic intracranial bleeding: defining the role of recombinant factor VIIa.
Subdural Hematoma From an Acquired Factor VII Deficiency: Is It the Lupus or the Anticoagulant?
Use of recombinant factor VIIa in a preterm infant with coagulopathy and subdural hematoma.
Hematoma, Subdural, Acute
Recombinant coagulation factor VIIa for rapid preoperative correction of warfarin-related coagulopathy in patients with acute subdural hematoma.
Hematoma, Subdural, Intracranial
Bilateral Subdural Hematomas in an Adult With Hereditary Factor VII Deficiency: A Complication of Sit-ups and Inversion?
Hematuria
Acquired hemophilia A: A rare cause of gross hematuria.
Congenital factor VII deficiency presenting first time as isolated recurrent hematuria at late age.
Hematuria associated with continuous infusion of recombinant factor VIIa.
Off-label use of recombinant factor VIIa in patients following bone marrow transplantation.
Refractory hematuria from amyloidosis successfully treated by splenectomy.
Uncomplicated stereotactic and open neurosurgical procedures in patients with factor VII deficiency.
Use of Recombinant Factor VIIa in a Pediatric Patient With Initial Presentation of Refractory Acute Immune Thrombocytopenic Purpura and Severe Bleeding.
[Acquired hemophilia complicated with hemorrhage induced acute renal failure]
Hemochromatosis
Genotyping on a thermal gradient DNA chip.
Prediction of features of the course of chronic hepatitis C using Bayesian networks.
Hemoperitoneum
Congenital factor VII deficiency complicated with hemoperitoneum and intracranial hemorrhage: report of a case.
Recombinant activated factor VII for hemoperitoneum after transjugular intrahepatic portosystemic shunt.
Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
Hemophilia A
"Primary prophylaxis" with rFVIIa in a patient with severe haemophilia a and inhibitor.
40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors.
A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
A case of acquired hemophilia caused by factor VIII inhibitor with rheumatoid arthritis, successfully treated with immunosuppressive treatment and recombinant activated factor VII.
A cell-based model of coagulation and the role of factor VIIa.
A Comparison of Efficacy Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Hereditary FVIII Deficiency With Inhibitor.
A comparison of FVII:C and FVIIa assays for the monitoring of recombinant factor VIIa treatment.
A comparison of methods for the measurement of activated factor VII.
A comprehensive review of rFVIIa use in a tertiary care pediatric center.
A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil.
A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors.
A critical appraisal of the use of recombinant factor VIIa in acquired bleeding conditions.
A highly sensitive thrombin generation assay for assessment of recombinant activated factor VII therapy in haemophilia patients with an inhibitor.
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
A meta-analysis of the efficacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia.
A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven).
A novel approach to improving recombinant factor VIIa activity with a preserved platelet preparation.
A novel hemostatic agent: the potential role of recombinant activated factor VII (rFVIIa) in anesthetic practice.
A novel protocol for accurate and reliable postoperative bolus administration of recombinant factor VIIa using an automated mini-pump system.
A novel supplemental approach to capturing post-marketing safety information on recombinant factor VIIa in acquired hemophilia: the Acquired Hemophilia Surveillance project.
A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics.
A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors.
A prospective, observational, post-approval registry of inhibitor patients treated with multiple or single doses of recombinant activated factor VII.
A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.
A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group.
A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation.
A rare case of acquired hemophilia A associated with myelodysplastic syndrome.
A Retrospective Analysis of Clinical and Laboratory Data of Patients with Factor VII Deficiency: A Single Centre Experience.
A review of the off-label use of recombinant activated factor VII in a developing country tertiary care center.
A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors.
A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia.
A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia.
Acquired haemophilia A associated with autoimmune thyroiditis: a case report.
Acquired haemophilia in association with type III von Willebrand's disease: successful treatment with high purity von Willebrand's factor and recombinant factor VIIa.
Acquired haemophilia--a therapeutic challenge.
Acquired Hemophilia A: A Case Report.
Acquired Hemophilia A: Clinical Features, Surgery and Treatment of 34 Cases, and Experience of Using Recombinant Factor VIIa.
Acquired hemophilia in a 7-year-old girl successfully treated with recombinant FVIIA and steroids: A case report.
Activated prothrombin complex concentrate for acquired haemophilia when recombinant factor VIIa fails.
Activated recombinant factor VII (rFVIIa).
Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII.
Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the novoseven emergency-use program.
Activity of recombinant factor VIIa under different conditions in vitro: effect of temperature, pH, and haemodilution.
Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII.
Acute myocardial infarction following administration of recombinant activated factor VII (Novo Seven) in a patient with haemophilia A and inhibitor.
Administration of recombinant factor VIIa decreases blood loss after blunt trauma in noncoagulopathic pigs.
Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits.
Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis.
Advances in gene therapy using factor VIIa in hemophilia.
Advances in the treatment of inherited coagulation disorders.
Altered factor VII activity in hemophilia.
American experience with home use of NovoSeven: recombinant factor VIIa in hemophiliacs with inhibitors.
An immunological investigation of hemophilia B with a tentative classification of the disease into five variants.
An in vitro evaluation of standard rotational thromboelastography in monitoring of effects of recombinant factor VIIa on coagulopathy induced by hydroxy ethyl starch.
An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors.
Animal models of FVIIa gene expression: their role in the future development of haemophilia treatment.
Anti-HCV agent, ribavirin, elevates the activity of clotting factor VII in patients with hemophilia: a possible mechanism of decreased events of bleeding in patients with hemophilia by ribavirin.
Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors.
Antigenicity of activated recombinant factor VII followed through nine years of clinical experience.
aPCC vs. rFVIIa for the treatment of bleeding in patients with acquired haemophilia - a cost-effectiveness model.
Application of recombinant activated factor VII for treatment of impaired haemostasis during liver transplantation in recipients with Wilson's disease--a report of two cases.
Approaches towards successful home treatment in patients with inhibitors.
ARFI ultrasound monitoring of hemorrhage and hemostasis in vivo in canine von Willebrand disease and hemophilia.
Arthropathies in factor VII deficiency: a case report.
Aspects of current management: orthopaedic surgery in haemophilia.
Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.
Assessment of individual dose utilization vs. physician prescribing recommendations for recombinant activated factor VII (rFVIIa) in paediatric and adult patients with congenital haemophilia and alloantibody inhibitors (CHwI): the Dosing Observational Study in Hemophilia (DOSE).
Assessment of recombinant factor VIIa as an antidote for bleeding induced in the rabbit by low molecular weight heparin.
Associated prothrombotic conditions are probably responsible for the occurrence of thrombosis in almost all patients with congenital FVII deficiency. Critical review of the literature.
Associated risk of recombinant activated factor VIIa application.
Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors.
Biochemical characterization of LR769, a new recombinant factor VIIa bypassing agent produced in the milk of transgenic rabbits.
Blockade of endothelial cell protein C receptor augments factor VIIa hemostatic effect in hemophilia treatment.
Bringing new therapy options to the hemophilia community.
Cardiac tamponade in a patient with moderate hemophilia A and factor VIII Inhibitors.
Case report on recombinant coagulation factor VIIa in the treatment of three haemophilia A patients with inhibitors in Singapore.
Catalytic domain modification and viral gene delivery of activated Factor VII confers hemostasis at reduced expression levels and vector doses in vivo.
Challenges in the laboratory analyses of bleeding disorders.
Challenges in the therapeutic use of a "so-called" universal hemostatic agent: recombinant factor VIIa.
Challenges of antithrombotic therapy in the management of cardiovascular disease in patients with inherited bleeding disorders: A single-centre experience.
Change of coagulation after NovoSeven® use for bleeding during cardiac surgery.
Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity.
Chondrocalcinosis and haemophilia.
Clinical and echographical control protocol of haemarthrosis in haemophilia patients with inhibitors: evaluation of the efficacy of recombinant factor VIIa in the evolution process (EFFISEVEN protocol).
Clinical and laboratory features of 178 children with recurrent epistaxis.
Clinical audit of inherited bleeding disorders in a developing country.
Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VII and IX inhibitors.
Clinical efficacy of recombinant activated factor VII (rFVIIa) during acute bleeding episode and surgery in a patient with acquired hemophilia A with high inhibitor titer.
Clinical experience with human plasma-derived factor VIIa in patients with hemophilia A and high titer inhibitors.
Clinical experience with recombinant factor VIIa.
Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings.
Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors - Phase I trial.
Clinical trial to investigate the pharmacokinetics, pharmacodynamics, safety, and efficacy of recombinant factor VIIa in Japanese patients with hemophilia with inhibitors.
Clinical use of recombinant FVIIa (rFVIIa).
Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients.
Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma.
Combination of FVIII and low-dose rFVIIa improves haemostasis in acquired haemophilia A patients: a collaborative controlled study.
Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors - a thrombin generation-guided pilot study.
Combined factor VII and factor VIII deficiency due to a casual association of heterozygosis for factor VII deficiency and hemophilia A.
Combined treatment with APCC (FEIBA(®) ) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A - a two-centre experience.
Commentary on "Therapeutic doses of recombinant factor VIIa in hemophilia generates thrombin in platelet-dependent and -independent mechanisms".
Commentary on Knight et al.: A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors.
Comparative Biochemical and Functional Studies on a Branded Human Recombinant Factor VIIa and a Biosimilar Equivalent Product.
Comparative incidence of thrombosis in reported cases of deficiencies of factors of the contact phase of blood coagulation.
Comparing The Cost-Effectiveness of Apcc Vs Rfviia In on-Demand Treatment of Bleeds In Hemophilia A Patients With Inhibitors: A Brazilian Public Health System Perspective.
Comparison of bypassing agents in bleeding reduction in treatment of bleeding episodes in patients with haemophilia and inhibitors.
Comparison of coagulant activity of factor VII and activated factor VII activity assays when used for determination of recombinant activated factor VII levels in plasma.
Comparison of kaolin and tissue factor activated thromboelastography in haemophilia.
Comparison of the effect of plasma-derived and recombinant human FVIIa in vitro and in a rabbit model.
Comparison of the factor VII:C clot analysis and a modified activated factor VII analysis for monitoring factor VII activity in patients treated with recombinant activated factor VII (NovoSeven).
Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors.
Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia ?A with Inhibitors: Current Perspectives and Emerging Clinical Evidence.
Concurrent total hip and knee replacements in a patient with haemophilia with inhibitors using recombinant factor VIIa by continuous infusion.
Congenital combined factor VII and factor VIII deficiency.
Congenital Factor XI Deficiency: An Update.
Consecutive complex percutaneous coronary interventions using emicizumab and recombinant activated factor VII in a patient with severe haemophilia A and high-titre inhibitor.
Construction of a versatile expression library for all human single-pass transmembrane proteins for receptor pairings by high throughput screening.
Continuous infusion of recombinant activated factor VII: a review of data in congenital hemophilia with inhibitors and congenital factor VII deficiency.
Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in The Netherlands and Belgium.
Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection.
Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA.
Correction to: Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia.
Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.
Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
Cost Minimization Analysis of Activated Prothrombin Complex Concentrate (Apcc) Compared To Recombinant Factor Viia (Rfviia) for Hemophilia Patients With Inhibitors.
Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for haemophilia patients with inhibitors undergoing major orthopaedic surgeries.
Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran.
Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.
Cost-Effectiveness of rFVIIa versus pd-aPCC in the Management of Mild to Moderate Bleeds in Pediatric Patients with Hemophilia A with Inhibitors in Mexico.
Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran.
Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitors.
Crystal structure, epitope, and functional impact of an antibody against a superactive FVIIa provide insights into allosteric mechanism.
Current difficulties and recent advances in bypass therapy for the management of hemophilia with inhibitors: a new and practical formulation of recombinant factor VIIa.
Current status of hemophilia patients and recombinant coagulation factor concentrates in Japan.
Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.
Decline of factor VIII and factor IX inhibitors during long-term treatment with NovoSeven.
Decreasing the Need for Transfusion: Infant Cardiac Surgery Using Hemodilution and Recombinant Factor VIIa.
Design, synthesis and biological activity of novel peptidyl benzyl ketone FVIIa inhibitors.
Detection of factor X activation in humans.
Determinants of drug costs in hopitalised patients with haemophilia: impact of recombinant activated factor VII.
Determinants of plasma factor VIIa levels in humans.
Development and Validation of an Algorithm for Identifying Patients with Hemophilia A in an Administrative Claims Database.
Development of a flow cytometric assay for detection of coated platelets in dogs and evaluation of binding of coated platelets to recombinant human coagulation factor VIIa.
Development of a Transgenic Mouse Model with Immune Tolerance for Human Coagulation Factor VIIa.
Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors.
Diffuse alveolar hemorrhage after allogeneic hematopoietic stem-cell transplantation: treatment with recombinant factor VIIa.
Disorders of menstruation and their effect on the quality of life in women with congenital factor VII deficiency.
Distal deep venous thrombosis in a hemophilia A patient with inhibitor and severe infectious disease, 18 days after recombinant activated factor VII transfusion.
Distribution of the recombinant coagulation factor 125I-rFVIIa in rats.
Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: Improved efficacy with higher dosing.
Dose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors.
Dose titration of recombinant factor VIIa using thromboelastograph monitoring in a child with hemophilia and high titer inhibitors to factor VIII: a case report and brief review.
Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008).
Dosing and monitoring NovoSeven treatment.
Dosing factor VIIa (recombinant) in nonhemophiliac patients with bleeding after cardiac surgery.
Dosing with recombinant factor viia based on current evidence.
Early injection of high-dose recombinant factor VIIa decreases blood loss and prolongs time from injury to death in experimental liver injury.
Early treatment with recombinant factor VIIa results in greater efficacy with less product.
Early use of recombinant factor VIIa improves mean arterial pressure and may potentially decrease mortality in experimental hemorrhagic shock: a pilot study.
Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: Haemophilia registry data from the Czech Republic.
Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry.
Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors.
Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors.
Effect of activated recombinant human factor 7 (Niastase) on laboratory testing of inhibitors of factors VIII and IX.
Effect of glycoPEGylation on factor VIIa binding and internalization.
Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease.
Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients.
Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic.
Effective and safe use of recombinant factor VIIa (NovoSeven) in elderly mild haemophilia A patients with high-titre antibodies against factor VIII.
Effectiveness of recombinant activated factor VII (rFVII a) for controlling intractable postpartum bleeding: report of two cases and literature review.
Effects of binding of ligand (FVIIa) to induced tissue factor in human endothelial cells.
Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma.
Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review.
Efficacy of different doses of recombinant activated factor VII in the treatment of haemophilia children with inhibitor.
Efficacy of NovoSeven during surgery on a haemophiliac with previous history of inhibitors.
Efficacy of recombinant activated Factor VII in patients with massive uncontrolled bleeding: a retrospective observational analysis.
Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression.
Efficacy of recombinant factor VIIa administered by continuous infusion to haemophilia patients with inhibitors.
Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature.
Elective surgery in patients with congenital coagulopathies and inhibitors: experience of the National Haemophilia Centre of Venezuela.
Elevated function of blood clotting factor VIIa mutants that have enhanced affinity for membranes. Behavior in a diffusion-limited reaction.
Elimination of hepatitis C virus infection in patients with haemophilia in Belgium: A single-centre experience.
Engineering of a membrane-triggered activity switch in coagulation factor VIIa.
Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A.
Enhanced Pharmacokinetics of Factor VIIa as a Monomeric Fc Fusion.
Enhanced potency of recombinant factor VIIa with increased affinity to activated platelets.
Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes.
Entering new areas in known fields: recombinant fusion protein linking recombinant factor VIIa with recombinant albumin (rVIIa-FP) - advancing the journey.
Eptacog Alfa (Activated) Is Physically and Chemically Stable over 24 Hours when Administered as Bolus Injections in an Automated Infusion Pump.
Eptacog alfa activated: a recombinant product to treat rare congenital bleeding disorders.
Eptacog beta: a novel recombinant human factor VIIa for the treatment of hemophilia A and B with inhibitors.
Ethics & Evidence in Medical Debates: The Case of Recombinant Activated Factor VII.
Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors.
Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study).
Evaluation of Coagulation Factors Activity in Different Types of Plasma Preparations.
Evaluation of off-label recombinant activated factor VII for multiple indications in children.
Evaluation of rFVIIa (NovoSeven) in Glanzmann patients with thromboelastogram.
Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial.
Evidence for the use of recombinant factor VIIa in the prevention and treatment of bleeding in patients without hemophilia.
Evidence-based use of recombinant FVIIa (NovoSeven((R)), NiaStase((R))) for the treatment of hemophilia with inhibitors in children and adolescents.
Excision of pseudotumour in a patient with haemophilia A and inhibitor managed with recombinant factor VIIa.
Experience of recombinant activated factor VII usage during surgery in patients with haemophilia with inhibitors.
Experience with a single dose of recombinant activated factor VII for the management of mild-to-moderate bleeds in haemophilia.
Experience with use of recombinant activated factor VII.
Experiences in the prevention of arthropathy in haemophila patients with inhibitors.
Experiences with continuous infusion of recombinant activated factor VII.
Experiences with recombinant human factor VIIa in patients with thrombocytopenia.
Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma.
Exposure and safety of higher doses of recombinant factor VIIa ?250??g?kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008).
Expression of factor VII by muscle cells in vitro and in vivo following direct gene transfer: modelling gene therapy for haemophilia.
Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin.
Extensive Small-Angle X-ray Scattering Studies of Blood Coagulation Factor VIIa Reveal Interdomain Flexibility.
Factor VII and fibrinolytic response to deamino-8-D-argenine vasopressin in normal subjects and dissociate response in some patients with haemophilia and von Willebrand's disease.
Factor VII and haemostasis.
Factor VIIa analog has marked effects on platelet function and clot kinetics in blood from patients with hemophilia A.
Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A.
Factor VIIa and its potential therapeutic use in bleeding-associated pathologies.
Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection.
Factor VIIa in the treatment of haemophilia.
Factor VIIa induces extracellular vesicles from the endothelium: a potential mechanism for its hemostatic effect.
Factor VIIa interaction with EPCR modulates the hemostatic effect of rFVIIa in hemophilia therapy: Mode of its action.
Factor VIIA levels in patients with hemophilia.
Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A.
Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody.
Failure of Recombinant Activated Factor VII in Treatment of Diffuse Alveolar Hemorrhage due to Cryoglobulinemic Vasculitis.
Failure of recombinant FVIIa as treatment for abdominal bleeding in acquired hemophilia.
Familial haemophilia and factor VII deficiency.
Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice.
Fatal outcome of recombinant factor VIIa in heart transplantation with extracorporeal membrane oxygenation.
Fc-based half-life extension of human FVIIa - a new player for hemophilia treatment?
FEIBA versus NovoSeven in Hemophilia Patients with Inhibitors.
Fibrin gel structure obtained with a FVIIa analogue with enhanced FX-activating potential in haemophilia.
First 20 years with recombinant FVIIa (NovoSeven).
Formation of an inhibitor against factor VII as a postoperative complication in a severe case of hemophilia A.
Formulary management of recombinant factor VIIa at an academic medical center.
From theory to practice: applying current clinical knowledge and treatment strategies to the care of hemophilia a patients with inhibitors.
FVIIa as therapeutic agent in hemophilia and beyond.
FVIIa as used pharmacologically is not TF dependent in hemophilia B mice.
Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
Gene therapy in haemophilia--going for cure?
Gene-based continuous expression of FVIIa for the treatment of hemophilia.
Gene-based FVIIa prophylaxis modulates the spontaneous bleeding phenotype of hemophilia A rats.
General haemostatic agents--fact or fiction?
Genetic deficiency of factor VII and hemorrhagic diathesis. A case report and literature review.
Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force.
Haematuria in a young patient with severe haemophilia and inhibitor presence receiving prophylactic treatment with recombinant factor VIIa.
Haemophilia in Australia.
Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant activated factor VII?
Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial.
Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors.
Health economics of treating haemophilia A with inhibitors.
Hemophilia (AHG deficiency) and factor VII (stable factor) deficiency in the American Indian. Report of four cases.
Hemophilia A and concurrent factor VII deficiency. Studies of a patient with complicating cardiac tamponade.
Hemophilia home treatment. Economic analysis and implications for health policy.
Hemophilia in Iran.
Hemophilia. Treatment of patients with inhibitors: cost issues.
Hemostasis in liver resection surgery.
Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model.
Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice.
Hemostatic properties of the FVIIa analog NN1731.
Hereditary bleeding disorders in Riyadh, Saudi Arabia.
Heterozygous factor VII deficiency and severe hemophilia A in the same kindred.
High-dose recombinant factor VIIa therapy in hemophilia patients with inhibitors.
High-level expression of functional recombinant human coagulation factor VII in insect cells.
History of rFVIIa therapy.
Home treatment for patients with congenital bleeding disorders in a developing country.
Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial.
Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors: experience from developing countries.
Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
How factor VIIa works in hemophilia.
How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors.
Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors.
Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia.
Human platelets express endothelial protein C receptor, which can be utilized to enhance localization of factor VIIa activity.
IL-1 beta, IL-6, KC and MCP-1 are elevated in synovial fluid from haemophilic mice with experimentally induced haemarthrosis.
Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)?
Immunogenicity of novel recombinant human activated factor VII analogues on factor VII neonatally-tolerized rats.
Immunological aspects of recombinant factor VIIa (rFVIIa) in clinical use.
Impact of Telemedicine Tools on Record Keeping and Compliance in Haemophilia Care.
Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa.
Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP).
Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A.
In vitro characterization of MOD-5014, a novel long-acting carboxy-terminal peptide (CTP)-modified activated FVII.
In vitro evidence of a tissue factor-independent mode of action of recombinant factor VIIa in hemophilia.
In vitro stability of lyophilized and reconstituted recombinant activated factor VII formulated for storage at room temperature.
In vitro stability of two formulations of recombinant activated factor VIIa reconstituted in inappropriate solvents or at inappropriate volumes.
In vivo bypass of hemophilia A coagulation defect by factor XIIa implant.
In vivo clearance and metabolism of recombinant activated factor VII (rFVIIa) and its complexes with plasma protease inhibitors in the liver.
In vivo haemostatic effects of activated prothrombin complex concentrate and recombinant factor VIIa in a haemophilia A patient with inhibitors.
Induction of acquired factor IX inhibitors in cynomolgus monkey (Macaca fascicularis): a new primate model of hemophilia B.
Induction of tolerance after combined immunosuppression and -adsorption in two patients with acquired haemophilia after severe haemorrhages controlled by sequential administration of rFVIIa and FEIBA.
Influence of factor VIIa and phospholipids on coagulation in "acquired" hemophilia.
Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A.
Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa.
Inhibitors in hemophilia A: advances in elucidation of inhibitory mechanisms and in inhibitor management with bypassing agents.
Inhibitors in Patients with Congenital Bleeding Disorders Other Than Hemophilia.
International survey of attitudes towards secondary prophylaxis with recombinant factor VIIa in haemophilia A patients with inhibitors.
Intestinal surgery with activated recombinant factor VII prophylaxis in patients with haemophilia A and high responding inhibitors: a report of five cases.
Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients. A multi-centre, randomised trial.
Intracerebral hemorrhage: natural history and rationale of ultra-early hemostatic therapy.
Intraoperative use of recombinant activated factor VII (rFVIIa).
Intraoral hemostasis using a recombinant activated factor VII preparation in a hemophilia a patient with inhibitor.
Intravascular inhibition of factor VIIa and the analogue NN1731 by antithrombin.
Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries.
Ischemic stroke after recombinant factor VIIa treatment in acquired hemophilia A patient.
Ischemic strokes in congenital bleeding disorders: comparison with myocardial infarction and other acute coronary syndromes.
Isotypic analysis of antibodies against activated Factor VII in patients with Factor VII deficiency using the x-MAP technology.
Kaolin, used to trigger coagulation in thrombin generation test, increases sensitivity of the method in hemophilia patients.
Kinetic analysis and binding studies of a new recombinant human factor VIIa for treatment of haemophilia.
Kinetic modeling sheds light on the mode of action of recombinant factor VIIa on thrombin generation.
Knee joint arthroplasty in a patient with haemophilia A and high inhibitor titre using recombinant factor VIIa (NovoSeven): a new case report and review of the literature.
Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia.
Levels of prothrombin activation peptide F1+2 in patients with a bleeding tendency.
Life-threatening bleeding in a patient with pemphigoid-induced acquired hemophilia A and successfully treated with rituximab and rFVIIa: A case report.
Life-threatening hemorrhage in neonates: management with recombinant activated factor VII.
Life-threatening mediastinal-retroperitoneal hemorrhage in a child with moderate hemophilia A and high inhibitor titer: successful management with recombinant activated factor VII.
Limited factor VIIa surface localization requirement of the factor VIIa-induced overall thrombin generation in platelet-rich hemophilia A plasma.
Liver transplantation in a patient with mild haemophilia A and low-titres of factor VIII inhibitors treated with recombinant factor VIIa. The first Argentinean case.
Long-term expression of canine FVIIa in hemophilic dogs.
Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality.
Long-term secondary prophylaxis with recombinant activated factor VII (rFVIIa) in haemophilia A with inhibitors: a case report.
Low endoscopy bleeding risk in patients with congenital bleeding disorders.
Major orthopaedic surgeries for haemophilia with inhibitors using rFVIIa.
Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision.
Major surgery in severe haemophilia A with inhibitors using a recombinant factor VIIa and activated prothrombin complex concentrate hybrid regimen.
Management and monitoring of recombinant activated factor VII.
Management of bleeding in acquired haemophilia A with recombinant activated factor VII: does one size fit all? A report of four cases.
Management of oral bleedings with recombinant factor VIIa in children with haemophilia A and inhibitor.
Managing acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safety.
Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia.
Measurement of basal levels of factor VIIa in hemophilia A and B patients.
Mechanism of action of factor VIIa in the treatment of coagulopathies.
Mechanism of action, development and clinical experience of recombinant FVIIa.
Mechanism of factor VIIa-dependent coagulation in hemophilia blood.
Mechanism of the immune response to human factor VIII in murine hemophilia A.
Mechanisms of action of recombinant activated factor VII in the context of tissue factor concentration and distribution.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Methodologies for data collection in congenital haemophilia with inhibitors (CHwI): critical assessment of the literature and lessons learned from recombinant factor VIIa.
Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue.
Myelofibrosis and acquired hemophilia A: a case report.
Myocardial infarction occurring in a case of acquired haemophilia during the treatment course with recombinant activated factor VII.
N-/O-glycosylation analysis of human FVIIa produced in the milk of transgenic rabbits.
National survey of patients with hemophilia and other congenital bleeding disorders in Thailand.
New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa.
Non-catheter associated venous thrombosis in hemophilia A and B. A critical review of all reported cases.
Novel applications of recombinant factor VIIa for the management of pediatric coagulopathic diseases.
Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII.
NovoSeven (recombinant factor VIIa) in centeral nervous systems bleeds.
NovoSeven as a universal haemostatic agent.
NovoSeven in immune tolerance therapy.
NovoSeven: mode of action and use in acquired haemophilia.
Obstetric analgesia and anaesthesia in women with inherited bleeding disorders.
Occult hemophilia as a cause of postoperative and postpartum hemorrhage. With special reference to factor VII deficiency.
Occult hepatitis B virus infection in Greek patients with congenital bleeding disorders.
Off-Label Recombinant Factor VIIa Use and Thrombosis in Children: A Multi-center Cohort Study.
Off-label use of recombinant activated factor VII in surgical and non-surgical patients at 16 Canadian hospitals from 2007 to 2010 (Canadian Registry Report).
Off-label use of recombinant factor VIIa in patients following bone marrow transplantation.
Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records.
Off-label use of rFVIIa in children with excessive bleeding: A consecutive study of 153 off-label uses in 139 children.
On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII.
On-label versus off-label use of recombinant activated factor VII: a comprehensive review of use in two Canadian centers.
One amino acid in mouse activated factor VII defines its endothelial protein C receptor (EPCR) binding and modulates its EPCR-dependent hemostatic activity in vivo.
Ongoing NovoSeven trials.
Optimizing on-demand treatment with NovoSeven room temperature stable.
Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven) therapy in haemophilia A patients.
Orthopaedic surgery in haemophilic patients with inhibitors: an overview.
Orthopaedic surgery in severe bleeding disorders: a low-volume, high-cost procedure.
Overall experience with NovoSeven.
Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII.
Overcoming delayed in-vitro response to rFVIIa: effects of rFVIIa and rFVIIa analogue (vatreptacog alfa) concentration escalation in whole blood assays.
Overview of the human pharmacokinetics of recombinant activated factor VII.
Parallel use of by-passing agents in haemophilia with inhibitors: a critical review.
Patient- and caregiver-reported bleeding symptoms and reasons for starting and stopping treatment with recombinant factor VIIa: analysis of the Dosing Observational Study in Haemophilia (DOSE).
Patient/Caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE).
Perioperative use of recombinant activated factor VII in liver transplantation.
Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors.
Pharmacokinetic properties of two different recombinant activated factor VII formulations.
Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
Pharmacokinetics and pharmacodynamics of rFVIIa and new improved bypassing agents for the treatment of haemophilia.
Pharmacokinetics and safety of a 270?mcg?kg(-1) dose of room temperature stable recombinant activated factor VII in patients with haemophilia.
Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A.
Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.
Pharmacokinetics of recombinant activated factor VII (rFVIIa).
Pharmacokinetics, distribution, and excretion of (125)I-labeled human plasma-derived-FVIIa and -FX with MC710 (FVIIa/FX mixture) in rats.
Pharmacokinetics, pharmacodynamics and safety of recombinant canine FVIIa in a study dosing one haemophilia A and one haemostatically normal dog.
Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP).
Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice.
Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery.
Pharmacology and clinical use of recombinant activated factor seven in neurosciences.
Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia.
Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study of the rFVIIa Variant BAY 86-6150 in Hemophilia.
Phenotypic correction of hemophilia A by ectopic expression of activated factor VII in platelets.
Phenotypical variability in congenital FVII deficiency follows the ISTH-SSC severity classification guidelines: a review with illustrative examples from the clinic.
Plasma Exchange as an Initial Treatment for Severe Bleeding Induced by Acquired Factor V Deficiency: A Case Report and Mini Literature Review.
Platelet adhesiveness and aggregation in combined factor V and factor VIII deficiency and in combined factor VII and factor VIII deficiency.
Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity.
Platelet binding and activity of recombinant factor VIIa.
Platelet infusion supports recombinant factor VIIa in a patient with severe haemophilia A and inhibitor - Clinical outcome and laboratory observations.
Platelet-dependent thrombin generation assay for monitoring the efficacy of recombinant Factor VIIa.
Poly-N-Acetylglucosamine Fibers Amplify the Effectiveness of Recombinant Factor VIIA on Clot Formation in Hemophilia B Canine Blood.
Polymorphism in factor VII gene modifies phenotype of severe haemophilia.
Polyphosphate as a general procoagulant agent.
Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy.
Postsurgical coagulopathy in a hemophilia A patient with inhibitors: efficacy of recombinant factor VIIa.
Potential role of recombinant factor FVIIa in prophylaxis in severe hemophilia patients with inhibitors.
Potential role of recombinant factor VIIa as a hemostatic agent.
Prediction of human pharmacokinetics of activated recombinant factor VII and B-domain truncated factor VIII from animal population pharmacokinetic models of haemophilia.
Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis-treated haemophilia A patients with inhibitors.
Pregnancy in women with congenital factor VII deficiency.
Preparation of factor VII concentrate using CNBr-activated Sepharose 4B immunoaffinity chromatography.
Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI.
Prevention of arthropathy: may it be extrapolated from patients without inhibitors to patients with inhibitors?
PRO-PACT: Retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors.
Production of coagulation factor VII in human cell lines Sk-Hep-1 and HKB-11.
Prohemostatic Activity of Factor X in Combination With Activated Factor VII in Dilutional Coagulopathy.
Prolonged half-life of glycoPEGylated rFVIIa variants compared to native rFVIIa.
Prolonged in-vivo half-life of factor VIIa by fusion to albumin.
Prophylactic and therapeutic use of recombinant activated factor VII in patients with cirrhosis and coagulation impairment.
Prophylactic preparation and surgical extirpation of a very large abdominal blood cyst in a severe haemophilia A patient with inhibitors managed by rFVIIa.
Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors.
Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.
Prophylaxis in congenital hemophilia with inhibitors: the role of recombinant activated factor VII.
Prophylaxis in haemophilia with inhibitors: update from international experience.
Prophylaxis therapy with bypassing agents in patients with haemophilia A and inhibitors undergoing surgery: A cost analysis in Spain.
Prophylaxis with recombinant factor VIIa for the management of bleeding episodes during immune tolerance treatment in a boy with severe haemophilia A and high-response inhibitors.
Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery.
Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.
Quality of haemophilia treatment in Serbia: National Haemophilia Registry Report.
Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors.
Rapid rFVIIa enhanced on-demand dosing in haemophilia inhibitor patients.
Rational Use of Recombinant Factor VIIa in Clinical Practice.
Real-World Early Treatment with Room Temperature-Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7™ Post Hoc Analyses.
Real-world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registry.
Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients.
Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group.
Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors.
Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage.
Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development.
Recombinant activated factor VII (rFVIIa, NovoSeven).
Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies.
Recombinant activated factor VII as a general haemostatic agent: evidence-based efficacy and safety.
Recombinant activated factor VII as a universal haemostatic agent.
Recombinant activated factor VII controls chemotherapy-related hemorrhage in patients with solid intra-abdominal tumors: a report of three pediatric cases.
Recombinant activated factor VII for a warfarinised Jehovah's Witness with an acute subdural haematoma.
Recombinant activated factor VII for acute intracerebral hemorrhage.
Recombinant activated factor VII for adjunctive hemorrhage control in trauma.
Recombinant activated factor VII for diffuse alveolar hemorrhage in microscopic polyangiitis.
Recombinant activated factor VII for haemophilia patients with inhibitors undergoing orthopaedic surgery: a review of the literature.
Recombinant activated factor VII for intractable bleeding post splenectomy in a patient with myeloproliferative disorder.
Recombinant activated factor VII for massive hemoptysis in patients with cystic fibrosis.
Recombinant activated factor VII for treatment of intramuscular haemorrhages: a comparison of early versus late treatment.
Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry.
Recombinant activated factor VII in clinical practice: a 2014 update.
Recombinant activated factor VII in patients at high risk of bleeding.
Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders.
Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors.
Recombinant Activated Factor VII Is Reabsorbed in Renal Proximal Tubules and Is a Ligand to Megalin and Cubilin.
Recombinant activated factor VII safety and efficacy in the treatment of cranial haemorrhage in patients with congenital haemophilia with inhibitors: an analysis of the Hemophilia and Thrombosis Research Society Registry (2004-2008).
Recombinant activated factor VII therapy in acquired hemophilia of the elderly.
Recombinant activated factor VII use in the emergency department.
Recombinant activated factor VII: 30 years of research and innovation.
Recombinant Activated Factor VII: Current Perspectives and Epworth Experience.
Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage.
Recombinant activated factor VII: mechanisms of action and current indications.
Recombinant blood components: clinical administration today and tomorrow.
Recombinant coagulation factor VIIa: from the concept to clinical application in hemophilia treatment in 2000.
Recombinant factor IX.
Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX.
Recombinant Factor VIIa (Eptacog Alfa): A Review of its Use in Congenital Hemophilia with Inhibitors, Acquired Hemophilia, and Other Congenital Bleeding Disorders.
Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders.
Recombinant factor VIIa (Novoseven) and the safety of treatment.
Recombinant factor VIIa (Novoseven) as a hemostatic agent.
Recombinant factor VIIa (NovoSeven) as a hemostatic agent.
Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors.
Recombinant factor VIIa (r-FVIIa) in haemophilia management.
Recombinant factor VIIa (rFVIIa) and its use in severe bleeding in surgery and trauma: a review.
Recombinant factor VIIa (rFVIIa): its potential role as a hemostatic agent.
Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial.
Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa.
Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma.
Recombinant factor VIIa and factor VIII treatment for acquired factor VIII deficiency: a case of repeated thrombotic endotracheal occlusion in a mechanically ventilated patient.
Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with Haemophilia A and inhibitors.
Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors.
Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors.
Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count.
Recombinant factor VIIa for intracranial haemorrhage in a Jehovah's Witness with severe haemophilia A and factor VIII inhibitors.
Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia.
Recombinant factor VIIa for the treatment of severe postoperative and traumatic hemorrhage.
Recombinant factor VIIa in an infant with haemophilia A and inhibitors.
Recombinant factor VIIa in continuous infusion during central line insertion in a child with factor VIII high-titre inhibitor.
Recombinant factor VIIa in joint and muscle bleeding episodes.
Recombinant factor VIIa in paediatric bleeding disorders--a 2006 review.
Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile.
Recombinant factor VIIa in the management of a pseudotumour in acquired haemophilia.
Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors.
Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high-responding inhibitors.
Recombinant factor VIIa in the treatment of bleeding.
Recombinant Factor VIIa Reduces Bleeding after Blunt Liver Injury in a Pig Model of Dilutional Coagulopathy under Severe Hypothermia.
Recombinant factor VIIa reduces rebleed hemorrhage volume in a swine aortotomy model: a randomized double-blinded study.
Recombinant factor VIIa treatment for asymptomatic factor VII deficient patients going through major surgery.
Recombinant factor VIIa treatment for life-threatening haemoptysis.
Recombinant factor VIIa used to control massive haemorrhage during renal transplantation surgery; vascular graft remained patent.
Recombinant Factor VIIa-Mediated Activation of Prothrombin Complex Concentrates: Studies on the Comparison of NovoSeven With a Biosimilar Product.
Recombinant factor VIIa.
Recombinant Factor VIIa.
Recombinant factor VIIa: a universal hemostatic agent?
Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting.
Recombinant Factor VIIa: clinical applications for an intravenous hemostatic agent with broad-spectrum potential.
Recombinant Factor VIIa: Hemostatic Adjunct in the Coagulopathic Burn Patient.
Recombinant factor VIIa: its background, development and clinical use.
Recombinant factor VIIa: review of current "off license" indications and implications for practice.
Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors.
Recombinant factor VIIa: unregulated continuous use in patients with bleeding and coagulopathy does not alter mortality and outcome.
Recombinant FVIIa (NovoSeven) continuous infusion and total hip replacement in patients with haemophilia and high titre of inhibitors to FVIII: experience of two cases.
Recombinant FVIIa concentrate-associated thrombotic events in congenital bleeding disorders other than hemophilias.
Recombinant FVIIa in elective non-orthopaedic surgery of adults with haemophilia and inhibitors: A systematic literature review.
Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment.
Recombinant FVIIa in the management of uncontrolled hemorrhage.
Recombinant FVIIa in the treatment of bleeding in acquired hemophilia.
Recombinant human coagulation factor VIIa in Jehovah's Witness patients undergoing liver transplantation.
Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients.
Recombinant human factor VIIa (rFVIIa) in hemophilia: mode of action and evidence to date.
Recombinant human factor VIIa-induced alterations in tissue factor and thrombomodulin in patients with advanced liver cirrhosis.
Recombinant-activated coagulation factor VIIa (NovoSeven): current development.
Recombinant-activated factor VII for control and prevention of hemorrhage in nonhemophilic pediatric patients.
Redistribution and hemostatic action of recombinant activated factor VII associated with platelets.
Registry of Hemophilia and other bleeding disorders in Syria.
Relevance of a single dose of 270microg/kg recombinant factor VIIa for the treatment of patients with haemophilia and inhibitors.
Renal thromboembolism during treatment with recombinant activated factor VII (rFVIIa) in a child with hemophilia B with factor IX inhibitors.
Response of factor VIII and IX-deficient blood to wild type and high membrane affinity mutant factor VIIa in an in vitro whole blood clotting assay: possible correlation to clinical outcome.
Response to treatment and adverse events associated with use of recombinant activated factor VII in children: a retrospective cohort study.
Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors-phase I trial: 2nd report.
Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
Retroviral-mediated transfer and amplification of a functional human factor VIII gene.
Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study.
Review: Recombinant factor VIIa does not differ from placebo for prevention or treatment of bleeding in patients without hemophilia.
Ribavirin-induced intracellular GTP depletion activates transcription elongation in coagulation factor VII gene expression.
Risk-sharing approach for managing factor VIIa reimbursement in haemophilia patients with inhibitors.
Robustness of factor assays following cordocentesis in the prenatal diagnosis of haemophilia and other bleeding disorders.
Role of prothrombin complex concentrate in perioperative coagulation therapy.
Room-temperature-stable recombinant activated coagulation factor VII recombinant: chemical and microbiologic stability over 24 hours during continuous in vitroinfusion.
Rotational thromboelastometry can predict the probability of bleeding events in a translational rat model of haemophilia A following gene-based FVIIa prophylaxis.
Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.
Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors.
Safety and effectiveness of room temperature stable recombinant factor VIIa in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study.
Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studies and registries.
Safety and efficacy of recombinant activated factor VII for long-term secondary prophylaxis in a haemophilia boy with high-titre inhibitors.
Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label.
Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a phase I study.
Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa).
Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 ?g kg?¹) rFVIIa doses across clinical trials and registries.
Safety profile of recombinant factor VIIa.
Safety update on recombinant factor VIIa in the treatment of congenital and acquired hemophilia.
Safety update on the use of recombinant activated factor VII in approved indications.
Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors.
Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor.
Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study.
Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors.
Secondary prophylaxis with rFVIIa in hemophilia and inhibitors: recommendations from an experts committee from Argentina.
Sequential therapy with activated prothrombin complex concentrate (FEIBA) and recombinant factor VIIa in a patient with severe haemophilia A, inhibitor presence and refractory bleeding.
Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors.
Sequential therapy with activated prothrombin complex concentrates and recombinant activated factor VII to treat unresponsive bleeding in patients with hemophilia and inhibitors: a single center experience.
Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience.
Sequential treatment with bolus and continuous infusion of recombinant factor VIIa for hip arthroplasty in a patient with haemophilia A and inhibitor.
Severe acquired hemophilia A successfully treated with activated recombinant human factor VII.
Severe aquired haemophilia A treated with recombinant factor VIIa.
Short-course use of recombinant factor VIIa in a haemophilia patient with inhibitor undergoing cataract surgeries.
Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
Single higher dose of recombinant activated factor VII in the treatment of hemorrhages in patients with hemophilia complicated by inhibitors.
Single-dose (270 microg kg(-1)) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres.
Single-dose recombinant activated factor VII for the treatment of joint bleeds in hemophilia patients with inhibitors.
Single-dose recombinant activated factor VII therapy in hemophilia patients with inhibitors.
Small dose of recombinant factor VIIa (rFVIIa) to perform percutaneous liver biopsies in cirrhotic patients.
Some recent developments regarding arthropathy and inhibitors in haemophilia.
Spectrum of mutations in CRM-positive and CRM-reduced hemophilia A.
Spinal epidural haematoma in haemophilia A with inhibitors--efficacy of recombinant factor VIIa concentrate.
ST-Segment Elevation Myocardial Infarction (STEMI) and Pulmonary Embolism in a Hemophilia A Patient Receiving Emicizumab and recombinant Activated Factor VII.
Standardization and evaluation of the performance of the thrombin generation test under hypo- and hypercoagulability conditions.
Standardization of factor VII/activated factor VII measurement in plasma of patients treated with recombinant factor activated VII.
Studies of factor IX concentrate therapy in hemophilia.
Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety.
Successful concurrent triple surgery in an adolescent patient with haemophilia A and inhibitors treated with recombinant factor VIIa.
Successful hemostasis during a major orthopedic operation by using recombinant activated factor VII in a patient with severe hemophilia A and a potent inhibitor.
Successful management of Mallory-Weiss syndrome in a haemophilia A patient with inhibitor by recombinant activated factor VII.
Successful management of massive intraperitoneal bleeding in a hemophilia A patient with inhibitor by surgical debridement of the incomplete hematoma and administration of recombinant factor VIII and activated factor VII.
Successful total hip replacement in a patient with severe haemophilia A with inhibitors using recombinant factor VIIa.
Successful treatment of a patient with acquired haemophilia A with a combination of a low-dose rituximab and recombinant human FVIIa.
Successful treatment of acquired factor VIII deficiency in a child using activated factor VII concentrates: case report and review of the literature.
Successful treatment of canine hemophilia by continuous expression of canine FVIIa.
Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature.
Successful treatment of severe bleeding with recombinant factor VIIa after kidney transplantation.
Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII.
Successful urgent neurosugery management with rFVIIa mega doses in a child with haemophilia a and high titre inhibitor.
Successful use of recombinant factor VII in massive hemoptysis due to community-acquired pneumonia.
Successful use of recombinant factor VIIa for emergency fasciotomy in a patient with hemophilia A and high-titer inhibitor unresponsive to factor VIII inhibitor bypassing activity.
Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy.
Successful use of recombinant factor VIIa in pelvic fracture haemorrhage.
Surgery in patients with haemophilia and high responding inhibitors: Izmir experience.
Surgical Experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX.
Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review.
Sustained pro-haemostatic activity of rFVIIa in non-bleeding pigs may explain efficacy of once-daily prophylaxis in humans.
Synovectomy for haemophilic arthropathy: 6-21 years of follow-up in 16 patients.
Synthesis and characterization of recombinant factor VIIa-conjugated magnetic iron oxide nanoparticles for hemophilia treatment.
Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa.
Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors.
Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications.
Systemic venous thrombosis after recombinant factor VIIa in the control of bleeding after cardiac surgery.
Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography.
Ten-year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan.
The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series.
The concept of recombinant factor VIIa megadose for treating bleeding episodes in high-titer inhibitor patients with hemophilia: toward an expanding indication?
The danger of using a sledgehammer to crack a nut: ROTEM-guided administration of recombinant activated factor VII in a patient with refractory bleeding post-ventricular assist device implantation.
The effect of factor X level on thrombin generation and the procoagulant effect of activated factor VII in a cell-based model of coagulation.
The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia.
The effect of recombinant factor VIIa (NovoSeven(R)) on peri-operative bleeding during total knee replacement in a non-hemophiliac patient.
The effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries.
The effect of recombinant factor VIIa on noncoagulopathic pigs with grade V liver injuries.
The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents.
The efficacy of bypassing agents in surgery of hemophilia patients with inhibitors.
The emerging role of recombinant activated Factor VII (rFVIIa) in the treatment of blunt traumatic haemorrhage.
The endothelial protein C receptor enhances hemostasis of FVIIa administration in hemophilic mice in vivo.
The evidence for the use of recombinant factor VIIa in massive bleeding: development of a transfusion policy framework.
The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors.
The function of factor VIIa in hemophilia A: an hypothesis.
The intractable intra-abdominal hemorrhage with unknown etiology in a patient with severe hemophilia A.
The intraoperative use of recombinant FVIIa in child with hemophilia A with antibodies.
The Judicious Use of Recombinant Factor VIIa.
The pharmacokinetics and pharmacodynamics of single-dose and multiple-dose recombinant activated factor VII in patients with haemophilia A or B.
The pharmacokinetics of clotting factor therapy.
The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from the ADEPT2 trial.
The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review.
The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders.
The role of cell surfaces and cellular receptors in the mode of action of recombinant factor VIIa.
The role of factor VII in haemostasis: infusion studies of factor VIIa in a canine model of factor VIII deficiency.
The role of recombinant activated factor VII in neurosurgery: hope or hype?
The role of recombinant activated factor VII in the haematological management of elective orthopaedic surgery in haemophilia A patients with inhibitors.
The role of tissue factor and factor VIIa in hemostasis.
The safety and efficacy of the administration of recombinant activated factor VII in major surgery and trauma patients.
The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study.
The Use of Activated Factor VII for Ventricular Septal Defect Closure in a Pediatric Patient With Hemophilia A and a High Titer of Inhibitor.
The use of combination FEIBA and rFVIIa bypassing therapy, with TEG profiling, in uncontrollable bleeding associated with acquired haemophilia A.
The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia.
The use of recombinant activated coagulation factor VII for spine surgery.
The use of recombinant activated factor VII in congenital and acquired von Willebrand disease.
The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage.
The use of recombinant activated factor VII in patients with acquired haemophilia.
The use of recombinant activated factor VII to control bleeding during repair of a suprarenal abdominal aortic aneurysm.
The use of recombinant coagulation factor VIIa in patients undergoing surgical correction of scoliosis with the C-D method.
The use of recombinant factor VIIa for bleeding in paediatric practice.
The use of recombinant factor VIIa for severe intractable bleeding during spine surgery.
The use of recombinant factor VIIa in a patient with acquired haemophilia A undergoing surgery.
The use of recombinant factor VIIa in controlling surgical bleeding in non-haemophiliac patients.
The use of rFVIIa in non-haemophilia bleeding conditions in paediatrics. A systematic review.
Therapeutic challenges in acquired factor VIII deficiency.
Therapeutic doses of recombinant factor VIIa in hemophilia generates thrombin in platelet-dependent and -independent mechanisms.
Thrombelastgram as a hemostatic monitor during recombinant factor VIIa treatment in hemophilia A patients with inhibitor to factor VIII.
Thrombelastographic monitoring of recombinant factor VIIa in acquired haemophilia.
Thrombelastography-guided factor VIIa therapy in a surgical patient with severe hemophilia and factor VIII inhibitor.
Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions.
Thrombin generation in clinical conditions.
Thrombin generation in haemophilia A patients with factor VIII inhibitors after infusion of recombinant factor VIIa.
Thrombin generation in plasma of patients with haemophilia A and B with inhibitors: Effects of bypassing agents and antithrombin reduction.
Thromboelastography and recombinant factor VIIa-hemophilia and beyond.
Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.
Thrombosis: a study of coagulation parameters and mechanisms during allograft rejection.
Thrombotic events in neonates receiving recombinant factor VIIa or fresh frozen plasma.
Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC).
Tissue factor and factor VIIa as therapeutic targets in disorders of hemostasis.
To general haemostasis--the evidence-based route.
Total joint replacement in haemophilia A patients with high titre of inhibitor using a new brand recombinant factor VIIa (Aryoseven(®) ).
Toward optimal therapy for inhibitors in hemophilia.
Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors.
Tranexamic acid without prophylactic factor replacement for prevention of bleeding in hereditary bleeding disorder patients undergoing endoscopy: a pilot study.
Transfusion medicine service policies for recombinant factor VIIa administration.
Transplacental hemophilia A and prophylactic treatment with intravenous immunoglobulin and recombinant factor VIIa in the newborn period: a case report.
Treatment and prevention of bleeding in congenital hemophilia A patients with inhibitors.
Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery.
Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: data from the Italian registry of acquired hemophilia.
Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal.
Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: analysis of 10-year Japanese postmarketing surveillance data.
Treatment of bleeding after kidney biopsy with recombinant activated factor VII.
Treatment of bleeding episodes in patients with hemophilia and an inhibitor: comparison of two treatment protocols with recombinant activated factor VII.
Treatment of bleeding in acquired hemophilia A with the proper administration of recombinant activated factor VII: single-center study of 7 cases.
Treatment of bleeding in severe hemorrhagic pancreatitis with recombinant factor VIIa.
Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa.
Treatment of intra-abdominal bleeding with recombinant activated factor VII in a patient with disseminated intravascular coagulation secondary to septic shock.
Treatment Regimens with Bypassing Agents in Patients with Hemophilia A and Inhibitors: A Survey from the Italian Association of Hemophilia Centers (AICE).
Treatment with recombinant activated factor VII in a patient with hemophilia A and an inhibitor: advantages of administration by continuous infusion over bolus intermittent injections.
TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity.
Turnover of prothrombin, factor VII and factor IX in a patient with hemophilia A.
Two-incision laparoscopic appendectomy for a severe hemophilia A child patient with coagulation factor VII deficiency: Case report and review of literature.
U.S. survey of surgical capabilities and experience with surgical procedures in patients with congenital haemophilia with inhibitors.
Ulcerative Colitis in Hemophilia A Patient: Case Report.
Ultra-early hemostatic therapy for acute intracerebral hemorrhage.
Ultra-early hemostatic therapy for primary intracerebral hemorrhage: a review.
Uncomplicated neurosurgical resection of a malignant glioneuronal tumour under haemostatic cover of rFVIIa in a severe haemophilia patient with a high-titre inhibitor: a case report and literature review of rFVIIa use in major surgeries.
Uncontrolled bleeding in surgical patients: the role of recombinant activated factor VIIa.
Understanding the hemostatic effects of recombinant factor VIIa by clot wave form analysis.
Understanding the therapeutic action of recombinant factor VIIa in platelet disorders.
Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids.
Unlabeled uses of factor VIIa (recombinant) in pediatric patients.
Unprovoked Pulmonary Embolism in Factor VII Deficiency.
Update on Novo Nordisk's clinical trial programme on NovoSeven.
Updates in the management of severe coagulopathy in trauma patients.
US experience with recombinant factor VIIa for surgery and other invasive procedures in acquired haemophilia: analysis from the Hemostasis and Thrombosis Research Society Registry.
Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa.
Use of high dose factor VIIa in hemophilia patients.
Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors.
Use of Low-Dose Recombinant Factor ?a for Uncontrolled Perioperative Bleeding.
Use of recombinant activated factor VII for acute bleeding episodes in acquired hemophilia: final analysis from the Hemostasis and Thrombosis Research Society Registry acquired hemophilia study.
Use of Recombinant Activated Factor VII for Intractable Bleeding in Patients Without Hemophilia: A Developing Country Tertiary Care Center's Experience.
Use of recombinant activated factor VII for the treatment of perioperative bleeding in noncardiac surgery patients without hemophilia: A systematic review and meta-analysis of randomized controlled trials.
Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials.
Use of recombinant activated factor VII to treat the acquired coagulopathy of trauma.
Use of Recombinant Factor VII in Cardiac Surgery.
Use of recombinant factor VIIa (NovoSeven) in a haemophilia A patient with inhibitor in Kuwait.
Use of recombinant factor VIIa during excision of vascular anomalies.
Use of recombinant factor VIIa for massive postpartum haemhorrage: case series and review of literature.
Use of recombinant factor VIIa for the prevention and treatment of bleeding in patients without hemophilia: a systematic review and meta-analysis.
Use of recombinant factor VIIa in the management of severe bleeding episodes in patients with Bernard-Soulier syndrome.
Use of recombinant factor VIIa in the perioperative period.
Use of recombinant factor VIIa, Novo Seven, in the management of acute haemorrhage.
Use of the UKHCDO Database for a postmarketing surveillance study of different doses of recombinant factor VIIa in haemophilia.
Uses of recombinant factor VIIa in trauma.
Utilization of recombinant activated factor VII in southern Ontario in 85 patients with and without haemophilia.
Variability of thromboelastographic responses following the administration of rFVIIa to haemophilia A dogs supports the individualization of therapy with a global test of haemostasis.
Views on methods for monitoring recombinant factor VIIa in inhibitor patients.
Visual evaluation of blood coagulation during mural thrombogenesis under high shear blood flow.
Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa.
[A Jehovah's Witness child with hemophilia B and factor IX inhibitors undergoing scoliosis surgery]
[Acquired hemophilia A requiring plasma exchange and mechanical ventilation].
[Acquired hemophilia complicated with hemorrhage induced acute renal failure]
[Acquired inhibitory body hemophilia]
[Activated prothrombin complex preparations for the treatment of anticoagulant hemophilia. Preparation--method of operation--supply possibility]
[Acute treatment with recombinant factor VII is probably indicated for intracerebral haematoma]
[Aortic root replacement in Marfan syndrome with hemophilia A]
[Application of recombinant activated factor VII in treatment of intracranial haemorrhage in haemophilic patient with inhibitor]
[Comparison of modified Bethesda assay and Nijmegen assay in detecting FVII inhibitor in patients with hemophilia A]
[Continuous infusion of recombinant activated factor VII during and after elbow arthroplasty in a hemophilia A patient with inhibitors]
[Current status and trends in blood biologicals].
[Efficacy of Recombinant Activated Factor VII for Intractable Bleeding after Cardiovascular Surgery].
[Factor VII deficiency and surgery]
[Factors VII, VIII, IX, and X: molecular genetics and gene diagnosis]
[Health economics of inhibitor bypassing agents in haemophilia A-activated prothrombin complex concentrate (aPCC) and recombinant activated factor VIIa (rFVIIa)].
[Hemophilia and other inherited blood coagulation disorders in Poland]
[Hemophilia--present and past]
[Infective morbidity of replacement therapy in congenital coagulation deficiencies and its effects on demand of coagulation factors]
[Intraoperative use of plasma-derived activated factor VII (F VII a) in a hemophilia A patient with inhibitors]
[Lessons about recombinant activated factor VII. Ten years since its registration for use in hemophilia with inhibitor.]
[Long-term prophylaxis in congenital haemophilia with inhibitors - experiences with rFVIIa]
[New possibilities in the management of hemorrhagic diathesis caused by factor deficiency and thrombocytopenia: recombinant active factor VII concentrate]
[Our experince with the use of recombinant activated factor VII in postpartum haemorrhage]
[Panorama of congenital disorders of hemostasis diseases at University Hospital of Brazzaville, Congo]
[Perioperative use of recombinant activated factor VII (rF VIIa) in a patient with hemophilia A having inhibitors]
[Problems of conductor demonstration in haemophilia A: error possibilities in the determination of factor-VIII-associated antigen]
[Recombinant activated Factor VII (Novoseven Novo Nordisk) for hemostasis in acquired Factor VIII-inhibitor hemophilia]
[Recombinant activated factor VII for perioperative bleeding]
[Recombinant activated factor VII in paediatric practice. Universal hemostatic agent?]
[Recombinant activated factor VII: a new treatment for hemophilia]
[Recombinant factor VIIa (NovoSeven). A review of current and possible future indications]
[Recombinant factor VIIa. A new alternative for patients with hemophilia]
[Recombinant plasma proteins for therapeutic use--status and developmental trends]
[Rehabilitation in haemophilic children with inhibitors using recombinant activated factor VII]
[Serological markers of hepatitis B virus and cytomegalovirus in patients with hemophilia]
[Successful induction of immune tolerance and novel hemostatic effects in a hemophilia A with high-responder inhibitor by regular infusions of factor VIII]
[Successful treatment of hemothorax with recombinant factor VIIa in a hemophilic child with inhibitor]
[The use of activated recombinant factor VII in the treatment of nasopharyngeal hemorrhage in a patient with extensive fronto-basal injuries. Case report]
[Thrombocyte aggregation and the secretion reaction in hemophilia patients]
[Treatment and prevention of haemorrhage with recombinant activated factor VII, not only in hemophilia]
[Treatment of psoas haematoma in a patient with haemophilia and inhibitors]
[Use of recombinant activated factor VII]
[Use of recombinant, activated Factor VII in the treatment and prevention of bleeding complications in two female patients suffering from congenital XI factor deficiency during orthopedic and traumatology intervention. Case reports]
[Which urologic treatment alternatives are there for the hemophiliac patient?]
Hemophilia B
A Candidate Activation Pathway for Coagulation Factor VII.
A Factor VIIa Variant with Enhanced Tissue Factor Independent Activity Speeds Wound Healing in a Mouse Hemophilia B Model.
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency.
Advances in gene therapy using factor VIIa in hemophilia.
An immunological investigation of hemophilia B with a tentative classification of the disease into five variants.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors.
Antigenicity of activated recombinant factor VII followed through nine years of clinical experience.
Arthroscopic synovectomy of the elbow covered with rFVIIa in a haemophilia B juvenile with inhibitor.
Characterization of heterogeneity of haemophilia B for the detection of carriers.
Christmas disease associated with factor VII deficiency; case report with family survey.
Clinical and laboratory features of 178 children with recurrent epistaxis.
Clinical audit of inherited bleeding disorders in a developing country.
Comparison of the effect of plasma-derived and recombinant human FVIIa in vitro and in a rabbit model.
Current status of hemophilia patients and recombinant coagulation factor concentrates in Japan.
Determinants of coagulation activation in humans.
Determinants of plasma factor VIIa levels in humans.
Development of novel treatment options for patients with haemophilia.
Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease.
Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma.
Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin.
Factor IX variants of hemophilia B. The effect of activated factor XI and the reaction product of factor VII and tissue factor on the abnormal factor IX molecules.
Factor VII activity and antigen in haemophilia B variants.
Factor VIIa in the treatment of haemophilia.
Factor VIIa levels are decreased in patients with hemophilia B.
FVIIa as used pharmacologically is not TF dependent in hemophilia B mice.
Hemophilia B associated with a decreased factor VII activity.
Hemophilia B associated with decreased factor VII activity.
Hemophilia B with associated factor VII deficiency: a distinct variant of hemophilia B with low factor VII activity and normal factor VII antigen.
High dose factor VIIa improves clot structure and stability in a model of haemophilia B.
How factor VIIa works in hemophilia.
Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP).
Influence of factor VIIa and phospholipids on coagulation in "acquired" hemophilia.
Iron studies in hemophilia.
Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality.
Low endoscopy bleeding risk in patients with congenital bleeding disorders.
Major differences in bleeding symptoms between factor VII deficiency and hemophilia B.
Mechanism of factor VIIa-dependent coagulation in hemophilia blood.
Missense mutations and evolutionary conservation of amino acids: evidence that many of the amino acids in factor IX function as "spacer" elements.
Multiple congenital coagulopathies co-expressed with Von Willebrand's disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature.
Non-catheter associated venous thrombosis in hemophilia A and B. A critical review of all reported cases.
Novel products for haemostasis.
Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII.
NovoSeven in immune tolerance therapy.
Orthopaedic surgery in severe bleeding disorders: a low-volume, high-cost procedure.
Over-expression of factor VIIa in vivo.
Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
Poly-N-Acetylglucosamine Fibers Amplify the Effectiveness of Recombinant Factor VIIA on Clot Formation in Hemophilia B Canine Blood.
Pregnancy and oral contraceptives in congenital bleeding disorders of the vitamin K-dependent coagulation factors.
Prevalence of HIV infection in a cohort of patients with congenital coagulation defects of the prothrombin complex factors.
Prophylaxis Using a Mixture of Plasma-Derived Activated Factor VII and Factor X (pdFVIIa/FX) in a Patient with Hemophilia B Complicated by Inhibitors and Allergy to Factor IX Concentrates: A Case Report.
Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.
Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures.
Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders.
Recombinant factor IX.
Recombinant Factor VIIa (Eptacog Alfa): A Review of its Use in Congenital Hemophilia with Inhibitors, Acquired Hemophilia, and Other Congenital Bleeding Disorders.
Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders.
Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors.
Recombinant factor VIIa in the treatment of bleeding in hemophilic children with inhibitors.
Registry of Hemophilia and other bleeding disorders in Syria.
Renal thromboembolism during treatment with recombinant activated factor VII (rFVIIa) in a child with hemophilia B with factor IX inhibitors.
Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B.
Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
Robustness of factor assays following cordocentesis in the prenatal diagnosis of haemophilia and other bleeding disorders.
Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a phase I study.
The clotting system - a major player in wound healing.
Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions.
Very low activated factor VII and reduced factor VII antigen in familial abetalipoproteinaemia.
Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa.
[Acquired haemophilia B: a case report and literature review].
[Infective morbidity of replacement therapy in congenital coagulation deficiencies and its effects on demand of coagulation factors]
[On a case of Christmas disease associated with factor VII deficiency.]
[Successful completion of left total hip arthroplasty by inhibitor neutralization therapy in a hemophilia B patient with high responding inhibitor].
[Thrombocyte aggregation and the secretion reaction in hemophilia patients]
Hemoptysis
A case of massive airway clotting after use of activated factor VII for massive hemoptysis: management with flexible bronchoscopy and cryoadhesion.
Combined factor VII and protein C deficiency found in a patient with peripheral pulmonary artery stenosis accompanied by progressive pulmonary hypertension and hemoptysis.
Recombinant activated factor VII for massive hemoptysis in patients with cystic fibrosis.
Successful Off-Label Use of Recombinant Factor VIIa and Coil Embolization in an Adolescent with Massive Hemoptysis Due to Invasive Pulmonary Aspergillosis.
Successful treatment of massive hemoptysis in acute leukemia with recombinant factor VIIa.
Successful use of recombinant activated coagulation factor VII in a patient with massive hemoptysis from a penetrating thoracic injury.
Successful use of recombinant factor VII in massive hemoptysis due to community-acquired pneumonia.
Traumatic hemoptysis treated with recombinant human factor VIIa.
Hemorrhagic Disorders
Another patient with a congenital hemorrhagic disorder intermediate between factor X and factor VII deficiency.
Functional and Molecular Characterization of C91S Mutation in the Second Epidermal Growth Factor-Like Domain of Factor VII.
Genetic deficiency of factor VII and hemorrhagic diathesis. A case report and literature review.
Genotypic heterogeneity may explain phenotypic variations in inherited factor VII deficiency.
Hemorrhagic diathesis due to factor VII deficiency.
Phenotypic and genotypic characterization of four factor VII deficiency patients from central China.
Prevention of bleeding and hemorrhagic complications in surgical patients with inherited factor VII deficiency.
Recombinant Factor VIIa Use for Endoscopic Retrograde Cholangiopancreatography With Sphincterotomy in a Patient With Choledocholithiasis and Unusual Coagulopathy.
Recurrent intracranial haemorrhages in a patient with factor seven deficiency: a case report.
Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
Surgery in patients with congenital factor VII deficiency - a single center study.
Surgery in patients with congenital factor VII deficiency: A single center experience.
The use of recombinant activated factor VII in the circumcision operation in the case of a congenital factor VII deficiency.
Tissue factor-independent effects of recombinant factor VIIa on hemostasis.
Total hip arthroplasty in severe congenital factor VII deficiency: successful use of recombinant activated factor VII for hemostasis.
[A case of congenital hemorrhagic diathesis due to factor VII deficiency (hypoproconvertinemia)]
[APROPOS OF HEMORRHAGIC DIATHESIS CAUSED BY A DEFICIT OF FACTOR VII.]
[Clinical studies of familial hereditary factor VII deficiency (author's transl)]
[Congenital factor VII (SPCA) deficiency as the cause of hemophilic-type hemorrhagic diathesis.]
[Hemorrhagic diathesis caused by factor VII (proconvertin) deficiency.]
[Hemorrhagic diathesis due to factor VII deficiency (hypoproconvertinemia).]
[New possibilities in the management of hemorrhagic diathesis caused by factor deficiency and thrombocytopenia: recombinant active factor VII concentrate]
[Prophylactic use of a recombinant activated factor VII in delivery haemorrhage by caesarean in a woman with major factor VII deficiency: a case report].
Hemorrhagic Fever, Ebola
Multiple roles of the coagulation protease cascade during virus infection.
Hemorrhagic Stroke
Can a subset of intracerebral hemorrhage patients benefit from hemostatic therapy with recombinant activated factor VII?
Hemorrhagic stroke in a child with protein S and factor VII deficiencies.
Recombinant factor VIIa for hemorrhagic stroke treatment at earliest possible time (FASTEST): Protocol for a phase III, double-blind, randomized, placebo-controlled trial.
Safety of recombinant activated factor VII in patients with warfarin-associated hemorrhages of the central nervous system.
The role of recombinant-activated factor VII in bleeding trauma patients.
Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial.
[Management and predictors in patients with spontaneous intracerebral hemorrhage.]
Hemostatic Disorders
Disseminated intravascular coagulation associated with low factor VII. Evidence for a new type of hemostatic disorder.
Inadvertent propagation of factor VII deficiency in a canine mucopolysaccharidosis type I research breeding colony.
Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage.
[Use of recombinant activated factor VII]
Hemothorax
Cardiac tamponade in a patient with moderate hemophilia A and factor VIII Inhibitors.
Successful Treatment of Intractable Hemothorax with Recombinant Factor VIIa in a Nonhemophilic Patient.
[Successful treatment of hemothorax with recombinant factor VIIa in a hemophilic child with inhibitor]
Hepatic Encephalopathy
Treatment of fulminant hepatic failure with intravenous prostaglandin E1.
Hepatic Insufficiency
1-year survey of patients with advanced liver cirrhosis. Prognostic value of clinical and laboratory indexes identified by the Cox regression model.
Interrelation between factor VII, prekallikrein, and hyperfibrinolysis in advanced cirrhosis.
Prekallikrein and factor VII as prognostic indexes of liver failure.
Hepatic Veno-Occlusive Disease
[Hemostasis tests as markers of hepatic and endothelial toxicity in chemotherapy]
Hepatitis
Factor VII deficiency in pregnancy treated with recombinant factor VIIa.
Non-A/non-B hepatitis in experimentally infected chimpanzees: cross-challenge and electron microscopic studies.
Prekallikrein and factor VII as prognostic indexes of liver failure.
Segmental liver transplantation from non-heart beating donors-an early experience with implications for the future.
The predictive value factor VII in acute hepatitis and coagulapathy. Is it really predictive?
The predictive value of admission and follow up factor V and VII levels in patients with acute hepatitis and coagulopathy.
Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate.
Hepatitis A
Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate.
Hepatitis B
Heterozygous factor VII deficiency and severe hemophilia A in the same kindred.
Treatment of inherited platelet disorders.
[Serological markers of hepatitis B virus and cytomegalovirus in patients with hemophilia]
Hepatitis C
Congenital factor VII deficiency in Iraqi children (Single Centre Experience).
Correction of both prothrombin time and primary haemostasis by recombinant factor VII during therapeutic alcohol injection of hepatocellular cancer in liver cirrhosis.
Ribavirin-induced intracellular GTP depletion activates transcription elongation in coagulation factor VII gene expression.
Small dose of recombinant factor VIIa (rFVIIa) to perform percutaneous liver biopsies in cirrhotic patients.
Hepatitis C, Chronic
Small dose of recombinant factor VIIa (rFVIIa) to perform percutaneous liver biopsies in cirrhotic patients.
[Mathematic Model for Prediction of Liver Fibrosis Progression Rate in Patients with Chronic Hepatitis C Based on Combination of Genomic Markers].
Hepatitis, Chronic
Factor VII deficiency and its treatment in delivery with recombinant factor VII.
Prekallikrein and factor VII as prognostic indexes of liver failure.
Prolonged prothrombin time, Factor VII and activated FVII levels in chronic liver disease are partly dependent on Factor VII gene polymorphisms.
Hepatoblastoma
Recombinant factor VIIa for intraoperative bleeding in a child with hepatoblastoma and review of recombinant activated factor VIIa use in children undergoing surgery.
Segmental liver transplantation from non-heart beating donors-an early experience with implications for the future.
Two common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration.
Hepatolenticular Degeneration
Application of recombinant activated factor VII for treatment of impaired haemostasis during liver transplantation in recipients with Wilson's disease--a report of two cases.
Preemptive administration of recombinant factor VII (rVIIa) in patients transplanted due to fulminant Wilson's disease.
Whole-exome sequencing provides insights into monogenic disease prevalence in Northwest Russia.
Hermanski-Pudlak Syndrome
Successful thyroidectomy in a patient with Hermansky-Pudlak syndrome treated with recombinant activated factor VII and platelet concentrates.
Herpes Simplex
Coagulation factor VIIa binds to herpes simplex virus 1-encoded glycoprotein C forming a factor X-enhanced tenase complex oriented on membranes.
Herpes simplex virus type 1-encoded glycoprotein C enhances coagulation factor VIIa activity on the virus.
Novel Agents in the Management of Pancreatic Adenocarcinoma: Phase I Studies. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Hodgkin Disease
Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII.
Homocystinuria
Superior sagittal sinus thrombosis with homocystinuria and deficiency of antithrombin III and factor VII: case report.
Tissue factor pathway inhibitor levels in patients with homocystinuria.
[Factor VII deficiency and homocystinuria. Chance association or syndrome?]
[Homocystinuria and factor VII deficiency]
Hydrocephalus
A rare combination: congenital factor VII deficiency with Chiari malformation.
Familial factor VII deficiency with foetal and neonatal fatal cerebral haemorrhage associated with homozygosis to Gly180Arg mutation.
In silico method for identification of novel copper and iron metabolism proteins in various neurodegenerative disorders.
Unexpected posthemorrhagic hydrocephalus in patients treated with rFVIIa.
Hydronephrosis
A case of a novel mutant vasopressin receptor-dependent nephrogenic diabetes insipidus with bilateral non-obstructive hydronephrosis in a middle aged man: differentiation from aquaporin-dependent nephrogenic diabetes insipidus by response of factor VII and von Willebrand factor to 1-diamino-8-arginine vasopressin administration.
rFVIIa and obstructive hydronephrosis.
Hypercholesterolemia
Effect of monthly atorvastatin treatment on hemostasis.
Hemostatic effects of simvastatin in subjects with impaired glucose tolerance.
Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin.
Interrelationship of plasma triglyceride and coagulant factor VII levels in normotriglyceridemic hypercholesterolemia.
[Lipids/hemostasis interactions. A new approach to cardiovascular risk factors]
Hyperglycemia
Factor VIIa and tissue factor procoagulant activity in diabetes mellitus after acute ischemic stroke: impact of hyperglycemia.
Hemostasis and glycemic control in the cardiac surgical patient.
Whole-Blood Tissue Factor Procoagulant Activity Is Elevated in Type 1 Diabetes and Effects of Hyperglycemia and Hyperinsulinemia.
Hyperhomocysteinemia
Analysis of polymorphisms Leiden Factor V G1691A and prothrombin G20210A as risk factors for acute myocardial infarction.
Assessment of hemostatic risk factors in predicting arterial thrombotic events.
Hyperinsulinism
Cardiovascular risk factors: interactive effects of lipids, coagulation and fibrinolysis.
Characteristics of the insulin resistance syndrome in a Japanese population. The Jichi Medical School Cohort Study.
Hemostasis and glycemic control in the cardiac surgical patient.
Risk factors for vascular disease and arteriovenous fistula dysfunction in hemodialysis patients.
Whole-Blood Tissue Factor Procoagulant Activity Is Elevated in Type 1 Diabetes and Effects of Hyperglycemia and Hyperinsulinemia.
[Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome]
Hyperlipidemias
Activation of coagulation factor VII during alimentary lipemia.
Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency.
Atorvastatin and omega-3 fatty acids protect against activation of the coagulation system in patients with combined hyperlipemia.
Atorvastatin reduces plasma levels of factor VII activity and factor VII antigen in patients with hyperlipidemia.
Dietary fat and postprandial lipids.
Dietary fatty acids, hemostasis, and cardiovascular disease risk.
Do oxidized fatty acids activate coagulation factor VII during post-prandial lipemia in women?
Effect of individual dietary fatty acids on postprandial activation of blood coagulation factor VII and fibrinolysis in healthy young men.
Effect of interesterification of palmitic acid-rich triacylglycerol on postprandial lipid and factor VII response.
Effect of omega-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia.
Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients.
Hemostasis and cardiovascular risk. The British and European experience.
In vivo demonstration in humans that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway.
Increased activity of factor VII and factor VII-phospholipid complex measured using a Normotest system in subjects with hyperlipidemia.
Increased levels of factor VII, fibrinogen and activity of plasminogen activator inhibitor during postprandial triglyceridemia in patients with ischemic heart disease confirmed by angiography.
Influence of a stearic acid-rich structured triacylglycerol on postprandial lipemia, factor VII concentrations, and fibrinolytic activity in healthy subjects.
Influence of fatty acid chain length and cis/trans isomerization on postprandial lipemia and factor VII in healthy subjects (postprandial lipids and factor VII).
Influence of stearic acid on hemostatic risk factors in humans.
Influence of stearic acid on postprandial lipemia and hemostatic function.
Influence of triacylglycerol structure on the postprandial response of factor VII to stearic acid-rich fats.
Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias.
Long-chain n-3 polyunsaturated fatty acids and triacylglycerol metabolism in the postprandial state.
Phospholipase C sensitive FVII activity and FVII antigen in hypertriglyceridemia.
Plasma factor VII, triglyceride concentration and fibrin degradation products in primary hyperlipidemia: a clinical and laboratory study.
Relationship between apolipoprotein E polymorphism, postprandial hyperlipemia and hemostatic variables in patients with combined hyperlipemia.
Relationship between thyroid hormones and plasma D-dimer levels.
Risk factors for vascular disease and arteriovenous fistula dysfunction in hemodialysis patients.
The impact of postprandial lipemia in accelerating atherothrombosis.
The solid fat content of stearic acid-rich fats determines their postprandial effects.
Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components.
[Hemostasis profiles in thrombotic disease]
Hyperlipoproteinemia Type II
R353Q polymorphism in the factor VII gene and cardiovascular risk in Heterozygous Familial Hypercholesterolemia: a case-control study.
[The relationships between the lipoprotein profile and rheological-coagulation parameters in patients with hyperlipoproteinemia type II]
Hyperlipoproteinemias
Fibrinogen, factor VII, antithrombin III, cholesterol and triglycerides in young men with myocardial infarction and in their sons.
Increased activity of factor VII and factor VII-phospholipid complex measured using a Normotest system in subjects with hyperlipidemia.
Relationship between triglycerides and factor VIIc and plasminogen activator inhibitor type-1: lack of threshold value.
[Changes in the level of certain hemostatic factors during treatment with lovastatin in patients with primary hyperlipoproteinemia and phenotype IIa and IIb]
[The relationships between the lipoprotein profile and rheological-coagulation parameters in patients with hyperlipoproteinemia type II]
Hyperoxaluria, Primary
Segmental liver transplantation from non-heart beating donors-an early experience with implications for the future.
Hyperparathyroidism, Primary
Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-Dimer levels.
Hypersensitivity
Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
Prophylaxis Using a Mixture of Plasma-Derived Activated Factor VII and Factor X (pdFVIIa/FX) in a Patient with Hemophilia B Complicated by Inhibitors and Allergy to Factor IX Concentrates: A Case Report.
Thrombelastography monitoring of platelet substitution therapy and rFVIIa administration in haemato-oncological patients with severe thrombocytopenia.
Hypersensitivity, Immediate
Avoiding Cardiovascular Collapse: Pediatric Cutaneous Mastocytosis and Anesthetic Challenges.
Hypertension
Are risk factors for atherothrombotic disease associated with back pain sickness absence? The Whitehall II Study.
Association between factor VII polymorphisms and blood pressure: the Stanislas Cohort.
Characteristics of the insulin resistance syndrome in a Japanese population. The Jichi Medical School Cohort Study.
Effect of transdermal hormone therapy on platelet haemostasis in menopausal women.
Effects of lipids and lipid-lowering therapy on hemostatic factors in patients with myocardial infarction.
Exercise training in mild hypertension: effects on blood pressure, left ventricular mass and coagulation factor VII and fibrinogen.
Factor VII activity is an independent predictor of cardiovascular mortality in elderly women of a Sicilian population: results of an 11-year follow-up.
Factor VII hyperactivity and endothelial cell damage are found in elderly hypertensives only when concomitant with microalbuminuria.
Factor VII levels, R353Q and -323P0/10 Factor VII variants, and the risk of acute coronary syndrome among Arab-African Tunisians.
Fluorogenic assay of activated factor VII. Plasma factor VIIa levels in relation to arterial cardiovascular diseases in Japanese.
Haemostatic and other cardiovascular risk factors, and socioeconomic status among middle-aged Finnish men and women.
Haemostatic markers are associated with measures of vascular disease in adults with hypertension.
High factor VIII, von Willebrand factor, and fibrinogen levels and risk of venous thromboembolism in blacks and whites.
Hyperlipidemia, hypercoagulability, and accelerated thrombosis: studies in congenitally hyperlipidemic rats and in rats and monkeys with induced hyperlipidemia.
Microalbuminuria and endothelial dysfunction in essential hypertension.
Procoagulant stress reactivity and recovery in apparently healthy men with systolic and diastolic hypertension.
Prothrombin fragment 1.2 in both treated and untreated hypertensive patients.
Reducing the burden of diabetes: managing cardiovascular disease.
Sex hormones and hemostatic risk factors for coronary heart disease in men with hypertension.
Successful placement of a right ventricular assist device for treatment of a presumed amniotic fluid embolism.
Takayasu Arteritis Presenting as Renovascular Hypertension and Renal Failure in a Patient with Factor VII Deficiency.
[Activated factor VII as a new cardiovascular risk factor of atherothrombotic disease]
[Polymorphism (353)R>Q of Gene of Blood Clotting Factor FVII and Plasma Hemostasis].
Hypertension, Portal
Splenectomy Improves Hemostatic and Liver Functions in Hepatosplenic Schistosomiasis Mansoni.
Splenic embolization in a Jehovah's Witness: role of recombinant human factor VIIa.
[Recombinant activated factor VII in the treatment of intractable non-surgical bleeding following major vascular procedures]
Hypertension, Pulmonary
Combined factor VII and protein C deficiency found in a patient with peripheral pulmonary artery stenosis accompanied by progressive pulmonary hypertension and hemoptysis.
Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant.
Hypertension, Renovascular
Takayasu Arteritis Presenting as Renovascular Hypertension and Renal Failure in a Patient with Factor VII Deficiency.
Hyperthyroidism
Contact system activation and high thrombin generation in hyperthyroidism.
Effects of Thyroid Function on Hemostasis, Coagulation, and Fibrinolysis: A Mendelian Randomization Study.
Hypertriglyceridemia
Atorvastatin and omega-3 fatty acids protect against activation of the coagulation system in patients with combined hyperlipemia.
Coagulation factor VII and plasma triglycerides. Decreased catabolism as a possible mechanism of factor VII hyperactivity.
Effects of fish oil supplements in NIDDM subjects. Controlled study.
Fibrinogen, factor VII, antithrombin III, cholesterol and triglycerides in young men with myocardial infarction and in their sons.
Hypercoagulability and factor VII in hypertriglyceridemia.
Phospholipase C sensitive FVII activity and FVII antigen in hypertriglyceridemia.
Hypertrophy, Left Ventricular
Canonical correlation analysis for gene-based pleiotropy discovery.
[The indices of the fibrinolysis, blood coagulation and lipid transport systems in hypertension patients]
Hypocalcemia
Resuscitation and transfusion principles for traumatic hemorrhagic shock.
Hypoglycemia
Rabbit hemorrhagic viral disease: characterization of a new animal model of fulminant liver failure.
Hypoprothrombinemias
Comparison between the one-stage prothrombin time and factor VII and X complex determination in bishydroxycoumarin-induced hypoprothrombinemia countered by phytonadione.
Diagnosis, clinical manifestations and management of rare bleeding disorders in Iran.
[Effects of vitamin K1 on factor VII and prothrombin deficiency in newborn.]
[Idiopathic hemorrhagic disease due to factor VII and prothrombin deficiency.]
Hypotension
Acute hypotension associated with intraoperative cell salvage using a leukocyte depletion filter during management of obstetric hemorrhage due to amniotic fluid embolism.
Damage control resuscitation: a sensible approach to the exsanguinating surgical patient.
Recombinant tissue factor pathway inhibitor prevents lipopolysaccharide-induced systemic hypotension in rats by inhibiting excessive production of nitric oxide.
Reducing perioperative blood loss and allogeneic blood transfusion in patients undergoing major spine surgery.
[Trauma-induced coagulopathy--mechanisms and state of the art treatment].
Hypothyroidism
Acquired von Willebrand syndrome type 1 in hypothyroidism: reversal after treatment with thyroxine.
Effects of Thyroid Function on Hemostasis, Coagulation, and Fibrinolysis: A Mendelian Randomization Study.
Hemostasis in Hypothyroidism and Autoimmune Thyroid Disorders.
Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.
Ichthyosis
Description of breed ancestry and genetic health traits in arctic sled dog breeds.
Idiopathic Pulmonary Fibrosis
Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease.
Role of Protease-Activated Receptor-2 in Idiopathic Pulmonary Fibrosis.
IgA Vasculitis
Successful use of recombinant factor VIIa in a child with Schoenlein-Henoch purpura presenting with compartment syndrome and severe factor XIII deficiency.
Immunoglobulin Light-chain Amyloidosis
Acquired factor VII deficiency causing severe bleeding disorder secondary to AL amyloidosis of the liver.
Successful perioperative management of factor X deficiency associated with primary amyloidosis.
Infarction, Middle Cerebral Artery
[Acute stroke therapy : Current developments.]
Infections
A new scoring system to determine thromboembolic risk after heart valve replacement.
Acquired factor VII deficiency associated with acute myeloid leukemia.
Avoiding Cardiovascular Collapse: Pediatric Cutaneous Mastocytosis and Anesthetic Challenges.
Bmal1 Regulates Coagulation Factor Biosynthesis in Mouse Liver in Streptococcus oralis Infection.
Distal deep venous thrombosis in a hemophilia A patient with inhibitor and severe infectious disease, 18 days after recombinant activated factor VII transfusion.
Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
Endogenous Heparinoids May Cause Bleeding in Mucor Infection and can be Detected by Nonactivated Thromboelastometry and Treated by Recombinant Activated Factor VII: A Case Report.
Factor VII deficiency and pregnancy: a case report and review of literature.
Genotype-specific increase in plasma concentrations of activated coagulation factor VII in response to experimental inflammation. A link between infection and acute myocardial infarction?
Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D.
Inhibition of the extrinsic or intrinsic coagulation pathway during pneumonia derived sepsis.
Isolated acquired factor VII deficiency: review of the literature.
Plasma levels of activated FVII in various diseases.
Prothrombotic changes in hemostatic parameters and C-reactive protein in the elderly with winter acute respiratory tract infections.
Recent bacterial and viral infection is a risk factor for cerebrovascular ischemia: clinical and biochemical studies.
Recombinant Human Factor VIIa for Alveolar Hemorrhage Following Allogeneic Stem Cell Transplantation.
Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease.
Septic miscarriage with toxic shock syndrome and disseminated intravascular coagulation (DIC): The role of surgery, recombinant activated factor VII and intravenous immunoglobulin (IVIG).
Successful induction of immune tolerance with FIX recombinant in a patient with haemophilia B with inhibitor.
The procoagulant envelope virus surface: contribution to enhanced infection.
Tissue factor and glycoprotein C on herpes simplex virus type 1 are protease activated receptor 2 cofactors that enhance infection.
[Acquired and repeated factor VII deficiency during infections outbreaks: case-report]
Insulin Resistance
Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients.
Analysis of the correlation between plasma coagulation factor VII, PAI-1, and uric acid with insulin resistance and macrovascular complications in elderly patients with type 2 diabetes.
Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women.
Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM.
Coagulation factor VII activity, Arg/Gln353 polymorphism and features of insulin resistance in first-degree-relatives of South Asian patients with stroke.
Dietary treatment of thrombogenic disorders related to the metabolic syndrome.
Estrogen replacement therapy and cardiovascular protection: lipid mechanisms are the tip of an iceberg.
Factor VII gene polymorphisms, factor VII:C levels and features of insulin resistance in non-insulin-dependent diabetes mellitus.
Inhibition of thrombin action ameliorates insulin resistance in type 2 diabetic db/db mice.
Interrelationship between coagulation factor VII and obesity in diabetes mellitus (type 2).
Interrelationships of factor VII activity and plasma leptin with insulin resistance in coronary heart disease.
Is there a menopausal metabolic syndrome?
Moderate red wine consumption and cardiovascular disease risk: beyond the "French paradox".
Obesity, haemostasis and the fibrinolytic system.
Polymorphisms of coagulation/fibrinolysis genes: gene environment interactions and vascular risk.
The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus.
[Atheroma and antithrombotic agents]
[Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome]
[Relationship between parameters of hemostasis and manifestations of the metabolic syndrome in men with mild and moderate hypertension]
Intellectual Disability
Congenital combined defects of factor VII: a critical review.
Congenital FX deficiency combined with other clotting defects or with other abnormalities: a critical evaluation of the literature.
Intestinal Atresia
Inherited thrombophilia: a possible cause of in utero vascular thrombosis in children with intestinal atresia.
Intra-Abdominal Hypertension
A novel use of recombinant factor VIIa in HELLP syndrome associated with spontaneous hepatic rupture and abdominal compartment syndrome.
Intracranial Aneurysm
A Rare Case Report of Multiple Intracranial Aneurysms with Factor VII Deficiency.
Multiple cerebral aneurysms in factor VII deficiency.
[Congenital factor VII deficiency and subarachnoidal haemorrhage due to intracranial aneurysm: a case report]
Intracranial Arteriosclerosis
The influence of the degree of cerebral atherosclerosis on the changes in hemostatic system in patients with ischemic brain disease and atherosclerotic encephalopathy.
Intracranial Arteriovenous Malformations
Use of recombinant factor VIIa in the treatment of massive retroperitoneal bleeding due to severe necrotizing pancreatitis.
Intracranial Embolism
Hypercoagulability in acute ischemic stroke: analysis of the extrinsic coagulation reactions in plasma by a highly sensitive automated method.
Intracranial Hemorrhage, Traumatic
The efficacy of factor VIIa in emergency department patients with warfarin use and traumatic intracranial hemorrhage.
Intracranial Hemorrhages
A case of intracranial hemorrhage in a neonate with congenital factor VII deficiency.
A Neonate with Acquired Factor VII Deficiency Successfully Managed with Immunomodulatory Therapy.
A novel homozygous missense mutation in the factor VII gene of severe factor VII deficiency in a newborn baby.
Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the novoseven emergency-use program.
Acute intracranial hemorrhage in a cirrhotic controlled with recombinant factor VIIa.
Asymptomatic intracranial hemorrhage in a newborn with congenital factor VII deficiency and successful treatment with recombinant activated factor VII.
Biochemical, molecular and clinical aspects of coagulation factor VII and its role in hemostasis and thrombosis.
Coagulation factor VIIa (recombinant) for warfarin-induced intracranial hemorrhage.
Comparison of a Low, Fixed Dose and a High, Weight-Based Dose of Recombinant Factor VIIa in the Treatment of Warfarin-Associated Intracranial Hemorrhage.
Congenital factor VII deficiency complicated with hemoperitoneum and intracranial hemorrhage: report of a case.
Congenital factor VII deficiency.
Dabigatran etexilate: management in acute ischemic stroke.
Effects of recombinant activated factor VII in traumatic nonsurgical intracranial hemorrhage.
Effects of recombinant factor VIIa on thrombin generation and thromboelastography in a patient with dabigatran-associated intracranial hemorrhage.
Factor VII deficiency with intracranial hemorrhage: a case report.
Fatal intracranial hemorrhage in a newborn with factor VII deficiency.
Genotype and phenotype correlation in intracranial hemorrhage in neonatal factor VII deficiency among Thai children.
Hereditary factor VII deficiency: report of a case of intracranial hemorrhage.
Heterozygous congenital Factor VII deficiency with the 9729del4 mutation, associated with severe spontaneous intracranial bleeding in an adolescent male.
Intracellular readthrough of nonsense mutations by aminoglycosides in coagulation factor VII.
Intracranial hemorrhage in congenital factor VII deficiency.
Management of Life-Threatening Hemorrhages and Unsafe Interventions in Nonhemophiliac Children by Recombinant Factor VIIa.
Mortality and Factors Associated With Hemorrhage During Pediatric Extracorporeal Membrane Oxygenation.
Multiple intracranial hemorrhages at the time of a transiently prolonged activated partial thromboplastin time in an infant with congenital factor VII deficiency.
Neonatal intracranial hemorrhage secondary to congenital factor VII deficiency: two case reports.
Novel IVS7+1G>T mutation of life-threatening congenital factor VII deficiency in neonates: A retrospective study in China.
Outcome of intracranial hemorrhage in infants with congenital factor VII deficiency.
Pharmacology and clinical use of recombinant activated factor seven in neurosciences.
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Phenotypical variability in congenital FVII deficiency follows the ISTH-SSC severity classification guidelines: a review with illustrative examples from the clinic.
Polymorphisms of clotting factors modify the risk for primary intracranial hemorrhage.
Prenatal exclusion of severe factor VII deficiency.
Prophylaxis Using a Mixture of Plasma-Derived Activated Factor VII and Factor X (pdFVIIa/FX) in a Patient with Hemophilia B Complicated by Inhibitors and Allergy to Factor IX Concentrates: A Case Report.
Rapid Warfarin Reversal in the Setting of Intracranial Hemorrhage: A Comparison of Plasma, Recombinant Activated Factor VII, and Prothrombin Complex Concentrate.
RBC Exposure in Pediatric Extracorporeal Membrane Oxygenation: Epidemiology and Factors Associated With Large Blood Transfusion Volume.
Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors.
Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage.
Recombinant Activated Factor VII Use in Critically Ill Patients: Clinical Outcomes and Thromboembolic Events (April).
Recombinant coagulation factor VIIa for rapid preoperative correction of warfarin-related coagulopathy in patients with acute subdural hematoma.
Recombinant factor VIIa for rapid reversal of anticoagulant effect in patients with intracranial hemorrhage: the Israeli experience and review of the literature.
Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage.
Recombinant factor VIIa for warfarin-associated intracranial bleeding.
Recombinant factor VIIa use in patients presenting with intracranial hemorrhage.
Recurrent intracranial hemorrhage in an infant with congenital factor VII deficiency.
rFVII for pediatric acute intracranial hemorrhage.
Successful prophylaxis against intracranial hemorrhage using weekly administration of activated recombinant factor VII in a newborn with severe factor VII deficiency.
Successful prophylaxis of intracranial hemorrhage in infants with severe congenital factor VII deficiency.
Successful treatment of acute lymphoblastic leukemia with L-asparaginase-induced intracranial hemorrhage to activated recombinant factor VIIa in a child.
Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature.
The Judicious Use of Recombinant Factor VIIa.
Thromboelastography to direct the administration of recombinant activated factor VII in a child with traumatic injury requiring massive transfusion.
Thromboembolic risks of recombinant factor VIIa Use in warfarin-associated intracranial hemorrhage: a case-control study.
Treatment of warfarin-related intracranial hemorrhage: a comparison of prothrombin complex concentrate and recombinant activated factor VII.
Uncomplicated stereotactic and open neurosurgical procedures in patients with factor VII deficiency.
Unlabeled uses of factor VIIa (recombinant) in pediatric patients.
Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage.
Use of three procoagulants in improving bleeding outcomes in the warfarin patient with intracranial hemorrhage.
[Factor VII deficiency revealed by intracranial hemorrhage.]
[Intracranial hemorrhage in an infant with congenital factor VII deficiency]
[Recurrent intracranial hemorrhage in a nursing infant with congenital factor VII deficiency. Survival and follow-up after neurosurgical intervention]
Intracranial Thrombosis
Hypercoagulability in acute ischemic stroke: analysis of the extrinsic coagulation reactions in plasma by a highly sensitive automated method.
Invasive Pulmonary Aspergillosis
Successful Off-Label Use of Recombinant Factor VIIa and Coil Embolization in an Adolescent with Massive Hemoptysis Due to Invasive Pulmonary Aspergillosis.
Iron Deficiencies
Congenital factor VII deficiency presenting as iron deficiency anaemia--Case report.
Treatment of inherited platelet disorders.
Ischemic Stroke
A genome-wide association study identifies new loci for factor VII and implicates factor VII in ischemic stroke etiology.
Antiphospholipid syndrome with catastrophic bleeding and recurrent ischemic strokes as initial presentation of systemic lupus erythematosus.
Assessing Circulating Factor VIIa-Antithrombin Complexes in Acute Ischemic Stroke: A Pilot Study.
Associated prothrombotic conditions are probably responsible for the occurrence of thrombosis in almost all patients with congenital FVII deficiency. Critical review of the literature.
Association of genetic variants with coronary artery disease and ischemic stroke in a longitudinal population-based genetic epidemiological study.
Associations of activated coagulation factor VII and factor VIIa-antithrombin levels with genome-wide polymorphisms and cardiovascular disease risk.
Blood coagulation and fibrinolysis in acute ischaemic and haemorrhagic (intracerebral and subarachnoid haemorrhage) stroke: does decreased plasmin inhibitor indicate increased fibrinolysis in subarachnoid haemorrhage compared to other types of stroke?
Case Report: A 70-Year-Old Man with Undiagnosed Factor VII Deficiency Presented with Acute Ischemic Stroke.
Complications of recombinant activated human coagulation factor VII.
Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII.
Decreased fibrinolytic potential in South Asian women with ischaemic cerebrovascular disease.
Factor VII -323 decanucleotide D/I polymorphism in atrial fibrillation: implications for the prothrombotic state and stroke risk.
Factor VII antigen levels are differentially associated to etiological subtypes of ischaemic stroke.
Factor VII gene haplotypes and risk of ischemic stroke.
Factor VIIa and tissue factor procoagulant activity in diabetes mellitus after acute ischemic stroke: impact of hyperglycemia.
Hemostatic factors as predictors of stroke and cardiovascular diseases: the FINRISK '92 Hemostasis Study.
Hemostatic risk factors in ischemic stroke.
Intracerebral hemorrhage: outcomes and eligibility for factor VIIa treatment in a National Stroke Registry.
Ischemic stroke after recombinant factor VIIa treatment in acquired hemophilia A patient.
Ischemic stroke in a patient with moderate to severe inherited factor VII deficiency.
Meta-Analysis of Factor V, Factor VII, Factor XII, and Factor XIII-A Gene Polymorphisms and Ischemic Stroke.
Multiple ischemic strokes associated with use of recombinant activated factor VII.
Polymorphisms in platelet glycoprotein 1balpha and factor VII and risk of ischemic stroke: a meta-analysis.
Polymorphisms in the factor VII gene and ischemic stroke in young adults.
Polymorphisms of Genes Encoding Coagulation Factors II, V, VII, and XIII in Relation to Pediatric Ischemic Stroke: Family-based and Case-Control Study.
Protein Z in ischaemic stroke.
Recombinant activated factor VII for acute intracerebral hemorrhage.
Repeat measurement of case-control data: corrections for measurement error in a study of ischaemic stroke and haemostatic factors.
Risk factors of diffuse alveolar hemorrhage after acute ischemic stroke treated with tissue-type plasminogen activator. The effectiveness of activated recombinant factor VII treatment.
Safety of Anticoagulation Reversal in Patients Supported with Continuous-flow Left-ventricular Assist Devices.
The effects of alcohol on coagulation and fibrinolytic factors: a controlled trial.
The tissue factor pathway in ischemic stroke.
Von Willebrand factor and risk of ischemic stroke.
[Acute treatment with recombinant factor VII is probably indicated for intracerebral haematoma]
Jaundice, Chronic Idiopathic
Active and inactive factor VII in Dubin-Johnson syndrome with factor-VII deficiency, hereditary factor-VII deficiency and on coumadin administration.
Age estimates of ancestral mutations causing factor VII deficiency and Dubin-Johnson syndrome in Iranian and Moroccan Jews are consistent with ancient Jewish migrations.
Hereditary deficiency of blood clotting factor VII and Dubin-Johnson syndrome in an Israeli family.
Joint Diseases
A syndrome of factor VII deficiency and abnormal platelet release reaction.
Arthropathies in factor VII deficiency: a case report.
Arthropathy and surgery in congenital factor VII deficiency.
Arthropathy in factor VII coagulation deficiency. Description of a clinical case.
Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
EPCR deficiency or function-blocking antibody protects against joint bleeding-induced pathology in hemophilia mice.
Long-term prophylaxis in severe factor VII deficiency.
Prevention of arthropathy: may it be extrapolated from patients without inhibitors to patients with inhibitors?
Prevention of haemarthrosis in a murine model of acute joint bleeding.
Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures.
Severe factor VII deficiency due to a mutation disrupting an Sp1 binding site in the factor VII promoter.
The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate.
Kasabach-Merritt Syndrome
The use of recombinant activated factor VII during major surgery in a child with Kasabach-Merritt syndrome.
Kidney Calculi
Percutaneous Nephrolithotomy in Rare Bleeding Disorders: A Case Report and Review of the Literature.
Kidney Diseases
Congenital Factor VII Deficiency in Association With Bicuspid Aortic Valve and Multicystic Dysplastic Kidney Disease in a Child.
Kidney Failure, Chronic
Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: effect of hemodialysis.
Kidney Transplant in a Patient With Factor VII Deficiency: Case Report.
Management of Kidney Transplantation in a Factor VII-Deficient Patient: Case Report.
Protracted bleeding after hirudin anticoagulation for cardiac surgery in a patient with HIT II and chronic renal failure.
Recombinant factor VIIa reduces bleeding risk in patients on platelet aggregation inhibitors immediately prior to renal transplantation--a retrospective analysis.
Successful use of recombinant factor VIIa (NovoSeven) in children with compartment syndrome: two case reports.
Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage.
[Coagulation factor VII levels in uremic patients and theirs influence factors]
Klippel-Trenaunay-Weber Syndrome
Control of disseminated intravascular coagulation in Klippel-Trenaunay-Weber syndrome using enoxaparin and recombinant activated factor VIIa: a case report.
Factor VII deficiency and a copper metabolism disorder in a patient with Klippel-Trenaunay syndrome.
Leiomyosarcoma
[Factor VII deficiency and surgery]
Leishmaniasis, Visceral
[Transitory deficiency of factor VII in a case of kala-azar]
Leptospirosis
Parenteral use of recombinant activated factor VII during diffuse alveolar hemorrhage secondary to leptospirosis.
Lethargy
Congenital factor VII deficiency.
Leukemia
Cerebral hemorrhage treated with NovoSeven in acute promyelocytic leukemia.
Elevated extracellular trap formation and contact system activation in acute leukemia.
IV. Anticoagulant activity of compound 48/80: inhibition of factor VII activation in leukemia THP-1 monocytes.
Management of Life-Threatening Hemorrhages and Unsafe Interventions in Nonhemophiliac Children by Recombinant Factor VIIa.
Recombinant activated factor VII for severe gastrointestinal bleeding after chemotherapy in an infant with acute megakaryoblastic leukemia.
Recombinant activated factor VII for severe uterine bleeding after chemotherapy in a woman with acute myeloid leukemia.
Recombinant activated factor VII usage in life threatening hemorrhage: a pediatric experience.
Successful treatment of massive gastrointestinal hemorrhage in acute biphenotypic leukemia with recombinant factor VIIa (NovoSeven).
Successful treatment of massive hemoptysis in acute leukemia with recombinant factor VIIa.
Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII : Report on one case and review of other uses in acute leukemias.
Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia.
[Hemostasis tests as markers of hepatic and endothelial toxicity in chemotherapy]
[Recombinant factor VIIa for the treatment of acute promyelocytic leukemia with severe bleeding: 8 cases report and literature review].
Leukemia, Biphenotypic, Acute
Successful treatment of massive gastrointestinal hemorrhage in acute biphenotypic leukemia with recombinant factor VIIa (NovoSeven).
Leukemia, Erythroblastic, Acute
Interference of activated factor VII in apoptosis of erytholeukemic K562 cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Massive oral bleeding after full-mouth extraction in a patient with B-cell lymphocytic leukemia/small lymphocytic lymphoma reversed with recombinant activated factor VII.
Leukemia, Megakaryoblastic, Acute
Recombinant activated factor VII for severe gastrointestinal bleeding after chemotherapy in an infant with acute megakaryoblastic leukemia.
Leukemia, Myeloid, Acute
Acquired factor VII deficiency associated with acute myeloid leukemia.
Acute Myelogenous Leukemia With Trisomy 8 and Concomitant Acquired Factor VII Deficiency.
Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII.
Massive pulmonary embolism after treatment with rFVIIa in a thrombocytopenic patient with acute myelogenous leukemia and intractable bleeding.
Recombinant activated factor VII for severe uterine bleeding after chemotherapy in a woman with acute myeloid leukemia.
Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature.
Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII : Report on one case and review of other uses in acute leukemias.
Successful use of recombinant activated factor VII in controlling upper gastrointestinal bleeding in a patient with relapsed acute myeloid leukemia.
Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa.
Leukemia, Promyelocytic, Acute
Cerebral hemorrhage treated with NovoSeven in acute promyelocytic leukemia.
[Recombinant factor VIIa for the treatment of acute promyelocytic leukemia with severe bleeding: 8 cases report and literature review].
Liposarcoma
Acquired factor VII deficiency associated with pleural liposarcoma.
Livedo Reticularis
Cerebral ischemia and livedo reticularis in a patient with impairment of coagulation factor VII and free protein S.
Liver Cirrhosis
Analysis of the substrate specificity of Factor VII activating protease (FSAP) and design of specific and sensitive peptide substrates.
Correction of both prothrombin time and primary haemostasis by recombinant factor VII during therapeutic alcohol injection of hepatocellular cancer in liver cirrhosis.
Effect of Recombinant Activated Factor VII in Critical Bleeding : Clinical Experience of a Single Center.
Effectiveness of the recombinant factor VIIa in patients with the coagulopathy of advanced child's B and C cirrhosis.
Enhanced lipid peroxidation in hepatic cirrhosis.
Enzyme-linked immunosorbent assay of human factor VII based upon a monoclonal antibody that recognizes the native conformation of the protein.
Expression of factor VII in the liver of patients with liver disease: correlations with the disease severity and impairment in the hemostasis.
Factor VII in liver cirrhosis.
Haemostasis unbalance in Pugh-scored liver cirrhosis: characteristic changes of plasma levels of protein C versus protein S.
Interrelation between factor VII, prekallikrein, and hyperfibrinolysis in advanced cirrhosis.
Measurement of the procoagulant activity of factor VII in patients with liver cirrhosis and normal prothrombin activity: evaluation of the bleeding risk.
Prekallikrein and factor VII as prognostic indexes of liver failure.
Prolonged prothrombin time, Factor VII and activated FVII levels in chronic liver disease are partly dependent on Factor VII gene polymorphisms.
Recombinant factor VIIa for variceal bleeding in liver cirrhosis: still only a hope.
Spontaneous hemorrhage after external ventricular drain placement in the setting of low factor VII secondary to liver cirrhosis.
The Marburg I polymorphism of factor VII activating protease is associated with low proteolytic and low pro-coagulant activity.
Validation and functional analysis of the critical proteins in combination with taurine, epigallocatechin gallate and genistein against liver fibrosis in rats.
[Mathematic Model for Prediction of Liver Fibrosis Progression Rate in Patients with Chronic Hepatitis C Based on Combination of Genomic Markers].
[Plasma factor VII levels in disseminated intravascular coagulation]
[The value of coagulation factors in severity categorization of hepatitis B-related liver cirrhosis]
Liver Cirrhosis, Alcoholic
Pericardiocentesis and pancreatic aspiration needle biopsy in coagulopathic and thrombocytopenic cirrhotic patient.
Small dose of recombinant factor VIIa (rFVIIa) to perform percutaneous liver biopsies in cirrhotic patients.
Liver Cirrhosis, Biliary
[Primary biliary cirrhosis combined with factor VII deficiency: a case report]
Liver Diseases
Acquired Factor VII Deficiency in Association with Pyelonephritis.
Acquired factor VII deficiency in hematopoietic stem cell transplant recipients.
Acquired isolated factor VII deficiency associated with severe bleeding and successful treatment with recombinant FVIIa (NovoSeven).
Blood loss in orthotopic liver transplantation: a retrospective analysis of transfusion requirements and the effects of autotransfusion of cell saver blood in 164 consecutive patients.
Characterization of the coagulation profile in children with liver disease and extrahepatic portal vein obstruction or shunt.
Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings.
Clinical use of recombinant FVIIa (rFVIIa).
Coagulation abnormalities in 22 cats with naturally occurring liver disease.
Coagulation Profile and its Correlation with Severity of Liver Dysfunction and Gastrointestinal Bleed in Alcoholic Liver Disease Patients.
Combined fresh frozen plasma with recombinant factor VIIa in restoring hemostasis for invasive procedures in children with liver diseases.
Comparison of Fresh Frozen Plasma, Four-Factor Prothrombin Complex Concentrates, and Recombinant Factor VIIa to Facilitate Procedures in Critically Ill Patients with Coagulopathy from Liver Disease: A Retrospective Cohort Study.
Coupled amidolytic assay for factor VII: its use with a clotting assay to determine the activity state of factor VII.
Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients.
Effect of activated recombinant human factor 7 (Niastase) on laboratory testing of inhibitors of factors VIII and IX.
Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and acquired coagulation disorders.
Experiences with recombinant factor VIIa for the prevention of bleeding in patients with chronic liver disease undergoing percutaneous liver biopsies and endoscopic retrograde cholangiopancreatography (ERCP).
Expression of factor VII in the liver of patients with liver disease: correlations with the disease severity and impairment in the hemostasis.
Factor VII as a marker of hepatocellular synthetic function in liver disease.
Factor VII deficiency - an enigma; clinicohematological profile in 12 cases.
FVIIa corrects the coagulopathy of fulminant hepatic failure but may be associated with thrombosis: a report of four cases.
Glycine conjugation of para-aminobenzoic acid (PABA): a quantitative test of liver function.
Hemostatic effect of activated recombinant factor VII (rFVIIa) in liver disease: studies in an in vitro model.
Hepatocyte transplantation for liver-based metabolic disorders.
Heterozygous factor VII deficiency and severe hemophilia A in the same kindred.
Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases.
Liver-enriched transcription factor expression relates to chronic hepatic failure in humans.
Monoclonal antibodies to human factor VII: a one step immunoradiometric assay for VII:Ag.
Monoclonal antibodies to human factor VII: production of immunodepleted plasma for VII:C assays.
NovoSeven as a universal haemostatic agent.
Ongoing NovoSeven trials.
Prolonged prothrombin time, Factor VII and activated FVII levels in chronic liver disease are partly dependent on Factor VII gene polymorphisms.
Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: a break from convention in need of controlled trials.
Recombinant activated factor VII as a universal haemostatic agent.
Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy.
Recombinant activated factor VII in chronic liver diseases: Should we be afraid of thromboembolic events?
Recombinant activated factor VII in liver patients: a retrospective cohort study from Australia and New Zealand.
Recombinant activated factor VII in patients at high risk of bleeding.
Recombinant factor VIIa as haemostatic therapy in advanced liver disease.
Recombinant factor VIIa for treatment of massive liver fracture in a premature infant.
Recombinant factor VIIa in the treatment of non-hemophiliac bleeding.
Recombinant factor VIIa reduces transfusion requirements in liver transplant patients with high MELD scores.
Recombinant factor VIIa to treat severe bleeding in patients with liver disease: pitfalls and possibilities.
Recombinant factor VIIa.
Recombinant factor VIIa: a universal hemostatic agent?
Recombinant factor VIIa: unregulated continuous use in patients with bleeding and coagulopathy does not alter mortality and outcome.
Recombinant FVIIa in children with liver disease.
Recombinant human factor VIIa-induced alterations in tissue factor and thrombomodulin in patients with advanced liver cirrhosis.
Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease.
Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy.
Small dose of recombinant factor VIIa (rFVIIa) to perform percutaneous liver biopsies in cirrhotic patients.
Successful outcome of a cirrhotic patient with postoperative haematuria treated with a single high dose of recombinant factor VIIa.
Synthetic factor VIIa concentrate to treat coagulopathy and gastrointestinal bleeding in an infant with end-stage liver disease.
The coagulopathy of liver disease: does vitamin K help?
The role of anti-fibrinolytics, rFVIIa and other pro-coagulants: prophylactic versus rescue?
The use of recombinant factor VIIa in liver diseases.
Treating coagulopathy in liver disease with plasma transfusions or recombinant factor VIIa: an evidence-based review.
Uncomplicated stereotactic and open neurosurgical procedures in patients with factor VII deficiency.
Use of factor-VII-rich prothrombin complex concentrate in liver disease.
Use of recombinant factor VII in hepatology.
Use of recombinant factor VIIa in pediatric patients with liver failure and severe coagulopathy.
Use of recombinant factor VIIa to correct the coagulation status of individuals with advanced liver disease prior to a percutaneous liver biopsy.
Vitamin K-dependent blood clotting changes in female rats treated with oestrogens.
Which coagulation factors interfere with the one-stage prothrombin time?
[Assay of factor VII antigen by enzyme-linked immunosorbent assay (ELISA)]
[Clinical studies on blood coagulation factors, prothrombin, factor V and factor VII liver diseases and their response to vitamin K1 and synka-vit.]
[Influence of massive doses if vitamin K1 on the coagulation factors prothrombin, factor V and factor VII in liver diseases.]
[Recombinant factor VIIa (NovoSeven). A review of current and possible future indications]
Liver Diseases, Alcoholic
Successful management of intra-abdominal hemorrhage in the presence of severe alcoholic liver disease with activated recombinant factor VII (rFVIIa; NovoSeven): a case report and review of the literature on approved and off-label use of rFVIIa.
Liver Failure
Clinical usefulness of recombinant activated factor VII in patients with liver failure undergoing invasive procedures.
Medical management of variceal bleeding in patients with cirrhosis.
Overall experience with NovoSeven.
Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review.
Prekallikrein and factor VII as prognostic indexes of liver failure.
Prevention of Bleeding Complications in Neonates With Liver Failure Undergoing Surgery Using Recombinant Factor VIIa.
Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation.
Recombinant Activated Factor VII Significantly Reduces Transfusion Requirements in Cardiothoracic Surgery.
Recombinant factor VIIa improves coagulopathy caused by liver failure.
Successful outcome of using recombinant activated factor VII (rFVIIa) in liver biopsy in a patient with liver failure.
Successful treatment of massive acute upper gastrointestinal bleeding in liver failure with activated recombinant factor VII (NovoSeven): a case report.
Successful use of recombinant factor VIIa (NovoSeven) in children with compartment syndrome: two case reports.
Unlabeled uses of factor VIIa (recombinant) in pediatric patients.
Use of recombinant factor VIIa in pediatric patients with liver failure and severe coagulopathy.
Liver Failure, Acute
Acute coagulopathy after reperfusion of the liver graft in children correction with recombinant activated factor VII.
Cost-Effectiveness Analysis of Plasma Versus Recombinant Factor VIIa for Placing Intracranial Pressure Monitors in Pretransplant Patients With Acute Liver Failure.
Erratum: Recombinant activated factor VIIa in case of pregnancy with acute hepatic failure and massive blood loss.
Factor VII levels as a guide to prognosis in fulminant hepatic failure.
FVIIa corrects the coagulopathy of fulminant hepatic failure but may be associated with thrombosis: a report of four cases.
Glycine conjugation of para-aminobenzoic acid (PABA): a quantitative test of liver function.
Insertion of intracranial pressure monitors in fulminant hepatic failure patients: early experience using recombinant factor VII.
Preliminary experience with use of recombinant activated factor VII to control postpartum hemorrhage in acute fatty liver of pregnancy and other pregnancy-related liver disorders.
Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII.
Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy.
Recombinant activated factor VII in patients with acute liver failure with UNOS Status 1A: a single tertiary academic centre experience.
Recombinant activated factor VIIa in a case of pregnancy with acute hepatic failure and massive blood loss.
Recombinant activated factor VIIa in case of pregnancy with acute hepatic failure and massive blood loss.
Recombinant activated factor VIIa in case of pregnancy with acute hepatic failure and massive blood loss: Reply.
Successful use of N-acetyl cysteine and activated recombinant factor VII in fulminant hepatic failure and massive bleeding secondary to dengue hemorrhagic fever.
The use of activated recombinant factor VII in a patient with fulminant hepatic failure requiring placement of an intracranial pressure monitor.
Total hepatectomy, recombinant activated factor VII and rescue liver transplantation.
Liver Neoplasms
Correction of both prothrombin time and primary haemostasis by recombinant factor VII during therapeutic alcohol injection of hepatocellular cancer in liver cirrhosis.
Factor VII light chain-targeted lidamycin shows intensified therapeutic efficacy for liver cancer.
Lung Diseases
Human alveolar macrophages synthesize factor VII in vitro. Possible role in interstitial lung disease.
Recombinant activated factor VII for massive hemoptysis in patients with cystic fibrosis.
Lung Diseases, Interstitial
Fibrinopeptide A reactive peptides and procoagulant activity in bronchoalveolar lavage: relationship to rheumatoid interstitial lung disease.
Human alveolar macrophages synthesize factor VII in vitro. Possible role in interstitial lung disease.
Lung Injury
Blockade of tissue factor: treatment for organ injury in established sepsis.
Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseases.
Nebulised recombinant activated factor VII (rFVIIa) does not attenuate the haemorrhagic effects of blast lung injury.
Lung Neoplasms
Circulating levels of coagulation and inflammation markers and cancer risks: individual participant analysis of data from three long-term cohorts.
Continuous infusion of recombinant activated factor VII for bleeding control after lobectomy in a patient with inherited factor VII deficiency.
Prognostic significance of blood coagulation tests in lung cancer.
Tissue factor is the only activator of coagulation in cultured human lung cancer cells.
Lupus Erythematosus, Systemic
Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays.
Increased factor VIIa levels in systemic lupus erythematosus patients with lupus anticoagulant.
Plasma levels of activated FVII in various diseases.
Treatment of diffuse alveolar hemorrhage in systemic lupus erythematosus patient with local pulmonary administration of factor VIIa (rFVIIa): a case report.
Treatment of diffuse alveolar hemorrhage secondary to lupus erythematosus with recombinant activated factor VII administered with a jet nebulizer.
Lymphatic Metastasis
[Ectopic expression and clinical significance of tissue factor/coagulation factor VII complex in colorectal cancer.]
Lymphohistiocytosis, Hemophagocytic
Control of bleeding associated with hemophagocytic syndrome in children: an audit of the clinical use of recombinant activated factor VII.
Hemophagocytic lymphohistiocytosis and congenital factor VII deficiency: a case report.
Recombinant activated factor VII in hemophagocytic lymphohistiocytosis with disseminated intravascular coagulation.
Lymphoma
A Rare Case of Factor VII Inhibitor in a Patient Presenting with Primary Splenic Marginal Zone Lymphoma.
Lymphoma, B-Cell
Effects of recombinant activated coagulation factor VII on apoptosis and expressions of Bcl-2 and Bax in rats with intracerebral hemorrhage.
Lymphoma, Non-Hodgkin
Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII.
Failure of Recombinant Activated Factor VII in Treatment of Diffuse Alveolar Hemorrhage due to Cryoglobulinemic Vasculitis.
Lymphoma, T-Cell
Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII.
Malaria
A new method for factor VII deficient substrate preparation and coagulation studies in malaria.
Mallory-Weiss Syndrome
Mallory-Weiss tear: use of recombinant factor VIIa for exsanguinating bleed.
Successful management of Mallory-Weiss syndrome in a haemophilia A patient with inhibitor by recombinant activated factor VII.
Malnutrition
Fluorogenic assay of activated factor VII. Plasma factor VIIa levels in relation to arterial cardiovascular diseases in Japanese.
Plasma fibrinogen and factor VII concentrations in adults after prenatal exposure to famine.
Marfan Syndrome
A case presenting concurrence of Marfan syndrome, Basedow's disease and Arg353Gln polymorphism-related factor VII deficiency.
Use of recombinant activated factor VII for bleeding following operations requiring cardiopulmonary bypass.
Massive Hepatic Necrosis
[Successful treatment of an infant with fulminant hepatitis by factor VII concentrate]
Mastocytosis, Cutaneous
Avoiding Cardiovascular Collapse: Pediatric Cutaneous Mastocytosis and Anesthetic Challenges.
Measles
Measles virus induction of human endothelial cell tissue factor procoagulant activity in vitro.
Meconium Aspiration Syndrome
Successful use of recombinant activated FVII and aminocaproic acid in four neonates with life-threatening hemorrhage.
Mediastinitis
Recombinant factor VIIa in intractable bleeding due to severe mediastinitis.
Medulloblastoma
Tissue Factor Regulation by miR-520g in Primitive Neuronal Brain Tumor Cells: A Possible Link between Oncomirs and the Vascular Tumor Microenvironment.
Melanoma
Interaction of human tumor cells with human platelets and the coagulation system.
Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ.
MDA-9/Syntenin Is Essential for Factor VIIa-induced Signaling, Migration, and Metastasis in Melanoma Cells.
Proteolytic activation of tissue plasminogen activator by plasma and tissue enzymes.
Melanoma, Experimental
Cytochalasin D promotes pulmonary metastasis of B16 melanoma through expression of tissue factor.
Meningioma
Surgical resection of a sphenoid wing meningioma in a patient with Glanzmann thrombasthenia.
Menorrhagia
Disorders of menstruation and their effect on the quality of life in women with congenital factor VII deficiency.
Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
Factor VII deficiency and pregnancy: a case report and review of literature.
Life-threatening menorrhagia secondary to Factor VII deficiency and leiomyomata.
Management of surgery, menorrhagia and child-birth for patients with unclassified bleeding disorders: a systematic review of cohort studies.
Menorrhagia caused by severe hereditary factor VII deficiency. Case 1.
Peculiar Congenital Factor VII Defect with the Proposita and Her Mother Showing the Same Compound Heterozygosity for Thr384Met and Arg413Gln.
Prophylactic treatment of hereditary severe factor VII deficiency in pregnancy.
Recombinant FVIIa therapy for heavy menstrual bleeding in patients with severe FV deficiency.
Severe menorrhagia due to factor VII deficiency successfully treated by thermal balloon endometrial ablation.
Successful treatment of severe menorrhagia at menarche with recombinant factor VIIa in an adolescent girl with type III von Willebrand's disease.
Successful use of recombinant factor VIIa for management of severe menorrhagia in an adolescent with an acquired inhibitor of human thrombin.
Successful use of recombinant VIIa (Novoseven) and endometrial ablation in a patient with intractable menorrhagia secondary to FVII deficiency.
Uncomplicated stereotactic and open neurosurgical procedures in patients with factor VII deficiency.
Women and inherited bleeding disorders: menstrual issues.
Women with congenital factor VII deficiency: clinical phenotype and treatment options from two international studies.
Mesenteric Ischemia
Complications of recombinant activated human coagulation factor VII.
Thromboembolic complications associated with factor VIIa administration.
Metabolic Diseases
Liver cell transplantation.
Metabolic Syndrome
Investigation of potential biomarkers for thrombosis related diseases in Turkish Cypriot population.
Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes.
Prediction of incident type 2 diabetes mellitus based on a twenty-year follow-up of the Ventimiglia heart study.
[Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome]
Metrorrhagia
Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits.
Comparison of bypassing agents in patients on emicizumab using global hemostasis assays.
Practical considerations for nonfactor-replacement therapies in the treatment of haemophilia with inhibitors.
Thrombin generation in plasma of patients with haemophilia A and B with inhibitors: Effects of bypassing agents and antithrombin reduction.
Microcephaly
Congenital combined defects of factor VII: a critical review.
Congenital FX deficiency combined with other clotting defects or with other abnormalities: a critical evaluation of the literature.
Factor VII deficiency and developmental abnormalities in a patient with partial monosomy of 13q and trisomy of 16p: case report and review of the literature.
Liver transplantation for treatment of severe S-adenosylhomocysteine hydrolase deficiency.
Microscopic Polyangiitis
Factor viia for alveolar hemorrhage in microscopic polyangiitis.
Recombinant activated factor VII for diffuse alveolar hemorrhage in microscopic polyangiitis.
Migraine Disorders
Migraine and prothrombotic genetic risk factors.
Migraine, cortical blindness, multiple cerebral infarctions and hypocoagulopathy in celiac disease.
Prothrombotic genetic risk factors in patients with coexisting migraine and ischemic cerebrovascular disease.
Mitral Valve Prolapse
Congenital FX deficiency combined with other clotting defects or with other abnormalities: a critical evaluation of the literature.
Mucopolysaccharidoses
Inadvertent propagation of factor VII deficiency in a canine mucopolysaccharidosis type I research breeding colony.
Mucopolysaccharidosis I
Inadvertent propagation of factor VII deficiency in a canine mucopolysaccharidosis type I research breeding colony.
Mucormycosis
Endogenous Heparinoids May Cause Bleeding in Mucor Infection and can be Detected by Nonactivated Thromboelastometry and Treated by Recombinant Activated Factor VII: A Case Report.
Multicystic Dysplastic Kidney
Congenital Factor VII Deficiency in Association With Bicuspid Aortic Valve and Multicystic Dysplastic Kidney Disease in a Child.
Multiple Myeloma
Elevated extracellular trap formation and contact system activation in acute leukemia.
[Combined deficiency of factor VII and X in a patient with multiple myeloma and amyloidosis]
Muscle Hypotonia
[Use of recombinant factor VIIa for the control of massive bleeding caused by uterine hypotonia in post-placental period]
Muscular Diseases
Liver transplantation for treatment of severe S-adenosylhomocysteine hydrolase deficiency.
Myelodysplastic Syndromes
Elevated extracellular trap formation and contact system activation in acute leukemia.
Use of recombinant activated factor VII in a patient with severe thrombocytopenia due to myelodysplastic syndrome with uncontrolled gastrointestinal bleeding.
Myeloproliferative Disorders
Recombinant activated factor VII for intractable bleeding post splenectomy in a patient with myeloproliferative disorder.
Myocardial Infarction
A functional haplotype in the 5' flanking region of the factor VII gene is associated with an increased risk of coronary heart disease.
A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men.
A novel polymorphism in intron 1a of the human factor VII gene (G73A): study of a healthy Italian population and of 190 young survivors of myocardial infarction.
Activated and total coagulation factor VII, and fibrinogen in coronary artery disease.
Activation of coagulation factor VII during alimentary lipemia.
Acute myocardial infarction following administration of recombinant activated factor VII (Novo Seven) in a patient with haemophilia A and inhibitor.
Acute myocardial infarction with decreased factor VII.
Angiotensin-converting enzyme insertion/deletion genotype is associated with the activities of plasma coagulation factor VII and X independent of triglyceride metabolism.
Associated prothrombotic conditions are probably responsible for the occurrence of thrombosis in almost all patients with congenital FVII deficiency. Critical review of the literature.
Association between the factor VII haplotype containing the -402A allele and myocardial infarction in a population of elderly men at high risk for coronary heart disease.
Association of coagulation factor VII with the risk of myocardial infarction in the Chinese.
Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction--the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction.
Augmented Hageman factor and prolactin titers, enhanced cold activation of factor VII, and spontaneous shortening of prothrombin time in survivors of myocardial infarction.
Behavior of coagulation factors and normal inhibitors of coagulation during the acute phase of myocardial infarction.
Blood coagulation factor VII activity and the risk of myocardial infarction: the novel identification of a genetic protection that can be mimicked by an old drug.
Changes in levels of factor VII and protein S after acute myocardial infarction: effects of low-dose warfarin.
Cigarette smoking doubles the risk of myocardial infarction in carriers of a protective polymorphism in the blood coagulation factor VII gene.
Coagulation factor VII and inflammatory markers in patients with coronary heart disease.
Coagulation factor VII and the risk of coronary heart disease in healthy men.
Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Role of plasma lipoproteins and factor VII genotype.
Coagulation factor VII, R353Q polymorphism, and serum choline-containing phospholipids in males at high risk for coronary heart disease.
Coagulation gene polymorphisms as risk factors for myocardial infarction in young Indian Asians.
Common polymorphisms and cardiovascular factors in patients with myocardial infarction of Costa Rica.
Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity.
Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease.
Complications of recombinant activated human coagulation factor VII.
Concurrent administration of sustained-release bezafibrate may counteract the increased thrombotic risk associated with oral estrogen therapy.
Congenital protein C deficiency and myocardial infarction:concomitant factor VII hyperactivity may play a role in the onset of arterial thrombosis.
Dietary effects on coagulation factor VII vary across genotypes of the R/Q353 polymorphism in elderly people.
Effects of recombinant active site-blocked activated factor VII in rabbit models of carotid stenosis and myocardial infarction.
Elevation of factor VII activity and mass in coronary artery disease of varying severity.
Experience with recombinant activated factor VII for severe post-partum hemorrhage in Japan, investigated by Perinatology Committee, Japan Society of Obstetrics and Gynecology.
Factor VII and extrinsic pathway inhibitor in acute coronary disease.
Factor VII and incidence of myocardial infarction in a Japanese population: The Jichi Medical School Cohort Study.
Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study.
Factor VII gene polymorphisms are not associated with myocardial infarction in young women.
Factor VII hyperactivity in acute myocardial thrombosis. A relation to the coagulation activation.
Factor VII polymorphisms and myocardial infarction: what is special in Italians? REGRESS study group. Regression Growth Evaluation Statin Study.
Factor VII Tokushima: the first case of factor VII Cys22Gly with the development of myocardial infarction in the proband receiving recombinant factor VIIa replacement therapy.
Factor VIIa as a predictor of cardiac events following myocardial infarction in women.
Factor-VII activity and ischaemic heart disease: fatal and non-fatal events.
Failure of thrombolytic therapy in patients with myocardial infarction is associated with high plasma levels of factor VII antigen.
Fibrinogen, factor VII, antithrombin III, cholesterol and triglycerides in young men with myocardial infarction and in their sons.
Genes, coagulation and cardiovascular risk.
Genetic polymorphisms, Biochemical Factors, and Conventional Risk Factors in Young and Elderly North Indian Patients With Acute Myocardial Infarction.
Genotype-specific increase in plasma concentrations of activated coagulation factor VII in response to experimental inflammation. A link between infection and acute myocardial infarction?
Hageman factor and risk of myocardial infarction in middle-aged men.
Heightened thrombin formation but normal plasma levels of activated factor VII in patients with acute coronary syndromes.
Hemostatic risk factors of coronary artery disease in the Chinese.
Hypercoagulability and reduced fibrinolysis in hyperlipidemia: relationship to the metabolic cardiovascular syndrome.
Imbalance of plasminogen activator inhibitor-I/ tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction.
Increased level of von Willebrand factor is significantly and independently associated with diabetes in postinfarction patients. THROMBO Investigators.
Influence of polymorphisms in the factor VII gene promoter on activated factor VII levels and on the risk of myocardial infarction in advanced coronary atherosclerosis.
Lack of association between polymorphisms of the coagulation factor VII and myocardial infarction in middle-aged Spanish men.
Myocardial infarction and other arterial occlusions in hemophilia a patients. A cardiological evaluation of all 42 cases reported in the literature.
Myocardial infarction following recombinant activated factor VII in a patient with type 2A von Willebrand disease.
Myocardial infarction occurring in a case of acquired haemophilia during the treatment course with recombinant activated factor VII.
Myocardial infarctions and other acute coronary syndromes in rare congenital bleeding disorders: a critical analysis of all reported cases.
No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age.
Plasma level of triglyceride-rich lipoprotein remnants is closely associated with the activation of coagulation factor VII in patients with myocardial infarction.
Plasma Levels and Distribution of Gene Polymorphisms of Factor VII in Turkish Population.
Plasma thrombomodulin activity, tissue factor activity and high levels of circulating procoagulant phospholipid as prognostic factors for acute myocardial infarction.
Polymorphism of R353Q (rs6046) in factor VII and the risk of myocardial infarction: A systematic review and meta-analysis.
Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction in patients undergoing coronary angiography.
Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction.
Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease.
Polymorphisms in the factor VII gene and the risk of myocardial infarction.
Polymorphisms in the genes for coagulation factor II, V, VII in patients undergoing coronary angiography.
Postprandial triglycerides and blood coagulation.
Prothrombotic gene polymorphisms and plasma factors in young north Indian survivors of acute myocardial infarction.
Prothrombotic genetic risk factors in young survivors of myocardial infarction.
R353Q polymorphism, activated factor VII, and risk of premature myocardial infarction in Japanese men.
Recombinant Activated Factor VII Safety in Trauma Patients: Results From the CONTROL Trial.
Relationships of insulin and intact and split proinsulin to haemostatic function in young men with and without coronary artery disease.
Serum lipids and regulation of tissue factor-induced coagulation in middle-aged men.
Sex hormones and hemostatic risk factors for coronary heart disease in men with hypertension.
Soluble fibrin, C-reactive protein, fibrinogen, factor VII, antithrombin, proteins C and S, tissue factor, D-dimer, and prothrombin fragment 1 + 2 in men with acute myocardial infarction
ST-Segment Elevation Myocardial Infarction (STEMI) and Pulmonary Embolism in a Hemophilia A Patient Receiving Emicizumab and recombinant Activated Factor VII.
Temporal and genotype-driven variation of factor VII levels in patients with acute myocardial infarction.
The decanucleotide insertion/deletion polymorphism in the promoter region of the coagulation factor VII gene and the risk of familial myocardial infarction.
The effects of genotype and infant weight on adult plasma levels of fibrinogen, factor VII, and LDL cholesterol are additive.
The PLAT Study: a multidisciplinary study of hemostatic function and conventional risk factors in vascular disease patients.
The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group.
The safety of recombinant factor VIIa in cardiac surgery.
Thrombogenic side-effects of recombinant factor VIIa after use in coronary artery bypass surgery.
Tissue factor and coagulation factor VII levels during acute myocardial infarction: association with genotype and adverse events.
Two polymorphisms of the FVII gene and their impact on the risk of myocardial infarction in poles under 45 years of age.
Use of recombinant activated factor VII in primary postpartum hemorrhage: the Northern European registry 2000-2004.
Variation of the factor VII gene and ischemic heart disease in Japanese subjects.
[Acute treatment with recombinant factor VII is probably indicated for intracerebral haematoma]
[Association between gene polymorphisms and myocardial infarction in Han Chinese of Yunnan province].
[Association of coagulation factor V, VII gene polymorphisms with coronary heart disease]
[Distributions of polymorphisms of genes of some components of hemostasis in patients with ischemic heart disease]
[Increased fibrinogen and factor VII activity levels in patients after myocardial infarction]
[Study of the polymorphism R353Q in the coagulation factor VII gene and the N700S in the thrombospondin-1 gene in young patients with acute myocardial infarction].
[Study on plasma coagulation factor VII (FVII) levels and polymorphisms of FVII gene in patients with coronary heart disease]
[The coagulation factor VII gene polymorphisms in patients with myocardial infarction in Ningxia Hui and Han populations]
[Value of plasma tissue factor, tissue factor pathway inhibitor and factor VII assessments in patients with acute myocardial and cerebral infarction]
Myocardial Ischemia
Association of beta-fibrinogen and factor VII polymorphism with plasma fibrinogen and factor VII levels, and no association of PAI-1 polymorphism with plasma PAI-1 levels in hemodialysis patients.
Correlation of factor VII activity and antigen with cholesterol and triglycerides in healthy young adults.
Correlation of vitamin K-dependent clotting factors with cholesterol and triglycerides in healthy young adults.
Dietary oleic and palmitic acids and postprandial factor VII in middle-aged men heterozygous and homozygous for factor VII R353Q polymorphism.
Effect of treatment with low-dose warfarin-aspirin on activated factor VII.
Effect of varying the ratio of n-6 to n-3 fatty acids by increasing the dietary intake of alpha-linolenic acid, eicosapentaenoic and docosahexaenoic acid, or both on fibrinogen and clotting factors VII and XII in persons aged 45-70 y: the OPTILIP study.
Effects of diet composition on coagulation pathways.
Effects of total fat content and fatty acid composition in diet on factor VII coagulant activity and blood lipids.
Elevation of factor VII activity and mass in young adults at risk of ischemic heart disease.
Factor VII and haemostasis.
Factor VII clotting assay: influence of different thromboplastins and factor VII-deficient plasmas. CISMEL Study Group.
Factor VII coagulant activity and antigen levels in healthy men are determined by interaction between factor VII genotype and plasma triglyceride concentration.
Factor VII polymorphisms in populations with different risks of cardiovascular disease.
Fibrinogen, factor VII, antithrombin III, cholesterol and triglycerides in young men with myocardial infarction and in their sons.
Increased levels of factor VII, fibrinogen and activity of plasminogen activator inhibitor during postprandial triglyceridemia in patients with ischemic heart disease confirmed by angiography.
Nutrition and thrombogenic factors.
Polymorphisms of the coagulation factor VII gene and its plasma levels in relation to acute cerebral infarction differences in allelic frequencies between Chinese Han and European populations.
Postprandial effects of an oleic acid-rich oil compared with butter on clotting factor VII and fibrinolysis in healthy men.
Postprandial elevation of activated factor VII in young adults.
Predictive value of coagulation tests in arterial thrombosis.
Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation.
Risks and mechanisms of cardiovascular events in users of oral contraceptives.
Role of coagulation factor VII in pathogenesis of ischemic heart disease.
The association of dietary fat and fiber with coagulation factor VII in the elderly: the Rotterdam Study.
The impact of cardiac ischemia and reperfusion on markers of activated haemostasis and fibrinolysis during cardiopulmonary bypass: comparison of plasma levels in arterial and coronary venous blood.
Thromboembolic complications associated with factor VIIa administration.
Variation of the factor VII gene and ischemic heart disease in Japanese subjects.
Vitamin K-dependent clotting factors are elevated in young adults who have close relatives with ischemic heart disease.
[Coagulant activity of factor VII (FVIIc) in the elderly with ischemic heart disease]
[Should hemostatic factors be considered in the prevention of cardiovascular disease?]
Myotonia Congenita
Frequency of five disease-causing genetic mutations in a large mixed-breed dog population (2011-2012).
Myxoma
Imaging and intervention of paraneoplastic effect of a right atrial myxoma on factor VII activity levels.
Open heart surgery with factor VII deficiency.
Neoplasm Metastasis
Activation of factor VII in patients with carcinoma of the prostate. A preliminary report.
Antiapoptotic effect of coagulation factor VIIa.
Cellular consequences upon factor VIIa binding to tissue factor.
Coagulation factors VIIa and Xa inhibit apoptosis and anoikis.
Cytochalasin D promotes pulmonary metastasis of B16 melanoma through expression of tissue factor.
Extrahepatic synthesis of coagulation factor VII by colorectal cancer cells promotes tumor invasion and metastasis.
Generation of a polyclonal rabbit anti-mouse tissue factor antibody by nucleic acid immunisation.
High factor VIIa levels do not promote tumor metastasis.
Immunological and functional analyses of the extracellular domain of human tissue factor.
Inducible expression of tissue factor in small-cell lung cancer: impact on morphology and matrix metalloproteinase secretion.
Inhibition of tissue factor-factor VIIa proteolytic activity blunts hepatic metastasis in colorectal cancer.
Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis.
Role of tissue factor in metastasis: functions of the cytoplasmic and extracellular domains of the molecule.
Selective attenuation of the extrinsic limb of the tissue factor-driven coagulation protease cascade by occupancy of a novel peptidyl docking site on tissue factor.
Signal transduction via the mitogen-activated protein kinase pathway induced by binding of coagulation factor VIIa to tissue factor.
The FVIIa-tissue factor complex induces the expression of MMP7 in LOVO cells in vitro.
The inhibition of pancreatic cancer invasion-metastasis cascade in both cellular signal and blood coagulation cascade of tissue factor by its neutralisation antibody.
Tissue factor as a novel target for treatment of breast cancer.
Tissue factor cytoplasmic domain stimulates migration by activation of the GTPase Rac1 and the mitogen-activated protein kinase p38.
Tissue Factor-Factor VIIa complex induces cytokine expression in coronary artery smooth muscle cells.
Tissue factor-factor VIIa complex induces epithelial ovarian cancer cell invasion and metastasis through a monocytes-dependent mechanism.
Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration.
Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor.
[Ectopic expression and clinical significance of tissue factor/coagulation factor VII complex in colorectal cancer.]
[The effects of tissue factor/activated factor VII complex on the invasion and metastasis of human ovarian cancer.]
Neoplasms
A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer.
Acquired factor VII deficiency associated with pleural liposarcoma.
Acquired Isolated FVII Deficiency: An Underestimated and Potentially Important Laboratory Finding.
Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII.
Activation of human factor VII by factors IXa and Xa on human bladder carcinoma cells.
Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli.
Acute Myelogenous Leukemia With Trisomy 8 and Concomitant Acquired Factor VII Deficiency.
Allosteric disulfide bonds in thrombosis and thrombolysis.
Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation.
An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.
Analysis of the substrate specificity of Factor VII activating protease (FSAP) and design of specific and sensitive peptide substrates.
Antiapoptotic effect of coagulation factor VIIa.
Apixaban Suppresses the Release of TF-Positive Microvesicles and Restrains Cancer Cell Proliferation through Directly Inhibiting TF-fVIIa Activity.
Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy.
Bleeding from endometrial and vaginal malignant tumors treated with activated recombinant factor VII.
Breast cancer phenotypes regulated by tissue factor-factor VII pathway: Possible therapeutic targets.
Case Report: Massive epistaxis from juvenile angiofibroma in an adolescent with severe haemophilia A.
Cellular consequences upon factor VIIa binding to tissue factor.
Changes of the coagulation and fibrinolysis system in malignancy: their possible impact on future diagnostic and therapeutic procedures.
Cholesterol Starvation and Hypoxia Activate the FVII Gene via the SREBP1-GILZ Pathway in Ovarian Cancer Cells to Produce Procoagulant Microvesicles.
Chronological expression of PAR isoforms in acute liver injury and its amelioration by PAR2 blockade in a rat model of sepsis.
Circulating levels of coagulation and inflammation markers and cancer risks: individual participant analysis of data from three long-term cohorts.
Coagulant and fibrinolytic activities of a metastasising and non-metastasising tumour line.
Coagulation and oxidative stress plasmatic levels in a type 2 diabetes population.
Coagulation factors VIIa and Xa inhibit apoptosis and anoikis.
Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE).
Congenital FX deficiency combined with other clotting defects or with other abnormalities: a critical evaluation of the literature.
Correction of both prothrombin time and primary haemostasis by recombinant factor VII during therapeutic alcohol injection of hepatocellular cancer in liver cirrhosis.
Cortactin activation by FVIIa/tissue factor and PAR2 promotes endothelial cell migration.
Cross-talk between the Tissue Factor/coagulation factor VIIa complex and the tyrosine kinase receptor EphA2 in cancer.
Different expression of procoagulant activity in human cancer cells cultured "in vitro" or in cells isolated from human tumor tissues.
Effect of all-trans-retinoic acid on the hypercoagulable state of patients with breast cancer.
Effects of tumor-expressed coagulation factors on cancer progression and venous thrombosis: is there a key factor?
Efficacy of recombinant activated factor VII in unselected patients with uncontrolled haemorrhage: a single centre experience.
Elevated extracellular trap formation and contact system activation in acute leukemia.
Enhanced Antitumor Activity of EGFP-EGF1-Conjugated Nanoparticles by a Multitargeting Strategy.
Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer.
Extrahepatic synthesis of coagulation factor VII by colorectal cancer cells promotes tumor invasion and metastasis.
Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor.
Factor VII light chain-targeted lidamycin targets tissue factor-overexpressing tumor cells for cancer therapy.
Factor VII promotes hepatocellular carcinoma progression through ERK-TSC signaling.
Factor VII, blood lipids and fat intake: gene-nutrient interaction and risk of coronary heart disease with the factor VII R353Q polymorphism.
Factor VIIa induces anti-inflammatory signaling via EPCR and PAR1.
Factor X-activating activity in normal and malignant colorectal tissue.
Fibrinogen deposition without thrombin generation in primary human breast cancer tissue.
Formation of tissue factor-factor VIIa-factor Xa complex promotes cellular signaling and migration of human breast cancer cells.
FVIIa Neutralization by a FXa Inhibitor: How It Could Dampen Tumorigenic Cancer Cell Phenotypes.
Gene expression profile of FVII and AR in primary prostate cancer.
Generation of a polyclonal rabbit anti-mouse tissue factor antibody by nucleic acid immunisation.
Genetics of intracerebral hemorrhage: Insights from candidate gene approaches.
Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation.
Hemostatic response to postprandial lipemia before and after exercise training.
Hepatocyte nuclear factor-4-independent synthesis of coagulation factor VII in breast cancer cells and its inhibition by targeting selective histone acetyltransferases.
High factor VIIa levels do not promote tumor metastasis.
High-level secretion of tissue factor-rich extracellular vesicles from ovarian cancer cells mediated by filamin-A and protease-activated receptors.
Identification of the integrin-binding site on coagulation factor VIIa required for proangiogenic PAR2 signaling.
Immunohistochemical identification of tissue factor in solid tumors.
In situ characterization of antigenic and functional tissue factor expression in human tumors utilizing monoclonal antibodies and recombinant factor VIIa as probes.
Inducible expression of tissue factor in small-cell lung cancer: impact on morphology and matrix metalloproteinase secretion.
Inhibition of tissue factor by ixolaris reduces primary tumor growth and experimental metastasis in a murine model of melanoma.
Interconnections between autophagy and the coagulation cascade in hepatocellular carcinoma.
Intramuscular Expression of Plasmid-Encoded FVII-Fc Immunoconjugate for Tumor Immunotherapy by Targeting Tumoral Blood Vessels and Cells.
Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy.
Intrinsic versus extrinsic coagulation. Kinetic considerations.
Isolated acquired factor VII deficiency: review of the literature.
Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue.
Localization of tissue factor in actin-filament-rich membrane areas of epithelial cells.
Longitudinal association of hemostatic factors with risk for cancers of the breast, colorectum, and lung among postmenopausal women.
Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ.
Mechanistic insight into the procoagulant activity of tumor-derived apoptotic vesicles.
Modular degradable dendrimers enable small RNAs to extend survival in an aggressive liver cancer model.
Natural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancer.
No significant association between the promoter region polymorphisms of factor VII gene and risk of venous thrombosis in cancer patients.
Occurrence of blood coagulation factors in situ in small cell carcinoma of the lung.
Periodontal disease and biomarkers related to cardiovascular disease.
Plasma levels of activated FVII in various diseases.
Platelets, Constant and Cooperative Companions of Sessile and Disseminating Tumor Cells, Crucially Contribute to the Tumor Microenvironment.
PO-58 - Cardiovascular risk profile in survivors of adult cancer - results from the general population study.
Potential blood biomarkers in chronic spontaneous urticaria.
Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review.
Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery.
Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells.
Procoagulant activity in cancer cells is dependent on tissue factor expression.
Properties of proteins in cancer procoagulant preparations that are detected by anti-tissue factor antibodies.
Protease-activated receptor 2 (PAR2) blocking peptide counteracts endotoxin-induced inflammation and coagulation and ameliorates renal fibrin deposition in a rat model of acute renal failure.
Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells.
Recent bacterial and viral infection is a risk factor for cerebrovascular ischemia: clinical and biochemical studies.
Recombinant activated factor VII controls chemotherapy-related hemorrhage in patients with solid intra-abdominal tumors: a report of three pediatric cases.
Recombinant activated factor VII in patients with cancer and hemorrhagic disseminated intravascular coagulation.
Role of phosphoinositide 3-kinase in adhesion of platelets to fibrinogen stimulated by cancer procoagulant.
Role of the coagulation system in tumor-cell-induced platelet aggregation and metastasis.
Roles of factor Xa beyond coagulation.
Selective attenuation of the extrinsic limb of the tissue factor-driven coagulation protease cascade by occupancy of a novel peptidyl docking site on tissue factor.
Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells.
Sequential 5-Aza 2'-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells.
Several murine metastasizing tumors possess a cysteine proteinase with cancer procoagulant characteristics.
Signal transduction via the mitogen-activated protein kinase pathway induced by binding of coagulation factor VIIa to tissue factor.
Successful control of massive coumarol-induced acute upper gastrointestinal bleeding and correction of prothrombin time by recombinant active factor VII (Eptacog-alpha, NovoSeven) in a patient with a prosthetic aortic valve and two malignancies (chronic lymphoid leukaemia and lung cancer).
Synergistic Inhibitory Effect of Traditional Chinese Medicine Astragaloside IV and Curcumin on Tumor Growth and Angiogenesis in an Orthotopic Nude-Mouse Model of Human Hepatocellular Carcinoma.
Systemic thrombin generation in cancer patients is correlated with extrinsic pathway activation.
Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice.
Targeting tissue factor-expressing tumor angiogenesis and tumors with EF24 conjugated to factor VIIa.
Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model.
The effect of short-term cold exposure on risk factors for cardiovascular disease.
The effect of Warfarin and factor VII on tissue procoagulant activity and pulmonary seeding.
The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
The production of coagulation factor VII by adipocytes is enhanced by tumor necrosis factor-? or isoproterenol.
The relationship between tissue factor and cancer progression: insights from bench and bedside.
The tick-derived inhibitor Ixolaris prevents tissue factor signaling on tumor cells.
The use of recombinant factor VIIa in a patient with acquired haemophilia A undergoing surgery.
Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer.
Tissue factor as a novel target for treatment of breast cancer.
Tissue factor cytoplasmic domain stimulates migration by activation of the GTPase Rac1 and the mitogen-activated protein kinase p38.
Tissue factor in cancer angiogenesis and metastasis.
Tissue factor isoforms in cancer and coagulation: may the best isoform win.
Tissue factor proangiogenic signaling in cancer progression.
Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis.
Tissue Factor-Factor VIIa complex induces cytokine expression in coronary artery smooth muscle cells.
Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration.
Tissue factor-like activity of the human monocytic tumor cell line U937.
Tissue Factor/ FVIIa prevents the extrinsic pathway of apoptosis by regulation of the tumor suppressor Death-Associated Protein Kinase 1 (DAPK1).
Tissue factor/factor VIIa induces cell survival and gene transcription by transactivation of the insulin-like growth factor 1 receptor.
Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism.
Transdermal Progesterone: Effects on Menopausal Symptoms and on Thrombotic, Anticoagulant, and Inflammatory Factors in Postmenopausal Women.
Tri(n-butyl) phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives.
Tumor cells expressing tissue factor influence the migration of smooth muscle cells in a catalytic activity-dependent way.
Tumor cells induce platelet aggregation and intraplatelet calcium ion movements.
Tumor microenvironment mediated by suppression of autophagic flux drives liver malignancy.
Uncomplicated neurosurgical resection of a malignant glioneuronal tumour under haemostatic cover of rFVIIa in a severe haemophilia patient with a high-titre inhibitor: a case report and literature review of rFVIIa use in major surgeries.
Unlabeled uses of factor VIIa (recombinant) in pediatric patients.
VIIa/tissue factor interaction results in a tissue factor cytoplasmic domain-independent activation of protein synthesis, p70, and p90 S6 kinase phosphorylation.
Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody.
Warfarin-induced venous limb ischemia/gangrene complicating cancer: a novel and clinically distinct syndrome.
[Acquired isolated factor VII deficiency and bronchogenic carcinoma. A case report]
[Anti-tumor effects of mouse factor VII-staphylococcus enterotoxin A (mfVII) chimeric protein in mice]
[Ectopic expression and clinical significance of tissue factor/coagulation factor VII complex in colorectal cancer.]
[Investigation of the mechanisms of coagulation factor VIIa-induced colon cancer SW620 cell proliferation and migration]
[Recombinant activated factor VII in the treatment of intractable non-surgical bleeding following major vascular procedures]
[Successful Anesthetic Management of a Patient with Critical Bleeding during Hepatectomy Using Recombinant Activated Factor VII and Intraoperative Blood Salvage].
[The effects of tissue factor/activated factor VII complex on the invasion and metastasis of human ovarian cancer.]
[Use of recombinant factor VIIa to reduce transfusional load in hemorrhaging patients after surgery for malignant tumors].
Nephrotic Syndrome
Changes of coagulation factors IX, VIII, VII, X, and V in nephrotic syndrome.
Factor VII deficiency associated with nephrotic syndrome.
Neuroblastoma
Successful outcome of DIC and life-threatening bleeding in a toddler with neuroblastoma treated with recombinant activated factor VII.
Tissue factor/FVIIa activates Bcl-2 and prevents doxorubicin-induced apoptosis in neuroblastoma cells.
Neurofibroma
Utilization of recombinant activated factor VII in a case of spontaneous massive haemothorax in a patient with Von Recklinghausen's disease.
Neurofibromatosis 1
Utilization of recombinant activated factor VII in a case of spontaneous massive haemothorax in a patient with Von Recklinghausen's disease.
Neurologic Manifestations
Use of recombinant activated factor VII for acute bleeding episodes in acquired hemophilia: final analysis from the Hemostasis and Thrombosis Research Society Registry acquired hemophilia study.
Nevus
Hypercoagulability and hyperfibrinolysis in patients with melanoma.
Non-alcoholic Fatty Liver Disease
Vascular Disease in Patients with Nonalcoholic Fatty Liver Disease.
Noonan Syndrome
The use of recombinant factor VIIa in a patient with Noonan syndrome and life-threatening bleeding.
Obesity
Adipokines and Thrombosis.
Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly: the Cardiovascular Health Study. Cardiovascular Health Study Investigators.
Cardiovascular risk factors: interactive effects of lipids, coagulation and fibrinolysis.
Dietary treatment of thrombogenic disorders related to the metabolic syndrome.
Factor VII activity is an independent predictor of cardiovascular mortality in elderly women of a Sicilian population: results of an 11-year follow-up.
Factor VII and ischaemic heart disease: epidemiological evidence.
Factor VII deficiency - an enigma; clinicohematological profile in 12 cases.
Factor VII, tissue factor pathway inhibitor, and monocyte tissue factor in diabetes mellitus: influence of type of diabetes, obesity index, and age.
Genetic determination of coagulation factor VIIc levels among healthy middle-aged women.
Haemostatic and other cardiovascular risk factors, and socioeconomic status among middle-aged Finnish men and women.
Inflammatory and prothrombotic parameters in normotensive non-diabetic obese women: effect of weight loss obtained by gastric banding.
Interrelationship between coagulation factor VII and obesity in diabetes mellitus (type 2).
Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men.
Population correlates of coagulation factor VII. Importance of age, sex, and menopausal status as determinants of activated factor VII.
Skinfold thickness, body mass index, and fatal coronary heart disease: 30 year follow up of the Northwick Park heart study.
The production of coagulation factor VII by adipocytes is enhanced by tumor necrosis factor-? or isoproterenol.
[Factor VII and cardiovascular risk in obese subjects]
[Hemostasis profiles in thrombotic disease]
Obesity, Abdominal
Coagulation, fibrinolysis and haemorheology in premenopausal obese women with different body fat distribution.
Effect of the factor VII R353Q missense mutation on plasma apolipoprotein B levels: impact of visceral obesity.
Effect of transdermal hormone therapy on platelet haemostasis in menopausal women.
Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men.
Obesity, haemostasis and the fibrinolytic system.
Obesity, Morbid
Postprandial factor VII activation does not increase plasma concentrations of prothrombin fragment 1 + 2 in patients with morbid obesity.
Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity.
Osteoarthritis
Total hip arthroplasty in severe congenital factor VII deficiency: successful use of recombinant activated factor VII for hemostasis.
Osteogenesis Imperfecta
Recombinant factor VIIa after aortic valve replacement in a patient with osteogenesis imperfecta.
Ovarian Neoplasms
Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII.
Cholesterol Starvation and Hypoxia Activate the FVII Gene via the SREBP1-GILZ Pathway in Ovarian Cancer Cells to Produce Procoagulant Microvesicles.
Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells.
Tissue Factor-Factor VII Complex As a Key Regulator of Ovarian Cancer Phenotypes.
[Study of the effect of TF/FVIIa complex on the expression of u-PAR mRNA in human ovarian cancer]
[The effects of tissue factor/activated factor VII complex on the invasion and metastasis of human ovarian cancer.]
Overweight
Impact of smoking, physical training and weight reduction on FVII, PAI-1 and hemostatic markers in sedentary men.
Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults.
Moderate weight reduction improves red cell aggregation and factor VII activity in overweight subjects.
[Prothrombotic and prethrombotic markers in obese diabetic and non-diabetic subjects]
Pancreatic Neoplasms
A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer.
Differing mechanisms of thrombin generation in live haematological and solid cancer cells determined by calibrated automated thrombography.
Novel Agents in the Management of Pancreatic Adenocarcinoma: Phase I Studies. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
PET Imaging of Tissue Factor in Pancreatic Cancer Using 64Cu-labeled Active Site Inhibited Factor VII.
The inhibition of pancreatic cancer invasion-metastasis cascade in both cellular signal and blood coagulation cascade of tissue factor by its neutralisation antibody.
Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody.
Pancreatitis
A double-blind, randomized, controlled study to explore the efficacy of rFVIIa on intraoperative blood loss and mortality in patients with severe acute pancreatitis.
Treatment of bleeding in severe hemorrhagic pancreatitis with recombinant factor VIIa.
Treatment of bleeding in severe necrotizing pancreatitis with recombinant factor VIIa.
Treatment with anti-factor VIIa in acute pancreatitis in rats: blocking both coagulation and inflammation?
Use of recombinant activated factor VII for bleeding in pancreatitis: a case series.
Use of recombinant activated factor VII for the treatment of perioperative bleeding in noncardiac surgery patients without hemophilia: A systematic review and meta-analysis of randomized controlled trials.
Use of recombinant factor VIIa for life-threatening bleeding in a patient with severe necrotizing pancreatitis.
Use of recombinant factor VIIa in the treatment of massive retroperitoneal bleeding due to severe necrotizing pancreatitis.
Pancreatitis, Acute Hemorrhagic
Treatment of bleeding in severe hemorrhagic pancreatitis with recombinant factor VIIa.
Pancreatitis, Chronic
Use of recombinant activated factor VII for bleeding in pancreatitis: a case series.
Pancytopenia
Observations on serum prothrombin conversion accelerator in radiation-induced pancytopenia.
Successful treatment of gastrointestinal bleeding with recombinant factor VIIa after kidney transplantation in patients with pancytopenia.
Paraneoplastic Syndromes
[Recombinant activated factor VII in haemostasis after radical nephrectomy]
Paraplegia
Contribution of D-Dimer determination in the exclusion of deep venous thrombosis in spinal cord injury patients.
Pediatric Obesity
Elevated circulating tissue factor procoagulant activity, factor VII, and plasminogen activator inhibitor-1 in childhood obesity: evidence of a procoagulant state.
Pemphigus
Coexistence of pemphigus foliaceus and acquired hemophilia A: A case report.
Pericardial Effusion
Intra-Pericardial Use of Recombinant Factor VIIa in a Patient With Acute Hemorrhagic Pericardial Effusion Following Transcutaneous Aortic Valve Replacement-A Case Report.
Treatment of hemopericardium caused by mitral balloon valvuloplasty with activated factor VII: a case report.
Pericarditis, Constrictive
Constrictive pericarditis in a patient with inherited factor VII deficiency.
Periodontal Diseases
Periodontal disease and biomarkers related to cardiovascular disease.
Peripheral Arterial Disease
A two adenine insertion polymorphism in the 3' untranslated region of factor VII gene is associated with peripheral arterial disease but not with venous thrombosis. Results of case-control studies.
Ankle-brachial index and hemostatic markers in the Atherosclerosis Risk in Communities (ARIC) study cohort.
Relation between hemostatic variables and increase of common carotid intima-media thickness in patients with peripheral arterial disease.
Peripheral Vascular Diseases
The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group.
Phenylketonurias
Whole-exome sequencing provides insights into monogenic disease prevalence in Northwest Russia.
Pilonidal Sinus
Bleeding characteristics and management of minor surgeries in rare bleeding disorders: report from a Turkish Pediatric Hematology Center.
Pituitary Neoplasms
Prophylaxis and therapy with factor VII concentrate (human) immuno, vapor heated in patients with congenital factor VII deficiency: a summary of case reports.
Placenta Accreta
Successful management by recombinant activated factor VII in a case of disseminated intravascular coagulopathy caused by obstetric hemorrhage.
Successful treatment of severe retro-peritoneal bleeding with recombinant factor VIIa in women with placenta percreta invading into the left broad ligament: unusual repeated ante-partum intra-abdominal bleeding.
Using recombinant activated factor VII, B-Lynch compression, and reversible embolization of the uterine arteries for treatment of severe conservatively intractable postpartum hemorrhage: new method for management of massive hemorrhage in cases of placenta increta.
Placenta Previa
Caesarean section for placenta praevia complicated by postpartum haemorrhage managed successfully with recombinant activated human coagulation Factor VIIa.
Topical application of recombinant activated factor VII during cesarean delivery for placenta previa.
Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa).
Platelet Storage Pool Deficiency
Management of platelet storage pool disease during pregnancy with recombinant factor VIIa.
Plummer-Vinson Syndrome
Plummer-Vinson Syndrome With Concomitant Factor VII Deficiency.
Pneumonia
Granulomatous Pneumocystis carinii pneumonia in a non-AIDS patient: an atypical presentation.
Inhibition of the extrinsic or intrinsic coagulation pathway during pneumonia derived sepsis.
Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia.
Protease-Activated Receptor 2 Facilitates Bacterial Dissemination in Pneumococcal Pneumonia.
Successful use of recombinant factor VII in massive hemoptysis due to community-acquired pneumonia.
Two elderly patients with difficult-to-treat acquired hemophilia A.
Use of recombinant activated factor VII concentrate to control postoperative hemorrhage in complex cardiovascular surgery.
Pneumonia, Pneumococcal
Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia.
Pneumonia, Pneumocystis
Granulomatous Pneumocystis carinii pneumonia in a non-AIDS patient: an atypical presentation.
Pneumothorax
Elevated Interleukin-6 Concentration and Alterations of the Coagulation System Are Associated with the Development of Intraventricular Hemorrhage in Extremely Preterm Infants.
Reversal of thrombocytopenia and bleeding tendency in a preterm neonate with recombinant activated factor VII: case report.
Polycythemia Vera
[Factor V and factor VII content in polycythemia vera.]
Polyuria
[Complications during epilepsy surgery. Experience after 102 interventions between 1997 and 2001]
Posterior Leukoencephalopathy Syndrome
Recombinant activated factor VII for diffuse alveolar hemorrhage in microscopic polyangiitis.
Postpartum Hemorrhage
A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage.
Diagnosis and treatment discussion of congenital factor VII deficiency in pregnancy: A case report.
Effectiveness of recombinant activated factor VII (rFVII a) for controlling intractable postpartum bleeding: report of two cases and literature review.
Factor VII deficiency detected in pregnancy: a case report.
Failure of recombinant factor VIIa to correct the coagulopathy in a case of severe postpartum hemorrhage.
Low-dose recombinant activated factor VII temporally stopped bleeding from small artery in severe postpartum hemorrhage: a case report.
Massive postpartum hemorrhage: recombinant factor VIIa use is safe but not effective.
Occult hemophilia as a cause of postoperative and postpartum hemorrhage. With special reference to factor VII deficiency.
Postpartum hemorrhage in a Jehovah's Witness patient controlled with Tisseel, tranexamic acid, and recombinant factor VIIa.
Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review.
Preliminary experience with use of recombinant activated factor VII to control postpartum hemorrhage in acute fatty liver of pregnancy and other pregnancy-related liver disorders.
Real efficacy of factor VIIa in the treatment of the postpartum hemorrhage.
Recombinant activated factor VII as a promising adjuvant therapy for postpartum hemorrhage in the practice of obstetric anesthesia: Experience from a university hospital in Taiwan.
Recombinant Activated Factor VII as a Second Line Treatment for Postpartum Hemorrhage.
Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry.
Recombinant factor VIIa after amniotic fluid embolism and disseminated intravascular coagulopathy.
Recombinant factor VIIa in the management of postpartum bleeds: an audit of clinical use.
Recombinant human factor VIIa prevents hysterectomy in severe postpartum hemorrhage: single center study.
Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial.
Successful management of maternal factor VII deficiency in a cesarean section.
Successful treatment of life-threatening postpartum hemorrhage with recombinant activated factor VII.
Successful use of recombinant factor VIIa for treatment of severe postpartum hemorrhage.
The role of recombinant activated factor VII in obstetric hemorrhage.
The use of recombinant activated FVII in postpartum hemorrhage.
The use of recombinant factor VIIa in severe postpartum hemorrhage.
Use of Activated Recombinant Factor VII in Severe Bleeding - Evidence for Efficacy and Safety in Trauma, Postpartum Hemorrhage, Cardiac Surgery, and Gastrointestinal Bleeding.
Use of recombinant activated factor VII for massive postpartum hemorrhage.
Use of recombinant activated factor VII in primary postpartum hemorrhage: the Northern European registry 2000-2004.
Using recombinant activated factor VII, B-Lynch compression, and reversible embolization of the uterine arteries for treatment of severe conservatively intractable postpartum hemorrhage: new method for management of massive hemorrhage in cases of placenta increta.
[Discussion of the article: Successful treatment of severe postpartum hemorrhage after cesarean section with recombinant activated factor VII]
[Efficiency and safety of recombinant activated factor VII in a case of severe postpartum hemorrhage].
[Life-threatening postpartum hemorrhage and recombinant activated factor rFVIIa NovoSeven use]
[Postpartum hemorrhage successfully treated with recombinant factor VIIa in Glanzmann thromboasthenia]
[Recombinant factor VIIa for treatment of postpartum hemorrhage due to uterine atony].
Pre-Eclampsia
Fetal corticotrophin-releasing hormone mRNA, but not phosphatidylserine-exposing microparticles, in maternal plasma are associated with factor VII activity in pre-eclampsia.
Fibrinogen and factor VII promoter polymorphisms in women with preeclampsia.
Hemostatic abnormalities may predict chronic hypertension after preeclampsia.
Plasma factor VII: a potential marker of pre-eclampsia.
Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII.
Intrapulmonary rFVIIa for life threatening pulmonary hemorrhage in a case of relapsing acute lymphoblastic leukemia and platelet refractoriness.
Successful treatment of acute lymphoblastic leukemia with L-asparaginase-induced intracranial hemorrhage to activated recombinant factor VIIa in a child.
Priapism
Progression of the Prothrombotic State in Aging Bmal1-Deficient Mice.
Primary Myelofibrosis
Use of Recombinant Factor VIIa for Bleeding Control in Treatment of Acute Extremity Compartment Syndrome Secondary to Primary Myelofibrosis: A Case Report.
Prolactinoma
BLOOD COAGULATION, FIBRINOLYSIS AND LIPID PROFILE IN PATIENTS WITH PROLACTINOMA.
Prostatic Neoplasms
Activation of factor VII in patients with carcinoma of the prostate. A preliminary report.
Activators and inhibitors of coagulation and fibrinolysis in patients with prostatic cancer treated with oestrogen or orchidectomy.
Effects of oestrogen therapy and orchidectomy on coagulation and prostanoid synthesis in patients with prostatic cancer.
Gene expression profile of FVII and AR in primary prostate cancer.
Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer.
Use of recombinant activated factor VII for the treatment of perioperative bleeding in noncardiac surgery patients without hemophilia: A systematic review and meta-analysis of randomized controlled trials.
Protein C Deficiency
Autologous bone marrow transplantation and factor XII, factor VII, and protein C deficiencies. Report of a new association and its possible relationship to endothelial cell injury.
Combined factor VII and protein C deficiency found in a patient with peripheral pulmonary artery stenosis accompanied by progressive pulmonary hypertension and hemoptysis.
Congenital protein C deficiency and myocardial infarction:concomitant factor VII hyperactivity may play a role in the onset of arterial thrombosis.
Detection of protein C deficiency during oral anticoagulant therapy--use of the protein C:factor VII ratio.
Factor XII deficiency acquired by orthotopic liver transplantation: case report and review of the literature.
Recurrent restenosis after percutaneous transluminal coronary angioplasty in a patient with congenital protein C deficiency and high activated factor VII level.
Suppression of plasma-activated factor VII levels by warfarin therapy.
[Levels of antithrombin III and proteins C in the newborn infant]
protein-glutamine gamma-glutamyltransferase deficiency
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.
Clinical audit of inherited bleeding disorders in a developing country.
Inherited bleeding disorders in Indian women with menorrhagia.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Rare inherited coagulation disorders in India.
Successful use of recombinant factor VIIa in a child with Schoenlein-Henoch purpura presenting with compartment syndrome and severe factor XIII deficiency.
Proteinuria
Haemostatic variables associated with diabetes and its complications.
Hemostatic function tests associated with diabetic microangiopathy.
Pulmonary Arterial Hypertension
Successful placement of a right ventricular assist device for treatment of a presumed amniotic fluid embolism.
Pulmonary Atresia
Palliative open heart surgery in an infant with factor VII deficiency.
Pulmonary Disease, Chronic Obstructive
Circulating tissue factor procoagulant activity is elevated in stable moderate to severe chronic obstructive pulmonary disease.
Development of Trypsin-Like Serine Protease Inhibitors as Therapeutic Agents: Opportunities, Challenges, and their Unique Structure-Based Rationales.
Thrombin generation in chronic obstructive pulmonary disease: Dependence on plasma factor composition.
Pulmonary Edema
Use of recombinant factor VIIa to correct the coagulation status of individuals with advanced liver disease prior to a percutaneous liver biopsy.
Pulmonary Embolism
Congenital FVII Deficiency and Pulmonary Embolism : A Critical Appraisal of All Reported Cases.
Congenital FVII deficiency and thrombotic events after replacement therapy.
Deep vein thrombosis and pulmonary embolism in congenital factor VII deficiency.
Experience with recombinant activated factor VII for severe post-partum hemorrhage in Japan, investigated by Perinatology Committee, Japan Society of Obstetrics and Gynecology.
Lack of bleeding in patients with severe factor VII deficiency.
Management of massive pulmonary embolism using recombinant activated Factor VII.
Massive pulmonary embolism after treatment with rFVIIa in a thrombocytopenic patient with acute myelogenous leukemia and intractable bleeding.
Medication-related complications in the trauma patient.
Postoperative pulmonary thromboembolism possibly associated with recombinant activated factor VII infusion for the treatment of uncontrolled hemorrhage during vertebral instrumentation.
Pulmonary embolism after administration of recombinant activated Factor VII for major obstetric hemorrhage.
Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient.
Pulmonary embolism in a patient with mild factor VII deficiency after administration of recombinant activated factor VII during a urological procedure.
Risk of thromboembolic complications after intracerebral hemorrhage according to ethnicity.
ST-Segment Elevation Myocardial Infarction (STEMI) and Pulmonary Embolism in a Hemophilia A Patient Receiving Emicizumab and recombinant Activated Factor VII.
Therapeutic plasma exchange as part of multimodal treatment of acquired hemophilia in a patient with concurrent acute intracerebral bleed and pulmonary embolism.
Thromboembolism in patients with hereditary deficiency of coagulation factors.
Unprovoked Pulmonary Embolism in Factor VII Deficiency.
Purpura
[Hemostasis anomalies and prognosis during severe infectious purpura in children. Retrospective study in 69 cases]
Purpura Fulminans
First manifestation of a hereditary homozygous factor VII deficiency in a 3-year-old girl suspected as purpura fulminans.
Purpura, Thrombocytopenic, Idiopathic
Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts.
Diminished response to recombinant factor VIIa in a patient with idiopathic thrombocytopenic purpura.
Experiences with recombinant FVIIa in the emergency treatment of patients with autoimmune thrombocytopenia: a review of the literature.
Heparin-induced thrombocytopenia and other immune thrombocytopenias: lessons from mouse models.
Plasma levels of activated FVII in various diseases.
Recombinant factor VIIa for refractive haemorrhage in autoimmune idiopathic thrombocytopenic purpura.
Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment.
Screening bleeding disorders in adolescents and young women with menorrhagia.
Severe gastrointestinal haemorrhage responding to recombinant factor VIIa in a Jehovah's Witness with refractory immune thrombocytopenia.
Successful control of severe postoperative bleeding with recombinant factor VIIa in a case of refractory idiopathic thrombocytopenic purpura.
Use of Recombinant Factor VIIa in a Pediatric Patient With Initial Presentation of Refractory Acute Immune Thrombocytopenic Purpura and Severe Bleeding.
[Serious congenital deficiency of FVII and acquired idiopathic thrombocytopenic purpura--the rare combination of two bleeding disorders]
[Use of recombinant activated factor VII (NovoSeven) in the treatment of a patient with idiopathic thrombocytopenic purpura complicated with subarachnoid and parenchimatous hemorrhage]
Pyelonephritis
Acquired Factor VII Deficiency in Association with Pyelonephritis.
Avoiding Cardiovascular Collapse: Pediatric Cutaneous Mastocytosis and Anesthetic Challenges.
Quadriplegia
Contribution of D-Dimer determination in the exclusion of deep venous thrombosis in spinal cord injury patients.
Rectal Neoplasms
Anesthetic management of a patient with factor VII deficiency undergoing laparoscopic colectomy: a case report.
Refsum Disease
Liver cell transplantation.
Refsum Disease, Infantile
Hepatocyte transplantation for liver-based metabolic disorders.
Renal Insufficiency
A role for very low-dose recombinant activated factor VII in refractory bleeding after cardiac surgery: Lessons from an observational study.
Impact of Early, Low-Dose Factor VIIa on Subsequent Transfusions and Length of Stay in Cardiac Surgery.
Outcomes Following Three-Factor Inactive Prothrombin Complex Concentrate Versus Recombinant Activated Factor VII Administration During Cardiac Surgery.
Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel.
Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery.
Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin.
Takayasu Arteritis Presenting as Renovascular Hypertension and Renal Failure in a Patient with Factor VII Deficiency.
Use of recombinant activated factor VII concentrate to control postoperative hemorrhage in complex cardiovascular surgery.
[Activated factor VII as a new cardiovascular risk factor of atherothrombotic disease]
[Pathophysiological and therapeutic aspects of amniotic fluid embolism (anaphylactoid syndrome of pregnancy): case report with lethal outcome and overview]
Renal Insufficiency, Chronic
Factor VII coagulant activity (VIIc) and hypercoagulability in chronic renal disease and dialysis: relationship with dyslipidaemia, inflammation, and factor VII genotype.
Respiratory Distress Syndrome
A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome*
Procoagulant activity in bronchoalveolar lavage in the adult respiratory distress syndrome. Contribution of tissue factor associated with factor VII.
Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials.
Recombinant Activated Factor VII Safety in Trauma Patients: Results From the CONTROL Trial.
The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage.
Respiratory Insufficiency
Recombinant activated factor VII for exsanguinating haemorrhage post bilateral lung transplantation for extra-corporeal lung support-dependent respiratory failure.
[Primary myelofibrosis complicated by acquired hemophilia A and subsequent development of acute myeloid leukemia].
Respiratory Tract Infections
Prothrombotic changes in hemostatic parameters and C-reactive protein in the elderly with winter acute respiratory tract infections.
Retinal Vein Occlusion
Is activated factor VII associated with retinal vein occlusion?
Rhabdomyosarcoma
Recombinant activated factor VII controls chemotherapy-related hemorrhage in patients with solid intra-abdominal tumors: a report of three pediatric cases.
Rheumatic Diseases
Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays.
Sagittal Sinus Thrombosis
Superior sagittal sinus thrombosis with homocystinuria and deficiency of antithrombin III and factor VII: case report.
Sarcoidosis
Human alveolar macrophages synthesize factor VII in vitro. Possible role in interstitial lung disease.
Sarcoma
Role of factor VII in correcting dilutional coagulopathy and reducing re-operations for bleeding following non-traumatic major gastrointestinal and abdominal surgery.
Successful treatment with recombinant factor VIIa for intractable bleeding at pelvic surgery.
Schistosomiasis
Splenectomy Improves Hemostatic and Liver Functions in Hepatosplenic Schistosomiasis Mansoni.
Scleroderma, Systemic
Low levels of activated factor VII in systemic sclerosis.
Scoliosis
Bleeding and coagulation changes during spinal fusion surgery: a comparison of neuromuscular and idiopathic scoliosis patients.
Recombinant coagulation factor VIIa--a novel haemostatic agent in scoliosis surgery?
Surgery for scoliosis in congenital factor VII deficiency.
The use of recombinant coagulation factor VIIa in patients undergoing surgical correction of scoliosis with the C-D method.
[A Jehovah's Witness child with hemophilia B and factor IX inhibitors undergoing scoliosis surgery]
Seizures
Congenital factor VII deficiency.
High-dose tranexamic acid is related to increased risk of generalized seizures after aortic valve replacement.
Medication-related complications in the trauma patient.
Multiple intracranial hemorrhages at the time of a transiently prolonged activated partial thromboplastin time in an infant with congenital factor VII deficiency.
Novel IVS7+1G>T mutation of life-threatening congenital factor VII deficiency in neonates: A retrospective study in China.
Successful control of central nervous system bleeding in two newborns with severe factor VII deficiency using rFVIIa administered via Port-a-Cath.
Sepsis
Acquired isolated factor VII deficiency during sepsis.
Acquired Isolated FVII Deficiency: An Underestimated and Potentially Important Laboratory Finding.
Acute Myelogenous Leukemia With Trisomy 8 and Concomitant Acquired Factor VII Deficiency.
Anaesthetic management of a parturient with factor VII deficiency and sepsis.
Blockade of tissue factor: treatment for organ injury in established sepsis.
Effects of plasma kallikrein specific inhibitor and active-site blocked factor VIIa on the pulmonary vascular injury induced by endotoxin in rats.
Expression of tissue factor in experimental bovine pneumonic pasteurellosis and endotoxemia.
Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients.
Failure of recombinant factor VIIa in a patient with severe polymicrobial sepsis and postoperative uncontrolled intraabdominal bleeding.
Hepatocyte transplantation for inherited factor VII deficiency.
Human leukocyte elastase and cathepsin G inactivate factor VII by limited proteolysis.
Increased mortality in systemic inflammatory response syndrome patients with high levels of coagulation factor VIIa.
Induction of human endothelial tissue factor expression by Neisseria meningitidis: the influence of bacterial killing and adherence to the endothelium.
Inhibition of the extrinsic or intrinsic coagulation pathway during pneumonia derived sepsis.
Inhibition of the tissue factor/factor VIIa pathway does not influence the inflammatory or antibacterial response to abdominal sepsis induced by Escherichia coli in mice.
Initiation of blood coagulation: the tissue factor/factor VIIa complex.
Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia.
Low plasma FVII:C and activated FVII as predictive markers for overt disseminated intravascular coagulation.
Management of Life-Threatening Hemorrhages and Unsafe Interventions in Nonhemophiliac Children by Recombinant Factor VIIa.
Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review.
Recombinant Activated Factor VII Use in Critically Ill Patients: Clinical Outcomes and Thromboembolic Events (April).
Recombinant factor VII (activated) for haemorrhagic complications of severe sepsis treated with recombinant protein C (activated).
Review of cellular and molecular pathways linking thrombosis and innate immune system during sepsis.
Safety profile of recombinant factor VIIa.
Selective attenuation of the extrinsic limb of the tissue factor-driven coagulation protease cascade by occupancy of a novel peptidyl docking site on tissue factor.
Structure of the extracellular domain of human tissue factor: location of the factor VIIa binding site.
The development of hypoprothrombinaemia following antibiotic therapy in malnourished patients with low serum vitamin K1 levels.
Tissue factor as an evolutionary conserved cytokine receptor: Implications for inflammation and signal transduction.
Tissue factor in experimental acute lung injury.
Use of recombinant factor VIIa in the treatment of massive retroperitoneal bleeding due to severe necrotizing pancreatitis.
VIIa/tissue factor interaction results in a tissue factor cytoplasmic domain-independent activation of protein synthesis, p70, and p90 S6 kinase phosphorylation.
[Life-threatening postpartum hemorrhage and recombinant activated factor rFVIIa NovoSeven use]
[Studies on low protein C-expression in severe sepsis]
Severe Dengue
Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study.
Effectiveness of Recombinant Activated Factor VII (rFVII a) for Controlling Intractable Postpartum Bleeding in a case of Dengue Hemorrhagic Fever.
Recombinant activated factor VII usage in life threatening hemorrhage: a pediatric experience.
Successful use of N-acetyl cysteine and activated recombinant factor VII in fulminant hepatic failure and massive bleeding secondary to dengue hemorrhagic fever.
The use of recombinant activated factor VII for controlling life-threatening bleeding in Dengue Shock Syndrome.
[Treatment of hemorrhagic dengue in the pediatric population: a systematic review].
Shock, Cardiogenic
Activated recombinant factor VII for control of diffuse bleeding after implantation of ventricular assist device.
Shock, Septic
Can Coagulation System Disorders and Cytokine and Inflammatory Marker Levels Predict the Temporary Clinical Deterioration or Improvement of Septic Patients on ICU Admission?
Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients.
Septic miscarriage with toxic shock syndrome and disseminated intravascular coagulation (DIC): The role of surgery, recombinant activated factor VII and intravenous immunoglobulin (IVIG).
Treatment of intra-abdominal bleeding with recombinant activated factor VII in a patient with disseminated intravascular coagulation secondary to septic shock.
[Bleeding associated with septic shock treated successfully with recombinant activated factor VII: a case report]
Sinus Thrombosis, Intracranial
Cerebral sinus thrombosis in a trauma patient after recombinant activated factor VII infusion.
Cerebral Venous Sinus Thrombosis in a Patient with Undiagnosed Factor VII Deficiency.
Sleep Apnea Syndromes
Factor VII deficiency and developmental abnormalities in a patient with partial monosomy of 13q and trisomy of 16p: case report and review of the literature.
Sleep Deprivation
Chronic sleep deprivation markedly reduces coagulation factor VII expression.
Spastic Paraplegia, Hereditary
Coexistence of Factor VII Deficiency and Hereditary Spastic Paraplegia in Two Siblings.
Spinal Cord Diseases
Description of breed ancestry and genetic health traits in arctic sled dog breeds.
Splenic Rupture
[Case of factor VII deficiency with systemic amyloidosis having a unique clinical course such as splenic rupture]
Starvation
Anti-apoptotic genes are synergistically activated in OVSAYO cells cultured under conditions of serum starvation and hypoxia.
Cholesterol Starvation and Hypoxia Activate the FVII Gene via the SREBP1-GILZ Pathway in Ovarian Cancer Cells to Produce Procoagulant Microvesicles.
Stenosis, Pulmonary Artery
Combined factor VII and protein C deficiency found in a patient with peripheral pulmonary artery stenosis accompanied by progressive pulmonary hypertension and hemoptysis.
Stomach Neoplasms
Major surgery for a gastric cancer in a haemophilic with high inhibitor titre successfully performed by the use of recombinant FVIIa.
[Gastrectomy for a patient with congenital factor VII deficiency--a case report]
Stroke
A meta-analysis of the efficacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia.
ACE gene polymorphisms influence t-PA-induced brain vessel reopening following ischemic stroke.
Analysis of the substrate specificity of Factor VII activating protease (FSAP) and design of specific and sensitive peptide substrates.
Anticoagulation Therapy Considerations in Factor VII Deficiency.
Association of coagulation-related and inflammation-related genes and factor VIIc levels with stroke: the Cardiovascular Health Study.
Associations of plasma fibrinogen and factor VII clotting activity with coronary heart disease and stroke: prospective cohort study from the screening phase of the Thrombosis Prevention Trial.
Blood coagulation and fibrinolysis in acute ischaemic and haemorrhagic (intracerebral and subarachnoid haemorrhage) stroke: does decreased plasmin inhibitor indicate increased fibrinolysis in subarachnoid haemorrhage compared to other types of stroke?
Clinical Strategies Against Early Hematoma Expansion Following Intracerebral Hemorrhage.
Coagulation factor VII activity, Arg/Gln353 polymorphism and features of insulin resistance in first-degree-relatives of South Asian patients with stroke.
Concurrent administration of sustained-release bezafibrate may counteract the increased thrombotic risk associated with oral estrogen therapy.
Congenital factor VII deficiency and cerebrovascular stroke.
Decreased fibrinolytic potential in South Asian women with ischaemic cerebrovascular disease.
Effect of Recombinant Activated Coagulation Factor VII on Hemorrhage Expansion Among Patients With Spot Sign-Positive Acute Intracerebral Hemorrhage: The SPOTLIGHT and STOP-IT Randomized Clinical Trials.
Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage.
Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study of Women's Health Across the Nation (SWAN).
Factor VII -323 decanucleotide D/I polymorphism in atrial fibrillation: implications for the prothrombotic state and stroke risk.
Factor VII deficiency in major artery occlusion stroke.
Factor VII gene haplotypes and risk of ischemic stroke.
Factor VII R353Q polymorphism and lacunar stroke in Japanese hypertensive patients and normotensive controls.
Factor VIIa and tissue factor procoagulant activity in diabetes mellitus after acute ischemic stroke: impact of hyperglycemia.
Haemostatic variables in Pacific Islanders apparently free from stroke and ischaemic heart disease--the Kitava Study.
Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study.
Hypercoagulability in acute ischemic stroke: analysis of the extrinsic coagulation reactions in plasma by a highly sensitive automated method.
Intracerebral hemorrhage: outcomes and eligibility for factor VIIa treatment in a National Stroke Registry.
Lp(a), homocysteine and a family history of early ischemic cerebral stroke.
Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk?
Novel anticoagulant therapy: principle and practice.
Polymorphisms of the factor VII gene and circulating FVII:C levels in relation to acute cerebrovascular disease and poststroke mortality.
Recent bacterial and viral infection is a risk factor for cerebrovascular ischemia: clinical and biochemical studies.
Recombinant activated factor VII in cardiac surgery: a meta-analysis.
Recombinant Activated Factor VII Increases Stroke in Cardiac Surgery: A Meta-analysis.
Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery.
Recombinant factor VIIa for hemorrhagic stroke treatment at earliest possible time (FASTEST): Protocol for a phase III, double-blind, randomized, placebo-controlled trial.
Recombinant factor VIIa in a case of pontine hemorrhage.
Recombinant factor VIIa use in acute type A aortic dissection repair: A multicenter propensity-score-matched report from the Nordic Consortium for Acute Type A Aortic Dissection.
Recombinant factor VIIa use in patients presenting with intracranial hemorrhage.
Reversal of warfarin-induced anticoagulation with factor VIIa prior to rt-PA in acute stroke.
Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery.
Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease.
The safety of recombinant factor VIIa in cardiac surgery.
The tissue factor pathway in ischemic stroke.
Tissue factor/factor VIIa pathway mediates coagulation activation in induced-heat stroke in the baboon.
[Acute stroke therapy : Current developments.]
[Intracerebral haemorrhage, what's new?]
Stroke, Lacunar
Factor VII R353Q polymorphism and lacunar stroke in Japanese hypertensive patients and normotensive controls.
Subarachnoid Hemorrhage
Congenital deficiency of factor VII in subarachnoid hemorrhage.
Invasive EEG-electrodes in presurgical evaluation of epilepsies: Systematic analysis of implantation-, video-EEG-monitoring- and explantation-related complications, and review of literature.
Perioperative Use of Recombinant Factor VII to Prevent Intraoperative Aneurysm Rupture in High Risk Patients: A Preliminary Safety Evaluation.
Recombinant factor VIIa as an adjunct in nonoperative management of solid organ injuries in children.
Synovitis
EPCR deficiency or function-blocking antibody protects against joint bleeding-induced pathology in hemophilia mice.
Hemophilic synovitis: factor VII and the potential role of extravascular factor VIIa.
Prevention of haemarthrosis in a murine model of acute joint bleeding.
Takayasu Arteritis
Takayasu Arteritis Presenting as Renovascular Hypertension and Renal Failure in a Patient with Factor VII Deficiency.
Telangiectasis
[Successful gastric resection in a male patient with factor VII deficiency and telangiectasia]
Teratoma
Recombinant factor VIIa for treatment of massive liver fracture in a premature infant.
Refractory bleeding following major surgery of a giant sacrococcygeal teratoma in a premature infant: successful use of recombinant factor VIIa.
Tetralogy of Fallot
Recombinant factor VIIa to control excessive bleeding following surgery for congenital heart disease in pediatric patients.
Thrombasthenia
A case of Glanzmann's thrombasthenia successfully treated with recombinant factor viia during a surgical procedure: observations on the monitoring and the mechanism of action of this drug.
A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa.
A patient with Glanzmann's thrombasthenia for emergent abdominal surgery.
A rare case of Glanzmann's thrombasthenia and factor VII deficiency due to a combination of pathogenic and non-pathogenic gene variants.
Bleeding and surgery in children with Glanzmann thrombasthenia with and without the use of recombinant factor VII a.
Buccal mucosa bleeding time is prolonged in canine models of primary hemostatic disorders.
Change of coagulation after NovoSeven® use for bleeding during cardiac surgery.
Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.
Confirmation of high dose recombinant factor VIIa in treating patients with Glanzmann thrombasthenia.
Control of severe bleeding episode in case of Glanzmann's thrombasthenia refractory to platelet transfusion therapy by administering recombinant factor VIIa.
Eptacog alfa activated: a recombinant product to treat rare congenital bleeding disorders.
Gene Therapy for Inherited Bleeding Disorders.
Glanzmann thrombasthenia successfully operated for nasal deformation with recombinant factor VIIA.
Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents.
Increased local procoagulant action: a mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disorders.
Independent Adjudicator Assessments of Platelet Refractoriness and rFVIIa Efficacy in Bleeding Episodes and Surgeries from the Multinational Glanzmann's Thrombasthenia Registry.
Inherited bleeding disorders in the Eastern Province of Saudi Arabia.
Inherited Bleeding Disorders in the Obstetric Patient.
Intensive Menstrual Bleeding Successfully Treated With Recombinant Factor VIIa in Glanzmann Thrombasthenia.
Low Concentrations of Recombinant Factor VIIa May Improve the Impaired Thrombin Generation of Glanzmann Thrombasthenia Patients.
Management of Pregnancy in a Chilean Patient with Congenital Deficiency of Factor VII and Glanzmann's Thrombasthenia Variant.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
New Insights Into the Treatment of Glanzmann Thrombasthenia.
NovoSeven (recombinant factor VIIa) for the treatment of bleeding episodes and perioperative management in patients with Glanzmann's thrombasthenia.
NovoSeven as a universal haemostatic agent.
Pharmacokinetic properties of two different recombinant activated factor VII formulations.
Pharmacology and clinical use of recombinant activated factor seven in neurosciences.
Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey.
Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VII and platelet transfusions.
Rational Use of Recombinant Factor VIIa in Clinical Practice.
Recognition and management of platelet-refractory bleeding in patients with Glanzmann's thrombasthenia and other severe platelet function disorders.
Recombinant Activated Factor VII (Eptacog Alfa Activated, NovoSeven®) in Patients with Rare Congenital Bleeding Disorders. A Systematic Review on its Use in Surgical Procedures.
Recombinant activated factor VII (rFVIIa, NovoSeven).
Recombinant activated factor VII and epsilon aminocaproic acid treatment of a patient with Glanzmann's thrombasthenia for nasal polipectomy.
Recombinant activated factor VII and the anaesthetist.
Recombinant activated factor VII as a universal haemostatic agent.
Recombinant Activated Factor VII Combined with Desmopressin in Preventing Bleeding from Dental Extraction in a Patient with Glanzmann's Thrombasthenia.
Recombinant activated factor VII combined with local measures in preventing bleeding from invasive dental procedures in patients with Glanzmann thrombasthenia.
Recombinant activated factor VII in clinical practice: a 2014 update.
Recombinant activated factor VII in patients at high risk of bleeding.
Recombinant activated factor VII usage in life threatening hemorrhage: a pediatric experience.
Recombinant activated factor VII: 30 years of research and innovation.
Recombinant activated factor VII: mechanisms of action and current indications.
Recombinant Factor VIIa (Eptacog Alfa): A Review of its Use in Congenital Hemophilia with Inhibitors, Acquired Hemophilia, and Other Congenital Bleeding Disorders.
Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders.
Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation.
Recombinant factor VIIa in a patient with Glanzmann's thrombasthenia undergoing gynecological surgery: open issues in light of successful treatment.
Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia.
Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factor-independent fibrin generation.
Recombinant factor VIIa: a universal hemostatic agent?
Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
Safety update on the use of recombinant activated factor VII in approved indications.
Screening bleeding disorders in adolescents and young women with menorrhagia.
Study of the Relationship between HPA-1 and HPA-5 Gene Polymorphisms and Refractory to Platelet Therapy and Recombinant Factor VII in Glanzmann Thrombasthenia Patients in Southeast of Iran.
Successful epistaxis control in a patient with Glanzmann thrombasthenia by increased bolus injection dose of recombinant factor VIIa.
Successful surgery using recombinant factor VIIa for recurrent, idiopathic nonulcer duodenal bleeding in a patient with Glanzmann's thrombasthenia.
Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia.
Successful use of recombinant factor VIIa in a patient with acquired Glanzmann thrombasthenia.
Surgical procedures in patients with Glanzmann's thrombasthenia: case series and literature review.
Surgical resection of a sphenoid wing meningioma in a patient with Glanzmann thrombasthenia.
The danger of using a sledgehammer to crack a nut: ROTEM-guided administration of recombinant activated factor VII in a patient with refractory bleeding post-ventricular assist device implantation.
The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia.
The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia.
The international, prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention.
The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia.
The Judicious Use of Recombinant Factor VIIa.
The Use of Recombinant Activated Factor VII in Patients with Glanzmann's Thrombasthenia.
The use of recombinant factor VIIa in a patient with severe Glanzmann's thrombasthenia to facilitate insertion of a Port-a-Cath.
The use of recombinant FVIIa in a patient with Glanzmann thrombasthenia with uncontrolled bleeding after tonsillectomy.
Thromboelastographic evaluation of recombinant factor VIIa in a child with Glanzmann's thrombasthenia.
Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC).
Tissue factor-independent effects of recombinant factor VIIa on hemostasis.
To general haemostasis--the evidence-based route.
Total Extraction as a Treatment for Anaemia in a Patient of Glanzmann's Thrombasthenia with Chronic Gingival Bleed: Case Report.
Treatment of bleeding after kidney biopsy with recombinant activated factor VII.
Treatment of bleeding in patients with platelet disorders: is there a place for recombinant factor VIIa?
Understanding the therapeutic action of recombinant factor VIIa in platelet disorders.
Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: a review of the literature.
Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia.
Use of recombinant factor VIIa for bleeding in children with Glanzmann thrombasthenia.
Use of recombinant factor VIIa for post-operative haemorrhage in a patient with Glanzmann's thrombasthenia and human leucocyte antigen antibodies.
Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures.
Use of rFVIIa in 4 children with Glanzmann thrombasthenia.
Use of rFVIIa in Preventing Recurrent Intra-articular Hemorrhages in a 15-Year-Old Patient With Glanzmann Thrombasthenia.
Weekly low-dose recombinant factor VIIa prophylaxis in Glanzmann thrombasthenia.
[Activated Factor VII - 31 years experience on clinical grounds].
[Application of rFVIIa for controlling acute bleeding in the obstetric and gynecologic practice]
[Bleeding after cardiac surgery: the role of recombinant factor VIIa]
[Efficacy of Recombinant Activated Factor VII for Intractable Bleeding after Cardiovascular Surgery].
[Inherited bleeding disorders common in Jews].
[Panorama of congenital disorders of hemostasis diseases at University Hospital of Brazzaville, Congo]
[Postpartum hemorrhage successfully treated with recombinant factor VIIa in Glanzmann thromboasthenia]
[Recombinant activated factor VII in paediatric practice. Universal hemostatic agent?]
[Recombinant factor VIIa in patients with platelet function disorders or thrombocytopenia]
[Therapy of inherited diseases of platelet function. Interdisciplinary S2K guideline of the Permanent Paediatric Committee of the Society of Thrombosis and Haemostasis Research (GTH e.?V.)].
[Thrombasthenia of Glanzmann. Vaginal hysterectomy treated with recombinant factor VIIa]
[Use of recombinant factor VII in Glanzmann thrombasthenia: a case report].
Thrombocytopenia
A novel hemostatic agent: the potential role of recombinant activated factor VII (rFVIIa) in anesthetic practice.
Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII.
Acute left atrial thrombus after recombinant factor VIIa administration during left ventricular assist device implantation in a patient with heparin-induced thrombocytopenia.
Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review.
Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with thrombocytopenia due to chronic bone marrow failure: a network meta-analysis and systematic review.
Clinical and laboratory features of 178 children with recurrent epistaxis.
Clinical experience with recombinant factor VIIa in patients with thrombocytopenia.
Coagulopathy of Liver Disease.
Combination therapy with rFVIIa and platelets for hemorrhage in patients with severe thrombocytopenia and alloimmunization.
Congenital FX deficiency combined with other clotting defects or with other abnormalities: a critical evaluation of the literature.
Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII.
Diminished response to recombinant factor VIIa in a patient with idiopathic thrombocytopenic purpura.
Effect of a factor VIII concentrate on type IIB von Willebrand's disease-associated thrombocytopenia presenting during pregnancy in identical twin mothers.
Effect of recombinant factor VIIa (Novoseven) on thrombocytopenia-like conditions in vitro.
Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage.
Experiences with recombinant activated factor VII in the treatment of severe refractory thrombocytopenia.
Experiences with recombinant human factor VIIa in patients with thrombocytopenia.
Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant activated factor VII?
Hemostatic consequences of a non-fresh or reconstituted whole blood small volume cardiopulmonary bypass prime in neonates and infants.
Heparin-induced thrombocytopenia and cardiopulmonary bypass: anticoagulation with unfractionated heparin and the GPIIb/IIIa inhibitor tirofiban and successful use of rFVIIa for post-protamine bleeding due to persistent platelet blockade.
High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system.
Increased local procoagulant action: a mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disorders.
Levels of prothrombin activation peptide F1+2 in patients with a bleeding tendency.
Management of bleeding complications of hematologic malignancies.
Management of bleeding in a multi-transfused patient with positive HLA class I alloantibodies and thrombocytopenia associated with platelet dysfunction refractory to transfusion of cross-matched platelets.
Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa?
Mechanism of action of factor VIIa in the treatment of coagulopathies.
Neonatal thrombocytopenia: Thrombin generation in presence of reduced platelet counts and effects of rFVIIa in cord blood.
New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa.
On the mechanism of action of recombinant activated factor VII administered to patients with severe thrombocytopenia and life-threatening haemorrhage: focus on prothrombin activation.
Ongoing NovoSeven trials.
Overall experience with NovoSeven.
Platelet membrane fragments enhance the procoagulant effect of recombinant factor VIIa in studies with circulating human blood under conditions of experimental thrombocytopenia.
Point-of-Care Thromboelastography for Intrathecal Drain Management in Patients With Coagulopathy and Thoracic Aorta Surgery: A Case Report.
Potential role of recombinant factor VIIa as a hemostatic agent.
Prophylactic recombinant factor VIIa administration to an infant with congenital systemic juvenile xanthogranuloma.
Recombinant activated coagulation factor VII and bleeding trauma patients.
Recombinant activated Factor VII as a hemostatic agent in very low birth weight preterms with gastrointestinal hemorrhage and disseminated intravascular coagulation.
Recombinant activated factor VII as a universal haemostatic agent.
Recombinant activated factor VII as an additional agent in the management of bleeding in patients with chemotherapy-induced thrombocytopenia.
Recombinant activated factor VII for hemostatic cover of orthopedic interventions in a girl with thrombocytopenia with absent radii syndrome.
Recombinant activated factor VII in liver patients: a retrospective cohort study from Australia and New Zealand.
Recombinant activated factor VII in patients at high risk of bleeding.
Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage.
Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count.
Recombinant factor VIIa for bleeding in refractory thrombocytopenia.
Recombinant factor VIIa for treatment of massive liver fracture in a premature infant.
Recombinant factor VIIa is an effective therapy for abdominal surgery and severe thrombocytopenia: a case report.
Recombinant factor VIIa reduces bleeding in severely thrombocytopenic rabbits.
Recombinant factor VIIa: a universal hemostatic agent?
Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment.
Reversal of thrombocytopenia and bleeding tendency in a preterm neonate with recombinant activated factor VII: case report.
Successful treatment of massive gastrointestinal hemorrhage in acute biphenotypic leukemia with recombinant factor VIIa (NovoSeven).
Successful treatment of severe bleeding with recombinant factor VIIa after kidney transplantation.
Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII : Report on one case and review of other uses in acute leukemias.
The evidence for the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorders.
The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation.
The use of recombinant activated coagulation factor VII for spine surgery.
The use of recombinant factor viia in a jehovah's witness with auto-immune thrombocytopenia and post-splenectomy haemorrhage.
Thrombelastography monitoring of platelet substitution therapy and rFVIIa administration in haemato-oncological patients with severe thrombocytopenia.
Thromboelastography-guided recombinant factor VIIa administration in a patient with refractory autoimmune idiopathic thrombocytopenia.
To general haemostasis--the evidence-based route.
Transfusion medicine service policies for recombinant factor VIIa administration.
Treatment of bleeding in patients with platelet disorders: is there a place for recombinant factor VIIa?
Understanding the therapeutic action of recombinant factor VIIa in platelet disorders.
Use of low dose of rFVIIa (recombinant Factor VII activated) to control late bleeding after percutaneous dilational tracheostomy.
Use of recombinant activated factor VII in a patient with severe thrombocytopenia due to myelodysplastic syndrome with uncontrolled gastrointestinal bleeding.
Use of Recombinant Factor VII in Cardiac Surgery.
Use of recombinant factor VIIa (NovoSeven) to reduce postoperative bleeding after total hip arthroplasty in a patient with cirrhosis and thrombocytopenia.
Use of recombinant factor VIIa in uncontrolled gastrointestinal bleeding after hematopoietic stem cell transplantation among patients with thrombocytopenia.
Whole blood coagulation in children with thrombocytopenia and the response to platelet replacement, recombinant factor VIIa, and a potent factor VIIa analogue.
[Clinical assessment of potential fields of application of recombinant factor VIIa in internal and pediatric diseases. Recommendations of an expert group.]
[Coagulation factor VII--new physiopathological and therapeutic aspects]
[Hemostasis anomalies and prognosis during severe infectious purpura in children. Retrospective study in 69 cases]
[New possibilities in the management of hemorrhagic diathesis caused by factor deficiency and thrombocytopenia: recombinant active factor VII concentrate]
[Pharmacological alternatives to blood transfusion: what is new about?]
[Recombinant activated factor VII use for the bleeding implications prevention during central venous catheterization in pediatric patients with acute leucosis and thrombocytopenia].
[Recombinant factor VIIa in patients with platelet function disorders or thrombocytopenia]
[Use of recombinant activated factor VII (NovoSeven) in the treatment of a patient with idiopathic thrombocytopenic purpura complicated with subarachnoid and parenchimatous hemorrhage]
[Use of recombinant activated factor VII]
Thrombocytopenia, Neonatal Alloimmune
Neonatal thrombocytopenia: Thrombin generation in presence of reduced platelet counts and effects of rFVIIa in cord blood.
Thromboembolism
An evaluation of eptacog alfa in nonhaemophiliac conditions.
Analysis of Outcomes Using Low-Dose and Early Administration of Recombinant Activated Factor VII in Cardiac Surgery.
Case report: Intraoperative thrombosis cardiac arrest in extended right hepatectomy involving use of local haemostatic agent in intraoperative cell salvage (ICS) and administration of recombinant activated factor VII (rFVIIa).
Change of coagulation after NovoSeven® use for bleeding during cardiac surgery.
Coagulation factor abnormalities after the Fontan procedure and its modifications.
Complications of recombinant activated human coagulation factor VII.
Efficacy of recombinant factor VIIa for severe bleeding complicated by platelet transfusion refractoriness in patients with hematologic malignancies.
Factor VII in subjects at risk for thromboembolism: activation or increased synthesis?
Haemostatic drug therapies for acute primary intracerebral haemorrhage.
Individualized antithrombotic therapy.
Low-dose warfarin and low-dose aspirin in the primary prevention of ischemic heart disease.
Parallel use of by-passing agents in haemophilia with inhibitors: a critical review.
Recombinant activated factor VII (rFVIIa) in refractory haemorrhage for non-haemophiliacs: an eleven-year single-centre experience.
Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta-analysis of published data.
Recombinant factor VIIa reduces bleeding after blunt liver injury in coagulopathic, hypofibrinogenaemic pigs.
Renal thromboembolism during treatment with recombinant activated factor VII (rFVIIa) in a child with hemophilia B with factor IX inhibitors.
The incidence of thromboembolism formation following the use of recombinant factor VIIa in patients suffering blunt force compared to penetrating trauma: a systematic review protocol.
The incidence of thromboembolism formation following the use of recombinant factor VIIa in patients suffering from blunt force trauma compared with penetrating trauma: a systematic review.
Thromboembolic complications associated with factor VIIa administration.
Thromboembolic risks of recombinant factor VIIa Use in warfarin-associated intracranial hemorrhage: a case-control study.
Thromboembolism and Factor VII defect.
Thromboembolism in congenital factor VII deficiency.
Thrombosis in a bleeding disorder: case of thromboembolism in factor VII deficiency.
Unopposed estrogen increases total plasma factor VII, but not active factor VII--a short-term placebo-controlled study in healthy postmenopausal women.
Use of recombinant activated factor VII in primary postpartum hemorrhage: the Northern European registry 2000-2004.
Thrombophilia
Absence of hypercoagulability in acute Kawasaki disease.
Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coli L-asparaginase. A GIMEMA study.
Assessment of hemostatic risk factors in predicting arterial thrombotic events.
Clotting factors after emergency contraception.
Coagulation factor VII and plasma triglycerides. Decreased catabolism as a possible mechanism of factor VII hyperactivity.
Contribution of D-Dimer determination in the exclusion of deep venous thrombosis in spinal cord injury patients.
Degree of hypercoagulability and hyperfibrinolysis is related to organ failure and prognosis after burn trauma.
Does recombinant factor VIIa, apart from overall hemostasis, regulate TAFI dependent fibrinolysis? In vitro analysis using overall hemostasis potential (OHP) assay.
Effects of total fat content and fatty acid composition in diet on factor VII coagulant activity and blood lipids.
Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms--the Leiden Thrombophilia Study (LETS).
Factor VII coagulant activity (VIIc) and hypercoagulability in chronic renal disease and dialysis: relationship with dyslipidaemia, inflammation, and factor VII genotype.
Factor Xa generation by computational modeling: an additional discriminator to thrombin generation evaluation.
Genetic markers for inherited thrombophilia are associated with fetal growth retardation in the population of Central Russia.
Hypercoagulability and factor VII in hypertriglyceridemia.
Hypercoagulability in venous and arterial thrombosis.
Is activated factor VII associated with retinal vein occlusion?
Is veno-occlusive disease a specific syndrome or the exacerbation of physiopathologic hemostatic changes in hematopoietic stem cell transplantation (HSCT)?
Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias.
Lipoproteins and the haemostatic system in atherothrombotic disorders.
Morning hypercoagulability and hypofibrinolysis. Diurnal variations in circulating activated factor VII, prothrombin fragment F1+2, and plasmin-plasmin inhibitor complex.
Plasma levels of activated FVII in various diseases.
Plasma markers of hypercoagulability in patients with serious infections and risk of septic shock.
Polycations selectively blocking tissue factor-dependent FVII activation: collective in vitro anticoagulation studies.
Pro-thrombotic states and their diagnosis.
Recombinant factor VIIa does not induce hypercoagulability in vitro.
Recombinant factor VIIa: safety and efficacy.
Role of adipose tissue in haemostasis, coagulation and fibrinolysis.
Simultaneous genotyping of four single nucleotide polymorphisms associated with risk factors of hemostasis disorders.
Standardization and evaluation of the performance of the thrombin generation test under hypo- and hypercoagulability conditions.
Systematic review on the effect of glucocorticoid use on procoagulant, anticoagulant and fibrinolytic factors.
The Northwick Park Heart Study: Evidence from the Laboratory.
Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations.
Warfarin-induced venous limb ischemia/gangrene complicating cancer: a novel and clinically distinct syndrome.
[Diagnosis and treatment of coagulation disorders]
[Myocardial infarction and thromboembolism during pregnancy]
Thrombophlebitis
Postoperative use of rFVIIa by continuous infusion in a haemophilic boy.
Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
Recombinant FVIIa (NovoSeven) continuous infusion and total hip replacement in patients with haemophilia and high titre of inhibitors to FVIII: experience of two cases.
Ten-year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan.
Thrombosis
8(th) Symposium on Hemostasis: Translational and Basic Science Discoveries.
A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
A cyclic pentapeptide derived from the second EGF-like domain of Factor VII is an inhibitor of tissue factor dependent coagulation and thrombus formation.
A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate.
A high-fat meal does not activate blood coagulation factor VII in minipigs.
A multiscale model of venous thrombus formation with surface-mediated control of blood coagulation cascade.
A novel immunoassay for the quantification of human tissue factor binding to activated factor VII.
A Retrospective Analysis of Clinical and Laboratory Data of Patients with Factor VII Deficiency: A Single Centre Experience.
A selective, slow binding inhibitor of factor VIIa binds to a nonstandard active site conformation and attenuates thrombus formation in vivo.
A two adenine insertion polymorphism in the 3' untranslated region of factor VII gene is associated with peripheral arterial disease but not with venous thrombosis. Results of case-control studies.
Acquired Antibodies to ?IIb?3 in Glanzmann Thrombasthenia: From Transfusion and Pregnancy to Bone Marrow Transplants and Beyond.
Activation of coagulation factor VII during alimentary lipemia.
Active site-blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model.
Active site-inactivated factor VIIa prevents thrombosis without increased surgical bleeding: topical and intravenous administration in a rat model of deep arterial injury.
Active-site inactivated FVIIa decreases thrombosis and necrosis in a random skin flap model of acute ischemia.
Acute Aortic Valve Thrombosis Secondary to Recombinant Factor VIIa.
Acute left atrial thrombus after recombinant factor VIIa administration during left ventricular assist device implantation in a patient with heparin-induced thrombocytopenia.
Administration of a small molecule tissue factor/factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time.
Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis.
Aeruginosin analogs and other compounds with rigid bicyclic structure as potential antithrombotic agents.
Age-related changes in factor VII proteolysis in vivo.
An economic analysis of different treatments for bleeding in patients with acquired haemophilia.
An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A.
Analysis of the substrate specificity of Factor VII activating protease (FSAP) and design of specific and sensitive peptide substrates.
Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma.
Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway.
Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis.
Antithrombotic efficacy of inactivated active site recombinant factor VIIa is shear dependent in human blood.
Aortic valve thrombosis after treatment with recombinant factor VIIa: letter 2.
aPCC vs. rFVIIa for the treatment of bleeding in patients with acquired haemophilia - a cost-effectiveness model.
Arg 304 Gln (FVII Padua) and Ala 294 Val mutations are equally present in patients with FVII deficiency and thrombosis.
Arterial thrombosis is accelerated in histidine-rich glycoprotein deficient mice.
Assessment of acquired hemophilia patient demographics in the United States: the Hemostasis and Thrombosis Research Society Registry.
Associated prothrombotic conditions are probably responsible for the occurrence of thrombosis in almost all patients with congenital FVII deficiency. Critical review of the literature.
Association of coagulation-related and inflammation-related genes and factor VIIc levels with stroke: the Cardiovascular Health Study.
Associations of plasma fibrinogen and factor VII clotting activity with coronary heart disease and stroke: prospective cohort study from the screening phase of the Thrombosis Prevention Trial.
Atherosclerosis and coronary bypass surgery in hereditary factor VII deficiency.
Biochemical, molecular and clinical aspects of coagulation factor VII and its role in hemostasis and thrombosis.
Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
Blood coagulation-dependent inflammation. Coagulation-dependent inflammation and inflammation-dependent thrombosis.
Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study.
Case 6--2007: massive intraoperative thrombosis and death after recombinant activated factor VII administration.
Case report: Intraoperative thrombosis cardiac arrest in extended right hepatectomy involving use of local haemostatic agent in intraoperative cell salvage (ICS) and administration of recombinant activated factor VII (rFVIIa).
Cerebral Venous Sinus Thrombosis in a Patient with Undiagnosed Factor VII Deficiency.
Characterization of a tissue factor/factor VIIa-dependent model of thrombosis in hypercholesterolemic rabbits.
Characterization of the coagulation profile in children with liver disease and extrahepatic portal vein obstruction or shunt.
Circulating markers of arterial thrombosis and late-stage age-related macular degeneration: a case-control study.
Clinical management of thrombosis in inherited factor VII deficiency: a description of two cases.
Clinical study of recovery and half-life of vapor-heated factor VII concentrate.
Coagulation activation in young survivors of myocardial infarction (MI)--a population-based case-control study.
Coagulation factor VII and plasma triglycerides. Decreased catabolism as a possible mechanism of factor VII hyperactivity.
Coagulation factor VII and the risk of coronary heart disease in healthy men.
Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity.
Congenital factor VII deficiency: therapy with recombinant activated factor VII -- a critical appraisal.
Congenital factor XI and factor VII deficiencies assure an apparent opposite protection against arterial or venous thrombosis: An intriguing observation.
Congenital FVII deficiency and thrombotic events after replacement therapy.
Congenital protein C deficiency and myocardial infarction:concomitant factor VII hyperactivity may play a role in the onset of arterial thrombosis.
Continuous infusion of monoclonal antibody-purified factor VIII: rational approach to serious hemorrhage in patients with allo-/autoantibodies to factor VIII.
Coronary artery stenosis treatment in aging patients with inherited Factor VII deficiency: Where do we stand?
Cost-Effectiveness Analysis of Plasma Versus Recombinant Factor VIIa for Placing Intracranial Pressure Monitors in Pretransplant Patients With Acute Liver Failure.
Crystal structures of uninhibited factor VIIa link its cofactor and substrate-assisted activation to specific interactions.
Darexaban: anticoagulant effects in mice and human plasma in vitro, antithrombotic effects in thrombosis and bleeding models in mice and effects of anti-inhibitor coagulant complex and recombinant factor VIIa.
Decreased plasma levels of activated factor VII in patients with deep vein thrombosis.
Deep vein thrombosis after recombinant factor VIIa infusion to control severe recurrent postoperative bleeding.
Deep vein thrombosis and pulmonary embolism in congenital factor VII deficiency.
Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex.
Determinants of plasma factor VIIa levels in humans.
Development of a subdural vein thrombosis following aggressive factor VII replacement for postnatal intracranial haemorrhage in a homozygous factor VII-deficient infant.
Development of Trypsin-Like Serine Protease Inhibitors as Therapeutic Agents: Opportunities, Challenges, and their Unique Structure-Based Rationales.
Dietary fatty acids and the haemostatic system.
Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors.
Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function.
Distal deep venous thrombosis in a hemophilia A patient with inhibitor and severe infectious disease, 18 days after recombinant activated factor VII transfusion.
Does ovarian stimulation for in-vitro fertilization induce a hypercoagulable state?
Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008).
Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric versus adult patients: The experience of the Hemostasis and Thrombosis Research Society (HTRS) Registry (2004-2008).
Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
Effect of chitosan and coagulation factors on the wound repair phenotype of bioengineered blood clots.
Effect of extra virgin olive oil on experimental thrombosis and primary hemostasis in rats.
Effect of lipid-lowering treatment on factor VII profile in hyperlipidemic patients.
Effect of locally-applied active site-blocked activated factor VII (ASIS) on experimental arterial thrombosis.
Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis.
Effect of transdermal hormone therapy on platelet haemostasis in menopausal women.
Effects of recombinant active site-blocked activated factor VII in rabbit models of carotid stenosis and myocardial infarction.
Efficacy and safety of continuous infusion of factor VII concentrate in a factor VII-deficient patient at high risk for arterial thrombosis.
Emicizumab Augments Thrombus Formation in Whole Blood from Patients with Hemophilia A under High Shear Flow Conditions.
Encryption and decryption of tissue factor.
Endothelial cell protein C receptor-mediated redistribution and tissue-level accumulation of factor VIIa.
Endotoxin-induced activation of the coagulation cascade in humans: effect of acetylsalicylic acid and acetaminophen.
Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model.
Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis.
Evaluation of the Antihemostatic and Antithrombotic Effects of Lowering Coagulation Factor VII Levels in a Non-human Primate.
Evidence for Activation of Tissue Factor by an Allosteric Disulfide Bond.
Experience with recombinant activated factor VII for severe post-partum hemorrhage in Japan, investigated by Perinatology Committee, Japan Society of Obstetrics and Gynecology.
Exposure and safety of higher doses of recombinant factor VIIa ?250??g?kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008).
Expression and purification of recombinant rabbit factor VII.
Extracellular protein disulfide isomerase regulates coagulation on endothelial cells through modulation of phosphatidylserine exposure.
Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms--the Leiden Thrombophilia Study (LETS).
Factor VII and haemostasis.
Factor VII and heparin in thrombosis.
Factor VII deficiency and pregnancy: a case report and review of literature.
Factor VII hyperactivity in acute myocardial thrombosis. A relation to the coagulation activation.
Factor VII in subjects at risk for thromboembolism: activation or increased synthesis?
Factor VIIa and other haemostatic variables following bone marrow transplantation.
Factor VIIa inhibitors: Chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model.
Factor VIIa stimulates endothelin-1 synthesis in TNF-primed endothelial cells by activation of protease-activated receptor 2.
Factor VIIa-tissue factor: functional importance of protein-membrane interactions.
Failure of an Abiomed left ventricular assist device in association with factor VIIa administration.
Fatal outcome of recombinant factor VIIa in heart transplantation with extracorporeal membrane oxygenation.
Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII.
Fatal Thrombosis After Factor VII Administration During Extracorporeal Membrane Oxygenation.
Fatal thrombosis with activated factor VII in a paediatric patient on extracorporeal membrane oxygenation.
FVIIa corrects the coagulopathy of fulminant hepatic failure but may be associated with thrombosis: a report of four cases.
Genetic polymorphisms modify the response of factor VII to oral contraceptive use: an example of gene-environment interaction.
Genetic polymorphisms of factor VII are not associated with arterial thrombosis.
Genetic Polymorphisms of Hemostatic Factors and Thrombotic Risk in Non BCR-ABL Myeloproliferative Neoplasms: A Pilot Study.
Haemostatic function and arterial disease.
Hemostasis: old system, new players, new directions.
Hemostatic effect of activated factor VII without promotion of thrombus growth in melagatran-anticoagulated primates.
Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives.
Hemostatic system activation in patients with lupus anticoagulant and essential thrombocythemia.
Heparin blunts endotoxin-induced coagulation activation.
Hip surgery in a patient with severe factor VII deficiency.
Hypercoagulation following brain death cannot be reversed by the neutralization of systemic tissue factor.
Incidence and risk factors for venous thromboembolism in critically ill children after trauma.
Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor.
Increased factor VIIa levels in systemic lupus erythematosus patients with lupus anticoagulant.
Inherited thrombophilia: a possible cause of in utero vascular thrombosis in children with intestinal atresia.
Inhibition of acute vascular thrombosis in chimpanzees by an anti-human tissue factor antibody targeting the factor X binding site.
Inhibition of arterial thrombosis by a soluble tissue factor mutant and active site-blocked factors IXa and Xa in the guinea pig.
Inhibitors of Factor VIIa/tissue factor.
Inhibitors of the initiation of coagulation.
Interaction of activated factor VII and active site-inhibited activated factor VII with tissue factor.
Interrelationship of plasma triglyceride and coagulant factor VII levels in normotriglyceridemic hypercholesterolemia.
Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions.
Investigation of potential biomarkers for thrombosis related diseases in Turkish Cypriot population.
Is recombinant activated factor VII effective in the treatment of excessive bleeding after paediatric cardiac surgery?
Is recombinant activated factor VII useful for intractable bleeding after cardiac surgery?
Is the coexistence of thromboembolic events and Factor VII deficiency fortuitous?
Is there a high thrombosis rate associated with recombinant factor VIIa use in intractable hemorrhage in Australia?
Ischemic stroke in a patient with moderate to severe inherited factor VII deficiency.
Lack of association between potential prothrombotic genetic risk factors and arterial and venous thrombosis.
Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias.
Local application of FFR-rFVIIa reduces thrombus formation at arterial anastomosis in rats.
Local application of recombinant active-site inhibited human clotting factor VIIa reduces thrombus weight and improves patency in a rabbit venous thrombosis model.
Long-lasting antithrombotic effects of a single dose of human recombinant, active site-blocked factor VII: insights into possible mechanism(s) of action.
Low risk of viral infection after administration of vapor-heated factor VII concentrate or factor IX complex in first-time recipients of blood components. International Factor Safety Study Group.
Lower extremity compartment syndrome in the setting of iliofemoral deep vein thrombosis, phlegmasia cerulea dolens and factor VII deficiency.
Lower extremity salvage complicated by recurrent microvascular thrombosis in a patient with congenital factor VII deficiency.
Management of recurrent thrombosis in liver transplant recipients: a case report.
Mechanisms of hydroxyethyl starch induced dilutional coagulopathy.
Medication-related complications in the trauma patient.
Middle Cerebral Arterial Thrombosis in a Patient with Hypofibrinogenemia, 5 Days After rFVIIa and FFP Infusion.
Modulators of the coagulation cascade: focus and recent advances in inhibitors of tissue factor, factor VIIa and their complex.
Molecular dynamics simulations of the binary complex of human tissue factor (TF(1-242) ) and factor VIIa (TF(1-242) /fVIIa) on a 4:1 POPC/POPS lipid bilayer.
Neutral macrocyclic factor VIIa inhibitors.
New insight into how tissue factor allosterically regulates factor VIIa.
Occurrence of thrombosis in rare bleeding disorders.
Off-Label Recombinant Factor VIIa Use and Thrombosis in Children: A Multi-center Cohort Study.
Off-label use of recombinant activated coagulation factor VII for bleeding may raise the risk of arterial thrombosis.
Over-expression of factor VIIa in vivo.
Paradoxical thrombosis part 1: factor replacement therapy, inherited clotting factor deficiencies and prolonged APTT.
Parallel use of by-passing agents in haemophilia with inhibitors: a critical review.
Pathogenetic role of Factor VII deficiency and thrombosis in cross-reactive material positive patients.
Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model.
Phenotypical variability in congenital FVII deficiency follows the ISTH-SSC severity classification guidelines: a review with illustrative examples from the clinic.
Plasma factor VII, triglyceride concentration and fibrin degradation products in primary hyperlipidemia: a clinical and laboratory study.
Plasma factor VIIa: measurement and potential clinical significance.
Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and coagulation factor VII Arg353-->Gln polymorphism in Korean patients with coronary artery disease.
Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke: a population-based, prospective genetic analysis.
Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease.
Polymorphisms of the coagulation factor VII gene and its plasma levels in relation to acute cerebral infarction differences in allelic frequencies between Chinese Han and European populations.
Prevention of experimental arterial thrombosis by topical administration of active site-inactivated factor VIIa.
Probable right atrial thrombus immediately after recombinant activated factor VII administration.
Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey.
Protein anticoagulants targeting factor VIIa-tissue factor complex: a comprehensive review.
Prothrombotic genetic risk factors in young survivors of myocardial infarction.
Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity.
Recent advances in the discovery of tissue factor/factor VIIa inhibitors and dual inhibitors of factor VIIa/factor Xa.
Recombinant activated factor VII and prothrombin complex concentrates have different effects on bleeding and arterial thrombosis in the haemodiluted rabbit.
Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies.
Recombinant activated factor VII decreases bleeding without increasing arterial thrombosis in rabbits.
Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel.
Recombinant activated factor VII efficacy and safety in a model of bleeding and thrombosis in hypothermic rabbits: a blind study.
Recombinant activated factor VII in critical bleeding after orthotopic liver transplantation.
Recombinant activated factor VII in neonatal cardiac surgery.
Recombinant activated factor VII in patients with acute liver failure with UNOS Status 1A: a single tertiary academic centre experience.
Recombinant activated factor VII safety and efficacy in the treatment of cranial haemorrhage in patients with congenital haemophilia with inhibitors: an analysis of the Hemophilia and Thrombosis Research Society Registry (2004-2008).
Recombinant activated factor VII use in critically ill infants with active hemorrhage.
Recombinant activated factor VIIa treatment for refractory hemorrhage in infants.
Recombinant expression of biologically active murine soluble EPCR.
Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery.
Recombinant factor VIIa and fibrinogen display additive effect during in vitro haemodilution with crystalloids.
Recombinant factor VIIa in major abdominal surgery and liver transplantation.
Recombinant Factor VIIa in Pediatric Cardiac Surgery.
Recombinant factor VIIA in traumatic intracerebral hemorrhage: results of a dose-escalation clinical trial.
Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants.
Recombinant factor VIIa to prevent surgical bleeding in factor XI deficiency.
Recombinant factor VIIa used to control massive haemorrhage during renal transplantation surgery; vascular graft remained patent.
Recombinant human activated factor VII is thrombogenic in a rabbit model of cyclic flow reduction and does not reduce intra-abdominal bleeding.
Recombinant human factor VIIa (rFVIIa) in a rabbit stasis model.
Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor.
Recombinant porcine FVIII for bleed treatment in acquired hemophilia A: findings from a single-center, 18-patient cohort.
Reduced procedural risk for coronary catheter interventions in carriers of the coagulation factor VII-Gln353 gene.
Reduced thrombus formation in native blood of homozygous factor VII-deficient patients at high arterial wall shear rate.
Regulation of the procoagulant response to arterial injury.
Relationships of plasma factor VIIa-antithrombin complexes to manifest and future cardiovascular disease.
Response to treatment and adverse events associated with use of recombinant activated factor VII in children: a retrospective cohort study.
Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents.
Review Article: Review of the Off-Label Use of Recombinant Activated Factor VII in Pediatric Cardiac Surgery Patients.
Risk factors for thromboembolic events in renal failure.
Risk factors for vascular disease and arteriovenous fistula dysfunction in hemodialysis patients.
Roles of factor Xa beyond coagulation.
Safety and efficacy of recombinant activated factor VII for refractory hemorrhage in pediatric patients on extracorporeal membrane oxygenation: a single center review.
Safety of recombinant activated factor VII in patients with warfarin-associated hemorrhages of the central nervous system.
Safety profile of recombinant factor VIIa.
Safety update on the use of recombinant activated factor VII in approved indications.
Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits.
Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex.
Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells.
Serum lipids and regulation of tissue factor-induced coagulation in middle-aged men.
Severe arterial thrombosis in a congenitally factor VII deficient patient.
Severe Congenital Factor VII Deficiency with Normal Perioperative Coagulation Profile Based on ROTEM Analysis in a Hepatectomy.
Single pretransplant bolus of recombinant activated factor VII ameliorates influence of risk factors for blood loss during orthotopic liver transplantation.
Structure of the extracellular domain of human tissue factor: location of the factor VIIa binding site.
Structure, function, and activation of coagulation factor VII.
Structure-based drug design of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex.
Studies on coagulation incompatibilities for xenotransplantation.
Successful management of bleeding with recombinant factor VIIa (NovoSeven) in a patient with Burkitt lymphoma and thrombosis of the left femoral and left common iliac veins.
Surgical Experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX.
The effects of alcohol on coagulation and fibrinolytic factors: a controlled trial.
The factor VII zymogen structure reveals reregistration of beta strands during activation.
The impact of postprandial lipemia in accelerating atherothrombosis.
The paradoxical association between inherited factor VII deficiency and venous thrombosis.
The pleiotropic effects of tissue factor: a possible role for factor VIIa-induced intracellular signalling?
The study of gene-environment interactions that influence thrombosis and fibrinolysis. Genetic variation at the loci for factor VII and plasminogen activator inhibitor-1.
The tissue factor and plasminogen activator inhibitor type-1 response in pediatric sepsis-induced multiple organ failure.
Therapeutic choices for patients with hemophilia and high-titer inhibitors.
Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Thrombogenic side-effects of recombinant factor VIIa after use in coronary artery bypass surgery.
Thrombosis and factor VII activity.
Thrombosis and recombinant factor VIIa.
Thrombosis and recombinant factor VIIa: letter 1.
Thrombosis associated with the use of recombinant activated factor VII: profiling two events.
Thrombosis in a bleeding disorder: case of thromboembolism in factor VII deficiency.
Thrombosis in inherited factor VII deficiency.
Thrombosis incidence after recombinant active factor VII administration in paediatric cardiac surgery.
Thrombosis related to emergency factor VIIa treatment.
Thrombotic complications of COVID-19 may reflect an upregulation of endothelial tissue factor expression that is contingent on activation of endosomal NADPH oxidase.
Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants.
Thrombotic risk of recombinant factor seven in pediatric cardiac surgery: a single institution experience.
Thrombus precursor protein, endogenous thrombin potential, von-Willebrand factor and activated factor VII in suspected deep vein thrombosis: is there a place for new parameters?
Tissue factor and cardiovascular disease: quo vadis?
Tissue factor de-encryption, thrombus formation, and thiol-disulfide exchange.
Tissue factor structure and function.
Tissue factor upregulation drives a thrombosis-inflammation circuit in relation to cardiovascular complications.
Tissue factor-enriched vesicles are taken up by platelets and induce platelet aggregation in the presence of factor VIIa.
Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal.
Unchanged global fibrinolytic capacity despite increased factor VIIa activity in Behçet's disease: evidence of a prethrombotic state.
Unprovoked Pulmonary Embolism in Factor VII Deficiency.
Update on genetic risk factors for thrombosis and atherosclerotic vascular disease.
US experience with recombinant factor VIIa for surgery and other invasive procedures in acquired haemophilia: analysis from the Hemostasis and Thrombosis Research Society Registry.
Use of Factor VIIa and Anti-inhibitor Coagulant Complex in Pediatric Cardiac Surgery Patients.
Use of recombinant activated factor VII after axillofemoral bypass grafting.
Use of recombinant activated factor VII concentrate to control postoperative hemorrhage in complex cardiovascular surgery.
Use of recombinant activated factor VII for acute bleeding episodes in acquired hemophilia: final analysis from the Hemostasis and Thrombosis Research Society Registry acquired hemophilia study.
Use of recombinant activated factor VII for bleeding following operations requiring cardiopulmonary bypass.
Use of Recombinant Activated Factor VII for Controlling Refractory Postoperative Bleeding in Children Undergoing Cardiac Surgery With Cardiopulmonary Bypass.
Use of recombinant factor VIIa for refractory hemorrhage during extracorporeal membrane oxygenation.
Uses of recombinant factor VIIa in trauma.
Utilization of Emicizumab in Acquired Factor VIII Deficiency.
Vena porta thrombosis in patient with inherited factor VII deficiency.
Vitamin K-Dependent Coagulation Factors That May be Responsible for Both Bleeding and Thrombosis (FII, FVII, and FIX).
Warfarin skin necrosis. The role of factor VII.
Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa.
[Diagnosis and treatment of coagulation disorders]
[Fibrinogen and factor VII: 2 risk factors for arterial thrombosis]
[Hemostatic status in subjects with deep venous thrombosis]
[Homocystinuria. A type with vascular thrombosis and factor VII deficiency]
[Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis]
[Inhibition of thrombus formation by anti-Willebrand monoclonal antibodies in the guinea pig]
[Life-threatening postpartum hemorrhage and recombinant activated factor rFVIIa NovoSeven use]
[Predisposing factors for thrombosis]
[Recombinant activated factor VII as a life-saving therapy for severe postpartum haemorrhage unresponsive to conservative traditional management]
[Study on plasma coagulation factor VII (FVII) levels and polymorphisms of FVII gene in patients with coronary heart disease]
[The advisability of modifying the current outline of blood coagulation]
[Thrombin: antithrombotic properties and pharmacological consequences]
Thrombotic Microangiopathies
Comparison of bypassing agents in patients on emicizumab using global hemostasis assays.
Evaluating the safety of emicizumab in patients with hemophilia A.
Recombinant activated factor VII for diffuse alveolar hemorrhage in microscopic polyangiitis.
Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.
Thrombotic Stroke
Efficacy of recombinant activated factor VII in unselected patients with uncontrolled haemorrhage: a single centre experience.
Thyroiditis, Autoimmune
Acquired haemophilia A associated with autoimmune thyroiditis: a case report.
Transfusion Reaction
Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review.
Cost-Effectiveness Analysis of Plasma Versus Recombinant Factor VIIa for Placing Intracranial Pressure Monitors in Pretransplant Patients With Acute Liver Failure.
Transfusion-Related Acute Lung Injury
Blood product replacement for postpartum hemorrhage.
Proteomic analyses of human plasma: Venus versus Mars.
Transfusion Related Acute Lung Injury (TRALI): A Single Institution Experience of 15 Years.
Urea Cycle Disorders, Inborn
Liver cell transplantation.
Uremia
The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia.
[Coagulation factor VII levels in uremic patients and theirs influence factors]
Urinary Tract Infections
Avoiding Cardiovascular Collapse: Pediatric Cutaneous Mastocytosis and Anesthetic Challenges.
Urticaria Pigmentosa
Avoiding Cardiovascular Collapse: Pediatric Cutaneous Mastocytosis and Anesthetic Challenges.
Uterine Hemorrhage
Anticoagulation Therapy Considerations in Factor VII Deficiency.
Difficulty in controlling heavy menstrual bleeding at menarche in a patient with Glanzmann's thrombasthenia.
Management of Refractory Menstrual Bleeding in an Adolescent with Glanzmann Thrombasthenia: A Case Report and Review.
Near-fatal uterine hemorrhage during induction chemotherapy for acute myeloid leukemia: a case report of bilateral uterine artery embolization.
Prophylactic treatment of hereditary severe factor VII deficiency in pregnancy.
Recombinant activated factor VII for severe uterine bleeding after chemotherapy in a woman with acute myeloid leukemia.
Uterine Inertia
Desmopressin-induced Moschcowitz-like syndrome after treatment of uterine atonic bleeding in a 28-year-old pregnant woman: case report and overview of the literature.
Obstetric hemorrhage.
Use of recombinant activated factor VII in a case of severe postpartum haemorrhage.
[Peripartal life-threating haemorrhage - intensive care and haematological treatment].
[Recombinant factor VIIa for treatment of postpartum hemorrhage due to uterine atony].
Vaccinia
Defective vaccinia virus as a biologically safe tool for the overproduction of recombinant human secretory proteins.
Varicose Veins
Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices.
Vascular Diseases
Age-related changes in factor VII activation in healthy women.
Effect of locally-applied active site-blocked activated factor VII (ASIS) on experimental arterial thrombosis.
Extrahepatic synthesis of factor VII in human atherosclerotic vessels.
Fibrinogen and factor VII as risk factors in vascular disease.
Haemostatic balance in patients with acute focal cerebral vasculopathy.
Haemostatic markers are associated with measures of vascular disease in adults with hypertension.
Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin.
Plasma coagulation factor VII activity and its correlates in healthy men.
Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction.
The effect of near-normoglycaemic control on plasma levels of coagulation factor VII and the anticoagulant proteins C and S in insulin-dependent diabetic patients.
Vascular Malformations
Early experience in endoscopic management of massive intraventricular hemorrhage with literature review.
Vascular System Injuries
A detailed morphological evaluation of the evolution of the haemostatic plug in normal, factor VII and factor VIII deficient dogs.
A peptide derived from a tissue factor loop region functions as a tissue factor--factor VIIa antagonist.
Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII.
Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis.
Congenital factor VII deficiency: therapy with recombinant activated factor VII -- a critical appraisal.
Distribution of the recombinant coagulation factor 125I-rFVIIa in rats.
Effect of nafamostat mesilate on pulmonary vascular injury induced by lipopolysaccharide in rats.
Effect of recombinant factor VIIa as an adjunctive therapy in damage control for wartime vascular injuries: a case control study.
Effects of plasma kallikrein specific inhibitor and active-site blocked factor VIIa on the pulmonary vascular injury induced by endotoxin in rats.
Engineering of a membrane-triggered activity switch in coagulation factor VIIa.
Gene targeting in hemostasis. Factor VII.
Identification of the factor VIIa binding site on tissue factor by homologous loop swap and alanine scanning mutagenesis.
Involvement of human decidual cell-expressed tissue factor in uterine hemostasis and abruption.
Lipoprotein metabolism and thrombosis.
Molecular Basis of Enhanced Activity in Factor VIIa-Trypsin Variants Conveys Insights into Tissue Factor-mediated Allosteric Regulation of Factor VIIa Activity.
New insights into how blood clots: implications for the use of APTT and PT as coagulation screening tests and in monitoring of anticoagulant therapy.
Posttraumatic cerebral infarction: incidence, outcome, and risk factors.
Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity.
Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors.
Recombinant Factor VIIa (Eptacog Alfa): A Review of its Use in Congenital Hemophilia with Inhibitors, Acquired Hemophilia, and Other Congenital Bleeding Disorders.
Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile.
Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation.
Reducing the risk of ICH enlargement.
Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage.
Safety update on the use of recombinant activated factor VII in approved indications.
Sites involved in intra- and interdomain allostery associated with the activation of factor viia pinpointed by hydrogen-deuterium exchange and electron transfer dissociation mass spectrometry.
Successful use of recombinant VIIa (Novoseven) and endometrial ablation in a patient with intractable menorrhagia secondary to FVII deficiency.
The cofactor function of the N-terminal domain of tissue factor.
The extrinsic system.
The factor VII zymogen structure reveals reregistration of beta strands during activation.
The interaction of factor VIIa with rehydrated, lyophilized platelets.
The origins of enhanced activity in factor VIIa analogs and the interplay between key allosteric sites revealed by hydrogen exchange mass spectrometry.
The tissue factor-factor VII complex: recent advances towards elucidating the structure and function of the initiator of haemostasis.
Thromboembolic complications associated with factor VIIa administration.
Tissue Factor in Coagulation. Which? Where? When?
Tissue factor structure and function.
Tissue factor: a key molecule in hemostatic and nonhemostatic systems.
Ultra-early hemostatic therapy for intracerebral hemorrhage.
Vascular injury and thrombotic potential: a note of caution about recombinant factor VIIa.
Vasculitis
Failure of Recombinant Activated Factor VII in Treatment of Diffuse Alveolar Hemorrhage due to Cryoglobulinemic Vasculitis.
Venous Thromboembolism
A genome-wide association study identifies new loci for factor VII and implicates factor VII in ischemic stroke etiology.
Activated Factor XI is Increased in Plasma in Response to Surgical Trauma but not to Recombinant Activated FVII-Induced Thrombin Formation.
Associated prothrombotic conditions are probably responsible for the occurrence of thrombosis in almost all patients with congenital FVII deficiency. Critical review of the literature.
Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE).
Congenital FVII Deficiency and Pulmonary Embolism : A Critical Appraisal of All Reported Cases.
Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review.
Efficacy and Safety of Recombinant Activated Factor VII Off-label Use in a Pediatric Hematology/Oncology Cohort.
Factor VII coagulant activity, factor VII -670A/C and -402G/A polymorphisms, and risk of venous thromboembolism.
New anticoagulants for venous thromboembolic disease.
Reversal of low-molecular-weight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VII concentrate.
Venous Thrombosis
A two adenine insertion polymorphism in the 3' untranslated region of factor VII gene is associated with peripheral arterial disease but not with venous thrombosis. Results of case-control studies.
Acquired Antibodies to ?IIb?3 in Glanzmann Thrombasthenia: From Transfusion and Pregnancy to Bone Marrow Transplants and Beyond.
Activation of the factor VII-tissue factor pathway.
Administration of a small molecule tissue factor/factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time.
Age-related changes in factor VII proteolysis in vivo.
Altered regulation of in-vivo coagulation in orthopedic patients prior to knee or hip replacement surgery.
Coagulation factor VII R353Q polymorphism and the risk of puerperal cerebral venous thrombosis.
Complications of recombinant activated human coagulation factor VII.
Congenital factor XI and factor VII deficiencies assure an apparent opposite protection against arterial or venous thrombosis: An intriguing observation.
Decreased plasma levels of activated factor VII in patients with deep vein thrombosis.
Deep vein thrombosis after recombinant factor VIIa infusion to control severe recurrent postoperative bleeding.
Deep vein thrombosis and pulmonary embolism in congenital factor VII deficiency.
Discrepant ratios of arterial vs. venous thrombosis in hemophilias A and B as compared to FVII deficiency.
Distal deep venous thrombosis in a hemophilia A patient with inhibitor and severe infectious disease, 18 days after recombinant activated factor VII transfusion.
Effect of extra virgin olive oil on experimental thrombosis and primary hemostasis in rats.
Experience with recombinant activated factor VII for severe post-partum hemorrhage in Japan, investigated by Perinatology Committee, Japan Society of Obstetrics and Gynecology.
Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms--the Leiden Thrombophilia Study (LETS).
Factor VIIA determination compared to D-Dimer in diagnosis of deep venous thrombosis.
Genetic polymorphisms in the FVII gene is associated with lower extremity deep venous thrombosis: A case-control study.
Local application of recombinant active-site inhibited human clotting factor VIIa reduces thrombus weight and improves patency in a rabbit venous thrombosis model.
Low-dose warfarin and low-dose aspirin in the primary prevention of ischemic heart disease.
Lower extremity compartment syndrome in the setting of iliofemoral deep vein thrombosis, phlegmasia cerulea dolens and factor VII deficiency.
Medication-related complications in the trauma patient.
No significant association between the promoter region polymorphisms of factor VII gene and risk of venous thrombosis in cancer patients.
Occurrence of thrombosis in rare bleeding disorders.
Recombinant activated factor VII use in critically ill infants with active hemorrhage.
Recombinant factor VIIA in traumatic intracerebral hemorrhage: results of a dose-escalation clinical trial.
Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents.
Risk of thromboembolic complications after intracerebral hemorrhage according to ethnicity.
Safety of recombinant activated factor VII in patients with warfarin-associated hemorrhages of the central nervous system.
Surgical prophylaxis in von Willebrand's disease: a difficult balance to manage.
Systemic venous thrombosis after recombinant factor VIIa in the control of bleeding after cardiac surgery.
The paradoxical association between inherited factor VII deficiency and venous thrombosis.
Thromboembolic complications associated with factor VIIa administration.
Thrombosis in a bleeding disorder: case of thromboembolism in factor VII deficiency.
Thrombus precursor protein, endogenous thrombin potential, von-Willebrand factor and activated factor VII in suspected deep vein thrombosis: is there a place for new parameters?
Triglyceride dependence of factor VII coagulant activity in deep venous thrombosis.
Use of recombinant activated factor VII (rFVIIa-NovoSeven) in the treatment of uncontrolled postsurgical hemorrhage in a patient with deep venous thrombosis and caval filter. A case report.
Venous thrombosis in relation to fibrinogen and factor VII genes among African-Americans.
Warfarin skin necrosis. The role of factor VII.
[Hemostatic status in subjects with deep venous thrombosis]
Ventricular Dysfunction
Combined use of recombinant activated factor VII and ECMO in severe postoperative bleeding after cardiac surgery in a newborn: death due to ventricular dysfunction.
Ventricular Dysfunction, Left
Thrombogenic side-effects of recombinant factor VIIa after use in coronary artery bypass surgery.
Virus Diseases
Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes.
Clinical study of recovery and half-life of vapor-heated factor VII concentrate.
Continuous infusion of recombinant activated factor VII during caesarean section delivery in a patient with congenital factor VII deficiency.
Heterozygous factor VII deficiency and severe hemophilia A in the same kindred.
Low risk of viral infection after administration of vapor-heated factor VII concentrate or factor IX complex in first-time recipients of blood components. International Factor Safety Study Group.
Vitamin K Deficiency
Acquired Factor VII deficiency - a rare but important consideration.
Acquired Factor VII Deficiency in Association with Pyelonephritis.
Acquired factor VII deficiency in hematopoietic stem cell transplant recipients.
Acquired isolated factor VII deficiency associated with severe bleeding and successful treatment with recombinant FVIIa (NovoSeven).
Causes of an elevated international normalized ratio in the intensive care unit and the implications for plasma transfusion.
Diagnostic Error of a Patient with Combined Inherited Factor VII and Factor X Deficiency due to Accidental Ingestion of a Diphacinone Rodenticide.
Factor VII activity and antigen in haemophilia B variants.
Factor VII deficiency - an enigma; clinicohematological profile in 12 cases.
Japanese family with congenital factor VII deficiency.
Neonatal asphyxia and renal failure as the presentation of non-inherited protein C deficiency.
Uncomplicated stereotactic and open neurosurgical procedures in patients with factor VII deficiency.
Vitamin K administration to elderly patients with osteoporosis induces no hemostatic activation, even in those with suspected vitamin K deficiency.
von Willebrand Disease, Type 1
Recombinant factor VIIa (NovoSeven) for post-prostatectomy hemorrhage in a patient with type I von Willebrand disease.
von Willebrand Disease, Type 2
Myocardial infarction following recombinant activated factor VII in a patient with type 2A von Willebrand disease.
von Willebrand Disease, Type 3
Robustness of factor assays following cordocentesis in the prenatal diagnosis of haemophilia and other bleeding disorders.
von Willebrand Diseases
A review of long-term prophylaxis in the rare inherited coagulation factor deficiencies.
Acquired haemophilia in association with type III von Willebrand's disease: successful treatment with high purity von Willebrand's factor and recombinant factor VIIa.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Associated prothrombotic conditions are probably responsible for the occurrence of thrombosis in almost all patients with congenital FVII deficiency. Critical review of the literature.
Bleeding symptoms in heterozygous carriers of inherited coagulation disorders in southern Iran.
Buccal mucosa bleeding time is prolonged in canine models of primary hemostatic disorders.
Clinical and laboratory features of 178 children with recurrent epistaxis.
Continuous infusion of recombinant factor VIIa (NovoSeven) in the treatment of a patient with type III von Willebrand's disease and alloantibodies against von Willebrand factor.
Detecting coagulopathy in pediatric patients with post-tonsillectomy hemorrhage.
Detection of two missense mutations and characterization of a repeat polymorphism in the factor VII gene (F7).
Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease.
Elective surgery in patients with congenital coagulopathies and inhibitors: experience of the National Haemophilia Centre of Venezuela.
Factor VII and fibrinolytic response to deamino-8-D-argenine vasopressin in normal subjects and dissociate response in some patients with haemophilia and von Willebrand's disease.
First report of combined factor VII Padua defect and von Willebrand's disease due to casual association of the two defects.
Gene Therapy for Inherited Bleeding Disorders.
Genetic Panel Screening of Nearly 100 Mutations Reveals New Insights into the Breed Distribution of Risk Variants for Canine Hereditary Disorders.
Home treatment for patients with congenital bleeding disorders in a developing country.
Improving care and treatment options for women and girls with bleeding disorders.
In vivo dissociation of factor VII (AHF) activity and factor VII-related antigen in von Willebrand's disease.
Ischemic strokes in congenital bleeding disorders: comparison with myocardial infarction and other acute coronary syndromes.
Low endoscopy bleeding risk in patients with congenital bleeding disorders.
Management of bleeding complications of hematologic malignancies.
Myocardial infarction following recombinant activated factor VII in a patient with type 2A von Willebrand disease.
National survey of patients with hemophilia and other congenital bleeding disorders in Thailand.
Obstetric analgesia and anaesthesia in women with inherited bleeding disorders.
Occult hepatitis B virus infection in Greek patients with congenital bleeding disorders.
Outcome of laparoscopic ovariohysterectomy or ovariectomy in dogs with von Willebrand disease or factor VII deficiency: 20 cases (2012-2014).
Paradoxical thrombosis part 1: factor replacement therapy, inherited clotting factor deficiencies and prolonged APTT.
Postoperative tonsil/adenoidectomy bleeding management in patients with diagnosed bleeding disorders.
Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.
Recombinant activated factor VII as a universal haemostatic agent.
Recombinant activated factor VII in patients at high risk of bleeding.
Recombinant coagulation factor VIIa in the management of bleeding in patients with von Willebrand disease type 2A.
Recombinant factor VIIa (NovoSeven) for post-prostatectomy hemorrhage in a patient with type I von Willebrand disease.
Recombinant FVIIa concentrate-associated thrombotic events in congenital bleeding disorders other than hemophilias.
Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa.
Robustness of factor assays following cordocentesis in the prenatal diagnosis of haemophilia and other bleeding disorders.
Screening bleeding disorders in adolescents and young women with menorrhagia.
Successful treatment of an injury bleeding on a patient suffering from mild von Willebrand's disease and predisposition to allergic diseases, with recombinant factor VIIA.
Successful treatment of severe menorrhagia at menarche with recombinant factor VIIa in an adolescent girl with type III von Willebrand's disease.
Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease.
Synovectomy for haemophilic arthropathy: 6-21 years of follow-up in 16 patients.
The animal models for hemorrhage and thrombosis in the neonate.
The use of recombinant activated factor VII in congenital and acquired von Willebrand disease.
The use of recombinant-activated factor VII in von Willebrand disease: a case series.
Thrombosis in rare bleeding disorders.
Tranexamic acid without prophylactic factor replacement for prevention of bleeding in hereditary bleeding disorder patients undergoing endoscopy: a pilot study.
Unprovoked Pulmonary Embolism in Factor VII Deficiency.
Use of Recombinant Factor VII in Cardiac Surgery.
Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor.
Use of Recombinant Factor VIIa in Inherited and Acquired von Willebrand Disease.
Women and inherited bleeding disorders - A review with a focus on key challenges for 2019.
[Clinical assessment of potential fields of application of recombinant factor VIIa in internal and pediatric diseases. Recommendations of an expert group.]
[Infective morbidity of replacement therapy in congenital coagulation deficiencies and its effects on demand of coagulation factors]
[Panorama of congenital disorders of hemostasis diseases at University Hospital of Brazzaville, Congo]
Wilms Tumor
Acquired factor VII deficiency associated with Wilms tumor.
Xanthogranuloma, Juvenile
Prophylactic recombinant factor VIIa administration to an infant with congenital systemic juvenile xanthogranuloma.